

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Office of the President</u>				
<u>WUKY</u>				
Yelton, Stacy L	3048105177	\$6,000.	\$0.	\$6,000.
Lexarts Tonic: Arts and Music Magazine				
WUKY	Totals:	\$6,000.	\$0.	\$6,000.
Office of the President Totals:		\$6,000.	\$0.	\$6,000.
<u>Commercialization & Economic Development</u>				
<u>Business Development</u>				
Harvey, Dean E	3048104677	\$165,700.	\$0.	\$165,700.
Economic Development Administration University of Kentucky Technology Development Center				
Harvey, Dean E	3048104881	\$170,000.	\$0.	\$170,000.
KY Science and Technology Co Inc KSTC ICC Project				
Harvey, Dean E	3048104881	\$0.	\$5,000.	\$5,000.
KY Science and Technology Co Inc KSTC ICC Project				
Business Development	Totals:	\$335,700.	\$5,000.	\$340,700.
<u>Small Business Development Center</u>				
Naugle, Lottie Becky	3048105317	\$100,000.	\$0.	\$100,000.
Small Business Administration Veterans Assistance and Services Program				
Naugle, Lottie Becky	3048105412	\$0.	\$158,414.	\$158,414.
Small Business Administration Kentucky Small Business Development Center				
Naugle, Lottie Becky	3048105412	\$1,239,664.	\$0.	\$1,239,664.
Small Business Administration Kentucky Small Business Development Center				
Small Business Development Center	Totals:	\$1,339,664.	\$158,414.	\$1,498,078.
Commercialization & Economic Development Totals:		\$1,675,364.	\$163,414.	\$1,838,778.
<u>Fiscal Affairs and Information Technology</u>				
<u>Fiscal Affairs and Information Technology</u>				
Friskney, Doyle N	3048105199	\$6,000.	\$0.	\$6,000.
Southeastern Universities Research Association Inc A Demonstration Microsoft Cluster Compute Server Environment for Bioinformatics				
Fiscal Affairs and Information Technology	Totals:	\$6,000.	\$0.	\$6,000.
Fiscal Affairs and Information Technology Totals:		\$6,000.	\$0.	\$6,000.
<u>Research</u>				
<u>VP for Research</u>				
Tracy, James W	3048103738	\$0.	\$63,135.	\$63,135.
KY Department of Environmental Protection Supplemental Environmental Project Compliance Assistance Tools and Services				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>VP for Research</u>				
Tracy, James W	3048103738	\$0.	\$8,629.	\$8,629.
KY Department of Environmental Protection Supplemental Environmental Project Compliance Assistance Tools and Services				
Tracy, James W	3048104799	\$1,422,094.	\$0.	\$1,422,094.
Health Resources and Services Administration High Bandwidth Network Connection to Support Health Care Delivery and Critical Clinical and Biomedical Research				
VP for Research	Totals:	\$1,422,094.	\$71,764.	\$1,493,858.
<u>KY Geological Survey</u>				
Anderson, Warren H	3048105184	\$0.	\$298,452.	\$298,452.
University of Illinois Assessment of Geological Carbon Sequestration Options in the Illinois Basin-Phase II & III				
Andrews, William M	3048104778	\$215,005.	\$0.	\$215,005.
US Geological Survey Quaternary and Surficial Geologic Mapping for Geotechnical and Geophysical Applications in Kentucky				
Cobb, James C	3048105152	\$59,000.	\$0.	\$59,000.
KY Energy and Environment Cabinet CAER and KGS Advisory Support of State Energy Related Issues				
Currens, James C	3048105673	\$29,062.	\$0.	\$29,062.
QK4 Mapping Karst Groundwater Basin Boundaries Along the Edward T. Breathitt, Pennyriple Parkway				
Eble, Cortland F	3046986300	\$0.	\$-6,250.	\$-6,250.
KY Office of Energy Policy Seed Grant: Exploring for Economic Coal Bed Methane in Eastern Kentucky				
Eble, Cortland F	3048105561	\$50,000.	\$0.	\$50,000.
Marshall Miller and Associates Inc KY Coal and Shale Analysis for the Southeast Regional Carbon Sequestration Partnership (SECARB) Phase II Task 10 Project				
Greb, Stephen F	3046917300	\$0.	\$15,000.	\$15,000.
US Geological Survey Kentucky Coal Data for the National Coal Resource Data System				
Greb, Stephen F	3046917300	\$0.	\$15,000.	\$15,000.
US Geological Survey Kentucky Coal Data for the National Coal Resource Data System				
Greb, Stephen F	3046957200	\$0.	\$21,000.	\$21,000.
Virginia Polytechnic Institute and State University Southeast Kentucky: Coals as CO2 Sequestration Reservoirs (part of Southeast Regional Carbon Sequestration Partnership Phase 2 Project)				
Greb, Stephen F	3046957200	\$0.	\$12,574.	\$12,574.
Virginia Polytechnic Institute and State University Southeast Kentucky: Coals as CO2 Sequestration Reservoirs (part of Southeast Regional Carbon Sequestration Partnership Phase 2 Project)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>KY Geological Survey</u>				
Greb, Stephen F	3046961500	\$0.	\$72,697.	\$72,697.
Battelle Memorial Institute Kentucky Part of Phase 2 of the Midwest Regional Carbon Sequestration Partnership (MRCSP)				
Hickman, John B	3048104896	\$62,862.	\$0.	\$62,862.
KY Office of Energy Policy Rough Creek Graben Year Two				
Lynch, Michael J	3048104792	\$15,000.	\$0.	\$15,000.
KY Board of Registration for Professional Geologists Communication Specilist Liaison				
Nuttall, Brandon C	3048105184	\$115,890.	\$0.	\$115,890.
University of Illinois Assessment of Geological Carbon Sequestration Options in the Illinois Basin-Phase II & III				
Nuttall, Brandon C	3048105690	\$80,000.	\$0.	\$80,000.
KY Energy and Environment Cabinet Preliminary Assessment of Oil and Gas Possibilities on State and University owned Lands in Kentucky (SJR67)				
Wang, Zhenming N	3048091700	\$0.	\$4.	\$4.
US Geological Survey Operation of the Mid-American Integrated Seismic Network-UKY				
Wang, Zhenming N	3048091700	\$0.	\$55,800.	\$55,800.
US Geological Survey Operation of the Mid-American Integrated Seismic Network-UKY				
Wang, Zhenming N	3048091700	\$0.	\$37,139.	\$37,139.
US Geological Survey Operation of the Mid-American Integrated Seismic Network-UKY				
Weisenfluh, Gerald A	3048019600	\$0.	\$125,000.	\$125,000.
KY Transportation Cabinet Integrating Geotechnical Drill Hole Data with Geologic Information				
Weisenfluh, Gerald A	3048105091	\$24,647.	\$0.	\$24,647.
US Geological Survey National Catalog Metadata Submissions for Kentucky Sites				
KY Geological Survey	Totals:	\$651,466.	\$646,416.	\$1,297,882.
<u>Appalachian Center</u>				
Billings, Dwight B	3048105617	\$57,739.	\$0.	\$57,739.
National Science Foundation Fellowship for Fitzgerald: The Messy Politics of Clean Coal, Contested Energy Alternatives in the Appalachian Coalfields				
Appalachian Center	Totals:	\$57,739.	\$0.	\$57,739.
<u>Interdisc Human Development Institute</u>				
Compton, Jonathan F	3048105234	\$217,100.	\$0.	\$217,100.
KY Department of Education UK Post Secondary Transition				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Interdisc Human Development Institute</u>				
Farley, Joanne	3048105186	\$10,411.	\$0.	\$10,411.
KY Cabinet for Health and Family Services Aging Disability Resources Centers				
Farley, Joanne	3048105379	\$45,000.	\$0.	\$45,000.
University of Tennessee Tennessee State Improvement Grant				
Hall, Meada G	3048104789	\$100,573.	\$0.	\$100,573.
KY Department of Education UK Community Based Work Transition (CBWT)				
Hall, Meada G	3048105246	\$152,943.	\$0.	\$152,943.
KY Department of Vocational Rehabilitation Community Based Work Transition Program 09-10				
Harrison, Elizabeth	3048105212	\$112,040.	\$0.	\$112,040.
KY Department of Education ParaEducators of Kentucky (PEK)				
Harrison, Elizabeth	3048105229	\$193,335.	\$0.	\$193,335.
KY Council on Developmental Disabilities KY's Postsecondary Inclusion Project (PIP)				
Harrison, Elizabeth	3048105498	\$26,500.	\$0.	\$26,500.
University of North Carolina Secondary Transition Technical Assistance Center Team Planning Institute				
Harrison, Ron N	3048105095	\$3,100,029.	\$0.	\$3,100,029.
Department for Mental Health Mental Retardation Service Supports for Community Living				
Harrison, Ron N	3048105201	\$0.	\$15,258.	\$15,258.
KY Department of Vocational Rehabilitation UK Migrant Program 09-10				
Harrison, Ron N	3048105201	\$260,931.	\$0.	\$260,931.
KY Department of Vocational Rehabilitation UK Migrant Program 09-10				
Kearns, Jacqueline	3048104454	\$0.	\$39,995.	\$39,995.
University of Minnesota Multi-State General Supervision Enhancement Grant Consortium				
Kleinert, Harold L	3048104741	\$520,000.	\$0.	\$520,000.
Administration for Children and Families University Center for Excellence in Developmental Disabilities				
Lewis, Preston O	3048084500	\$0.	\$42,262.	\$42,262.
University of Oregon National Center for the Study for the Study of Supported Text in Electronic Learning Environments				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Interdisc Human Development Institute</u>				
Lewis, Preston O	3048103717	\$0.	\$200,000.	\$200,000.
Department of Education Supported Math Accessibility Reading Tool (SMART)				
Lewis, Richard J	3046824700	\$0.	\$1,300,000.	\$1,300,000.
Department of Education Mid-South Regional Resource Center				
Rous, Beth	3048104410	\$0.	\$40,000.	\$40,000.
University of North Carolina Early Childhood Personnel Center				
Rous, Beth	3048104682	\$2,670,570.	\$0.	\$2,670,570.
KY Families and Children Cabinet IHD Child Care Quality Enhancement Initiative				
Rous, Beth	3048104682	\$0.	\$371,123.	\$371,123.
KY Families and Children Cabinet IHD Child Care Quality Enhancement Initiative				
Rous, Beth	3048104785	\$375,000.	\$0.	\$375,000.
KY Health Services Cabinet Training Into Practice Project Services FY09/Z915				
Rous, Beth	3048104786	\$80,000.	\$0.	\$80,000.
KY Department of Education Kentucky Early Childhood Transition Project Part B				
Rous, Beth	3048104787	\$220,000.	\$0.	\$220,000.
KY Department of Education Early Childhood Data Platform				
Rous, Beth	3048104805	\$150,059.	\$0.	\$150,059.
KY Health Services Cabinet Kentucky Early Childhood Data System (KEDS) First Steps				
Rous, Beth	3048105008	\$58,014.	\$0.	\$58,014.
KY Department for Public Health UK First Steps Transition Activities				
Rous, Beth	3048105058	\$264,038.	\$0.	\$264,038.
Rutgers University Kentucky Teacher Qualifications Comparison Study				
Rous, Beth	3048105058	\$0.	\$94,301.	\$94,301.
Rutgers University Kentucky Teacher Qualifications Comparison Study				
Rous, Beth	3048105058	\$0.	\$80,461.	\$80,461.
Rutgers University Kentucky Teacher Qualifications Comparison Study				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Interdisc Human Development Institute</u>				
Rous, Beth	3048105085	\$5,705,020.	\$0.	\$5,705,020.
KY Cabinet for Health and Family Services Child Care CCR&R Services SFY 09-10				
Sheppard-Jones, Kathleen A	3046935400	\$0.	\$83,961.	\$83,961.
Department of Education Ky. Resident Training Program in Rehabilitation Technology				
Sheppard-Jones, Kathleen A	3048104788	\$402,916.	\$0.	\$402,916.
KY Department of Vocational Rehabilitation Consumer Satisfaction Survey 09-10				
Sheppard-Jones, Kathleen A	3048105119	\$28,988.	\$0.	\$28,988.
KY Department for the Blind UK Client Satisfaction Survey				
Sheppard-Jones, Kathleen A	3048105228	\$1,132,759.	\$0.	\$1,132,759.
KY Cabinet for Health and Family Services Human Development Services - Home Modifications				
Taub, Deborah A.	3048105218	\$81,985.	\$0.	\$81,985.
Edcount LLC ILSSA EdCount				
Tyree, Milton S	3048104783	\$411,952.	\$0.	\$411,952.
KY Department of Vocational Rehabilitation Kentucky Support Employment 09-10				
Tyree, Milton S	3048104846	\$19,231.	\$0.	\$19,231.
Lifeskills Inc The ROLES Initiative (Real Opportunities for Lifestyles Enriched through valued Social roles)				
Wickham, Donna R	3046846000	\$0.	\$567,257.	\$567,257.
Pearson Educational Measurement ILSSA NJ				
Wickham, Donna R	3046846000	\$0.	\$250,000.	\$250,000.
Pearson Educational Measurement ILSSA NJ				
Wickham, Donna R	3046846000	\$0.	\$707,164.	\$707,164.
Pearson Educational Measurement ILSSA NJ				
Wickham, Donna R	3048104780	\$257,500.	\$0.	\$257,500.
KY Department of Education Kentucky Alternate Portfolio				
Wickham, Donna R	3048104780	\$0.	\$446,648.	\$446,648.
KY Department of Education Kentucky Alternate Portfolio				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Interdisc Human Development Institute</u>				
Wickham, Donna R	3048104990	\$50,136.	\$0.	\$50,136.
KY Department of Education ILSSA Georgia Enhanced Assessment Grant				
Wickham, Donna R	3048104990	\$0.	\$6,000.	\$6,000.
KY Department of Education ILSSA Georgia Enhanced Assessment Grant				
Wickham, Donna R	3048105028	\$14,971.	\$0.	\$14,971.
Edcount LLC edCount Assessment				
Wickham, Donna R	3048105155	\$513,022.	\$0.	\$513,022.
University of Guam Pacific Rim ILSSA				
Wickham, Donna R	3048105217	\$330,148.	\$0.	\$330,148.
Pearson Educational Measurement Inclusive Large Scale Standards and Assessment-Puerto Rico Alternative Assessment				
Wickham, Donna R	3048105641	\$343,844.	\$0.	\$343,844.
Government of District of Columbia ILSSA DC				
Wickham, Donna R	3048105747	\$71,253.	\$0.	\$71,253.
Virgin Islands Department of Education ILSSA Virgin Islands				
Interdisc Human Development Institute	Totals:	\$17,920,268.	\$4,244,430.	\$22,164,698.
<u>Computational Sciences</u>				
Connolly, John W	3048104850	\$0.	\$1,000,000.	\$1,000,000.
KY Council on Postsecondary Education State EPSCoR: Transforming Kentucky's New Economy				
Connolly, John W	3048105113	\$2,434,000.	\$0.	\$2,434,000.
National Science Foundation NSF/EPSCoR: Transforming Kentucky's New Economy with EPSCoR				
Connolly, John W	3048105250	\$254,815.	\$0.	\$254,815.
National Science Foundation Collaborative Research: CRIF: CRF: Extensible Cyberenvironments for Empirical and Semiempirical Hamiltonian Parameter Optimization and Dissemination				
Computational Sciences	Totals:	\$2,688,815.	\$1,000,000.	\$3,688,815.
<u>KY Water Resources Institute</u>				
Ormsbee, Lindell E	3046738000	\$0.	-\$2,490,130.	-\$2,490,130.
Department of Energy Kentucky Research Consortium for Energy and Environment				
Ormsbee, Lindell E	3046738000	\$0.	\$677.	\$677.
Department of Energy Kentucky Research Consortium for Energy and Environment				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>KY Water Resources Institute</u>				
Ormsbee, Lindell E	3046738000	\$0.	\$-1.	\$-1.
Department of Energy Kentucky Research Consortium for Energy and Environment				
Ormsbee, Lindell E	3046738000	\$0.	\$2,490,130.	\$2,490,130.
Department of Energy Kentucky Research Consortium for Energy and Environment				
Ormsbee, Lindell E	3046989200	\$0.	\$92,335.	\$92,335.
US Geological Survey State Water Research Institute Program				
Ormsbee, Lindell E	3048104771	\$0.	\$-548.	\$-548.
Stantec Consulting Services Inc Water Resources Technical Support Services				
Ormsbee, Lindell E	3048104771	\$9,828.	\$0.	\$9,828.
Stantec Consulting Services Inc Water Resources Technical Support Services				
Ormsbee, Lindell E	3048104837	\$95,795.	\$0.	\$95,795.
KY River Authority Watershed Management Service				
Ormsbee, Lindell E	3048104942	\$94,201.	\$0.	\$94,201.
KY Department for Public Health UK Maxey Flats				
Ormsbee, Lindell E	3048104943	\$453,983.	\$0.	\$453,983.
KY Department for Public Health UK Paducah Gaseous Diffusion Plant-AIP				
Ormsbee, Lindell E	3048104981	\$14,020.	\$0.	\$14,020.
KY Natural Resources Environmental Protection Cabinet Environmental Protection Scholarship Program				
Ormsbee, Lindell E	3048104981	\$0.	\$105,980.	\$105,980.
KY Natural Resources Environmental Protection Cabinet Environmental Protection Scholarship Program				
Ormsbee, Lindell E	3048105293	\$3,158.	\$0.	\$3,158.
KY Department of Environmental Protection Development of Pathogen TMDLs for Four Streams in the Kentucky River Basin				
Ormsbee, Lindell E	3048105399	\$148,189.	\$0.	\$148,189.
KY Energy and Environment Cabinet TMDLs for Critical Watersheds in the Kentucky River Basin				
KY Water Resources Institute	Totals:	\$819,174.	\$198,443.	\$1,017,617.
<u>Ctr for Applied Energy Research</u>				
Andrews, Rodney	3048104562	\$0.	\$-8,503.	\$-8,503.
Materials Sciences Corp Multifunctional Polymer Composites SBIR Phase II				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Ctr for Applied Energy Research</u>				
Andrews, Rodney	3048104562	\$0.	\$8,503.	\$8,503.
Materials Sciences Corp Multifunctional Polymer Composites SBIR Phase II				
Andrews, Rodney	3048104562	\$0.	\$79,622.	\$79,622.
Materials Sciences Corp Multifunctional Polymer Composites SBIR Phase II				
Andrews, Rodney	3048104956	\$0.	\$-50,000.	\$-50,000.
Department of Energy Coal Fuel Alliance (CFA): Design and Construction of Early Lead Mini Fischer-Tropsch Refinery at the University of Kentucky Center for Applied Energy Research				
Andrews, Rodney	3048104956	\$1,370,065.	\$0.	\$1,370,065.
Department of Energy Coal Fuel Alliance (CFA): Design and Construction of Early Lead Mini Fischer-Tropsch Refinery at the University of Kentucky Center for Applied Energy Research				
Andrews, Rodney	3048104964	\$123,000.	\$0.	\$123,000.
KY Office of Energy Policy GOEP Matching: Establishment of a Laboratory for Biofuels Research at the University of Kentucky				
Andrews, Rodney	3048105043	\$492,000.	\$0.	\$492,000.
Department of Energy Establishment of a Laboratory for Biofuels at the University of Kentucky				
Andrews, Rodney	3048105144	\$120,000.	\$0.	\$120,000.
KY Energy and Environment Cabinet CAER and KGS Advisory Support of State Energy Related Issues				
Andrews, Rodney	3048105144	\$0.	\$-59,000.	\$-59,000.
KY Energy and Environment Cabinet CAER and KGS Advisory Support of State Energy Related Issues				
Andrews, Rodney	3048105200	\$567,021.	\$0.	\$567,021.
KY Office of Energy Policy Development of an Algae-Based System for CO2 Mitigation from Coal-Fired Power Plants				
Andrews, Rodney	3048105359	\$836,964.	\$0.	\$836,964.
National Institute for Hometown Security Carbon Foam-Based Protection Systems				
Andrews, Rodney	3048105615	\$2,490,130.	\$0.	\$2,490,130.
Department of Energy Kentucky Research Consortium for Energy and Environment				
Crocker, Mark	3046947300	\$0.	\$44,078.	\$44,078.
Department of Energy Investigation of Aging Mechanisms in Lean NOx Traps				
Crocker, Mark	3046947300	\$0.	\$30,000.	\$30,000.
Department of Energy Investigation of Aging Mechanisms in Lean NOx Traps				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Ctr for Applied Energy Research</u>				
Crocker, Mark	3046947300	\$0.	\$51,000.	\$51,000.
Department of Energy Investigation of Aging Mechanisms in Lean NOx Traps				
Crocker, Mark	3046947300	\$0.	\$21,058.	\$21,058.
Department of Energy Investigation of Aging Mechanisms in Lean NOx Traps				
Davis, Burtron H	3048105170	\$1,088,066.	\$0.	\$1,088,066.
Department of Energy Sensitivity of Fischer-Tropsch Synthesis and Water-Gas Shift Catalysts to Poisons from High-Temperature High-Pressure Entrained-Flow (EF) Oxygen-Blown Gasifier Gasification of Coal/Biomass Mixtures				
Davis, Burtron H	3048105626	\$239,823.	\$0.	\$239,823.
VSE Corporation Production of High Hydrogen Content Coal Derived Liquids				
Hiatt, John K	3048104790	\$220,687.	\$0.	\$220,687.
KY Department for Natural Resources Mine Mapping Program				
Hower, James C	3048099600	\$0.	\$17,500.	\$17,500.
US Geological Survey Vitrinite maximum reflectance and maceral studeis in support of USGS coal research.				
Lipka, Steve	3048104401	\$0.	\$81,000.	\$81,000.
US Office of Naval Research High Energy Density Carbons for Electrochemical Capacitors				
Liu, Kunlei	3048105493	\$0.	\$349,998.	\$349,998.
Multiple Industry Sponsors Carbon Management Research Group				
Liu, Kunlei	3048105493	\$2.	\$0.	\$2.
Multiple Industry Sponsors Carbon Management Research Group				
Liu, Kunlei	3048105595	\$1,000,000.	\$0.	\$1,000,000.
KY Office of Energy Policy Carbon Management Research Group				
Robl, Thomas L	3046735300	\$0.	\$-4,040.	\$-4,040.
Department of Energy Advanced Multi-Product Coal Utilization By-product Processing Plant				
Robl, Thomas L	3048105360	\$991,408.	\$0.	\$991,408.
National Institute for Hometown Security Rapidly Deployable System for the Structural Stabilization of Shock Damaged Structures				
Taulbee, Darrell N	3048105267	\$14,969.	\$0.	\$14,969.
KY Office of Energy Policy Project Revision: Demonstration of the Combustion Characteristics of Fuel Briquettes made from Fine Coal and Biomass				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Ctr for Applied Energy Research</u>				
Weisenberger, Matthew	3048105585	\$90,488.	\$0.	\$90,488.
Materials Sciences Corp Integrated Carbon Nanotube-Based EMI Shielding and Thermal Solutions: High Volume Fraction CNT Coatings for Composites				
Weisenberger, Matthew	3048105697	\$98,977.	\$0.	\$98,977.
Materials Sciences Corp Development and Characterization of Aligned Multiwall Nanotube Arrays for Thermally Conductive Film Adhesives				
Weisenberger, Matthew	3048105743	\$39,585.	\$0.	\$39,585.
Materials Sciences Corp Preparation of Multiwall Carbon Nanotubes Functionalized for High Loadings in Epoxy Matrices				
Ctr for Applied Energy Research	Totals:	\$9,783,185.	\$561,216.	\$10,344,401.
<u>Magnetic Resonance Imaging System Cntr</u>				
Smith, Charles D	3048105804	\$500,000.	\$0.	\$500,000.
National Center for Research Resources Upgrade to Multicenter 3T Magnetic Resonance Imager				
Magnetic Resonance Imaging System Cntr	Totals:	\$500,000.	\$0.	\$500,000.
<u>Div of Laboratory Animal Research</u>				
Smiley, Jeffrey R	3048104678	\$0.	\$54,540.	\$54,540.
National Center for Research Resources Enhancement of BBSRB Vivarium				
Div of Laboratory Animal Research	Totals:	\$0.	\$54,540.	\$54,540.
	Research Totals:	\$33,842,741.	\$6,776,809.	\$40,619,550.
<u>Dentistry</u>				
<u>Dentistry Research & Graduate Studies</u>				
Ebersole, Jeffrey L	3048105103	\$350,500.	\$0.	\$350,500.
KY Cabinet for Health and Family Services Support for Dental Public Health Activities				
Ebersole, Jeffrey L	3048105147	\$2,031,636.	\$0.	\$2,031,636.
National Center for Research Resources Center for the Biological Basis of Oral/Systemic Disease: AEC				
Ebersole, Jeffrey L	3048105208	\$2.	\$0.	\$2.
Center for Disease Control and Prevention Obtain Specimens and Supporting Clinical Information to Establish A Standardized National Repository of Control Serum Samples for the Study of Lyme Borreliosis (Periodontitis)				
Novak, Karen F	3048104412	\$0.	\$18,312.	\$18,312.
National Institute of Dental Research Analyses of Host-Biofilm Interactions: A Novel Polymicrobial Model				
Novak, Karen F	3048104412	\$0.	\$164,813.	\$164,813.
National Institute of Dental Research Analyses of Host-Biofilm Interactions: A Novel Polymicrobial Model				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Dentistry</u>				
<u>Dentistry Research & Graduate Studies</u>				
Novak, Michael J	3048104411	\$0.	\$28,541.	\$28,541.
University of Minnesota Effects of Periodontal Therapy on Preterm Birth				
Dentistry Research & Graduate Studies	Totals:	\$2,382,138.	\$211,666.	\$2,593,804.
<u>Oral Health Science</u>				
De Leeuw, Rinskje	3046972300	\$0.	\$135,000.	\$135,000.
National Institute of Dental Research Central Pain Processing in Chronic Face Pain: fMRI Study				
Raybould, Ted P	3048105056	\$278,880.	\$0.	\$278,880.
Health Resources and Services Administration Residency Training in General and Pediatric Dentistry: Advocacy and Care Disparities				
Oral Health Science	Totals:	\$278,880.	\$135,000.	\$413,880.
<u>Oral Health Practice</u>				
Kovarik, Robert E	3048105138	\$473,707.	\$0.	\$473,707.
Health Resources and Services Administration Designated Health Projects: Kentucky Oral Health Network				
Kovarik, Robert E	3048105138	\$0.	\$780.	\$780.
Health Resources and Services Administration Designated Health Projects: Kentucky Oral Health Network				
Miller, Craig S	3048103659	\$0.	\$181,111.	\$181,111.
National Institute of Dental Research Effects of ART on Oral Epithelial Cell Biology				
Miller, Craig S	3048105535	\$140,719.	\$0.	\$140,719.
University of Texas at Austin Development of a Multianalyte Lab-on-a-Chip System for Saliva-Bases Diagnostics				
Yepes, Juan F	3048104388	\$0.	\$5,748.	\$5,748.
Amarillo Biosciences Inc Eval of Natural Human Interferon Alpha in the Treatment of Oral Warts in HIV				
Oral Health Practice	Totals:	\$614,426.	\$187,639.	\$802,065.
	Dentistry Totals:	\$3,275,444.	\$534,305.	\$3,809,749.
<u>Nursing</u>				
<u>Nursing</u>				
Chung, Misook L	3048032000	\$0.	\$97,939.	\$97,939.
National Institute for Nursing Research Impact of Family Distress and Burden on Patients Outcomes in Heart Failure				
Chung, Misook L	3048105427	\$75,000.	\$0.	\$75,000.
American Heart Association Sodium Watcher Program for Adults with Heart Failure				
Hahn, Ellen J	3048093000	\$0.	\$557,829.	\$557,829.
National Heart Lung and Blood Institute An Intervention for Promoting Smoke-free Policy in Rural Kentucky				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Nursing</u>				
<u>Nursing</u>				
Hahn, Ellen J	3048104094	\$0.	\$50,000.	\$50,000.
Foundation for a Healthy KY UK Tobacco Policy Research Program - Kentucky Center for Smoke-Free Policy				
Hahn, Ellen J	3048104804	\$225,000.	\$0.	\$225,000.
Robert Wood Johnson Foundation Tobacco Policy Change: A Collaborative for Healthier Communities and States				
Hahn, Ellen J	3048104849	\$0.	\$19,700.	\$19,700.
KY Department for Public Health Indoor Radon Project				
Hahn, Ellen J	3048104849	\$25,500.	\$0.	\$25,500.
KY Department for Public Health Indoor Radon Project				
Hahn, Ellen J	3048104878	\$189,850.	\$0.	\$189,850.
KY Health Services Cabinet Community Partnerships for Tobacco Cessation and Prevention				
Hahn, Ellen J	3048104878	\$0.	\$16,024.	\$16,024.
KY Health Services Cabinet Community Partnerships for Tobacco Cessation and Prevention				
Hahn, Ellen J	3048105291	\$16,500.	\$0.	\$16,500.
Foundation for a Healthy KY Clean Indoor Air Partnership - UK Tobacco Policy Research Program - Kentucky Center for Smoke-Free Policy - RWJF Match				
Hahn, Ellen J	3048105485	\$13,740.	\$0.	\$13,740.
KY Youth Advocates Rural Media Tobacco Prevention Project				
Hahn, Ellen J	3048105495	\$7,740.	\$0.	\$7,740.
University of Louisville Impact of Smoke-Free Laws on Tobacco Marketing Among College Students				
Hahn, Ellen J	3048105668	\$0.	\$9,890.	\$9,890.
National Heart Lung and Blood Institute ARRA: An Intervention for Promoting Smoke-free Policy Development in Rural Kentucky				
Hahn, Ellen J	3048105668	\$9,890.	\$0.	\$9,890.
National Heart Lung and Blood Institute ARRA: An Intervention for Promoting Smoke-free Policy Development in Rural Kentucky				
Howard, Patricia B	3048104724	\$63,553.	\$0.	\$63,553.
Health Resources and Services Administration Advanced Education Nursing Traineeships				
Moore, Kathryn M.	3048105476	\$15,000.	\$0.	\$15,000.
Foundation for Air Medical Research and Education Integration of Evidence Based Practice into Air Medical Practice				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Nursing</u>				
<u>Nursing</u>				
Moore, Kathryn M.	3048105478	\$500.	\$0.	\$500.
Foundation for Air Medical Research and Education Pre-Hospital Registered Nurse and Paramedic Knowledge of Evidence Based Ischemic Stroke Care				
Moser, Debra K	3046987000	\$0.	\$600.	\$600.
Patient Centered Education and Research Pain Assessment, Incidence, and Nature in Heart Failure (PAIN-HF)				
Moser, Debra K	3048060900	\$0.	\$207,934.	\$207,934.
University of California San Francisco Improving Self Care Behaviors and Outcomes in Rural Patients with Heart Failure				
Moser, Debra K	3048104417	\$0.	\$12,800.	\$12,800.
University of California San Francisco Post Discharge Nausea and Vomiting: Incidence and Management Strategies				
Moser, Debra K	3048104417	\$0.	\$7,498.	\$7,498.
University of California San Francisco Post Discharge Nausea and Vomiting: Incidence and Management Strategies				
Moser, Debra K	3048104719	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship/Jia-Rong Wu: Effect of a Medication Taking Behavior Feedback, Theory-Based Intervention on Outcomes in Patients with Heart Failure				
Moser, Debra K	3048105083	\$227,064.	\$0.	\$227,064.
National Institute for Nursing Research Center for Biobehavioral Research in Self-Management of Cardiopulmonary Disease				
Moser, Debra K	3048105497	\$10,000.	\$0.	\$10,000.
American Association of Critical Care Nurses Hammash: Cardiac Rhythm during Mechanical Ventilation and Weaning from Ventilation				
Moser, Debra K	3048105546	\$70,225.	\$0.	\$70,225.
University of Arkansas Predicting CHD Events in Black and White Women				
Moser, Debra K	3048105623	\$3,000.	\$0.	\$3,000.
Southern Nursing Research Society Hammash: Cardiac Rhythm during Mechanical Ventilation and Weaning from Ventilation				
Prevost, Suzanne	3048105594	\$142,433.	\$0.	\$142,433.
Vanderbilt University Crafting the Ultimate Faculty Simulation Experience				
Reed, Deborah B	3048104034	\$0.	\$348,050.	\$348,050.
National Institute of Occupational Safety and Health Refinement and Enhancement of Agricultural Safety Curricula for Children (REACCH)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Nursing</u>				
<u>Nursing</u>				
Reed, Deborah B	3048105445	\$7,000.	\$0.	\$7,000.
University of Cincinnati Identifying Environmental influences on Obesity Risk Factors of Commerical Truckers				
Nursing	Totals:	\$1,144,995.	\$1,328,264.	\$2,473,259.
	Nursing Totals:	\$1,144,995.	\$1,328,264.	\$2,473,259.
<u>Medicine</u>				
<u>Area Health Educ Ctr</u>				
Norton, James C	3048104768	\$918,737.	\$0.	\$918,737.
KY Health Services Cabinet FY09 SAAA UK Area Health Education Centers				
Norton, James C	3048104975	\$25,000.	\$0.	\$25,000.
KY Department for Public Health AHEC Hispanic Health Education				
Norton, James C	3048105055	\$262,900.	\$0.	\$262,900.
University of Louisville Model State Supported AHEC project				
Area Health Educ Ctr	Totals:	\$1,206,637.	\$0.	\$1,206,637.
<u>Kentucky Telecare</u>				
Sprang, Robert R	3048105556	\$30,000.	\$0.	\$30,000.
AT&T Foundation ADHD parent Training using Telemedicine				
Kentucky Telecare	Totals:	\$30,000.	\$0.	\$30,000.
<u>Spinal Cord & Brain Injury Res Ctr</u>				
Geddes, James W	3048103705	\$0.	\$44,000.	\$44,000.
American Heart Association Great Rivers Affiliate Fellowship for Naga: Role of cyclophilin D in the vulnerability of neuronal and synaptic mitochondria to undergo permeability transition.				
Geddes, James W	3048104347	\$0.	\$99,089.	\$99,089.
KY Spinal Cord and Head Injury Research Trust Inhibition of ERK 1/2 Signaling Following Spinal Cord Injury				
Geddes, James W	3048104350	\$0.	\$99,971.	\$99,971.
KY Spinal Cord and Head Injury Research Trust Implications of High Neuronal Cyclophilin D Levels for Spinal Cord Injury				
Hall, Edward D	3046888000	\$0.	\$453,006.	\$453,006.
National Institute of Neurological Disorders & Stroke UK Spinal Cord & Brain Injury Research Center Core Grant				
Hall, Edward D	3048105191	\$269,131.	\$0.	\$269,131.
National Institute on Drug Abuse Therapeutic Strategies for Neurodegeneration Training Grant				
Hall, Edward D	3048105247	\$46,826.	\$0.	\$46,826.
National Institute of Neurological Disorders & Stroke Fellowship Radhika Vaishnav: Therapuetic Strategies for Spinal Cord Injury				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Spinal Cord & Brain Injury Res Ctr</u>				
Hall, Edward D	3048105270	\$26,000.	\$0.	\$26,000.
National Institute of Neurological Disorders & Stroke 26th National Neurotrauma Symposium 2008				
Hall, Edward D	3048105447	\$42,676.	\$0.	\$42,676.
Stallion Therapeutics Inc Novel Neuroprotectants for TBI				
Lifshitz, Jonathan	3048104351	\$0.	\$99,801.	\$99,801.
KY Spinal Cord and Head Injury Research Trust Somatosensory Circuit Disruption and Rehabilitation after Diffuse Brain Injury				
Rabchevsky, Alexander G	3048105500	\$99,616.	\$0.	\$99,616.
KY Spinal Cord and Head Injury Research Trust Effects of acety-l-carnitine treatment on mitochondrial function, tissue sparing and hind limb locomotor recovery following contusion spinal cord injury				
Saatman, Kathryn	3048104348	\$0.	\$98,855.	\$98,855.
KY Spinal Cord and Head Injury Research Trust Neuroprotective Efficacy of Regionally Targeted IGF-1 Overexpression for Traumatic Brain Injury				
Snow, Diane M	3048104905	\$326,000.	\$0.	\$326,000.
National Institute of Neurological Disorders & Stroke Designer PGs for CNS Injury				
Snow, Diane M	3048105449	\$0.	\$5,000.	\$5,000.
Christopher Reeve Paralysis Foundation Designer PGs for Spinal Cord Injury				
Snow, Diane M	3048105449	\$75,000.	\$0.	\$75,000.
Christopher Reeve Paralysis Foundation Designer PGs for Spinal Cord Injury				
Sullivan, Patrick G	3048104842	\$7,000.	\$0.	\$7,000.
National Institute of Neurological Disorders & Stroke 14th Annual KSCHIRT Symposium 2008				
Spinal Cord & Brain Injury Res Ctr	Totals:	\$892,249.	\$899,722.	\$1,791,971.
<u>Graduate Center for Toxicology</u>				
Gu, Liya	3046878300	\$0.	\$237,849.	\$237,849.
National Cancer Institute DNA Mismatch Repair Deficiency and Leukemia Relapse				
Li, Guo-Min	3046967200	\$0.	\$227,814.	\$227,814.
National Institute of General Medical Sciences Dissection and Reconstitution of Mismatch Repair				
Mellon, Isabel	3048105400	\$150,000.	\$0.	\$150,000.
KY Lung Cancer Research Fund Inhibition of Nucleotide Excision Repair by Cigarette Smoke				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Graduate Center for Toxicology</u>				
Orren, David K	3048104760	\$0.	\$30,033.	\$30,033.
University of Massachusetts Regulation WRN Deacetylation by SIRT1 After DNA Damage				
Orren, David K	3048104927	\$240,260.	\$0.	\$240,260.
National Cancer Institute Telomeric Dysfunction and the Premature Aging and Cancer-Prone Disease Werner Syndrome				
Shi, Xianglin	3048054000	\$0.	\$204,522.	\$204,522.
National Cancer Institute Mechanisms of As-induced Carcinogenesis				
Shi, Xianglin	3048054000	\$0.	\$22,725.	\$22,725.
National Cancer Institute Mechanisms of As-induced Carcinogenesis				
Shi, Xianglin	3048083200	\$0.	\$27,835.	\$27,835.
National Cancer Institute Oxidative Stress in Cr(VI)-Induced Carcinogenesis				
Shi, Xianglin	3048083200	\$0.	\$250,515.	\$250,515.
National Cancer Institute Oxidative Stress in Cr(VI)-Induced Carcinogenesis				
Shi, Xianglin	3048089500	\$0.	\$331,091.	\$331,091.
National Institute of Environmental Health Sciences Apple Peel Extract Protects UV-induced Carcinogenesis				
Shi, Xianglin	3048104536	\$0.	\$296,663.	\$296,663.
National Institute of Environmental Health Sciences Reactive Oxygen Species in Ni(II) Carcinogenesis				
St Clair, Daret K	3046887100	\$0.	\$212,530.	\$212,530.
National Cancer Institute Mechanism of MnSOD Expression in Normal and Tumor Cells				
St Clair, Daret K	3048105006	\$0.	\$15,000.	\$15,000.
National Cancer Institute Redox Regulation of Tumor Suppression by MnSOD				
St Clair, Daret K	3048105006	\$368,990.	\$0.	\$368,990.
National Cancer Institute Redox Regulation of Tumor Suppression by MnSOD				
St Clair, Daret K	3048105194	\$270,000.	\$0.	\$270,000.
National Cancer Institute MnSOD in Chemotherapeutic-Induced Cardiac Injury				
VORE, MARY	3048104322	\$0.	\$297,190.	\$297,190.
National Institute of Child Health and Human Develop Hepatic Drug Elimination in Pregnancy				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Graduate Center for Toxicology</u>				
VORE, MARY	3048104352	\$0.	\$34,160.	\$34,160.
National Institute of Environmental Health Sciences Summer Educational Experience for Research in Toxicology				
VORE, MARY	3048104815	\$149,844.	\$0.	\$149,844.
National Institute of Environmental Health Sciences NRSA T32: Molecular Mechanisms of Toxicity Training Grant				
VORE, MARY	3048105232	\$270,000.	\$0.	\$270,000.
National Cancer Institute The Role of MRP1 in Protection of Cardiac Injury				
Wang, Zhigang	3048103777	\$0.	\$72,043.	\$72,043.
KY Lung Cancer Research Fund A Transgenic Mouse Model for Understanding Rev1 and Lung Cancer				
Yang, Hsin-Sheng	3048105499	\$293,000.	\$0.	\$293,000.
National Cancer Institute The Role of Pcd4 in Colorectal Tumor Progression				
Graduate Center for Toxicology	Totals:	\$1,742,094.	\$2,259,970.	\$4,002,064.
<u>McDowell Cancer Network</u>				
Armstrong, Debra K	3048104882	\$2,500.	\$0.	\$2,500.
East Tennessee State University Kentucky Appalachian Regional Roundtable Discussions				
Armstrong, Debra K	3048104883	\$5,000.	\$0.	\$5,000.
East Tennessee State University Comprehensive Cancer Control Plan for Appalachian Communities: Kentucky Appalachian Cancer Forum				
Armstrong, Debra K	3048104936	\$28,144.	\$0.	\$28,144.
KY Department for Public Health Kentucky Cancer Program Demonstration Project				
Armstrong, Debra K	3048105179	\$10,500.	\$0.	\$10,500.
KY Breast Cancer Trust and Research Fund Horses and Hope				
D'Orazio, John A	3048103790	\$0.	\$73,250.	\$73,250.
National Cancer Institute Defining the role of MC1R in UV-induced oxidative damage and DNA repair				
D'Orazio, John A	3048104922	\$164,813.	\$0.	\$164,813.
National Cancer Institute Coleus forskohlii extract: melanization and UV protection by a natural product				
Durbin, Eric B	3048105190	\$4,500.	\$0.	\$4,500.
KY Department for Public Health KCR Data Matching Project				
Means, Robert T	3046572100	\$0.	\$1,929,816.	\$1,929,816.
KY Lung Cancer Research Fund Kentucky Lung Cancer Research Program				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>McDowell Cancer Network</u>				
Mullett, Timothy	3048104949	\$0.	\$1,900.	\$1,900.
Eli Lilly and Company Non-Small Cell Lung Cancer: The Impact of Ethnic Origin on Patients being Treated Second Line with Pemetrexed - an Observational Study				
Mullett, Timothy	3048104949	\$0.	\$940.	\$940.
Eli Lilly and Company Non-Small Cell Lung Cancer: The Impact of Ethnic Origin on Patients being Treated Second Line with Pemetrexed - an Observational Study				
Mullett, Timothy	3048104949	\$2.	\$0.	\$2.
Eli Lilly and Company Non-Small Cell Lung Cancer: The Impact of Ethnic Origin on Patients being Treated Second Line with Pemetrexed - an Observational Study				
Mullett, Timothy	3048105584	\$2.	\$0.	\$2.
Proacta Inc A Randomized Phase II, Multi-Center, Open-Label, Trial of PR104 and Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer				
O'CONNOR, KATHLEEN	3048105702	\$137,831.	\$0.	\$137,831.
National Cancer Institute Ingegrin Contributions to Pancreatic Cancer				
Pierce, Andrew	3048105436	\$149,996.	\$0.	\$149,996.
KY Lung Cancer Research Fund The Gene Cluster Instability Assay as ClinicalLung Cancer Biomarker				
Rinehart, John J	3046955200	\$0.	\$92,000.	\$92,000.
Lily Research Laboratories Randomized Phase II Trail of Carboplatin and Gemcitabine with or without Dexmethasone in Patients with Untreated Stage IIIB Pleural Effusion and Stage IV Non-Small Cell Lung Cancer				
Rinehart, John J	3048076000	\$0.	\$3,198.	\$3,198.
Lily Research Laboratories SubContract Account for 3046955200 - Randomized Phase II Trail of Carboplatin and Gemcitabine with or without Dexmethasone in Patients with Untreated Stage IIIB Pleural Effusion and Stage IV Non-Small Cell Lung Cancer				
Shelton, Brent J	3048105622	\$10,000.	\$0.	\$10,000.
North American Association Central Cancer Registries Multiple Imputation for Incomplete Cancer Registry Data				
Tucker, Thomas C	3046921300	\$0.	\$900,200.	\$900,200.
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program Expansion				
Tucker, Thomas C	3046921300	\$0.	\$110,267.	\$110,267.
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program Expansion				
Tucker, Thomas C	3048104870	\$1,177,491.	\$0.	\$1,177,491.
Center for Disease Control and Prevention National Program of Cancer Registries				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>McDowell Cancer Network</u>				
Tucker, Thomas C	3048105016	\$111,320.	\$0.	\$111,320.
Macro International Co Surveillance Pilot Project for Precancerous Lesions Among Cancer Registries in Monitoring the Impact of HPV				
Wyatt, Stephen W	3046859900	\$0.	\$345,555.	\$345,555.
National Cancer Institute Cancer Information Services				
McDowell Cancer Network	Totals:	\$1,802,099.	\$3,457,126.	\$5,259,225.
<u>Sanders-Brown Center on Aging</u>				
Blonder, Lee X	3048011400	\$0.	\$355,629.	\$355,629.
National Institute of Mental Health Neuroimaging Studies of Depression in Parkinson's Disease				
Head, Elizabeth	3048105504	\$0.	\$625.	\$625.
National Institute on Aging Beta-Amyloid Immunization in a Canine Model of Aging				
Head, Elizabeth	3048105504	\$602,354.	\$0.	\$602,354.
National Institute on Aging Beta-Amyloid Immunization in a Canine Model of Aging				
Head, Elizabeth	3048105552	\$225,025.	\$0.	\$225,025.
National Institute on Aging The Effect of Antioxidants and Behavioral Enrichment on Gene Expression in Aged C.				
Head, Elizabeth	3048105552	\$0.	\$-42,475.	\$-42,475.
National Institute on Aging The Effect of Antioxidants and Behavioral Enrichment on Gene Expression in Aged C.				
Jicha, Gregory A	3048089900	\$0.	\$-28,722.	\$-28,722.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
Jicha, Gregory A	3048089900	\$0.	\$11,059.	\$11,059.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
Jicha, Gregory A	3048089900	\$0.	\$37,472.	\$37,472.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
Jicha, Gregory A	3048089900	\$0.	\$10,875.	\$10,875.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
Jicha, Gregory A	3048089900	\$0.	\$12,750.	\$12,750.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
Jicha, Gregory A	3048089900	\$0.	\$10,625.	\$10,625.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Sanders-Brown Center on Aging</u>				
Jicha, Gregory A	3048089900	\$0.	\$-3,000.	\$-3,000.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
Jicha, Gregory A	3048103730	\$0.	\$28,213.	\$28,213.
Alzheimers Association Telemedicine Assessment of Cognition in Rural Kentucky: the TACK Study				
Jicha, Gregory A	3048103788	\$0.	\$29,156.	\$29,156.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
Jicha, Gregory A	3048103788	\$0.	\$9,163.	\$9,163.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
Jicha, Gregory A	3048103788	\$0.	\$15,481.	\$15,481.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
Jicha, Gregory A	3048103788	\$0.	\$12,219.	\$12,219.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
Jicha, Gregory A	3048104560	\$0.	\$4,967.	\$4,967.
University of California San Diego A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the Efficacy and Safety of 18 Months Treatment with PF-04494700 in Participants with Mild-to-Moderate AD (RAGE)				
Jicha, Gregory A	3048104560	\$0.	\$32,403.	\$32,403.
University of California San Diego A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the Efficacy and Safety of 18 Months Treatment with PF-04494700 in Participants with Mild-to-Moderate AD (RAGE)				
Jicha, Gregory A	3048104560	\$0.	\$28,722.	\$28,722.
University of California San Diego A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the Efficacy and Safety of 18 Months Treatment with PF-04494700 in Participants with Mild-to-Moderate AD (RAGE)				
Jicha, Gregory A	3048104818	\$0.	\$19,623.	\$19,623.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				
Jicha, Gregory A	3048104818	\$0.	\$6,244.	\$6,244.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Sanders-Brown Center on Aging</u>				
Jicha, Gregory A	3048104818	\$2.	\$0.	\$2.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				
Jicha, Gregory A	3048104818	\$0.	\$6,069.	\$6,069.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				
Jicha, Gregory A	3048104819	\$0.	\$843.	\$843.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				
Jicha, Gregory A	3048104819	\$0.	\$19,623.	\$19,623.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				
Jicha, Gregory A	3048104819	\$2.	\$0.	\$2.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				
Jicha, Gregory A	3048105559	\$2.	\$0.	\$2.
University of California San Diego Study of the Safety and Effectiveness of Immune Globulin Intravenous (IGIV) for the Treatment of Mild to Moderate Alzheimer Disease				
LeVine, Harry	3048058200	\$0.	\$46,958.	\$46,958.
Alzheimers Association Chaperone-Mediated Protein Refolding Dysfunction in Alzheimer's Disease				
Lovell, Mark	3048105024	\$155,656.	\$0.	\$155,656.
National Institute on Aging Aberrant Protein Complexes as Biomarkers of Alzheimer's Disease				
Markesbery, William	3046969700	\$0.	\$-1,220.	\$-1,220.
Oregon Health and Sciences University Genetic Associations with Alzheimer-Free Survival				
Markesbery, William	3048104432	\$0.	\$1,809,945.	\$1,809,945.
National Institute on Aging Beta Amyloid and Oxidative Stress in Alzheimer's Disease				
Markesbery, William	3048104499	\$0.	\$1,295,383.	\$1,295,383.
National Institute on Aging Prevention of Alzheimer's Disease by Vitamin E and Selenium				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Sanders-Brown Center on Aging</u>				
Markesbery, William	3048104692	\$1,267,485.	\$0.	\$1,267,485.
National Institute on Aging Alzheimer's Disease Core Center				
Markesbery, William	3048104773	\$0.	\$13,320.	\$13,320.
University of Washington National Alzheimer's Coordinating Center (NACC) - Year 10				
Markesbery, William	3048104773	\$28,900.	\$0.	\$28,900.
University of Washington National Alzheimer's Coordinating Center (NACC) - Year 10				
Nelson, Peter	3048105044	\$50,000.	\$0.	\$50,000.
Alzheimers Association New Investigators Research Grant Program: Mechanism and therapeutic significance of an AD-relevant microRNA pathway				
Nelson, Peter	3048105195	\$320,469.	\$0.	\$320,469.
National Institute of Neurological Disorders & Stroke A Specific microRNA (MIR-107) is a Potential Therapeutic Target in Alzheimer's Disease				
Nelson, Peter	3048105195	\$0.	\$288,422.	\$288,422.
National Institute of Neurological Disorders & Stroke A Specific microRNA (MIR-107) is a Potential Therapeutic Target in Alzheimer's Disease				
Nelson, Peter	3048105195	\$0.	\$32,047.	\$32,047.
National Institute of Neurological Disorders & Stroke A Specific microRNA (MIR-107) is a Potential Therapeutic Target in Alzheimer's Disease				
Norris, Christopher M	3046825900	\$0.	\$91,166.	\$91,166.
National Institute on Aging Calcineurin and Biobehavioral Markers of Brain Aging				
Scheff, Stephen W	3048049400	\$0.	\$263,479.	\$263,479.
National Institute on Aging Synaptic Change in Mild Cognitive Impairment				
Scheff, Stephen W	3048105031	\$73,836.	\$0.	\$73,836.
University of Pittsburgh Neurobiology of Mild Cognitive Impairment in the Elderly				
Scheff, Stephen W	3048105377	\$99,402.	\$0.	\$99,402.
KY Spinal Cord and Head Injury Research Trust Hyperglycemia and Traumatic Brain Injury				
Schmitt, Frederick A	3046648500	\$0.	\$7,125.	\$7,125.
University of California San Diego A multi-centered, randomized, double-blind, placebo-controlled trial of Simvastatin to slow the progression of Alzheimer's disease				
Telling, Glenn	3046631200	\$0.	\$131,175.	\$131,175.
Colorado State University US Based Collaboration in Emerging Viral and Prion Diseases				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Sanders-Brown Center on Aging</u>				
Telling, Glenn	3046631200	\$0.	\$150,000.	\$150,000.
Colorado State University US Based Collaboration in Emerging Viral and Prion Diseases				
Telling, Glenn	3048105286	\$440,060.	\$0.	\$440,060.
University of Texas Medical Branch at Galveston Pathogenesis, Transmission and Detection of Zoonotic Prion Diseases				
Telling, Glenn	3048105579	\$49,594.	\$0.	\$49,594.
PrioNet Canada Endpoint Titration of CWD-Affected Elk Brain Samples in Tg(CerPrP)1536 and Tg(CerPrP-E226)5037 Mice				
Telling, Glenn	3048105664	\$210,475.	\$0.	\$210,475.
University of Texas Health Science Center at Houston Pathogenesis, Transmission and Detection of Zoonotic Prion Disease				
Sanders-Brown Center on Aging	Totals:	\$3,523,262.	\$4,705,364.	\$8,228,626.
<u>Mag Resonance Imag Sys Ctr</u>				
Smith, Charles D	3046940800	\$0.	\$2,500.	\$2,500.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
Smith, Charles D	3046940800	\$0.	\$15,500.	\$15,500.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
Smith, Charles D	3046940800	\$0.	\$17,975.	\$17,975.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
Smith, Charles D	3046940800	\$0.	\$30,469.	\$30,469.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
Smith, Charles D	3046940800	\$0.	\$33,093.	\$33,093.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
Mag Resonance Imag Sys Ctr	Totals:	\$0.	\$99,537.	\$99,537.
<u>Rural Ky Healthcare</u>				
Allen, Larry	3048104699	\$30,000.	\$0.	\$30,000.
KY Department for Public Health Rural Cooperative Agreement				
Allen, Larry	3048104702	\$147,700.	\$0.	\$147,700.
Health Resources and Services Administration State Offices of Rural Health Grant Program				
Allen, Larry	3048105036	\$493,000.	\$0.	\$493,000.
Health Resources and Services Administration Medicare Rural Hospital Flexibility Grant Program				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Rural Ky Healthcare</u>				
Allen, Larry	3048105129	\$340,013.	\$0.	\$340,013.
Health Resources and Services Administration Small Rural Hospital Improvement Grant Program (SHIP)				
Allen, Larry	3048105261	\$270,000.	\$0.	\$270,000.
Health Resources and Services Administration Kentucky State Loan Repayment Program				
Casey, Baretta R	3048105140	\$173,263.	\$0.	\$173,263.
National Institute of General Medical Sciences Appalachian Kentucky Bridges to Success				
Feltner, Frances J	3048104700	\$0.	\$230,293.	\$230,293.
KY Department for Public Health Kentucky Homeplace				
Feltner, Frances J	3048104700	\$0.	-\$730,293.	-\$730,293.
KY Department for Public Health Kentucky Homeplace				
Feltner, Frances J	3048104700	\$1,919,900.	\$0.	\$1,919,900.
KY Department for Public Health Kentucky Homeplace				
Feltner, Frances J	3048104700	\$0.	\$80,000.	\$80,000.
KY Department for Public Health Kentucky Homeplace				
Feltner, Frances J	3048105635	\$29,750.	\$0.	\$29,750.
Appalachian Regional Healthcare Inc The Appalachian Regional Healthcare (ARH) System Patient Navigation Program				
Rural Ky Healthcare	Totals:	\$3,403,626.	-\$420,000.	\$2,983,626.
<u>Center on Drug and Alcohol Research</u>				
Havens, Jennifer Rochussen	3048104775	\$0.	\$546,594.	\$546,594.
National Institute on Drug Abuse Social Networks and HIV Risk Among Rural Drug Users				
Havens, Jennifer Rochussen	3048104775	\$0.	\$60,733.	\$60,733.
National Institute on Drug Abuse Social Networks and HIV Risk Among Rural Drug Users				
Leukefeld, Carl G	3048104959	\$5,759,193.	\$0.	\$5,759,193.
KY Health Services Cabinet TAP and Substance Abuse and Domestic Violence Project				
Leukefeld, Carl G	3048105294	\$715,539.	\$0.	\$715,539.
National Institute on Drug Abuse Central States Criminal Justice Drug Abuse Center (CJDATS)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Center on Drug and Alcohol Research</u>				
Lofwall, Michelle Renee	3048105475	\$198,325.	\$0.	\$198,325.
Reckitt Benckiser Pharmaceuticals Inc Evaluating the Uptake of Instruction for Office-based Opioid Addiction Practices Aimed at Decreasing and Preventing Buprenorphine Diversion and Misuse				
Shannon, Lisa	3048105484	\$120,000.	\$0.	\$120,000.
KY Administrative Office of the Courts Treatment Drug Court Service Enhancement Project - Floyd County				
Shannon, Lisa	3048105537	\$50,000.	\$0.	\$50,000.
Community Action Council for Lexington Fayette et Comprehensive Treatment Service for Homeless Individuals and Families				
Stoops, William W	3048103671	\$0.	\$149,225.	\$149,225.
National Cancer Institute Internet Based Voucher Reinforcement for Smoking Cessation				
Tindall, Michele Staton	3046928800	\$0.	\$80,000.	\$80,000.
HOPE Center of Lexington Evaluation for the Center on Substance Abuse Treatment				
Tindall, Michele Staton	3048104810	\$140,000.	\$0.	\$140,000.
KY Department of Corrections Treatment Outcome Study for Prison-Based Substance Abuse Treatment Program 08-09 (CJ-KTOS)				
Walker, James R	3048104615	\$0.	\$60,000.	\$60,000.
KY River Community Care Inc Program Evaluation, Clinical Training, and Consultative Services for KRCC Staff				
Walker, James R	3048104906	\$0.	\$6.	\$6.
Department for Mental Health Mental Retardation Service FS/OP (TAA6, TAA7, TAAU) -- Kentucky Treatment Outcome Study				
Walker, James R	3048104906	\$1,290,744.	\$0.	\$1,290,744.
Department for Mental Health Mental Retardation Service FS/OP (TAA6, TAA7, TAAU) -- Kentucky Treatment Outcome Study				
Walker, James R	3048104906	\$0.	\$101,631.	\$101,631.
Department for Mental Health Mental Retardation Service FS/OP (TAA6, TAA7, TAAU) -- Kentucky Treatment Outcome Study				
Walker, James R	3048105562	\$45,664.	\$0.	\$45,664.
Eastern KY University UTC Division of Child Care - STARS Project				
Walker, James R	3048105701	\$0.	\$-48,483.	\$-48,483.
Eastern KY University UTC Division of Child Care - STARS Project				
Walker, James R	3048105701	\$48,483.	\$0.	\$48,483.
Eastern KY University UTC Division of Child Care - STARS Project				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Center on Drug and Alcohol Research</u>				
Walker, James R	3048105736	\$48,483.	\$0.	\$48,483.
KY Cabinet for Health and Family Services UTC Division of Child Care - STARS Project				
Walsh, Sharon L	3046966600	\$0.	\$458,590.	\$458,590.
National Institute on Drug Abuse Licit & Illicit Opioids: Comparative Studies in Humans				
Walsh, Sharon L	3048048600	\$0.	\$617,144.	\$617,144.
National Institute on Drug Abuse Evaluation of Novel Treatments for Stimulant Dependence				
Walsh, Sharon L	3048092200	\$0.	\$348,516.	\$348,516.
National Institute on Drug Abuse Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial				
Walsh, Sharon L	3048105221	\$0.	\$27,088.	\$27,088.
Catalyst Pharmaceutical Partners Inc Vigabatrin For Treatment of Methamphetamine Dependence: A Phase II Study				
Walsh, Sharon L	3048105221	\$2.	\$0.	\$2.
Catalyst Pharmaceutical Partners Inc Vigabatrin For Treatment of Methamphetamine Dependence: A Phase II Study				
Webster, John Matthew	3048104821	\$73,250.	\$0.	\$73,250.
National Institute on Alcohol Abuse and Alcoholism Drugged Driving in Alcohol-restricted Rural Appalachia				
Webster, John Matthew	3048105295	\$219,750.	\$0.	\$219,750.
National Institute on Drug Abuse A Web-based Employment Intervention for Drug Court Participants				
Wunsch, Martha J	3048105326	\$2,808.	\$0.	\$2,808.
Carilion Medical Center The Treatment of Neonatal Opioid Withdrawal: A Comparison of Methadone Loading and Tapering Regimens				
Wunsch, Martha J	3048105327	\$2,808.	\$0.	\$2,808.
Carilion Medical Center Prescription Medication Misuse in an Outpatient Clinic: A Study of Prevalance and Screening				
Center on Drug and Alcohol Research	Totals:	\$8,715,049.	\$2,401,044.	\$11,116,093.
<u>Anatomy & Neurobiology</u>				
Bueler, Hans Rudolf	3048105092	\$50,000.	\$0.	\$50,000.
American Parkinsons Disease Association Identification of PINK1 Substrates Using Conditional PINK1 Knockout Cells and Quantitative Phosphoproteomics				
Bueler, Hans Rudolf	3048105258	\$29,507.	\$0.	\$29,507.
Parkinson Schweiz Identification of Novel PINK1 Substrates Using Proteomics and Conditional PINK1 Knockout Cells				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Anatomy & Neurobiology</u>				
Bueler, Hans Rudolf	3048105733	\$197,132.	\$0.	\$197,132.
National Institute of Neurological Disorders & Stroke ARRA-Testing the efficacy of PGC-1alpha as a therapeutic target for Parkinson's disease by rAAV-mediated expression in MPTP-treated mice				
Cass, Wayne A	3048103646	\$0.	\$179,463.	\$179,463.
National Institute on Drug Abuse Calcitriol and Methamphetamine Neurotoxicity				
Duncan, Marilyn J	3048103522	\$0.	\$294,319.	\$294,319.
National Institute on Aging Neural Mechanisms Resetting the Aged Circadian Pacemaker				
Duncan, Marilyn J	3048104274	\$0.	\$264,619.	\$264,619.
National Institute of Neurological Disorders & Stroke Multiple Circadian oscillators: Regulation of a neuroendocrine rhythm				
Duncan, Marilyn J	3048104274	\$0.	\$29,402.	\$29,402.
National Institute of Neurological Disorders & Stroke Multiple Circadian oscillators: Regulation of a neuroendocrine rhythm				
Gash, Don M	3048091000	\$0.	\$85,851.	\$85,851.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
Gash, Don M	3048091000	\$0.	\$32,583.	\$32,583.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
Gash, Don M	3048091000	\$0.	\$298,980.	\$298,980.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
Gash, Don M	3048091000	\$0.	\$63,445.	\$63,445.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
Gash, Don M	3048091000	\$0.	\$110,779.	\$110,779.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
Gash, Don M	3048091000	\$0.	\$54,660.	\$54,660.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
Gash, Don M	3048100000	\$0.	-\$38,459.	-\$38,459.
Johnson and Johnson Screening Dopaminergic Trophic Factors in Rat Model Systems				
Gash, Don M	3048103727	\$0.	-\$16,521.	-\$16,521.
Johnson and Johnson Screening Dopaminergic Trophic Factors in Rat Model Systems				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Anatomy & Neurobiology</u>				
Gash, Don M	3048103727	\$0.	\$33,783.	\$33,783.
Johnson and Johnson Screening Dopaminergic Trophic Factors in Rat Model Systems				
Gash, Don M	3048103727	\$0.	\$137,372.	\$137,372.
Johnson and Johnson Screening Dopaminergic Trophic Factors in Rat Model Systems				
Gerhardt, Greg A	3046967500	\$0.	\$27,316.	\$27,316.
Medical University of South Carolina Dual Hit Hypothesis of Aging Related DA Dysfunction				
Gerhardt, Greg A	3048078800	\$0.	\$81,913.	\$81,913.
Ohio State University High-Speed detection of Stimulant-induced Cortical ACh Release				
Gerhardt, Greg A	3048105018	\$1,120,083.	\$0.	\$1,120,083.
National Institute of Neurological Disorders & Stroke Project 1 Morris K. Udall Parkinson's Center of Excellence: Restoration of Dopaminergic Function in Parkinson's Disease				
Gerhardt, Greg A	3048105744	\$234,660.	\$0.	\$234,660.
National Institute on Aging NRSA T32: Cellular and Molecular Basis of Brain Aging				
Gold, Brian T	3048105251	\$125,313.	\$0.	\$125,313.
National Science Foundation The Cognitive Neuroscience of Bilingual Advantages in Executive Control				
Grondin, Richard C	3046956000	\$0.	\$94,031.	\$94,031.
Medtronics Inc New Neural Therapy Studies: 2005-1				
Jennes, Lothar H	3046887300	\$0.	\$279,068.	\$279,068.
National Institute on Aging Neuroendocrine Mechanisms of Reproductive Aging				
Joseph, Jane E	3048103764	\$0.	\$59,294.	\$59,294.
Autism Speaks Exploring Functional Brain Connectivity for Visual Cognition in Autism Spectrum Disorder				
Stein, Pamela Ann	3048105402	\$2,400.	\$0.	\$2,400.
American Dental Education Association Muscles of Mastication Tutorial CD ROM				
Zhang, Zhiming	3048092900	\$0.	\$32,047.	\$32,047.
National Institute of Neurological Disorders & Stroke Relationship between BOLD Effects and DA Degeneration				
Zhang, Zhiming	3048092900	\$0.	\$288,422.	\$288,422.
National Institute of Neurological Disorders & Stroke Relationship between BOLD Effects and DA Degeneration				
Anatomy & Neurobiology	Totals:	\$1,759,095.	\$2,392,367.	\$4,151,462.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Anesthesiology</u>				
Holtman, Joseph R	3048104940	\$77,529.	\$0.	\$77,529.
Insys Therapeutics Inc Cannabinoid and Opioid Combination Therapy				
Holtman, Joseph R	3048104941	\$73,369.	\$0.	\$73,369.
Insys Therapeutics Inc Morphine-6-O-sulfate for Treatment of Pain				
Anesthesiology	Totals:	\$150,898.	\$0.	\$150,898.
<u>Emergency Medicine</u>				
Humphries, Roger L	3048087100	\$0.	\$1,998.	\$1,998.
MedImmune Inc An Epidemiological Study to Evaluate the Seasonality of Respiratory Syncytial Virus-Associated Lower Respiratory TRact Infections (LRI) or Apnea in Infants in the Emergency Department				
Humphries, Roger L	3048100900	\$0.	\$194,118.	\$194,118.
National Institute of Neurological Disorders & Stroke UK NETT Clinical Site hub				
Humphries, Roger L	3048104000	\$0.	\$352,330.	\$352,330.
University of Michigan UK NETT Clinical Hub Site				
Emergency Medicine	Totals:	\$0.	\$548,446.	\$548,446.
<u>Behavioral Science</u>				
Andrykowski, Michael A	3046794500	\$0.	\$128,411.	\$128,411.
National Cancer Institute Psychological and Behavioral Impact of Cancer Screening				
Andrykowski, Michael A	3046847000	\$0.	\$159,950.	\$159,950.
H Lee Moffitt Cancer Center and Research I Cognitive Behavioral Aspects of Cancer-Related Fatigue				
Andrykowski, Michael A	3048105422	\$149,516.	\$0.	\$149,516.
KY Lung Cancer Research Fund Disparities in Mental Health Outcomes Between Rural and Nonrural Lung Cancer Survivors				
Cole, Cynthia M	3048021500	\$0.	\$-9,631.	\$-9,631.
People Encouraging People Inc Evaluation of the Lee County People Encouraging People (PEP) Coalition				
Garrity, Thomas F	3048104974	\$275,539.	\$0.	\$275,539.
National Institute on Drug Abuse Research Training in Drug Abuse Behavior				
Kelly, Thomas H	3048103866	\$0.	\$52,763.	\$52,763.
National Institute on Drug Abuse Separate and Combined Effects of Progesterone and Triazolam in Healthy Women				
Knudsen, Hannah K	3048104382	\$0.	\$28,293.	\$28,293.
University of Georgia CTN Membership and Adoption of Innovative TX Practices				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Behavioral Science				
Knudsen, Hannah K	3048104713	\$0.	\$506,554.	\$506,554.
National Institute on Drug Abuse Smoking Cessation Practices in Community Tx Programs				
Knudsen, Hannah K	3048105288	\$115,584.	\$0.	\$115,584.
Robert Wood Johnson Foundation Barriers to the Adoption of Pharmacotherapies in Publicly Funded Substance Abuse Treatment: Policy Barriers and Access to Physicians				
Knudsen, Hannah K	3048105325	\$25,843.	\$0.	\$25,843.
University of Georgia Use of Evidence-Based Practices in Alcoholism Treatment				
Leukefeld, Carl G	3048077800	\$0.	\$251,656.	\$251,656.
National Center for Research Resources TRY-IT Translating Reserach to Youth through Information Technology				
Lile, Joshua	3046902300	\$0.	\$148,209.	\$148,209.
National Institute on Drug Abuse A Pharmacological Analysis of Delta 9-THC in Humans				
Lile, Joshua	3048105287	\$366,250.	\$0.	\$366,250.
National Institute on Drug Abuse GABA Drugs for Cannabis-Use Disorders: Initial Mechanistic Studies in Humans				
Rush, Craig R	3046956200	\$0.	\$340,325.	\$340,325.
National Institute on Drug Abuse Preventing Cocaine Relapse: Developing Pharmacotherapies				
Rush, Craig R	3048004600	\$0.	\$348,516.	\$348,516.
National Institute on Drug Abuse Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications				
Rush, Craig R	3048105279	\$329,625.	\$0.	\$329,625.
National Institute on Drug Abuse GABAA Modulation as a Target for Developing Medications for Methamphetamine Abuse				
Rush, Craig R	3048105510	\$366,250.	\$0.	\$366,250.
National Institute on Drug Abuse Agonist Replacement Therapy for Methamphetamine Dependence: Human Lab Studies				
Schoenberg, Nancy E	3048104728	\$0.	\$164,813.	\$164,813.
National Cancer Institute Increasing Colorectal Cancer Screening for Patients with Multiple Morbidities				
Schoenberg, Nancy E	3048104977	\$579,454.	\$0.	\$579,454.
National Center on Minority Health and Health Disparities Faith Moves Mountains: A CBPR Appalachian Wellness & Cancer Prevention Program				
Schoenberg, Nancy E	3048104977	\$0.	\$520,368.	\$520,368.
National Center on Minority Health and Health Disparities Faith Moves Mountains: A CBPR Appalachian Wellness & Cancer Prevention Program				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Behavioral Science</u>				
Schoenberg, Nancy E	3048105145	\$577,274.	\$0.	\$577,274.
National Institute Diabetes & Digestive & Kidney An Intergenerational CBPR Intervention to Reduce Appalachian Health Disparities				
Behavioral Science	Totals:	\$2,785,335.	\$2,640,227.	\$5,425,562.
<u>Graduate Center for Nutritional Sciences</u>				
Cassis, Lisa A	3048104794	\$21,000.	\$0.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship for Xuan Zhang: Androgen Regulation of the AT1a Receptor (AT1aR) in Angiotensin II-Induced Abdominal Aortic Aneurysms				
Cassis, Lisa A	3048104798	\$21,000.	\$0.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship for Manisha Gupte: ACE2 Expression in Adipocytes and Regulation in Obesity-Related Hypertension				
Cassis, Lisa A	3048105444	\$46,826.	\$0.	\$46,826.
National Heart Lung and Blood Institute Fellowship for Sean Thatcher: ACE2 in Hypercholesterolemia and Angiotensin II - Induced Vascular Diseases				
Glauert, Howard P	3048103660	\$0.	\$73,250.	\$73,250.
National Cancer Institute Prevention of Cigarette Smoke-Induced Lung Cancer by Dietary Selenium				
Glauert, Howard P	3048105533	\$160,868.	\$0.	\$160,868.
Institute for Science and Health Cigarette Smoke and Pancreatic Carcinogenesis				
Shao, Jianhua	3048103750	\$0.	\$197,500.	\$197,500.
American Diabetes Association Inc Transcriptional Regulation of Adiponectin Gene Expression				
Shao, Jianhua	3048104484	\$0.	\$263,700.	\$263,700.
National Institute Diabetes & Digestive & Kidney Adiponectin and Regulation of Triglyceride Metabolism				
Shao, Jianhua	3048104484	\$0.	\$29,300.	\$29,300.
National Institute Diabetes & Digestive & Kidney Adiponectin and Regulation of Triglyceride Metabolism				
St Clair, Daret K	3048104989	\$78,659.	\$0.	\$78,659.
National Institute Diabetes & Digestive & Kidney NRSA T32: Training Program in Oxidative Stress and Nutrition				
Wang, Shuxia	3048104980	\$110,000.	\$0.	\$110,000.
Juvenile Diabetes Research Foundation Increased PKG Activity Prevents the Development of Diabetic Nephropathy				
Graduate Center for Nutritional Sciences	Totals:	\$438,353.	\$563,750.	\$1,002,103.
<u>Molecular & Cellular Biochemistry</u>				
Chi, Young-In	3048104812	\$197,500.	\$0.	\$197,500.
American Diabetes Association Inc Structural Studies of HNF 1alpha and HNF 4alpha				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Molecular & Cellular Biochemistry</u>				
Chi, Young-In	3048104812	\$0.	\$-3,000.	\$-3,000.
American Diabetes Association Inc Structural Studies of HNF 1alpha and HNF 4alpha				
Chi, Young-In	3048104911	\$25,000.	\$0.	\$25,000.
KY Diabetes Research Trust Fund Identification of HNF and HNF4 Mediated Regulators of Insulin Secretion in Beta-Cells				
Creamer, Trevor P	3048105151	\$69,999.	\$0.	\$69,999.
KY Science and Technology Co Inc R&D Excellence: Using Calmodulin to Probe the Role of Intrinsic Disorder in Biomolecular Recognition				
Creamer, Trevor P	3048105437	\$159,035.	\$0.	\$159,035.
National Science Foundation Calmodulin Mediated Disorder-to-Order Transitions: Calcineurin as a Model System				
Dickson, Robert C	3048105149	\$366,250.	\$0.	\$366,250.
National Institute on Aging Characterization of the Sch9 Longevity Pathway in Yeast				
Dickson, Robert C	3048105541	\$300,325.	\$0.	\$300,325.
National Institute on Aging Characterization of the Sch9 Longevity Pathway in Yeast				
Dutch, Rebecca	3048103832	\$0.	\$215,575.	\$215,575.
National Institute of Allergy and Infectious Diseases HMPV Fusion Protein-host Cell Interactions				
Dutch, Rebecca	3048105529	\$296,166.	\$0.	\$296,166.
National Institute of Allergy and Infectious Diseases Paramyxovirus F protein mediated membrane fusion				
Dutch, Rebecca	3048105703	\$143,075.	\$0.	\$143,075.
SERCEB Foundation Cathepsin L Processing of the Henipavirus F Proteins				
Fried, Michael Gregory	3046889200	\$0.	\$247,257.	\$247,257.
National Institute of General Medical Sciences Cooperative Interactions in DNA Repair				
Gentry, Matthew Shawn	3048105237	\$232,725.	\$0.	\$232,725.
National Institute of Neurological Disorders & Stroke Novel Model Systems Link Floridean Starch Metabolism to Lafora Disease				
Hersh, Louis B	3048090500	\$0.	\$287,499.	\$287,499.
National Institute on Drug Abuse Degradation of Opioid Peptides				
Hersh, Louis B	3048104542	\$0.	\$50,000.	\$50,000.
Institute of the Study of Aging Inc Neprilysin and Peripheral Clearance of Amyloid Peptides				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Molecular & Cellular Biochemistry</u>				
Hersh, Louis B	3048104635	\$0.	\$45,676.	\$45,676.
KY Science and Technology Co Inc COMM FUND: Development of an enzyme-based treatment for Alzheimer's Disease				
Hersh, Louis B	3048104910	\$157,252.	\$0.	\$157,252.
National Institute on Drug Abuse NRSA T32: Training in Drug Abuse Related Research				
Hersh, Louis B	3048104925	\$77,442.	\$0.	\$77,442.
Alzheimers Association A Modified Neprilysin for Gene Therapy				
Hersh, Louis B	3048105053	\$2,003,172.	\$0.	\$2,003,172.
National Center for Research Resources Center of Biomedical Research Excellence in the Molecular Basis of Human Disease - Administrative Core				
Moncman, Carole	3048105265	\$219,750.	\$0.	\$219,750.
National Eye Institute Temporal and Spatial Patterns of Structural Proteins in Extraocular Muscles				
Murphy, Michael Paul	3048096300	\$0.	\$7,348.	\$7,348.
University of Southern California Progesterone in Brain Aging and Alzheimer's Disease				
Murphy, Michael Paul	3048104202	\$0.	\$288,422.	\$288,422.
National Institute of Neurological Disorders & Stroke Cellular Nucleic Acid Binding Protein (CNBP) in Aging and Disease				
Ozcan, Sabire	3046861800	\$0.	\$26,953.	\$26,953.
National Institute Diabetes & Digestive & Kidney Histone Acetylation and Insulin Gene Expression				
Ozcan, Sabire	3046861800	\$0.	\$242,585.	\$242,585.
National Institute Diabetes & Digestive & Kidney Histone Acetylation and Insulin Gene Expression				
Ozcan, Sabire	3048103415	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Megan Sampley: PDX-1 Regulates Insulin Biosynthesis by Interaction with Transcription and Translation				
Ozcan, Sabire	3048104718	\$47,000.	\$0.	\$47,000.
American Heart Association Great Rivers Affiliate Fellowship/Muniappan: Identification for miRNAs Regulated by Beta-Cell Transcription Factors				
Ozcan, Sabire	3048105534	\$172,500.	\$0.	\$172,500.
American Diabetes Association Inc Role of Histone Deacetylation and Protein Phosphatases in Insulin Gene Expression				
Rodgers, David W	3046504700	\$0.	-\$329,625.	-\$329,625.
National Institute of Neurological Disorders & Stroke Neuropeptidase Function				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Molecular & Cellular Biochemistry</u>				
Rodgers, David W	3048105045	\$329,625.	\$0.	\$329,625.
National Institute of Neurological Disorders & Stroke Neuropeptidase Function				
Spielmann, H Peter	3048104852	\$289,574.	\$0.	\$289,574.
National Institute of General Medical Sciences Synthetic Probes of Protein Prenylation				
Stamm, Stefan	3048104302	\$0.	\$32,713.	\$32,713.
University of Massachusetts Tau Missplicing Caused by RNA Processing Proteins Located on th Chromosome 21NIH				
Stamm, Stefan	3048105550	\$45,000.	\$0.	\$45,000.
Prader Willi Syndrome Association Role of snoRNAs in Prader-Willi Syndrome				
Tang, Xiaoqing	3048103834	\$0.	\$101,505.	\$101,505.
National Institute Diabetes & Digestive & Kidney Role of microRNAs in insulin production and secretion in pancreatic beta-cells				
Tang, Xiaoqing	3048103834	\$0.	\$1,080.	\$1,080.
National Institute Diabetes & Digestive & Kidney Role of microRNAs in insulin production and secretion in pancreatic beta-cells				
Turco, Salvatore J	3048105277	\$280,707.	\$0.	\$280,707.
Washington University Glycosylation Mutants of Leishmania				
Turco, Salvatore J	3048105277	\$0.	\$12,911.	\$12,911.
Washington University Glycosylation Mutants of Leishmania				
Waechter, Charles J	3046925500	\$0.	\$312,545.	\$312,545.
National Institute of General Medical Sciences Regulation of Protein N-Glycosylation in the CNS				
Whiteheart, Sidney W	3048104711	\$0.	\$256,375.	\$256,375.
National Heart Lung and Blood Institute The Platelet Secretory Machinery				
Zhu, Haining	3046809700	\$0.	\$73,250.	\$73,250.
National Institute of Neurological Disorders & Stroke Proteomic and Functional Studies of Mitochondria in ALS				
Zhu, Haining	3046809700	\$0.	\$253,622.	\$253,622.
National Institute of Neurological Disorders & Stroke Proteomic and Functional Studies of Mitochondria in ALS				
Zhu, Haining	3048105148	\$658,905.	\$0.	\$658,905.
US Army Medical Research and Materiel Command Biomarker Discovery and Mechanistic Studies of Prostate Cancer using Targeted Proteomic Approaches				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Molecular & Cellular Biochemistry</u>				
Zhu, Haining	3048105150	\$231,250.	\$0.	\$231,250.
National Institute on Aging Role of P62 in Protein Aggregation and Neurodegeneration in ALS				
Zhu, Haining	3048105538	\$34,275.	\$0.	\$34,275.
Brigham and Womens Hospital Fellowship for: Xiaohu Tang - Abrogating Interaction between Mutant SOD1 and Dynein: A Novel ALS Therapeutic Strategy				
Molecular & Cellular Biochemistry	Totals:	\$6,336,527.	\$2,143,691.	\$8,480,218.
<u>Internal Medicine</u>				
Ain, Kenneth B	3048093400	\$0.	\$1,886.	\$1,886.
AstraZeneca Pharmaceuticals An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
Ain, Kenneth B	3048093400	\$0.	\$1,834.	\$1,834.
AstraZeneca Pharmaceuticals An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
Ain, Kenneth B	3048093400	\$0.	\$1,834.	\$1,834.
AstraZeneca Pharmaceuticals An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
Ain, Kenneth B	3048093400	\$0.	\$1,860.	\$1,860.
AstraZeneca Pharmaceuticals An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
Ain, Kenneth B	3048104863	\$126,000.	\$0.	\$126,000.
National Cancer Institute Transcriptional Repression of Sodium Iodide Symporter in Thyroid Carcinoma				
Arnold, Susanne M	3046259800	\$0.	\$4,000.	\$4,000.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046259800	\$0.	\$6,000.	\$6,000.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046259800	\$0.	\$300.	\$300.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046259800	\$0.	\$2,000.	\$2,000.
Southwest Oncology Group Southwest Oncology Group Studies				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Arnold, Susanne M	3046259800	\$0.	\$-250.	\$-250.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046259800	\$0.	\$16,000.	\$16,000.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046259800	\$0.	\$150.	\$150.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046259800	\$0.	\$150.	\$150.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046259800	\$0.	\$50.	\$50.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046259800	\$0.	\$550.	\$550.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046828600	\$0.	\$-1,355.	\$-1,355.
Eli Lilly and Company A Randomized Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Lung Cancer				
Arnold, Susanne M	3046828600	\$0.	\$1,800.	\$1,800.
Eli Lilly and Company A Randomized Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Lung Cancer				
Arnold, Susanne M	3046976200	\$0.	\$27,333.	\$27,333.
Eli Lilly and Company A Phase One Trail of Gemcitavine and Paclitaxel (GEMTAX) Plus Low Dose Radiation in Patients with Recurrent Head and Neck Cancer				
Arnold, Susanne M	3048062300	\$0.	\$-5,424.	\$-5,424.
Eli Lilly and Company A Randomized Phase 3 Trail of Alimta (Pemetrexed) and Carboplatin vs Etoposide and Carboplatin in Extensive-stage Small Cell Lung Cancer				
Arnold, Susanne M	3048062300	\$0.	\$-1,800.	\$-1,800.
Eli Lilly and Company A Randomized Phase 3 Trail of Alimta (Pemetrexed) and Carboplatin vs Etoposide and Carboplatin in Extensive-stage Small Cell Lung Cancer				
Arnold, Susanne M	3048065800	\$0.	\$82,260.	\$82,260.
Arno Therapeutics Inc A Phase 1 Study of DB-67 (7-t-butylidimethylsilyl-10-hydroxycamptothecin) in Adult Patients with Refractory or Metastatic Solid Malignancies				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Arnold, Susanne M	3048065800	\$0.	\$68,850.	\$68,850.
Arno Therapeutics Inc A Phase 1 Study of DB-67 (7-t-butylidimethylsilyl-10-hydroxycamptothecin) in Adult Patients with Refractory or Metastatic Solid Malignancies				
Arnold, Susanne M	3048065800	\$0.	\$-2,000.	\$-2,000.
Arno Therapeutics Inc A Phase 1 Study of DB-67 (7-t-butylidimethylsilyl-10-hydroxycamptothecin) in Adult Patients with Refractory or Metastatic Solid Malignancies				
Arnold, Susanne M	3048076600	\$0.	\$2,682.	\$2,682.
AstraZeneca Pharmaceuticals A Phase III, International, RANdomized, Double-BLind, Parallel-Group, Multi-Center, Study to Assess the Efficacy of ZD6474 Versus Erlotinib (TARCEVA) in Patients with Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC)				
Arnold, Susanne M	3048076600	\$0.	\$7,352.	\$7,352.
AstraZeneca Pharmaceuticals A Phase III, International, RANdomized, Double-BLind, Parallel-Group, Multi-Center, Study to Assess the Efficacy of ZD6474 Versus Erlotinib (TARCEVA) in Patients with Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC)				
Arnold, Susanne M	3048104325	\$0.	\$6,248.	\$6,248.
AMGen A Randomized, Open Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First Line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer and Cross				
Arnold, Susanne M	3048104326	\$0.	\$435.	\$435.
AMGen A Phase 2, Single-Arm, Open Label, Multi-Center Trial of Panitumumab Monotherapy in Patients with Platinum Refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck				
Arnold, Susanne M	3048104326	\$0.	\$8,530.	\$8,530.
AMGen A Phase 2, Single-Arm, Open Label, Multi-Center Trial of Panitumumab Monotherapy in Patients with Platinum Refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck				
Arnold, Susanne M	3048104326	\$0.	\$3,503.	\$3,503.
AMGen A Phase 2, Single-Arm, Open Label, Multi-Center Trial of Panitumumab Monotherapy in Patients with Platinum Refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck				
Arnold, Susanne M	3048104326	\$0.	\$15,819.	\$15,819.
AMGen A Phase 2, Single-Arm, Open Label, Multi-Center Trial of Panitumumab Monotherapy in Patients with Platinum Refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck				
Arsenescu, Razvan I	3046847900	\$0.	\$15,933.	\$15,933.
Otsuka America Pharmaceutical Inc A Randomized, Prospective, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Ulcerative Colitis				
Arsenescu, Razvan I	3046964400	\$0.	\$6,474.	\$6,474.
Robarts Research Institute A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Arsenescu, Razvan I	3048061500	\$0.	\$11,277.	\$11,277.
Robarts Research Institute				
A Prospective, Open-Label Study to Evaluate the Adacolumn Aphersis System for the Treatment of Moderate to Severe Crohn's Disease				
Arsenescu, Razvan I	3048061500	\$0.	\$3,497.	\$3,497.
Robarts Research Institute				
A Prospective, Open-Label Study to Evaluate the Adacolumn Aphersis System for the Treatment of Moderate to Severe Crohn's Disease				
Arsenescu, Razvan I	3048061500	\$0.	\$5,834.	\$5,834.
Robarts Research Institute				
A Prospective, Open-Label Study to Evaluate the Adacolumn Aphersis System for the Treatment of Moderate to Severe Crohn's Disease				
Arsenescu, Razvan I	3048103221	\$0.	\$20,415.	\$20,415.
AstraZeneca Pharmaceuticals				
Role of Polymeric Immunoglobulin Receptor (pIgR) in the Pathogenesis of Crohn's Disease				
Arsenescu, Razvan I	3048104014	\$0.	\$5,562.	\$5,562.
Alba Therapeutics Corp				
A Phase IIb, randomized, double-blind, placebo controlled, dose ranging multicenter study to determine the safety, tolerance, and efficacy of AT-001 in celiac disease subjects during a gluten challenge				
Arsenescu, Razvan I	3048104014	\$0.	\$3,077.	\$3,077.
Alba Therapeutics Corp				
A Phase IIb, randomized, double-blind, placebo controlled, dose ranging multicenter study to determine the safety, tolerance, and efficacy of AT-001 in celiac disease subjects during a gluten challenge				
Arsenescu, Razvan I	3048104014	\$0.	\$13,500.	\$13,500.
Alba Therapeutics Corp				
A Phase IIb, randomized, double-blind, placebo controlled, dose ranging multicenter study to determine the safety, tolerance, and efficacy of AT-001 in celiac disease subjects during a gluten challenge				
Arsenescu, Razvan I	3048104014	\$0.	\$4,855.	\$4,855.
Alba Therapeutics Corp				
A Phase IIb, randomized, double-blind, placebo controlled, dose ranging multicenter study to determine the safety, tolerance, and efficacy of AT-001 in celiac disease subjects during a gluten challenge				
Arsenescu, Razvan I	3048104522	\$0.	\$1,481.	\$1,481.
Robarts Research Institute				
An observational prospective study to identify clinical, endoscopic and/or biological predictors that correlate with histopathologic findings in subjects with moderate to severe ulcerative colitis				
Arsenescu, Razvan I	3048104625	\$0.	\$1,000.	\$1,000.
Alba Therapeutics Corp				
A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease with AT-1001				
Arsenescu, Razvan I	3048104625	\$0.	\$4,676.	\$4,676.
Alba Therapeutics Corp				
A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease with AT-1001				
Arsenescu, Razvan I	3048104894	\$80,600.	\$0.	\$80,600.
UCB Pharma				
Role of Adiponectin in the Pathogenesis of Inflammatory Bowel Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Booth, David C	3046763700	\$0.	\$171.	\$171.
ENCYSIVE LP FPH02-X An Open-Label Study to Evaluate the Long-Term Safety of Sitaxsentan Sodium Treatment with a Bosentan Arm in Patients with Pulmonary Arterial Hypertension (STRIDE II-X)				
Booth, David C	3046763800	\$0.	\$-171.	\$-171.
ENCYSIVE LP admin by ResearchPoint A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension (STRIDE-III)				
Booth, David C	3046763800	\$0.	\$1,108.	\$1,108.
ENCYSIVE LP admin by ResearchPoint A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension (STRIDE-III)				
Booth, David C	3048012300	\$0.	\$1,089.	\$1,089.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
Booth, David C	3048012300	\$0.	\$1,890.	\$1,890.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
Booth, David C	3048012300	\$0.	\$3,780.	\$3,780.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
Booth, David C	3048012300	\$0.	\$1,089.	\$1,089.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
Booth, David C	3048012300	\$0.	\$4,725.	\$4,725.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
Booth, David C	3048012300	\$0.	\$1,890.	\$1,890.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
Booth, David C	3048012300	\$0.	\$1,890.	\$1,890.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Booth, David C	3048012300	\$0.	\$490.	\$490.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
Bruemmer, Dennis C	3046985800	\$0.	\$355,629.	\$355,629.
National Heart Lung and Blood Institute Role of the Nuclear Receptor Nor-1 in Atherosclerosis and Vascular Injury				
Bruemmer, Dennis C	3048103420	\$0.	\$44,000.	\$44,000.
American Heart Association Ohio Valley Affiliate Gizard Post-Doc Fellowship: Role of Telomerase in Macrophage Inflammation and Atherosclerosis				
Bruemmer, Dennis C	3048104987	\$21,000.	\$0.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship for Yue Zhao: The Regulation of Function of NOR1 in Endothelial Cells				
Bruemmer, Dennis C	3048105001	\$25,000.	\$0.	\$25,000.
KY Diabetes Research Trust Fund Telomeres in Obesity and Diabetes				
Bruemmer, Dennis C	3048105383	\$177,750.	\$0.	\$177,750.
American Diabetes Association Inc Telomere Attrition in Adipose Tissue Senescence and Insulin Resistance				
Bryson, James S	3048105378	\$150,000.	\$0.	\$150,000.
KY Lung Cancer Research Fund Allogeneic Immunotherapy of Lung Cancer				
Callahan, Leigh Ann	3048099900	\$0.	\$355,629.	\$355,629.
National Heart Lung and Blood Institute Oxidant Mediated Diaphragm Dysfunction in Diabetes				
Campbell, Charles L.	3046979000	\$0.	\$2,300.	\$2,300.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vyturin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$9,250.	\$9,250.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vyturin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$750.	\$750.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vyturin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$2,100.	\$2,100.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vyturin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$900.	\$900.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vyturin Efficacy International Trail				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Campbell, Charles L.	3046979000	\$0.	\$1,900.	\$1,900.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$5,250.	\$5,250.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$900.	\$900.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$800.	\$800.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
Campbell, Charles L.	3048010500	\$0.	\$3,250.	\$3,250.
Eli Lilly and Company A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel				
Campbell, Charles L.	3048103622	\$0.	\$2,000.	\$2,000.
AstraZeneca Pharmaceuticals Plato: A Randomized, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes				
Campbell, Charles L.	3048104421	\$0.	\$1,000.	\$1,000.
Scios Inc Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				
Campbell, Charles L.	3048104421	\$0.	\$2,250.	\$2,250.
Scios Inc Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				
Campbell, Charles L.	3048104421	\$0.	\$6,500.	\$6,500.
Scios Inc Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				
Campbell, Charles L.	3048104421	\$0.	\$2,000.	\$2,000.
Scios Inc Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				
Campbell, Charles L.	3048104421	\$0.	\$1,000.	\$1,000.
Scios Inc Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				
Campbell, Charles L.	3048104421	\$0.	\$3,000.	\$3,000.
Scios Inc Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Campbell, Charles L.	3048104421	\$0.	\$2,250.	\$2,250.
Scios Inc Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				
Campbell, Charles L.	3048104547	\$0.	\$1,500.	\$1,500.
Portola Pharmaceuticals Inc ERASE-MI: Early Rapid Reversal of Platelet Thrombosis with Intravenous PRT060128 before PCI to optimize Reperfusion in Acute MI				
Campbell, Charles L.	3048104547	\$0.	\$7,748.	\$7,748.
Portola Pharmaceuticals Inc ERASE-MI: Early Rapid Reversal of Platelet Thrombosis with Intravenous PRT060128 before PCI to optimize Reperfusion in Acute MI				
Cassis, Lisa A	3048105204	\$2,082,003.	\$0.	\$2,082,003.
National Center for Research Resources COBRE: Center of Research in Obesity and Cardiovascular Disease				
Caudill, Timothy S	3046875600	\$0.	\$2,925.	\$2,925.
AstraZeneca Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein				
Caudill, Timothy S	3046875600	\$0.	\$3,420.	\$3,420.
AstraZeneca Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein				
Chasen, Craig A	3046783200	\$0.	\$2,344.	\$2,344.
Novartis ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension):				
Chasen, Craig A	3046783200	\$0.	\$45.	\$45.
Novartis ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension):				
Chen-Izu, Ye	3048103817	\$0.	\$-643.	\$-643.
American Heart Association Ca ²⁺ and Calmodulin Signaling in the Cardiac Myocyte under Hypertensive Stress				
Crofford, Leslie J	3046988500	\$0.	\$34,419.	\$34,419.
University of Pittsburgh Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and				
Crofford, Leslie J	3048103683	\$0.	\$70,653.	\$70,653.
University of Cincinnati Development of a Fibromyalgia Responder Index				
Crofford, Leslie J	3048104953	\$0.	\$14,998.	\$14,998.
Psychiatric Professional Services Inc Development and Testing of a Fibromyalgia Diagnostic Screening Instrument for Primary Care				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Crofford, Leslie J	3048104953	\$2.	\$0.	\$2.
Psychiatric Professional Services Inc Development and Testing of a Fibromyalgia Diagnostic Screening Instrument for Primary Care				
Crofford, Leslie J	3048105027	\$0.	\$4,998.	\$4,998.
Boehringer Ingelheim A Randomized, Double-Blind, Placebo-Controlled, Dose Titration, Efficacy & Safety Study of Pramipexole ER (0.75 mg to 4.5 mg) Administered Orally Once Daily Versus Placebo Over a 16-week Maintenance Phase in Patients				
Crofford, Leslie J	3048105027	\$2.	\$0.	\$2.
Boehringer Ingelheim A Randomized, Double-Blind, Placebo-Controlled, Dose Titration, Efficacy & Safety Study of Pramipexole ER (0.75 mg to 4.5 mg) Administered Orally Once Daily Versus Placebo Over a 16-week Maintenance Phase in Patients				
Daugherty, Alan	3046989400	\$0.	\$1.	\$1.
National Heart Lung and Blood Institute Mechanisms of Abdominal Aortic Aneurysm Formation				
Daugherty, Alan	3046989400	\$0.	\$1,686,306.	\$1,686,306.
National Heart Lung and Blood Institute Mechanisms of Abdominal Aortic Aneurysm Formation				
Daugherty, Alan	3048012400	\$0.	\$83,733.	\$83,733.
James Cook University Osteoprotegerin and osteopontin in aortic aneuysm				
Daugherty, Alan	3048104603	\$0.	\$23,440.	\$23,440.
University of Virginia G2A Receptor in Atherosclerosis				
Daugherty, Alan	3048104738	\$0.	\$55,000.	\$55,000.
University of Virginia ABCG1 Function in Diabetes				
Daugherty, Alan	3048104843	\$232,701.	\$0.	\$232,701.
Novartis Comparitive Efficacy of Selected Modes of Inhibiting the Renin Angiotensin System on the Development of Hypercholesterolemia-Induced Atherosclerosis				
Daugherty, Alan	3048104844	\$166,419.	\$0.	\$166,419.
Novartis The Efficacy of Renin Inhibition on Progression and Regression of Hypercholesterolemia-Induced Atherosclerosis				
Daugherty, Alan	3048104960	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship for Venkateswaran Subramanian: Role of peroxisome proliferator activated receptor gamma in angiotensin II induced abdominal aortic aneurysm				
Daugherty, Alan	3048105369	\$366,250.	\$0.	\$366,250.
National Heart Lung and Blood Institute Sources and Effects of Angiotensin Peptides in Atherosclerosis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Daugherty, Alan	3048105539	\$50,463.	\$0.	\$50,463.
Johnson and Johnson Determine the Effect of Compounds on Development of Abdominal Aortic Aneurysms in LDL Receptor Knockout Mice				
De Villiers, Willem	3046569500	\$0.	\$3,226.	\$3,226.
Centocor Inc A Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate and Efficacy of Infliximab in Patients with Active Ulcerative Colitis				
De Villiers, Willem	3046828400	\$0.	\$900.	\$900.
Centocor Inc Remicade Safety Under Long Term Study in Ulcerative Colitis (RESULTS-UC)				
De Villiers, Willem	3046864500	\$0.	\$672.	\$672.
Abbott Laboratories Multi-Center Open Labeled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease				
De Villiers, Willem	3046978300	\$0.	\$2,700.	\$2,700.
PDL BioPharma Inc Visilizumab				
De Villiers, Willem	3046978300	\$0.	\$3,660.	\$3,660.
PDL BioPharma Inc Visilizumab				
De Villiers, Willem	3048054200	\$0.	\$5,445.	\$5,445.
Ocera Therapeutics Inc A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Mild to Moderately Active Crohn's Patients with Fistulas				
De Villiers, Willem	3048066700	\$0.	\$1,170.	\$1,170.
Procter & Gamble Company A Double-Blind, Randomized, 6-week, Parallel-Group Clinical Trial to Assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg Mesalamine Tablet) Versus Asacol 2.4 g/day (400 mg Mesalamine Tablet) for the Treatment of Moderately Active Ulcerative Colitis				
De Villiers, Willem	3048073100	\$0.	\$-13,500.	\$-13,500.
Salix Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Actively Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium 3.3g Bid vs. Mesalamine (5-ASA) As Asacol 0.8 G Tid ub Mildly to				
De Villiers, Willem	3048103743	\$0.	\$3,613.	\$3,613.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103743	\$0.	\$12,854.	\$12,854.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103743	\$0.	\$556.	\$556.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
De Villiers, Willem	3048103743	\$0.	\$6,590.	\$6,590.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103743	\$0.	\$9,047.	\$9,047.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103743	\$0.	\$4,919.	\$4,919.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103743	\$0.	\$6,397.	\$6,397.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103743	\$0.	\$556.	\$556.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103744	\$0.	\$2,695.	\$2,695.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$1,980.	\$1,980.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$641.	\$641.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$2,495.	\$2,495.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$5,391.	\$5,391.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$1,955.	\$1,955.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$1,856.	\$1,856.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$3,737.	\$3,737.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
De Villiers, Willem	3048103744	\$0.	\$-3,737.	\$-3,737.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048104103	\$0.	\$13,906.	\$13,906.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
De Villiers, Willem	3048104103	\$0.	\$1,903.	\$1,903.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
De Villiers, Willem	3048104103	\$0.	\$6,905.	\$6,905.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
De Villiers, Willem	3048104254	\$0.	\$1,893.	\$1,893.
Quintiles Inc A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
De Villiers, Willem	3048104255	\$0.	\$833.	\$833.
Quintiles Inc A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
De Villiers, Willem	3048104255	\$0.	\$1,257.	\$1,257.
Quintiles Inc A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
De Villiers, Willem	3048104557	\$0.	\$9,950.	\$9,950.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
De Villiers, Willem	3048104557	\$0.	\$5,646.	\$5,646.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
De Villiers, Willem	3048104557	\$0.	\$32,497.	\$32,497.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
De Villiers, Willem	3048104557	\$0.	\$25,250.	\$25,250.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
De Villiers, Willem	3048104557	\$0.	\$17,443.	\$17,443.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
De Villiers, Willem	3048104557	\$0.	\$35,849.	\$35,849.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
De Villiers, Willem	3048104557	\$0.	\$7,200.	\$7,200.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
De Villiers, Willem	3048105249	\$2.	\$0.	\$2.
Genentech Inc A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous rhuMAb Beta 7				
De Villiers, Willem	3048105249	\$0.	\$9,998.	\$9,998.
Genentech Inc A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous rhuMAb Beta 7				
De Villiers, Willem	3048105468	\$0.	\$2,498.	\$2,498.
Quintiles Inc A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter, Multiple Dose Study for the Induction and Maintenance of Clinical Response and Remission with MLN0002 in Patients with Moderate to Severe Ulcerative Colitis				
De Villiers, Willem	3048105468	\$2.	\$0.	\$2.
Quintiles Inc A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter, Multiple Dose Study for the Induction and Maintenance of Clinical Response and Remission with MLN0002 in Patients with Moderate to Severe Ulcerative Colitis				
De Villiers, Willem	3048105469	\$2.	\$0.	\$2.
Quintiles Inc A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission with MLN0002 in Patients with Moderate to Severe Crohn's Disease				
De Villiers, Willem	3048105469	\$0.	\$2,498.	\$2,498.
Quintiles Inc A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission with MLN0002 in Patients with Moderate to Severe Crohn's Disease				
De Villiers, Willem	3048105470	\$2.	\$0.	\$2.
Quintiles Inc A Phase 3, Open-Label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
De Villiers, Willem	3048105470	\$0.	\$2,498.	\$2,498.
Quintiles Inc A Phase 3, Open-Label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease				
De Villiers, Willem	3048105649	\$2.	\$0.	\$2.
Centocor Inc Ustekinumab Therapy in Subjects with ... Crohn's Disease Previously Treated with TNF Antagonist Therapy (C0743T26)				
De Villiers, Willem	3048105688	\$0.	\$8,264.	\$8,264.
Elan Pharmaceuticals PLC A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-A Therapy				
De Villiers, Willem	3048105688	\$2.	\$0.	\$2.
Elan Pharmaceuticals PLC A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-A Therapy				
Desimone, Philip A	3046777200	\$0.	\$1,349.	\$1,349.
Hoffmann La Roche Inc A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") with/without Intravenous Bevacizumab (Q3W) versus Bolus and Continuous Infusion				
Desimone, Philip A	3048004400	\$0.	\$496.	\$496.
Roche Laboratories A Randomized Study of Intermittent Capcitabine in Combination with Oxaliplatin (XELOOX Q3W) and Bevacizumab vs Intermittent Capcitabine in Combinations with Oxaliplatin (XELOX Q2W) and Bevacizumab as First-Line Treatment for Patients				
Dignan, Mark B	3046909700	\$0.	\$384,756.	\$384,756.
National Cancer Institute Increasing Colorectal Cancer Screening in Rural Kentucky				
Dignan, Mark B	3046909700	\$0.	\$42,752.	\$42,752.
National Cancer Institute Increasing Colorectal Cancer Screening in Rural Kentucky				
Dignan, Mark B	3048103542	\$0.	\$443,742.	\$443,742.
National Cancer Institute Patient Navigation for Cervical Cancer in Appalachia				
Dignan, Mark B	3048104633	\$0.	\$80,421.	\$80,421.
National Cancer Institute Appalachia Community Cancer Network				
Dignan, Mark B	3048104633	\$0.	\$82,500.	\$82,500.
National Cancer Institute Appalachia Community Cancer Network				
Dignan, Mark B	3048105070	\$395,643.	\$0.	\$395,643.
National Cancer Institute Kentucky Cancer Prevention and Control Training Program				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Dignan, Mark B	3048105196	\$857,342.	\$0.	\$857,342.
Center for Disease Control and Prevention Kentucky Prevention Research Center				
Dignan, Mark B	3048105691	\$1,220,765.	\$0.	\$1,220,765.
National Cancer Institute Appalachia Community Cancer Network				
Doherty, Dennis E	3046623400	\$0.	\$350.	\$350.
Boehringer Ingelheim A Randomized Double-Blind, Placebo-Blind, Placebo-Controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function with Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD)				
Doherty, Dennis E	3048024400	\$0.	\$2,495.	\$2,495.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				
Doherty, Dennis E	3048024400	\$0.	\$2,993.	\$2,993.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				
Doherty, Dennis E	3048024400	\$0.	\$1,355.	\$1,355.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				
Doherty, Dennis E	3048024400	\$0.	\$2,646.	\$2,646.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				
Doherty, Dennis E	3048024400	\$0.	\$5,116.	\$5,116.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				
Doherty, Dennis E	3048024400	\$0.	\$2,708.	\$2,708.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				
Doherty, Dennis E	3048072200	\$0.	\$8,820.	\$8,820.
Ohio State University Long-Term Oxygen Treatment (LOTT) Trail				
Doherty, Dennis E	3048072200	\$0.	\$24,509.	\$24,509.
Ohio State University Long-Term Oxygen Treatment (LOTT) Trail				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Doherty, Dennis E	3048103685	\$0.	\$3,542.	\$3,542.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
Doherty, Dennis E	3048103685	\$0.	\$7,056.	\$7,056.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
Doherty, Dennis E	3048103685	\$0.	\$1,310.	\$1,310.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
Doherty, Dennis E	3048103685	\$0.	\$4,889.	\$4,889.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
Doherty, Dennis E	3048103685	\$0.	\$907.	\$907.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
Doherty, Dennis E	3048104260	\$0.	\$1,850.	\$1,850.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
Doherty, Dennis E	3048104260	\$0.	\$1,100.	\$1,100.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
Doherty, Dennis E	3048104260	\$0.	\$1,915.	\$1,915.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
Doherty, Dennis E	3048104260	\$0.	\$5,800.	\$5,800.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
Doherty, Dennis E	3048104260	\$0.	\$428.	\$428.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Doherty, Dennis E	3048104260	\$0.	\$7,943.	\$7,943.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
Doherty, Dennis E	3048104260	\$0.	\$9,290.	\$9,290.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
Doherty, Dennis E	3048104892	\$0.	\$599.	\$599.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048104892	\$0.	\$9,511.	\$9,511.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048104892	\$0.	\$1,953.	\$1,953.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048104892	\$0.	\$2,300.	\$2,300.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048104892	\$2.	\$0.	\$2.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048104892	\$0.	\$1,700.	\$1,700.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048104892	\$0.	\$2,524.	\$2,524.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048104892	\$0.	\$630.	\$630.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048105290	\$0.	\$6,293.	\$6,293.
Merck and Company Inc A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions of MK-0633 in Patients with COPD				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Doherty, Dennis E	3048105290	\$2.	\$0.	\$2.
Merck and Company Inc A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions of MK-0633 in Patients with COPD				
Doherty, Dennis E	3048105652	\$2.	\$0.	\$2.
Boehringer Ingelheim A Phase III Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution				
Fleischman, Roger A	3048095800	\$0.	\$23,774.	\$23,774.
Eli Lilly and Company PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
Fleischman, Roger A	3048095800	\$0.	\$100.	\$100.
Eli Lilly and Company PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
Fleischman, Roger A	3048095800	\$0.	\$8,534.	\$8,534.
Eli Lilly and Company PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
Fleischman, Roger A	3048095800	\$0.	\$200.	\$200.
Eli Lilly and Company PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
Fleischman, Roger A	3048095800	\$0.	\$4,928.	\$4,928.
Eli Lilly and Company PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
Fleischman, Roger A	3048095800	\$0.	\$200.	\$200.
Eli Lilly and Company PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
Fleischman, Roger A	3048095800	\$0.	\$5,000.	\$5,000.
Eli Lilly and Company PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
Fleischman, Roger A	3048103811	\$0.	\$13,558.	\$13,558.
Celgene A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid) in Combination with Dexamethasone in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma				
Fleischman, Roger A	3048104624	\$0.	\$1,500.	\$1,500.
Wyeth Pharmaceuticals Inc An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination with Rituximab Compared to a Defined Investigator's Choice Therapy in Subjects with Relapsed or Refractory, CD22- Positive, Follicular B-Cell				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Greenberg, Richard N	3046535000	\$0.	\$590.	\$590.
Bristol Myers Squibb Company Study of the Antiviral Efficacy and Safety of Atazanavir in Combination with Ritonavir or Saquinavir and the Combination of Lopinavir/Ritonavir Each With Tenofovir and Nucleoside in Subjects who Have Experienced Virologic Failure				
Greenberg, Richard N	3046665500	\$0.	\$444.	\$444.
Boehringer Ingelheim Randomized,Open-Label,Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (Resist 1:)				
Greenberg, Richard N	3046665500	\$0.	\$4,687.	\$4,687.
Boehringer Ingelheim Randomized,Open-Label,Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (Resist 1:)				
Greenberg, Richard N	3046665500	\$0.	\$1,280.	\$1,280.
Boehringer Ingelheim Randomized,Open-Label,Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (Resist 1:)				
Greenberg, Richard N	3046811300	\$0.	\$-4,360.	\$-4,360.
Tibotec Pharmaceuticals Ltd A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125M, in HIV-1 Infected Subjects with Documented Geotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations.				
Greenberg, Richard N	3046811300	\$0.	\$4,360.	\$4,360.
Tibotec Pharmaceuticals Ltd A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125M, in HIV-1 Infected Subjects with Documented Geotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations.				
Greenberg, Richard N	3046865800	\$0.	\$400.	\$400.
Bristol Myers Squibb Company Phase IV, Multicenter Cross-Sectional Study to Evaluate the I50L Substitution among subjects Experiencing Virologic Failure on a HART regimen containing Atazanavir (ATV)				
Greenberg, Richard N	3046865800	\$0.	\$150.	\$150.
Bristol Myers Squibb Company Phase IV, Multicenter Cross-Sectional Study to Evaluate the I50L Substitution among subjects Experiencing Virologic Failure on a HART regimen containing Atazanavir (ATV)				
Greenberg, Richard N	3046865800	\$0.	\$687.	\$687.
Bristol Myers Squibb Company Phase IV, Multicenter Cross-Sectional Study to Evaluate the I50L Substitution among subjects Experiencing Virologic Failure on a HART regimen containing Atazanavir (ATV)				
Greenberg, Richard N	3046865800	\$0.	\$350.	\$350.
Bristol Myers Squibb Company Phase IV, Multicenter Cross-Sectional Study to Evaluate the I50L Substitution among subjects Experiencing Virologic Failure on a HART regimen containing Atazanavir (ATV)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Greenberg, Richard N	3046865800	\$0.	\$-687.	\$-687.
Bristol Myers Squibb Company Phase IV, Multicenter Cross-Sectional Study to Evaluate the I50L Substitution among subjects Experiencing Virologic Failure on a HART regimen containing Atazanavir (ATV)				
Greenberg, Richard N	3046946700	\$0.	\$15,553.	\$15,553.
GlaxoSmithKline 96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
Greenberg, Richard N	3046946700	\$0.	\$1,484.	\$1,484.
GlaxoSmithKline 96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
Greenberg, Richard N	3046946700	\$0.	\$1,152.	\$1,152.
GlaxoSmithKline 96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
Greenberg, Richard N	3046955000	\$0.	\$36,424.	\$36,424.
Bavarian Nordic A Multicenter, Open-Label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN Smallpox Vaccine in HIV Infected Subjects (CD4 counts > 350 /ul) and Healthy Subjects with and without Previous Smallpox Vaccination				
Greenberg, Richard N	3046975000	\$0.	\$-4,360.	\$-4,360.
PPD Development Inc An Open-Label Trail with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				
Greenberg, Richard N	3046975000	\$0.	\$4,360.	\$4,360.
PPD Development Inc An Open-Label Trail with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				
Greenberg, Richard N	3046975000	\$0.	\$4,334.	\$4,334.
PPD Development Inc An Open-Label Trail with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				
Greenberg, Richard N	3046975000	\$0.	\$11,265.	\$11,265.
PPD Development Inc An Open-Label Trail with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				
Greenberg, Richard N	3046978600	\$0.	\$108,551.	\$108,551.
Origin Pharmaceutical Services Ltd Randomized, Double-Blind, Placebo-Controlled Phase II Trial of the Safety, Tolerability and Immunology of Lyophilized Chimerivax TM-WN02 West Nile Vaccine in Healthy Adults; Safety and Effectiveness of West Nile Vaccine in Healthy Adults				
Greenberg, Richard N	3048061700	\$0.	\$1,763.	\$1,763.
Tibotec Pharmaceuticals Ltd A Phase II randomized, double-blinded, placebo controlled trial to investigate the efficacy, tolerability and safety of TMC 125 as part of				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Greenberg, Richard N	3048061700	\$0.	\$384.	\$384.
Tibotec Pharmaceuticals Ltd A Phase II randomized, double-blinded, placebo controlled trial to investigate the efficacy, tolerability and safety of TMC 125 as part of				
Greenberg, Richard N	3048073000	\$0.	\$4,523.	\$4,523.
Bavarian Nordic A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis				
Greenberg, Richard N	3048073000	\$0.	\$12,073.	\$12,073.
Bavarian Nordic A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis				
Greenberg, Richard N	3048073000	\$0.	\$3,756.	\$3,756.
Bavarian Nordic A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis				
Greenberg, Richard N	3048073000	\$0.	\$23,871.	\$23,871.
Bavarian Nordic A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis				
Greenberg, Richard N	3048075800	\$0.	\$67.	\$67.
GlaxoSmithKline A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B5701) in subjects with and without Hypersensitivity to Abacavir				
Greenberg, Richard N	3048103306	\$0.	\$1,121.	\$1,121.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,708.	\$1,708.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,493.	\$1,493.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,572.	\$1,572.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Greenberg, Richard N	3048103306	\$0.	\$1,090.	\$1,090.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,437.	\$1,437.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,408.	\$1,408.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,090.	\$1,090.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,090.	\$1,090.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,635.	\$1,635.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,209.	\$1,209.
GlaxoSmithKline Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103895	\$0.	\$11,159.	\$11,159.
University of Massachusetts A Phase II Randomized, Double-Blind, Placebo Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium difficile Toxin A [GS-CDA1] and a Human Monoclonal Antibody to				
Greenberg, Richard N	3048104321	\$0.	\$25,024.	\$25,024.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				
Greenberg, Richard N	3048104321	\$0.	\$19,108.	\$19,108.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Greenberg, Richard N	3048104321	\$0.	\$19,117.	\$19,117.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				
Greenberg, Richard N	3048104321	\$0.	\$11,529.	\$11,529.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				
Greenberg, Richard N	3048104349	\$0.	\$18,873.	\$18,873.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified, Double-Blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months				
Greenberg, Richard N	3048104349	\$0.	\$17,798.	\$17,798.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified, Double-Blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months				
Greenberg, Richard N	3048104641	\$0.	\$-2,000.	\$-2,000.
Boehringer Ingelheim A randomized, double-blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapine with Truvada				
Greenberg, Richard N	3048104641	\$0.	\$4,998.	\$4,998.
Boehringer Ingelheim A randomized, double-blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapine with Truvada				
Greenberg, Richard N	3048104861	\$2.	\$0.	\$2.
Pfizer Inc An International, Multi-Center, Prospective, Observational Study of the Safety of Maraviroc Used With Optimized Background Therapy in Treatment Experienced HIV 1 Infected Patients				
Greenberg, Richard N	3048105117	\$0.	\$2,655.	\$2,655.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				
Greenberg, Richard N	3048105117	\$0.	\$2,591.	\$2,591.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				
Greenberg, Richard N	3048105117	\$0.	\$-2,000.	\$-2,000.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Greenberg, Richard N	3048105117	\$0.	\$757.	\$757.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				
Greenberg, Richard N	3048105117	\$0.	\$878.	\$878.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				
Greenberg, Richard N	3048105117	\$0.	\$2,498.	\$2,498.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				
Greenberg, Richard N	3048105117	\$2.	\$0.	\$2.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				
Greenberg, Richard N	3048105289	\$2.	\$0.	\$2.
Gilead Sciences Inc A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered with a Background Regimen in HIV-1				
Greenberg, Richard N	3048105289	\$0.	\$2,498.	\$2,498.
Gilead Sciences Inc A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered with a Background Regimen in HIV-1				
Guo, Zhenheng	3048104531	\$0.	\$366,250.	\$366,250.
National Heart Lung and Blood Institute A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases				
Guo, Zhenheng	3048104909	\$25,000.	\$0.	\$25,000.
KY Diabetes Research Trust Fund A Novel Mechanism by which Type 2 Diabetes Promotes Restenosis				
Gurley, John C	3046640500	\$0.	\$1,035.	\$1,035.
Medtronic Inc Insync Registry: Insync Post Market Registry Cardiac Resynchronization Therapy				
Gurley, John C	3046640500	\$0.	\$250.	\$250.
Medtronic Inc Insync Registry: Insync Post Market Registry Cardiac Resynchronization Therapy				
Gurley, John C	3046640500	\$0.	\$250.	\$250.
Medtronic Inc Insync Registry: Insync Post Market Registry Cardiac Resynchronization Therapy				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Gurley, John C	3046857600	\$0.	\$7,008.	\$7,008.
Atritech Inc WATCHMEN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation (Protect AF)				
Gurley, John C	3046857600	\$0.	\$5,618.	\$5,618.
Atritech Inc WATCHMEN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation (Protect AF)				
Gurley, John C	3048034600	\$0.	\$8,821.	\$8,821.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$900.	\$900.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$7,383.	\$7,383.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$2,654.	\$2,654.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$7,993.	\$7,993.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$21,194.	\$21,194.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$57.	\$57.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$5,065.	\$5,065.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$6,041.	\$6,041.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$7,879.	\$7,879.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Gurley, John C	3048034600	\$0.	\$20,869.	\$20,869.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$10,563.	\$10,563.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048105525	\$0.	\$1,998.	\$1,998.
AGA Medical Co Closure of Atrial Septal Defects with the Amplatzer Septal Occluder - Post Market Study II (ASD PMS II)				
Gurley, John C	3048105525	\$2.	\$0.	\$2.
AGA Medical Co Closure of Atrial Septal Defects with the Amplatzer Septal Occluder - Post Market Study II (ASD PMS II)				
Hamdalla, Hussam Nader	3048104582	\$0.	\$7,600.	\$7,600.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
Hamdalla, Hussam Nader	3048104582	\$0.	\$5,600.	\$5,600.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
Hamdalla, Hussam Nader	3048104582	\$0.	\$3,498.	\$3,498.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
Hamdalla, Hussam Nader	3048104582	\$0.	\$2,800.	\$2,800.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
Hamdalla, Hussam Nader	3048104582	\$0.	\$6,000.	\$6,000.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
Hamdalla, Hussam Nader	3048104582	\$0.	\$800.	\$800.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
Hamdalla, Hussam Nader	3048104582	\$0.	\$5,600.	\$5,600.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
Hamdalla, Hussam Nader	3048104582	\$0.	\$1,000.	\$1,000.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Hayslip, John	3048104985	\$0.	\$10,628.	\$10,628.
Celgene A Phase 2, Open label trial to evaluate the Efficacy and Safety of MGCD0103 Administered in Combination with Vidaza to subjects with Relapsed or Refractory Hodgkins or non-Hodgkin Lymphoma and to evaluate different formulations of MGCD0103				
Hayslip, John	3048104985	\$2.	\$0.	\$2.
Celgene A Phase 2, Open label trial to evaluate the Efficacy and Safety of MGCD0103 Administered in Combination with Vidaza to subjects with Relapsed or Refractory Hodgkins or non-Hodgkin Lymphoma and to evaluate different formulations of MGCD0103				
Hayslip, John	3048104995	\$0.	\$93,969.	\$93,969.
Cephalon Inc Frontline Treatment with Bendamustine in Combination with Rituximab in Adults Age 65 or Older with Chronic Lymphocytic Leukemia: A Phase II Study				
Hayslip, John	3048104995	\$2.	\$0.	\$2.
Cephalon Inc Frontline Treatment with Bendamustine in Combination with Rituximab in Adults Age 65 or Older with Chronic Lymphocytic Leukemia: A Phase II Study				
Hayslip, John	3048105235	\$0.	\$2,000.	\$2,000.
Celgene Azacitidine with Rituximab, Vincristine, and Cyclophosphamide in Refractory Follicular Lymphoma: A Phase I Trial				
Hayslip, John	3048105235	\$0.	\$15,695.	\$15,695.
Celgene Azacitidine with Rituximab, Vincristine, and Cyclophosphamide in Refractory Follicular Lymphoma: A Phase I Trial				
Hayslip, John	3048105235	\$2.	\$0.	\$2.
Celgene Azacitidine with Rituximab, Vincristine, and Cyclophosphamide in Refractory Follicular Lymphoma: A Phase I Trial				
Hirschowitz, Edward A	3048100100	\$0.	\$25,637.	\$25,637.
National Cancer Institute Autoantibodies in NSCLC as Markers of Disease				
Hirschowitz, Edward A	3048100100	\$0.	\$230,738.	\$230,738.
National Cancer Institute Autoantibodies in NSCLC as Markers of Disease				
Howard, Dianna S	3046762000	\$0.	\$34,248.	\$34,248.
New Millenium Pharmaceutical Research Institute A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin For the Treatment of Elderly (>60 Years) and Relapsed Patients with Acute Myelogenous Leukemia				
Howard, Dianna S	3046946600	\$0.	\$1,530.	\$1,530.
Johnson and Johnson Randomized, Controlled Study of DOXCIL/CAELYX and VELCADE or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Howard, Dianna S	3048037800	\$0.	\$675.	\$675.
Genzyme Corp 06-LEUK-GZ (CLO341000405): A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients>60 years old with Acute Myelogenous Leukemia (AML) who Have Relapsed or are Refractory after				
Howard, Dianna S	3048037800	\$0.	\$550.	\$550.
Genzyme Corp 06-LEUK-GZ (CLO341000405): A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients>60 years old with Acute Myelogenous Leukemia (AML) who Have Relapsed or are Refractory after				
Howard, Dianna S	3048037800	\$0.	\$2,636.	\$2,636.
Genzyme Corp 06-LEUK-GZ (CLO341000405): A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients>60 years old with Acute Myelogenous Leukemia (AML) who Have Relapsed or are Refractory after				
Howard, Dianna S	3048103404	\$0.	\$4,110.	\$4,110.
ViroPharma Inc A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants				
Howard, Dianna S	3048103404	\$0.	\$3,818.	\$3,818.
ViroPharma Inc A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants				
Howard, Dianna S	3048103404	\$0.	\$-6,095.	\$-6,095.
ViroPharma Inc A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants				
Howard, Dianna S	3048104472	\$0.	\$7,998.	\$7,998.
Pfizer Inc A prospective, randomized trial comparing the efficacy of anidulafungin and voriconazole in combination to that of voriconazole alone when used for primary therapy of proven or probable invasive aspergillosis				
Howard, Dianna S	3048104581	\$0.	\$-7,412.	\$-7,412.
i3 Research A Randomized, Blinded, Multicenter Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA-51 VG Adjuvant and Administered with GM-CSF in Elderly Patients with AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study				
Howard, Dianna S	3048104581	\$0.	\$950.	\$950.
i3 Research A Randomized, Blinded, Multicenter Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA-51 VG Adjuvant and Administered with GM-CSF in Elderly Patients with AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study				
Howard, Dianna S	3048104581	\$0.	\$15,040.	\$15,040.
i3 Research A Randomized, Blinded, Multicenter Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA-51 VG Adjuvant and Administered with GM-CSF in Elderly Patients with AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Karounos, Dennis G	3046861000	\$0.	\$1,085.	\$1,085.
George Washington University Natural History of the Development of Type 1 Diabetes				
Karounos, Dennis G	3046861000	\$0.	\$2,835.	\$2,835.
George Washington University Natural History of the Development of Type 1 Diabetes				
Karounos, Dennis G	3048103618	\$0.	\$98,783.	\$98,783.
American Diabetes Association Inc Mechanisms of preventing type 1 diabetes with inactive insulin				
Karounos, Dennis G	3048105225	\$2.	\$0.	\$2.
TKL Research Inc A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes Mellitus				
Karounos, Dennis G	3048105238	\$2.	\$0.	\$2.
Osiris Therapeutics Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Prochymal (ex vivo cultured adult human mesenchymal stem cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)				
Karounos, Dennis G	3048105238	\$0.	\$15,243.	\$15,243.
Osiris Therapeutics Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Prochymal (ex vivo cultured adult human mesenchymal stem cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)				
Karounos, Dennis G	3048105358	\$2.	\$0.	\$2.
Spherix Inc The Effects of Naturlose (Tagatose) on Glycemic Control and Safety of Naturlose Over One Year in Subjects with Type 2 Diabetes Under Diet Control and Exercise				
Karounos, Dennis G	3048105358	\$0.	\$2,548.	\$2,548.
Spherix Inc The Effects of Naturlose (Tagatose) on Glycemic Control and Safety of Naturlose Over One Year in Subjects with Type 2 Diabetes Under Diet Control and Exercise				
Kee, Bryan K	3048104993	\$2.	\$0.	\$2.
Amplimed Corp A Phase 2 Randomized, Double-Blind, Multicenter Trial with Amplimexon plus Gemcitabine versus Gemcitabine plus Placebo in Subjects with Metastatic Chemotherapy Naive Pancreatic Adenocarcinoma (Stage IV)				
Kern, Philip A.	3048105680	\$396,038.	\$0.	\$396,038.
National Institute Diabetes & Digestive & Kidney Effects of Fish Oil on Inflammation and Metabolic Syndrome				
King, Victoria L	3048104393	\$0.	\$366,250.	\$366,250.
National Heart Lung and Blood Institute The role of Prostaglandin E2 in Angiotensin II-induced vascular disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Koch, Alvaro	3046775800	\$0.	\$-22.	\$-22.
Schering Plough Co Comparison of PEG-Intron 1/5 mcg/kg/wk Plus REBETOL vs. PeG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1				
Koch, Alvaro	3046775800	\$0.	\$23,422.	\$23,422.
Schering Plough Co Comparison of PEG-Intron 1/5 mcg/kg/wk Plus REBETOL vs. PeG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1				
Koch, Alvaro	3048062500	\$0.	\$21,483.	\$21,483.
Integrated Therapeutics Technology Pegylated Interferon Alfa-2b and Ribavirin after Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy				
Koch, Alvaro	3048068400	\$0.	\$8,012.	\$8,012.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
Koch, Alvaro	3048068400	\$0.	\$1,115.	\$1,115.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
Koch, Alvaro	3048068400	\$0.	\$1,800.	\$1,800.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
Koch, Alvaro	3048068400	\$0.	\$6,330.	\$6,330.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
Koch, Alvaro	3048068400	\$0.	\$3,756.	\$3,756.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
Koch, Alvaro	3048072900	\$0.	\$600.	\$600.
Sanofi Aventis US Inc Satavaptan Cirrhotic Ascites Treatment Study: A Double-Blind, Randomized, Parallel Group Comparison of Treatment with Satavaptan at 5 to 10 mg daily Versus Placebo on top of Conventional Treatment in Patients with Ascites due to Cirrhosis of the Liver				
Koch, Alvaro	3048072900	\$0.	\$700.	\$700.
Sanofi Aventis US Inc Satavaptan Cirrhotic Ascites Treatment Study: A Double-Blind, Randomized, Parallel Group Comparison of Treatment with Satavaptan at 5 to 10 mg daily Versus Placebo on top of Conventional Treatment in Patients with Ascites due to Cirrhosis of the Liver				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Koch, Alvaro	3048072900	\$0.	\$1,500.	\$1,500.
Sanofi Aventis US Inc Satavaptan Cirrhotic Ascites Treatment Study: A Double-Blind, Randomized, Parallel Group Comparison of Treatment with Satavaptan at 5 to 10 mg daily Versus Placebo on top of Conventional Treatment in Patients with Ascites due to Cirrhosis of the Liver				
Koch, Alvaro	3048104481	\$0.	\$1,412.	\$1,412.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$2,008.	\$2,008.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$1,123.	\$1,123.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$3,264.	\$3,264.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$4,015.	\$4,015.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$1,223.	\$1,223.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$2,498.	\$2,498.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104827	\$0.	\$1,750.	\$1,750.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimona-bant 20 mg Daily for the Treatment of Non-Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				
Koch, Alvaro	3048104827	\$2.	\$0.	\$2.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimona-bant 20 mg Daily for the Treatment of Non-Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Koch, Alvaro	3048104827	\$0.	\$3,998.	\$3,998.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				
Koch, Alvaro	3048104828	\$2.	\$0.	\$2.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				
Koch, Alvaro	3048104828	\$0.	\$5,300.	\$5,300.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				
Koch, Alvaro	3048104828	\$0.	\$3,998.	\$3,998.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				
Koch, Alvaro	3048104828	\$0.	\$3,550.	\$3,550.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				
Koch, Alvaro	3048104830	\$2.	\$0.	\$2.
Sanofi Aventis US Inc Long Term Safety and Tolerability of Satavaptan in Patients with Cirrhosis of the Liver That Have Been Previously Randomized and Completed Treatment in Any of the Phase III Studies: EFC4492, EFC4493 or EFC6682:				
Koch, Alvaro	3048104830	\$0.	\$4,498.	\$4,498.
Sanofi Aventis US Inc Long Term Safety and Tolerability of Satavaptan in Patients with Cirrhosis of the Liver That Have Been Previously Randomized and Completed Treatment in Any of the Phase III Studies: EFC4492, EFC4493 or EFC6682:				
Koch, Alvaro	3048104830	\$0.	\$930.	\$930.
Sanofi Aventis US Inc Long Term Safety and Tolerability of Satavaptan in Patients with Cirrhosis of the Liver That Have Been Previously Randomized and Completed Treatment in Any of the Phase III Studies: EFC4492, EFC4493 or EFC6682:				
Koch, Alvaro	3048105298	\$2.	\$0.	\$2.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$71,757.	\$71,757.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$22,600.	\$22,600.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Koch, Alvaro	3048105298	\$0.	\$17,572.	\$17,572.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$9,998.	\$9,998.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Li, Zhenyu	3048105278	\$0.	\$623.	\$623.
American Heart Association The Role of Platelets in Sepsis				
Li, Zhenyu	3048105278	\$38,500.	\$0.	\$38,500.
American Heart Association The Role of Platelets in Sepsis				
Lohr, Kristine	3048104362	\$25,000.	\$0.	\$25,000.
American College of Rheumatology Rachel Chase Fellowship: Rheumatology Fellowship Training Award				
Luo, Jia	3048105463	\$227,233.	\$0.	\$227,233.
National Institute on Alcohol Abuse and Alcoholism GSK-3 beta, a Meditor of Ethanol Neurotoxicity				
Luo, Jia	3048105464	\$0.	\$296,663.	\$296,663.
National Institute on Alcohol Abuse and Alcoholism Alcohol and Breast Cancer				
Luo, Jia	3048105464	\$0.	\$32,962.	\$32,962.
National Institute on Alcohol Abuse and Alcoholism Alcohol and Breast Cancer				
Luo, Jia	3048105464	\$149,421.	\$0.	\$149,421.
National Institute on Alcohol Abuse and Alcoholism Alcohol and Breast Cancer				
Malluche, Hartmut H	3048057000	\$0.	\$17,097.	\$17,097.
Emory University Pyrosphate in Vascular Calcification of Renal Failure				
Malluche, Hartmut H	3048103863	\$0.	\$17,245.	\$17,245.
Childrens Hospital of Philadelphia Changes in Skeletal Microarchitecture Following Renal Transplantation				
Malluche, Hartmut H	3048103863	\$0.	\$-340.	\$-340.
Childrens Hospital of Philadelphia Changes in Skeletal Microarchitecture Following Renal Transplantation				
Malluche, Hartmut H	3048103863	\$0.	\$-16,905.	\$-16,905.
Childrens Hospital of Philadelphia Changes in Skeletal Microarchitecture Following Renal Transplantation				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Malluche, Hartmut H	3048105536	\$16,905.	\$0.	\$16,905.
Childrens Hospital of Philadelphia Changes in Skeletal Microarchitecture Following Renal Transplantation				
Malluche, Hartmut H	3048105737	\$392,826.	\$0.	\$392,826.
National Institute Diabetes & Digestive & Kidney Renal Osteodystrophy: A Fresh Approach				
Mardini, Houssam Eddin	3048103706	\$0.	\$1,050.	\$1,050.
PRS Clinical Inc Chemoprevention of Colorectal Adenomas				
Mardini, Houssam Eddin	3048103706	\$0.	\$1,750.	\$1,750.
PRS Clinical Inc Chemoprevention of Colorectal Adenomas				
Massarweh, Suleiman A.	3048104541	\$0.	\$33,145.	\$33,145.
Novartis A Phase II Study of Combined Fulvestrant (Fulvestrant) and RAD001 (Everolimus) in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure				
Massarweh, Suleiman A.	3048104541	\$0.	\$-2,000.	\$-2,000.
Novartis A Phase II Study of Combined Fulvestrant (Fulvestrant) and RAD001 (Everolimus) in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure				
McDonagh, Kevin T	3046946800	\$0.	\$676.	\$676.
Novartis A Randomized Open-label Study of 400 mg Versus 800 mg of Gleevac/Gilvac (imatinab mesylate) in patients with newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) using Molecular Endpoints				
McDonagh, Kevin T	3046946800	\$0.	\$22,057.	\$22,057.
Novartis A Randomized Open-label Study of 400 mg Versus 800 mg of Gleevac/Gilvac (imatinab mesylate) in patients with newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) using Molecular Endpoints				
McDonagh, Kevin T	3046952500	\$0.	\$1,411.	\$1,411.
Bristol Myers Squibb Company A Randomized Two Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phae or in Myeloid or Lymphoid				
McDonagh, Kevin T	3046952500	\$0.	\$3,150.	\$3,150.
Bristol Myers Squibb Company A Randomized Two Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phae or in Myeloid or Lymphoid				
McDonagh, Kevin T	3046959100	\$0.	\$750.	\$750.
Bristol Myers Squibb Company A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
McDonagh, Kevin T	3046959100	\$0.	\$750.	\$750.
Bristol Myers Squibb Company A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				
McDonagh, Kevin T	3048050100	\$0.	\$1,080.	\$1,080.
Cephalon Inc A Multicenter Phase III Study to Investigate the Safety and Efficacy of Treanda)Bendamustine HC1) in Patients with Indolent Non-Hodgkin's Lymphoma (NHL) who are Refractory to Rituximab (SDX-105-03)				
McDonagh, Kevin T	3048103824	\$0.	\$9,860.	\$9,860.
Proteolix Inc An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma				
McDonagh, Kevin T	3048103824	\$0.	\$6,119.	\$6,119.
Proteolix Inc An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma				
McDonagh, Kevin T	3048103824	\$0.	\$5,400.	\$5,400.
Proteolix Inc An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma				
McDonagh, Kevin T	3048103826	\$0.	\$5,020.	\$5,020.
Proteolix Inc An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma				
McDonagh, Kevin T	3048104375	\$0.	\$47,880.	\$47,880.
Erimos Pharmaceuticals LLC Phase I Study of Terameprocol (EM-1421), a Survivin and Cyclin-Dependent-Kinase-1 (Cdc2) Inhibitor, in Patients				
McDonagh, Kevin T	3048104375	\$0.	\$29,147.	\$29,147.
Erimos Pharmaceuticals LLC Phase I Study of Terameprocol (EM-1421), a Survivin and Cyclin-Dependent-Kinase-1 (Cdc2) Inhibitor, in Patients				
Miller, Beth A	3046829900	\$0.	\$3,222.	\$3,222.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$1,756.	\$1,756.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$864.	\$864.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$5,068.	\$5,068.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Miller, Beth A	3046829900	\$0.	\$4,167.	\$4,167.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$630.	\$630.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$100.	\$100.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$2,534.	\$2,534.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$1,736.	\$1,736.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$2,842.	\$2,842.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046994700	\$0.	\$-600.	\$-600.
Novartis A 26 Week, Randomized, Double-Blind, Parallel-Group-Controlled, Multi-center Study To Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy In Patients With Persistent Allergic Asthma				
Miller, Beth A	3046994700	\$0.	\$1,670.	\$1,670.
Novartis A 26 Week, Randomized, Double-Blind, Parallel-Group-Controlled, Multi-center Study To Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy In Patients With Persistent Allergic Asthma				
Miller, Beth A	3046994700	\$0.	\$-345.	\$-345.
Novartis A 26 Week, Randomized, Double-Blind, Parallel-Group-Controlled, Multi-center Study To Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy In Patients With Persistent Allergic Asthma				
Miller, Beth A	3048041000	\$0.	\$1,357.	\$1,357.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Miller, Beth A	3048041000	\$0.	\$16,931.	\$16,931.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
Miller, Beth A	3048041000	\$0.	\$11,975.	\$11,975.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
Miller, Beth A	3048041000	\$0.	\$10,559.	\$10,559.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
Miller, Beth A	3048041000	\$0.	\$1,260.	\$1,260.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
Miller, Beth A	3048104585	\$0.	\$3,687.	\$3,687.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
Miller, Beth A	3048104585	\$0.	\$6,063.	\$6,063.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
Miller, Beth A	3048104585	\$0.	\$863.	\$863.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
Miller, Beth A	3048104585	\$0.	\$3,238.	\$3,238.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
Miller, Beth A	3048104585	\$0.	\$4,670.	\$4,670.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Miller, Beth A	3048104585	\$0.	\$3,324.	\$3,324.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
Miller, Beth A	3048104585	\$0.	\$4,544.	\$4,544.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
Miller, Beth A	3048105366	\$0.	\$40,408.	\$40,408.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen Based Tablets Once Daily to Adult Patients				
Miller, Beth A	3048105366	\$0.	\$18,091.	\$18,091.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen Based Tablets Once Daily to Adult Patients				
Miller, Beth A	3048105366	\$0.	\$9,605.	\$9,605.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen Based Tablets Once Daily to Adult Patients				
Miller, Beth A	3048105366	\$2.	\$0.	\$2.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen Based Tablets Once Daily to Adult Patients				
Miller, Ralph E	3046644900	\$0.	\$250.	\$250.
Eli Lilly and Company Hypopituitary Control and Complications Study				
Miller, Ralph E	3046644900	\$0.	\$3,720.	\$3,720.
Eli Lilly and Company Hypopituitary Control and Complications Study				
Miller, Ralph E	3046644900	\$0.	\$3,720.	\$3,720.
Eli Lilly and Company Hypopituitary Control and Complications Study				
Miller, Ralph E	3046644900	\$0.	\$2,046.	\$2,046.
Eli Lilly and Company Hypopituitary Control and Complications Study				
Miller, Ralph E	3046644900	\$0.	\$1,000.	\$1,000.
Eli Lilly and Company Hypopituitary Control and Complications Study				
Miller, Ralph E	3046644900	\$0.	\$1,104.	\$1,104.
Eli Lilly and Company Hypopituitary Control and Complications Study				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Miller, Ralph E	3046644900	\$0.	\$682.	\$682.
Eli Lilly and Company Hypopituitary Control and Complications Study				
Miller, Ralph E	3046644900	\$0.	\$6,603.	\$6,603.
Eli Lilly and Company Hypopituitary Control and Complications Study				
Miller, Ralph E	3046644900	\$0.	\$4,338.	\$4,338.
Eli Lilly and Company Hypopituitary Control and Complications Study				
Moliterno, David Jon	3048105654	\$0.	\$4,998.	\$4,998.
Duke Clinical Research Institute Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of the Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Acute Myocardial Infarctions (REVEAL)				
Moliterno, David Jon	3048105654	\$2.	\$0.	\$2.
Duke Clinical Research Institute Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of the Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Acute Myocardial Infarctions (REVEAL)				
Morehead, Richard S	3046861300	\$0.	\$4,538.	\$4,538.
Ortho McNeil Pharmaceuticals Levofloxacin Pharmacokinetics in the Severely Obese				
Morris, Andrew	3046978800	\$0.	\$20,094.	\$20,094.
National Institute of General Medical Sciences Lysophosphatidic Acid - Synthesis, Actions and Inactivation				
Morris, Andrew	3048104961	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship for Hongmei Ren: Regulation of Triglyceride Synthesis by Membrane Targeting of Lipin/Type 1 Phosphatidic acid Phosphatase				
Morris, Andrew	3048105297	\$67,566.	\$0.	\$67,566.
National Institute of General Medical Sciences Role of Lipid Phosphatases in Cholesterol and Triglyceride Synthesis				
Mukherjee, Debabrata	3046910200	\$0.	\$2,205.	\$2,205.
Sanofi Synthelabo Inc SHINE: A Randomized Dose Ranging Study of Hexadecasaccharide				
Mukherjee, Debabrata	3046943700	\$0.	\$630.	\$630.
Conor Medsystems COSTAR II: Cobalt Chromium Stent with Antiproliferative for Restenosis II Trail Costar Paclitaxeluting Coronary Stent System				
Mukherjee, Debabrata	3046943700	\$0.	\$630.	\$630.
Conor Medsystems COSTAR II: Cobalt Chromium Stent with Antiproliferative for Restenosis II Trail Costar Paclitaxeluting Coronary Stent System				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Mukherjee, Debabrata	3048015400	\$0.	\$1,498.	\$1,498.
Mount Sinai FREEDOM Trial Future Revascularization in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) and all Amemdments there to.				
Mukherjee, Debabrata	3048061600	\$0.	\$700.	\$700.
Guidant CPI CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
Mukherjee, Debabrata	3048061600	\$0.	\$1,235.	\$1,235.
Guidant CPI CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
Mukherjee, Debabrata	3048061600	\$0.	\$2,675.	\$2,675.
Guidant CPI CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
Mukherjee, Debabrata	3048061600	\$0.	\$3,175.	\$3,175.
Guidant CPI CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
Mukherjee, Debabrata	3048061600	\$0.	\$3,000.	\$3,000.
Guidant CPI CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
Mukherjee, Debabrata	3048104415	\$0.	\$7,600.	\$7,600.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$11,600.	\$11,600.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$800.	\$800.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$800.	\$800.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$11,500.	\$11,500.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$800.	\$800.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Mukherjee, Debabrata	3048104415	\$0.	\$12,798.	\$12,798.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$200.	\$200.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$10,800.	\$10,800.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$1,600.	\$1,600.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$800.	\$800.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Murphy, Brian S	3048105667	\$74,166.	\$0.	\$74,166.
National Heart Lung and Blood Institute ARRA: Pneumocystis jirovecii and macrophages in COPD				
Nickl, Nicholas J	3046728400	\$0.	\$-194.	\$-194.
Medtronic Inc An Evaluation of the Medtronic Gatekeeper System in the Treatment of subjects with GERD				
Nickl, Nicholas J	3046728400	\$0.	\$2,007.	\$2,007.
Medtronic Inc An Evaluation of the Medtronic Gatekeeper System in the Treatment of subjects with GERD				
Nickl, Nicholas J	3048104763	\$0.	\$7,783.	\$7,783.
Repligen Corp A Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin) Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis				
Nickl, Nicholas J	3048104763	\$2.	\$0.	\$2.
Repligen Corp A Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin) Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis				
Nickl, Nicholas J	3048104763	\$0.	\$13,975.	\$13,975.
Repligen Corp A Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin) Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Nickl, Nicholas J	3048104763	\$0.	\$4,479.	\$4,479.
Repligen Corp A Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin) Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis				
Nickl, Nicholas J	3048104994	\$0.	\$71,997.	\$71,997.
Eurand SPA A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase (EUR-1008) in Chronic Pancreatitis (CP) Patients with Exocrine Pancreatic Insufficiency (EPI)				
Nickl, Nicholas J	3048104994	\$0.	\$1,258.	\$1,258.
Eurand SPA A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase (EUR-1008) in Chronic Pancreatitis (CP) Patients with Exocrine Pancreatic Insufficiency (EPI)				
Nickl, Nicholas J	3048104994	\$2.	\$0.	\$2.
Eurand SPA A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase (EUR-1008) in Chronic Pancreatitis (CP) Patients with Exocrine Pancreatic Insufficiency (EPI)				
Pena, Luis R	3048103663	\$0.	\$473.	\$473.
Solvay Pharmaceuticals A Study to Investigate the Effect of two Doses of CREON on Maldigestion in Patients with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis				
Pena, Luis R	3048103663	\$0.	\$7,126.	\$7,126.
Solvay Pharmaceuticals A Study to Investigate the Effect of two Doses of CREON on Maldigestion in Patients with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis				
Pena, Luis R	3048103663	\$0.	\$6,860.	\$6,860.
Solvay Pharmaceuticals A Study to Investigate the Effect of two Doses of CREON on Maldigestion in Patients with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis				
Pena, Luis R	3048103663	\$0.	\$10,250.	\$10,250.
Solvay Pharmaceuticals A Study to Investigate the Effect of two Doses of CREON on Maldigestion in Patients with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis				
Pena, Luis R	3048104984	\$0.	\$2,498.	\$2,498.
Roche Laboratories Prospective Observational Study on Predictors of Early-On Treatment, Response and Sustained Virological Response in a Cohort of Treatment Naive HCV-Infected Patients Treated with Pegylated Interferons				
Pena, Luis R	3048104984	\$2.	\$0.	\$2.
Roche Laboratories Prospective Observational Study on Predictors of Early-On Treatment, Response and Sustained Virological Response in a Cohort of Treatment Naive HCV-Infected Patients Treated with Pegylated Interferons				
Reynolds, L Raymond	3048027100	\$0.	\$2,254.	\$2,254.
Novo Nordisk Pharmaceuticals Inc Effect on Glycemic Control of Two Doses of Liraglutide versus Glimepiride in Type 2 Diabetes				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Rinehart, John J	3046945700	\$0.	\$39.	\$39.
Berlex Laboratories Inc Randomized Phase III Trail of Leukine vs Newpogen in Patients Receiving Cisplatin and Gemcitabine for Reionally Advanced or Metastatic Urothelial Cancer				
Rinehart, John J	3048027400	\$0.	\$2,563.	\$2,563.
Taiho Pharma USA Inc A Phase 1, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients with Impaired Hepatic Function				
Rinehart, John J	3048027500	\$0.	\$9,056.	\$9,056.
Taiho Pharma USA Inc A Phase 1, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients with Varying Degrees of Renal Function				
Rinehart, John J	3048028600	\$0.	\$-2,000.	\$-2,000.
Pfizer Inc A Phase 3, Open Label, Randomized, Comparative Study of Ticilimumab and Either Dacarbazine or Temozolomide in Patients with Advanced Melanoma				
Rinehart, John J	3048082900	\$0.	\$4,714.	\$4,714.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
Rinehart, John J	3048082900	\$0.	\$567.	\$567.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
Rinehart, John J	3048082900	\$0.	\$4,714.	\$4,714.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
Rinehart, John J	3048082900	\$0.	\$4,714.	\$4,714.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
Rinehart, John J	3048096700	\$0.	\$-2,000.	\$-2,000.
Tapestry Pharmaceuticals Inc A Phase 2 Trail of TPI 287 in Patients with Metastatic Prostate Cancer Who Have Progressive Neoplastic Disease Following Treatment with One Prior Taxane Regimen				
Rinehart, John J	3048103857	\$0.	\$3,901.	\$3,901.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				
Rinehart, John J	3048103857	\$0.	\$264.	\$264.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Rinehart, John J	3048103857	\$0.	\$398.	\$398.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				
Rinehart, John J	3048103857	\$0.	\$3,137.	\$3,137.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				
Rinehart, John J	3048103857	\$0.	\$75.	\$75.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				
Rinehart, John J	3048104413	\$0.	\$10,942.	\$10,942.
Wyeth Pharmaceuticals Inc A Randomized Trial of Temsilrolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy				
Rinehart, John J	3048104413	\$0.	\$3,200.	\$3,200.
Wyeth Pharmaceuticals Inc A Randomized Trial of Temsilrolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy				
Rinehart, John J	3048104488	\$0.	\$4,017.	\$4,017.
Schering Plough Co An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel				
Rinehart, John J	3048104488	\$0.	\$6,318.	\$6,318.
Schering Plough Co An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel				
Rinehart, John J	3048104826	\$2.	\$0.	\$2.
Cougar Biotechnology Inc A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (AB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy				
Rinehart, John J	3048104826	\$0.	\$4,546.	\$4,546.
Cougar Biotechnology Inc A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (AB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy				
Rinehart, John J	3048105506	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc A Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin) plus Temsirolimus (Torisel) versus Bevacizumab (Avastin) plus Interferon-Alfa (Roferon) as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Rinehart, John J	3048105506	\$0.	\$9,394.	\$9,394.
Wyeth Pharmaceuticals Inc A Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin) plus Temsirolimus (Torisel) versus Bevacizumab (Avastin) plus Interferon-Alfa (Roferon) as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma				
Romond, Edward H	3046177800	\$0.	\$150.	\$150.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$6,650.	\$6,650.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$100.	\$100.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$4,700.	\$4,700.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$10,700.	\$10,700.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$7,675.	\$7,675.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$-3,900.	\$-3,900.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$8,755.	\$8,755.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$13,000.	\$13,000.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$10,755.	\$10,755.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$-250.	\$-250.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$19,050.	\$19,050.
NSABP Foundation NSABP Master Agreement				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Romond, Edward H	3046177800	\$0.	\$-67.	\$-67.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$11,300.	\$11,300.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$13,000.	\$13,000.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$4,100.	\$4,100.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$2,000.	\$2,000.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$16,080.	\$16,080.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$10,000.	\$10,000.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$5,950.	\$5,950.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046350500	\$0.	\$300.	\$300.
NSABP Foundation STAR Trial Breast Cancer Prevention Trial (P-2)				
Romond, Edward H	3046350500	\$0.	\$900.	\$900.
NSABP Foundation STAR Trial Breast Cancer Prevention Trial (P-2)				
Romond, Edward H	3046350500	\$0.	\$3,900.	\$3,900.
NSABP Foundation STAR Trial Breast Cancer Prevention Trial (P-2)				
Romond, Edward H	3046350500	\$0.	\$25,800.	\$25,800.
NSABP Foundation STAR Trial Breast Cancer Prevention Trial (P-2)				
Romond, Edward H	3048040300	\$0.	\$33,087.	\$33,087.
Eli Lilly and Company A Randomized Phase II Trail of Paclitaxel and Bevacizumab versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Romond, Edward H	3048105106	\$0.	\$-2,000.	\$-2,000.
NSABP Foundation NSABP Master Agreement (TIND)				
Romond, Edward H	3048105106	\$0.	\$-2.	\$-2.
NSABP Foundation NSABP Master Agreement (TIND)				
Romond, Edward H	3048105106	\$0.	\$7,500.	\$7,500.
NSABP Foundation NSABP Master Agreement (TIND)				
Romond, Edward H	3048105106	\$2.	\$0.	\$2.
NSABP Foundation NSABP Master Agreement (TIND)				
Romond, Edward H	3048105721	\$2.	\$0.	\$2.
Bristol Myers Squibb Company IXTEND A Randomized Phase 2 Study to Evaluate the Combinations of IXabepilone plus Capecitabine or CapEcitabiNe plus Docetaxel in the Treatment of Metastatic Breast CA 163-131				
Rowland, Randall	3048103818	\$0.	\$315.	\$315.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103818	\$0.	\$100.	\$100.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103818	\$0.	\$790.	\$790.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103818	\$0.	\$165.	\$165.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103818	\$0.	\$150.	\$150.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103818	\$0.	\$1,325.	\$1,325.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103818	\$0.	\$2,170.	\$2,170.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103818	\$0.	\$600.	\$600.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Rowland, Randall	3048103819	\$0.	\$1,350.	\$1,350.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
Rowland, Randall	3048103819	\$0.	\$150.	\$150.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
Rowland, Randall	3048103819	\$0.	\$2,300.	\$2,300.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
Rowland, Randall	3048103819	\$0.	\$50.	\$50.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
Rowland, Randall	3048103819	\$0.	\$500.	\$500.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
Rowland, Randall	3048103819	\$0.	\$250.	\$250.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
Rowland, Randall	3048103819	\$0.	\$50.	\$50.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
Selby, Lisbeth Ann	3048105410	\$2.	\$0.	\$2.
University of California San Francisco A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease Exposed to Immunomodulators and Biologic Therapy				
Shedlofsky, Steven I	3046556300	\$0.	\$300.	\$300.
Hoffmann La Roche Inc NV15908-An Extension Protocol to Evaluate the Long-Term Effects of Treatment with Peg Interferon Alfa-2a (PEG-IFN) or Interferon (IFN)- Based Therapies for Patients with Chronic Hepatitis C				
Smyth, Susan	3048103401	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Cheng Pre-Doc Fellowship: Signaling of LPA Receptors 1 and 2 is Vital for Regulation of Pulmonary Vascular Tone				
Smyth, Susan	3048103403	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Federico Pre-Doc Fellowship: The Role of Pyk2 in Platelet-eukocyte Interactions and the Arterial Response to Injury				
Smyth, Susan	3048103742	\$0.	\$-5,516.	\$-5,516.
University of North Carolina Adhesion and Migration in Inflammation				
Smyth, Susan	3048103742	\$0.	\$275,848.	\$275,848.
University of North Carolina Adhesion and Migration in Inflammation				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Smyth, Susan	3048105739	\$240,762.	\$0.	\$240,762.
National Heart Lung and Blood Institute NRSA Training Grant: Clinical Scholars Training in Cardiovascular Science				
Steinhubl, Steven R	3046837600	\$0.	\$450.	\$450.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
Steinhubl, Steven R	3046837600	\$0.	\$-200.	\$-200.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
Steinhubl, Steven R	3046837600	\$0.	\$950.	\$950.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
Steinhubl, Steven R	3048012900	\$0.	\$945.	\$945.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
Steinhubl, Steven R	3048012900	\$0.	\$1,000.	\$1,000.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
Steinhubl, Steven R	3048012900	\$0.	\$500.	\$500.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
Steinhubl, Steven R	3048012900	\$0.	\$500.	\$500.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
Steinhubl, Steven R	3048047000	\$0.	\$9,743.	\$9,743.
Bristol Myers Squibb Company APPRAISE-1: Apixaban for Prevention of Acute Ischemic Safety Events				
Steinhubl, Steven R	3048047000	\$0.	\$11,119.	\$11,119.
Bristol Myers Squibb Company APPRAISE-1: Apixaban for Prevention of Acute Ischemic Safety Events				
Steinhubl, Steven R	3048103787	\$0.	\$120.	\$120.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$4,587.	\$4,587.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Steinhubl, Steven R	3048103787	\$0.	\$3,053.	\$3,053.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$1,610.	\$1,610.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$5,706.	\$5,706.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$220.	\$220.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$6,238.	\$6,238.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$2,145.	\$2,145.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$4,680.	\$4,680.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$1,130.	\$1,130.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Supinski, Gerald	3048103003	\$0.	\$355,629.	\$355,629.
National Heart Lung and Blood Institute Caspase Mediated Diaphragmatic Dysfunction				
Tannock, Lisa R	3048087500	\$0.	\$366,250.	\$366,250.
National Heart Lung and Blood Institute Angiotensin Induced Proteoglycans in Atherosclerosis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Thornton, Alice C	3048104840	\$165,000.	\$0.	\$165,000.
Emory University Kentucky AIDS Educational Training Center				
Thornton, Alice C	3048104855	\$0.	\$11,233.	\$11,233.
KY Health Services Cabinet Kentucky HIV/AIDS Care Coordinator Program				
Thornton, Alice C	3048104855	\$0.	\$106,500.	\$106,500.
KY Health Services Cabinet Kentucky HIV/AIDS Care Coordinator Program				
Thornton, Alice C	3048104855	\$0.	\$-106,500.	\$-106,500.
KY Health Services Cabinet Kentucky HIV/AIDS Care Coordinator Program				
Thornton, Alice C	3048104855	\$654,027.	\$0.	\$654,027.
KY Health Services Cabinet Kentucky HIV/AIDS Care Coordinator Program				
Thornton, Alice C	3048105593	\$344,466.	\$0.	\$344,466.
Health Resources and Services Administration Ryan White Part C Outpatient Early Intervention Services				
Van Der Westhuyzen, Deneys R	3046952300	\$0.	\$308,973.	\$308,973.
National Heart Lung and Blood Institute SR-BI and SR-BII Recycling and Selective Lipid Uptake				
Van Der Westhuyzen, Deneys R	3048101200	\$0.	\$1,412,371.	\$1,412,371.
National Heart Lung and Blood Institute HDL Function and Metabolism During Inflammation Admin Core A				
Van Zant, Gary	3046830100	\$0.	\$266,530.	\$266,530.
National Institute on Aging Aging Stem Cells and Their Microenvironment				
Van Zant, Gary	3046830100	\$0.	\$-5,556.	\$-5,556.
National Institute on Aging Aging Stem Cells and Their Microenvironment				
Van Zant, Gary	3048105105	\$219,612.	\$0.	\$219,612.
Ellison Medical Foundation Role of the microRNA-290 Gene Cluster in Stem Cell and Organismal Aging				
Van Zant, Gary	3048105418	\$343,986.	\$0.	\$343,986.
National Institute of Child Health and Human Develop Latexin's role in parsing stem cells				
Waid, Thomas	3048103709	\$0.	\$2,520.	\$2,520.
Novartis A 4-Week, Multicenter, Double-Blind, Randomized, Parallel Group Study to Compare the Gastrointestinal Safety and Tolerability of myfortic and MMF (Cellcept) When Administered in Combination with Calcineurin Inhibitors in Renal Transplant Recipients				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Waid, Thomas	3048104654	\$0.	\$52,950.	\$52,950.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
Waid, Thomas	3048104654	\$0.	\$4,998.	\$4,998.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
Waid, Thomas	3048104654	\$0.	\$7,605.	\$7,605.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
Waid, Thomas	3048104654	\$0.	\$2,425.	\$2,425.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
Waid, Thomas	3048104654	\$0.	\$5,145.	\$5,145.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
Ziada, Khaled M	3046900000	\$0.	\$500.	\$500.
Omnicare Clinical Research A Double-Blind, Randomized Comparator-Controlled Study in Subjects with Type II Diabetes Mellitus Comparing the Effects of Pioglitazone HCl versus Glimperide on the Rate of Progression of Coronary Atherosclerotic Disease				
Ziada, Khaled M	3046944600	\$0.	\$185.	\$185.
Sanofi Synthelabo Inc STRADIVARIUS - Strategy to Reduce Atheroclerosis Development involving Rimonabant				
Ziada, Khaled M	3046969200	\$0.	\$47,275.	\$47,275.
Schering Plough Co Transcendence-PCI				
Ziada, Khaled M	3048066800	\$0.	\$5,175.	\$5,175.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trail of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
Ziada, Khaled M	3048066800	\$0.	\$9,790.	\$9,790.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trail of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
Ziada, Khaled M	3048066800	\$0.	\$2,835.	\$2,835.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trail of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Ziada, Khaled M	3048066800	\$0.	\$4,785.	\$4,785.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
Ziada, Khaled M	3048066800	\$0.	\$3,330.	\$3,330.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
Ziada, Khaled M	3048104460	\$0.	\$1,500.	\$1,500.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$79.	\$79.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$12,825.	\$12,825.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$15,500.	\$15,500.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$4,800.	\$4,800.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$3,575.	\$3,575.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$1,500.	\$1,500.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$2,925.	\$2,925.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$1,775.	\$1,775.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Ziada, Khaled M	3048104460	\$0.	\$4,500.	\$4,500.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$11,275.	\$11,275.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104589	\$0.	\$14,698.	\$14,698.
AstraZeneca Pharmaceuticals A 104 Week, Randomized, Double-Blind, Parallel Arm, Multi-Center Phase IIIb Study Comparing the Effects of Treatment with Rosuvastatin 40 mg or Atorvastatin 80 mg on Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound in Patients				
Ziada, Khaled M	3048105414	\$0.	\$2,000.	\$2,000.
Abbott Laboratories XIENCE V Everolimus Eluting Coronary Stent System				
Ziada, Khaled M	3048105414	\$0.	\$2,498.	\$2,498.
Abbott Laboratories XIENCE V Everolimus Eluting Coronary Stent System				
Ziada, Khaled M	3048105414	\$2.	\$0.	\$2.
Abbott Laboratories XIENCE V Everolimus Eluting Coronary Stent System				
Ziada, Khaled M	3048105563	\$0.	\$3,998.	\$3,998.
Portola Pharmaceuticals Inc A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, A Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing				
Ziada, Khaled M	3048105563	\$2.	\$0.	\$2.
Portola Pharmaceuticals Inc A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, A Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing				
Internal Medicine	Totals:	\$9,418,520.	\$11,217,229.	\$20,635,749.
Microbiology, Immunology & Molecular Gen				
Bondada, Subbarao	3048105046	\$183,125.	\$0.	\$183,125.
National Institute of Allergy and Infectious Diseases Importance of CD5 for the function of regulatory T cells				
Cohen, Donald A	3048103719	\$0.	\$185,333.	\$185,333.
Danone Research Effect of the Consumption of a Fermented Dairy Product on Immune Parameters in Healthy Adults				
Cohen, Donald A	3048103719	\$0.	\$-10,000.	\$-10,000.
Danone Research Effect of the Consumption of a Fermented Dairy Product on Immune Parameters in Healthy Adults				
Garvy, Beth A	3048103511	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Lines Fellowship: Neonatal T cell responses to influenza virus				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Microbiology, Immunology & Molecular Gen</u>				
Garvy, Beth A	3048104324	\$0.	\$366,250.	\$366,250.
National Heart Lung and Blood Institute Role of B cells in host defense against Pneumocystis				
Kaetzel, Charlotte S	3048104092	\$0.	\$215,575.	\$215,575.
National Institute of Allergy and Infectious Diseases Novel in Vivo Models for Cell-Type Specific MyD88 Signaling in the Intestine				
Luo, Guangxiang	3048103820	\$0.	\$215,575.	\$215,575.
National Institute of Allergy and Infectious Diseases Hepatitis C Virus Infection and Lipoproteins				
Luo, Guangxiang	3048104384	\$0.	\$179,463.	\$179,463.
National Institute Diabetes & Digestive & Kidney Transgenic Mouse Models of hepatitis C Virus Replication				
Marti, Francesc	3048104425	\$0.	\$68,818.	\$68,818.
National Institute Arthritis Musculoskeletal & Skin Lck activity in autoimmune TSAD-deficient Mice				
McGillis, Joseph P	3048105448	\$150,000.	\$0.	\$150,000.
KY Lung Cancer Research Fund Genetic Regulatory Network Control of Tumoricidal and Tumor Promoting Macrophage Phenotypes				
Perry, Robert D	3046756200	\$0.	\$-120,000.	\$-120,000.
Arizona State University Attenuated Live and Recombinant Yersinia pestis Vaccines				
Perry, Robert D	3048105494	\$183,125.	\$0.	\$183,125.
National Institute of Allergy and Infectious Diseases Yersiniabactin and plague pathogenesis				
Sinai, Anthony P	3046975100	\$0.	\$36,625.	\$36,625.
National Institute of Allergy and Infectious Diseases Blockade of Host Apoptosis by Toxoplasma Gondii				
Spear, Brett T	3048104385	\$0.	\$294,319.	\$294,319.
National Institute Diabetes & Digestive & Kidney Albumin-AFP Gene Family Regulation in Fetal and Adult Liver				
Spear, Brett T	3048104650	\$0.	\$-34,934.	\$-34,934.
Innexus Biotechnology Inc IgG1 knock-in mouse				
Stevenson, Brian	3048104946	\$219,750.	\$0.	\$219,750.
National Institute of Allergy and Infectious Diseases Leptospira interrogans Len adhesins				
Stevenson, Brian	3048105669	\$219,750.	\$0.	\$219,750.
National Institute of Allergy and Infectious Diseases ARRA: CRASP-2 proteins of Lyme disease Borrelia				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Microbiology, Immunology & Molecular Gen</u>				
Straley, Susan C	3048103204	\$0.	\$448,096.	\$448,096.
National Institute of Allergy and Infectious Diseases YopM and Protective Innate Defenses Against Plague				
Suzuki, Yasuhiro	3048105746	\$130,889.	\$0.	\$130,889.
University of Chicago Towards a Vaccine to Prevent Toxoplasmosis				
Woodward, Jerold G	3048104077	\$0.	\$88,599.	\$88,599.
University of North Carolina Nanoparticle HIC Protein Vaccines for Cellular Responses				
Woodward, Jerold G	3048105035	\$256,375.	\$0.	\$256,375.
National Eye Institute To Produce Transgenic Mice Which Express T Cell Receptors Specific for (IRBP)				
Yannelli, John R	3048105252	\$175,800.	\$0.	\$175,800.
National Cancer Institute Cryopreparation of PBMC for Immunotherapy and Immune Assessment Studies				
Microbiology, Immunology & Molecular Gen	Totals:	\$1,518,814.	\$1,954,719.	\$3,473,533.
<u>Family Practice & Community Medicine</u>				
Dassow, Paul	3048044400	\$0.	\$-23,458.	\$-23,458.
State of Oregon Department of Justice Maximizing the Impact of a Critical Skills Curriculum for Prescribers				
Dassow, Paul	3048104740	\$185,548.	\$0.	\$185,548.
Health Resources and Services Administration Residency Training in Primary Care				
Joyce, Jennifer M	3048105013	\$10,000.	\$0.	\$10,000.
Good Samaritan Foundation Salvation Army Free Clinic				
Joyce, Jennifer M	3048105283	\$183,024.	\$0.	\$183,024.
Health Resources and Services Administration Pre-Doctoral Training in Rural Kentucky				
Matheny, Samuel C	3048105256	\$276,536.	\$0.	\$276,536.
Health Resources and Services Administration Academic Administrative Units in Primary Care: Serving the Community: Family Medicine Education and Research				
Pearce, Kevin	3048105236	\$5,000.	\$0.	\$5,000.
Southern KY Area Health Education Center Improvements in the Diagnosis and Treatment of Cardiac Risk Factors				
Roeder, Phillip W	3048103104	\$0.	\$24,322.	\$24,322.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048103104	\$0.	\$25,643.	\$25,643.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Family Practice & Community Medicine</u>				
Roeder, Phillip W	3048103104	\$0.	\$33,902.	\$33,902.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$136,173.	\$136,173.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$36,356.	\$36,356.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$24,631.	\$24,631.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$49,629.	\$49,629.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$49,368.	\$49,368.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$51,918.	\$51,918.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$52,794.	\$52,794.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$67,351.	\$67,351.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$2,785.	\$2,785.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$-1,000.	\$-1,000.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$65,105.	\$65,105.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$33,483.	\$33,483.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Family Practice & Community Medicine</u>				
Roeder, Phillip W	3048104606	\$0.	\$75,114.	\$75,114.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$2.	\$0.	\$2.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Stanley, Michael W	3048105674	\$650,000.	\$0.	\$650,000.
Health Resources and Services Administration ARRA: Health Center Cluster New Access Point (DHHS BPHC HRSA Section 330 Community Health Center)				
Stanley, Michael W	3048105706	\$650,916.	\$0.	\$650,916.
Health Resources and Services Administration Health Center Cluster (DHHS BPHC HRSA Section 330 Community Health Center)				
Stanley, Michael W	3048105818	\$170,732.	\$0.	\$170,732.
Health Resources and Services Administration ARRA:Health Center Integrated Services Development				
Family Practice & Community Medicine	Totals:	\$2,131,758.	\$704,116.	\$2,835,874.
<u>Obstetrics & Gynecology</u>				
Curry, Thomas E	3048105482	\$2,014,686.	\$0.	\$2,014,686.
National Center for Research Resources Center of Biomedical Research Excellence in Women's Health (COBRE)				
Ferguson, James E	3048102149	\$0.	\$500.	\$500.
March of Dimes Birth Defects Foundation Prematurity Prevention Initiative in Kentucky - Healthy Babies are Worth the Wait				
Ferguson, James E	3048102149	\$0.	\$65,000.	\$65,000.
March of Dimes Birth Defects Foundation Prematurity Prevention Initiative in Kentucky - Healthy Babies are Worth the Wait				
Ferguson, James E	3048102149	\$0.	\$300.	\$300.
March of Dimes Birth Defects Foundation Prematurity Prevention Initiative in Kentucky - Healthy Babies are Worth the Wait				
Ferguson, James E	3048104992	\$500,000.	\$0.	\$500,000.
National Institute on Drug Abuse Building Interdisciplinary Research Careers in Women's Health in Kentucky				
Muse, Kenneth N	3046771400	\$0.	\$2,011.	\$2,011.
TAP Pharmaceuticals Inc A Phase III, 12 Month, Extension Study to Evaluate the Safety of Asoprisnil in Subjects with Uterine Leiomyomata				
Muse, Kenneth N	3046856500	\$0.	\$2,171.	\$2,171.
Xanodyne Pharmaceuticals Inc A Twelve-Month, Open Label, Multicenter Study to Evaluate the Safety of a 1.3 g Oral Dose of a New Modified-Release Tranexamic Acid Formulation Administered Three Times Daily as Needed for up to 5 Days During the				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Obstetrics & Gynecology				
Muse, Kenneth N	3046856500	\$0.	\$2,289.	\$2,289.
Xanodyne Pharmaceuticals Inc A Twelve-Month, Open Label, Multicenter Study to Evaluate the Safety of a 1.3 g Oral Dose of a New Modified-Release Tranexamic Acid Formulation Administered Three Times Daily as Needed for up to 5 Days During the				
Muse, Kenneth N	3046961700	\$0.	\$18,472.	\$18,472.
Wyeth Research Protocol Number 3115A1-304-WW: A Double Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety Study of Bazedoxifene / Conjugated Estrogens Combinations for the Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in				
Muse, Kenneth N	3046961700	\$0.	\$5,277.	\$5,277.
Wyeth Research Protocol Number 3115A1-304-WW: A Double Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety Study of Bazedoxifene / Conjugated Estrogens Combinations for the Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in				
Muse, Kenneth N	3048078700	\$0.	\$10,364.	\$10,364.
Wyeth Pharmaceuticals Inc The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause				
Muse, Kenneth N	3048104346	\$0.	\$7,304.	\$7,304.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
Muse, Kenneth N	3048104346	\$0.	\$5,875.	\$5,875.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
Muse, Kenneth N	3048104346	\$0.	\$893.	\$893.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
Muse, Kenneth N	3048104346	\$0.	\$1,459.	\$1,459.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
Muse, Kenneth N	3048104346	\$0.	\$5,522.	\$5,522.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
Muse, Kenneth N	3048104346	\$0.	\$1,789.	\$1,789.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Obstetrics & Gynecology</u>				
Muse, Kenneth N	3048104346	\$0.	\$893.	\$893.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
Muse, Kenneth N	3048104550	\$0.	\$6,134.	\$6,134.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Disorder in Surgically Menopausal Women(testW008)				
Muse, Kenneth N	3048104551	\$0.	\$8,868.	\$8,868.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Desire in Postmenopausal Women(testW007)				
Muse, Kenneth N	3048104793	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc A double-blind, randomized, placebo-controlled study assessing the safety and efficacy of DVS SR for the treatment of vasomotor symptoms associated with menopause				
Muse, Kenneth N	3048105599	\$2.	\$0.	\$2.
Wyeth Research A Double-blind, randomized, placebo and active-controlled efficacy and safety study of the effects of Bazedoxifene / Conjugated Estrogens combinations on endometrial hyperplasia and prevention of osteoporosis in postmenopausal women				
Muse, Kenneth N	3048105676	\$2.	\$0.	\$2.
Ferring International Pharmascience Center US Inc A Multicenter, randomized, double-dummy, placebo-controlled study to assess the efficacy and safety of three dosage strengths of pulsatile GnRH delivered from iontophoretic patch (Lutrepatch) compared to oral treatment				
Ueland, Frederick R	3046897300	\$0.	\$17,600.	\$17,600.
Gynecologic Oncology Group Gynecologic Oncology Group				
Ueland, Frederick R	3046897300	\$0.	\$17,424.	\$17,424.
Gynecologic Oncology Group Gynecologic Oncology Group				
Ueland, Frederick R	3046897300	\$0.	\$8,000.	\$8,000.
Gynecologic Oncology Group Gynecologic Oncology Group				
Ueland, Frederick R	3046897300	\$0.	\$242.	\$242.
Gynecologic Oncology Group Gynecologic Oncology Group				
Ueland, Frederick R	3046897300	\$0.	\$15,840.	\$15,840.
Gynecologic Oncology Group Gynecologic Oncology Group				
Ueland, Frederick R	3046897300	\$0.	\$13,288.	\$13,288.
Gynecologic Oncology Group Gynecologic Oncology Group				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Obstetrics & Gynecology</u>				
Ueland, Frederick R	3048098500	\$0.	\$5,166.	\$5,166.
PrecisionMed Inc Whole Blood Protocol for OvaRI Assay Clinical Trial in Women with Ovarian Tumors				
Ueland, Frederick R	3048098700	\$0.	\$353.	\$353.
PrecisionMed Inc CLD2: To Compare the Effect of Different Type BD Vacutainer TUNes on OvaRi Assay				
Ueland, Frederick R	3048103872	\$0.	\$13,427.	\$13,427.
Genentech Inc A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Promary Peritoneal, or Fallopian Tube Carcinoma				
Ueland, Frederick R	3048103872	\$0.	\$4,926.	\$4,926.
Genentech Inc A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Promary Peritoneal, or Fallopian Tube Carcinoma				
Ueland, Frederick R	3048103872	\$0.	\$4,007.	\$4,007.
Genentech Inc A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Promary Peritoneal, or Fallopian Tube Carcinoma				
Ueland, Frederick R	3048103872	\$0.	\$3,000.	\$3,000.
Genentech Inc A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Promary Peritoneal, or Fallopian Tube Carcinoma				
Ueland, Frederick R	3048105547	\$2.	\$0.	\$2.
ImClone Systems CP12-0711: A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma				
VanNagell, John R	3048105004	\$975,000.	\$0.	\$975,000.
KY Council on Postsecondary Education Ovarian Cancer Screening in Kentucky				
Obstetrics & Gynecology	Totals:	\$3,489,694.	\$248,394.	\$3,738,088.
<u>Pathology & Lab Medicine</u>				
Cibull, Michael L	3048105633	\$21,763.	\$0.	\$21,763.
Gynecologic Oncology Group Ovarian Tissue Bank				
Pathology & Lab Medicine	Totals:	\$21,763.	\$0.	\$21,763.
<u>Pediatrics</u>				
Anstead, Michael I	3048103215	\$0.	\$7,542.	\$7,542.
PPD Development Inc Multi-center, multi-national, randomized, placebo-controlled trial of Azithromycin in participants with Cystic Fibrosis 6-18 years old, Culter negative for Pseuddomonas aeruginosa				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Pediatrics				
Anstead, Michael I	3048103215	\$0.	\$1,201.	\$1,201.
PPD Development Inc Multi-center, multi-national, randomized, placebo-controlled trial of Azithromycin in participants with Cystic Fibrosis 6-18 years old, Culter negative for Pseuddomonas aeruginosa				
Anstead, Michael I	3048103215	\$0.	\$3,266.	\$3,266.
PPD Development Inc Multi-center, multi-national, randomized, placebo-controlled trial of Azithromycin in participants with Cystic Fibrosis 6-18 years old, Culter negative for Pseuddomonas aeruginosa				
Anstead, Michael I	3048103215	\$0.	\$18,199.	\$18,199.
PPD Development Inc Multi-center, multi-national, randomized, placebo-controlled trial of Azithromycin in participants with Cystic Fibrosis 6-18 years old, Culter negative for Pseuddomonas aeruginosa				
Anstead, Michael I	3048105439	\$87,358.	\$0.	\$87,358.
Cystic Fibrosis Foundation Therapeutics Development Center				
Anstead, Michael I	3048105514	\$86,400.	\$0.	\$86,400.
Cystic Fibrosis Foundation University of Kentucky Therapeutic Development Center				
Bada, Henrietta S	3048103645	\$0.	\$7,700.	\$7,700.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
Bada, Henrietta S	3048104832	\$384,350.	\$0.	\$384,350.
KY Health Services Cabinet Infant Intensive Care				
Bada, Henrietta S	3048105011	\$0.	\$21,000.	\$21,000.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
Bada, Henrietta S	3048105011	\$0.	\$2,800.	\$2,800.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
Bada, Henrietta S	3048105011	\$0.	\$3,500.	\$3,500.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
Bada, Henrietta S	3048105011	\$36,273.	\$0.	\$36,273.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
Bada, Henrietta S	3048105285	\$22,083.	\$0.	\$22,083.
University of Tennessee Maternal Lifestyle Study Phase 4				
Bay, Carolyn A	3048104937	\$188,400.	\$0.	\$188,400.
KY Health Services Cabinet Genetic Services				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Pediatrics				
Bayliff, Sherry L	3048105102	\$0.	\$2,998.	\$2,998.
Quintiles Inc Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment				
Bayliff, Sherry L	3048105102	\$2.	\$0.	\$2.
Quintiles Inc Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment				
Bricker, J Timothy	3048104839	\$288,601.	\$0.	\$288,601.
KY Health Services Cabinet Newborn Screening				
Cottrill, Carol M	3048105440	\$2.	\$0.	\$2.
Merck and Company Inc A Phase III, Randomized, Open-Label, Parallel-Group, Dose Ranging Clinical Trial to Study the Safety and Efficacy of MK-0954/Losartan Potassium in Pediatric Patients with Hypertension				
Greenwood, Martha F	3048104875	\$0.	\$21,000.	\$21,000.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$31,957.	\$31,957.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$3,000.	\$3,000.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$26,627.	\$26,627.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$1,000.	\$1,000.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$13,993.	\$13,993.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$2.	\$0.	\$2.
National Childhood Cancer Foundation Children's Oncology Group				
Grigsby, Donna J	3048105433	\$18,000.	\$0.	\$18,000.
Reach out and Read Inc Reach Out and Read (ROAR)				
Hayes, Don	3048103855	\$0.	\$2,013.	\$2,013.
Novartis A Randomized, Open-Label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Comparec to TOBI in Cystic Fibrosis Subjects				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Pediatrics				
Hayes, Don	3048103855	\$0.	\$3,036.	\$3,036.
Novartis A Randomized, Open-Label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Comparec to TOBI in Cystic Fibrosis Subjects				
Hayes, Don	3048103855	\$0.	\$11,353.	\$11,353.
Novartis A Randomized, Open-Label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Comparec to TOBI in Cystic Fibrosis Subjects				
Hayes, Don	3048105362	\$12,000.	\$0.	\$12,000.
American Academy of Pediatrics Kentucky Asthma Management Program				
Kanga, Jamshed F	3046872500	\$0.	\$1,027.	\$1,027.
Cystic Fibrosis Foundation The EPIC Clinical Study: Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa (Pa) Airway Infection in Young Patients with Cystic Fibrosis				
Kanga, Jamshed F	3046874600	\$0.	\$4,245.	\$4,245.
Cystic Fibrosis Foundation The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF				
Kanga, Jamshed F	3048087000	\$0.	\$26,950.	\$26,950.
Inspire Pharmaceuticals A Multicenter, Double-Blind, Placebo Controlled, Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease				
Kanga, Jamshed F	3048104070	\$0.	\$5,400.	\$5,400.
Cystic Fibrosis Foundation Cystic Fibrosis Research TDN Grant				
Kanga, Jamshed F	3048104392	\$0.	\$3,148.	\$3,148.
Genentech Inc A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects with Severe Lung Disease				
Kanga, Jamshed F	3048104457	\$0.	\$6,294.	\$6,294.
Altus Pharmaceuticals Inc. A Phase III Randomized Double-Blind Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency				
Kanga, Jamshed F	3048104823	\$111,365.	\$0.	\$111,365.
Cystic Fibrosis Foundation Cystic Fibrosis Center Program				
Kanga, Jamshed F	3048105098	\$0.	\$17,941.	\$17,941.
Inspire Pharmaceuticals A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FEV ₁ => 75% but =<110% Predicted				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Pediatrics				
Kanga, Jamshed F	3048105098	\$2.	\$0.	\$2.
Inspire Pharmaceuticals A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Denufosal Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FEV ₁ => 75% but =<110% Predicted				
Kanga, Jamshed F	3048105677	\$2.	\$0.	\$2.
Seattle Childrens Research Institute The EPIC Observational Study: Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa (Pa) Airway Infection in Young Patients with Cystic Fibrosis				
Landers, Cheri D	3046775600	\$0.	\$500.	\$500.
Childrens Hospital Foundation Genomic Analysis of Pediatric Systemic Inflammatory Response Syndrome (SIRS)				
Li, Xiangan	3048104962	\$230,738.	\$0.	\$230,738.
National Institute of General Medical Sciences Role of SR-BI LPS detoxification				
Li, Xiangan	3048104962	\$0.	\$230,738.	\$230,738.
National Institute of General Medical Sciences Role of SR-BI LPS detoxification				
Liu, Jun	3048105084	\$146,500.	\$0.	\$146,500.
National Institute Diabetes & Digestive & Kidney The Roles of Integrin Receptors in Adipocyte Differentiation				
Lomenick, Jefferson	3048015500	\$0.	\$200.	\$200.
AstraZeneca Pharmaceuticals An Open -Label, Non-Comparative Trial to Evaluate the Saefy, Efficacy and Pharmacokinetics of FASLODEX (Fulvestrant) in Girls with Progressive Precocious Puberty Associated with McCune-Albright Syndrome				
Moscow, Jeffrey	3048104214	\$0.	\$150,000.	\$150,000.
Susan G Komen Breast Cancer Foundation Thiamine Starvation with Thiaminase I for Breast Cancer Therapy				
Moscow, Jeffrey	3048104680	\$170,800.	\$0.	\$170,800.
KY Commission for Children with Special Health Comprehensive Diagnosis				
Moscow, Jeffrey	3048104681	\$2,000.	\$0.	\$2,000.
KY Commission for Children with Special Health Comprehensive Hemophilia Program				
Moscow, Jeffrey	3048104776	\$0.	\$8,078.	\$8,078.
AAIPharma Inc An Open-Label Study to Assess the Pharmacokinetics of Leucovorin in Patients Receiving High Dose Methotrexate, with or without Voraxaze Treatment.				
Moscow, Jeffrey	3048104776	\$2.	\$0.	\$2.
AAIPharma Inc An Open-Label Study to Assess the Pharmacokinetics of Leucovorin in Patients Receiving High Dose Methotrexate, with or without Voraxaze Treatment.				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Pediatrics				
Northrip, Kimberly	3048105637	\$11,986.	\$0.	\$11,986.
American Academy of Pediatrics CATCH Planning Funds Grant- Medical Legal Partnership for Kentucky Children				
Northrip, Kimberly	3048105637	\$0.	\$-2,799.	\$-2,799.
American Academy of Pediatrics CATCH Planning Funds Grant- Medical Legal Partnership for Kentucky Children				
Omar, Hatim	3048105047	\$303,094.	\$0.	\$303,094.
KY Health Services Cabinet Young Parents Program				
Perman, Jay A	3048105239	\$73,250.	\$0.	\$73,250.
National Institute of Child Health and Human Develop Academic-Community Coalition for a School-Based Obesity Prevention/Treatment Program				
Perman, Jay A	3048105240	\$25,000.	\$0.	\$25,000.
KY Diabetes Research Trust Fund Academic-Community Coalition for a School-Based Obesity Prevention/Treatment Program				
Pinkstaff, Thomas H	3048104765	\$390,592.	\$0.	\$390,592.
KY Health Services Cabinet Medically Fragile Foster Family Practice FY09				
Radulescu, Vlad	3048104276	\$0.	\$800.	\$800.
Covance Hemophilia and Thrombosis Research Registry				
Radulescu, Vlad	3048105090	\$2.	\$0.	\$2.
Grifols Biologicals Inc A Postmarketing Obervational Study to Assess the Efficacy and Safety of the Factor VIII/von Willebrand Factor Complex (Human), Alphanate, in Preventing Excessive Bleeding During Surgery in Subjects with Congenital Type 3 von Willebrand Disease				
Radulescu, Vlad	3048105260	\$0.	\$-2,000.	\$-2,000.
Baxter Healthcare Co A Phase I, Randomized, Crossover Study to Compare the Pharmacokinetics and Daefy of rAHF-PFM Reconstituted in 2mL versus 5mL in Previously Treated Severe Hemophilia A Patients				
Radulescu, Vlad	3048105260	\$0.	\$8,834.	\$8,834.
Baxter Healthcare Co A Phase I, Randomized, Crossover Study to Compare the Pharmacokinetics and Daefy of rAHF-PFM Reconstituted in 2mL versus 5mL in Previously Treated Severe Hemophilia A Patients				
Radulescu, Vlad	3048105260	\$2.	\$0.	\$2.
Baxter Healthcare Co A Phase I, Randomized, Crossover Study to Compare the Pharmacokinetics and Daefy of rAHF-PFM Reconstituted in 2mL versus 5mL in Previously Treated Severe Hemophilia A Patients				
Radulescu, Vlad	3048105316	\$18,196.	\$0.	\$18,196.
American Thrombosis and Hemostasis Network ATHNdata.quality.Counts				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Pediatrics				
Radulescu, Vlad	3048105393	\$0.	\$498.	\$498.
Novartis reGISTry				
Radulescu, Vlad	3048105393	\$2.	\$0.	\$2.
Novartis reGISTry				
Reynolds, Eric W	3048065500	\$0.	\$108,000.	\$108,000.
National Institute of Child Health and Human Develop Cervical (Neck) Auscultation and Development Outcomes				
Shashidhar, Harohalli	3048059500	\$0.	\$-1,179.	\$-1,179.
Wyeth Pharmaceuticals Inc A Multi-Center, Open -label Pharmacokintic, Pharmacodynamic, Clinical Synptoms, and Safety Study of Pantoprazole Delayed-Released Granules Administered as A Suspension in Neonates and Preterm Infants with a Clinical Diagnosis of Gatroesophageal Disease.				
Shashidhar, Harohalli	3048072400	\$0.	\$-2,248.	\$-2,248.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-coated Spheroids in Children Ages 1 to 5				
Smart, Eric J	3046982800	\$0.	\$355,629.	\$355,629.
National Heart Lung and Blood Institute Saturated Fatty Acid and Cardiovascular Disease				
Smart, Eric J	3048048400	\$0.	\$285,783.	\$285,783.
National Institute Diabetes & Digestive & Kidney Protective Effects of Stearic Acid on Gestational and Acquired Diabetes Mellitus				
Vranicar, Mark	3046986600	\$0.	\$315.	\$315.
Bristol Myers Squibb Company A Phase III, Open-Label, Non-Randomized, International, Multicenter Trial to Evaluate the Efficacy and Safety of Cardiolite Myocardial Perfusion Imaging in Pediatric Subjects with Kawaski Disease				
Wallace, Carmel	3048105110	\$432,900.	\$0.	\$432,900.
KY Cabinet for Health and Family Services Pediatric Assessment, Case Management and Training				
Young, Thomas L	3048104762	\$16,000.	\$0.	\$16,000.
Lexington Fayette County Health Department William Wells Brown Elementary School Center				
Young, Thomas L	3048104764	\$16,000.	\$0.	\$16,000.
Lexington Fayette County Health Department Arlington Elementary School Center				
Young, Thomas L	3048104766	\$8,000.	\$0.	\$8,000.
Lexington Fayette County Health Department Tates Creek Elementary School Center				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Pediatrics</u>				
Young, Thomas L	3048104833	\$31,200.	\$0.	\$31,200.
Lexington Fayette County Health Department Harrison Elementary School Center				
Pediatrics	Totals:	\$3,111,104.	\$1,388,339.	\$4,499,443.
<u>Molecular & Biomedical Pharmacology</u>				
Craven, Rolf J	3048105435	\$149,978.	\$0.	\$149,978.
KY Lung Cancer Research Fund A Novel Approach for Targeting the Epidermal Growth Factor Receptor (EGFR) in Lung Cancer				
Kaetzel, David M	3048058700	\$0.	\$203,946.	\$203,946.
National Cancer Institute Molecular Mechanisms of Metastasis Suppression by NM23				
Landfield, Philip W	3046818000	\$0.	\$1,621,491.	\$1,621,491.
National Institute on Aging Calcium Regulation in Brain Aging and Alzheimer's Disease - Core A				
Plattner, Rina	3048103677	\$0.	\$269,444.	\$269,444.
National Cancer Institute ABI kinases in growth factor signaling, motility, and invasion.				
Swanson, Hollie	3048042200	\$0.	\$260,130.	\$260,130.
National Institute of Environmental Health Sciences AHR-Protac, a Novel Aryl Hydrocarbon Receptor Antagonist				
Molecular & Biomedical Pharmacology	Totals:	\$149,978.	\$2,355,011.	\$2,504,989.
<u>Physiology</u>				
Andrade, Francisco H	3048104851	\$28,132.	\$0.	\$28,132.
National Institute of General Medical Sciences NRSA Fellowship for Gamboa: Skeletal Muscle Adaptation to Hypoxia				
Andrade, Francisco H	3048105205	\$0.	\$35,209.	\$35,209.
National Eye Institute Determinants of Extraocular Muscle Function				
Andrade, Francisco H	3048105205	\$329,625.	\$0.	\$329,625.
National Eye Institute Determinants of Extraocular Muscle Function				
Andrade, Francisco H	3048105724	\$60,215.	\$0.	\$60,215.
National Eye Institute ARRA: Determinants of Extraocular Muscle Function				
Campbell, Kenneth S	3048105039	\$329,625.	\$0.	\$329,625.
National Heart Lung and Blood Institute Myocardial Stiffness in Diastolic Heart Failure				
Campbell, Kenneth S	3048105473	\$65,000.	\$0.	\$65,000.
American Heart Association Cycling Cross-Bridges Augment Passive Stiffness Componenets During Diastole				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Physiology				
Delisle, Brian P.	3048104544	\$0.	\$65,000.	\$65,000.
American Heart Association Abnormal Protein Folding caused by KCNH2 Mutations with Long QT Syndrome				
Delisle, Brian P.	3048104544	\$0.	-\$65,000.	-\$65,000.
American Heart Association Abnormal Protein Folding caused by KCNH2 Mutations with Long QT Syndrome				
Delisle, Brian P.	3048105124	\$65,000.	\$0.	\$65,000.
American Heart Association Abnormal Protein Folding caused by KCNH2 Mutations with Long QT Syndrome				
Derbenev, Andrei V.	3048105032	\$60,500.	\$0.	\$60,500.
American Heart Association Great Rivers Affiliate Regulation of Presympathetic RVLM Neurons by Cannabinoids				
Derbenev, Andrei V.	3048105438	\$219,750.	\$0.	\$219,750.
National Heart Lung and Blood Institute Regulation of presympathetic RVLM neurons by cannabinoids				
Esser, Karyn A	3048102201	\$0.	\$274,352.	\$274,352.
National Institute Arthritis Musculoskeletal & Skin Intracellular Signaling during Skeletal Muscle Hypertrophy				
Esser, Karyn A	3048104593	\$0.	\$290,070.	\$290,070.
National Institute Arthritis Musculoskeletal & Skin Circadian Rhythms and Skeletal Muscle				
Esser, Karyn A	3048105059	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship Miyazaki: Hypertension, Skeletal Muscle Disease and the Circadian Clock				
Frazier, Donald T	3048104948	\$118,789.	\$0.	\$118,789.
National Institute of General Medical Sciences Interactive Learning Modules for Writing Grant Proposals				
Frolenkov, Gregory I	3048105300	\$280,181.	\$0.	\$280,181.
National Institute on Deafness & Other Communications Role of Staircase Hair Bundle Morphology in Auditory Mechanotransduction				
Frolenkov, Gregory I	3048105300	\$0.	\$49,444.	\$49,444.
National Institute on Deafness & Other Communications Role of Staircase Hair Bundle Morphology in Auditory Mechanotransduction				
Frolenkov, Gregory I	3048105488	\$34,065.	\$0.	\$34,065.
Royal National Institute for Deaf People TRPA-1 mediated protection against noise-induced hearing loss				
Frolenkov, Gregory I	3048105618	\$280,181.	\$0.	\$280,181.
National Institute on Deafness & Other Communications Regulation of outer hair cell electromotility and noise-induced hearing loss				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Physiology				
Gu, Qihai	3048104860	\$77,000.	\$0.	\$77,000.
American Heart Association Modulation of Acid Sensing in Pulmonary C-Fiber Sensory Nerves by Protease-activated Receptor-2				
Gu, Qihai	3048105048	\$73,250.	\$0.	\$73,250.
National Institute of Allergy and Infectious Diseases PAR2, Bronchopulmonary Sensory Nerve and Pathogenesis of Asthma				
Lee, Lu Yuan	3046925700	\$0.	\$235,419.	\$235,419.
National Heart Lung and Blood Institute Chemosensitivity of Tachykinin-Containing Lung Afferents				
McClintock, Timothy S	3046977300	\$0.	\$31,824.	\$31,824.
National Institute on Deafness & Other Communications Genomics of Olfactory Regeneration				
McClintock, Timothy S	3046977300	\$0.	\$286,409.	\$286,409.
National Institute on Deafness & Other Communications Genomics of Olfactory Regeneration				
McClintock, Timothy S	3048105738	\$9,753.	\$0.	\$9,753.
National Institute on Deafness & Other Communications ARRA: Genomics of Olfactory Regeneration				
McMullen, Colleen A	3048105765	\$33,413.	\$0.	\$33,413.
National Institute on Deafness & Other Communications ARRA: Molecular mechanisms of aging in the intrinsic laryngeal muscles				
Nikolova-Karakashian, Mariana	3048091200	\$0.	\$294,319.	\$294,319.
National Institute on Aging Role of Neutral Spingomyelinase-2 in Aging				
Nikolova-Karakashian, Mariana	3048103526	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Rozenova Fellowship: The role of Acid Sphingomyelinase as a regulator of TNF-alpha levels in endotoxic shock model				
Randall, David C	3046945800	\$0.	\$317,923.	\$317,923.
National Institute of Neurological Disorders & Stroke Sympathetic Function in Diabetes				
Reid, Michael B	3048103527	\$0.	\$44,000.	\$44,000.
American Heart Association Ohio Valley Affiliate Fellowship: Leonardo Ferreira: Intracellular Signaling of Cytokine Stimulated Protein Degradation in Skeletal Muscle				
Reid, Michael B	3048105233	\$329,625.	\$0.	\$329,625.
National Space Biomedical Research Institute Redox Modulation of Skeletal Muscle Function in Microgravity				
Satin, Jonathan	3048103529	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Byse Fellowship: The L-Type Calcium Channel as a Signaling Molecule in Cardiac Development				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Physiology				
Satin, Jonathan	3048105528	\$29,029.	\$0.	\$29,029.
National Heart Lung and Blood Institute Fellowship William Lester: L-Type Calcium Entry Triggered Diastolic Sparks				
Smart, Eric J	3048103528	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Bradshaw: EG-VEGF Mediated Angiogenesis				
Smith, Bret N.	3048104952	\$219,750.	\$0.	\$219,750.
National Institute Diabetes & Digestive & Kidney Neural circuitry in the dorsal vagal complex				
Smith, Bret N.	3048105496	\$0.	\$32,962.	\$32,962.
National Institute Diabetes & Digestive & Kidney Glucocorticoids and endocannabinoids in vagal complex				
Smith, Bret N.	3048105496	\$318,638.	\$0.	\$318,638.
National Institute Diabetes & Digestive & Kidney Glucocorticoids and endocannabinoids in vagal complex				
Smith, George M	3046853900	\$0.	\$58,266.	\$58,266.
National Institute of Neurological Disorders & Stroke Axonal Growth and Guidance for Nervous System Repair				
Smith, George M	3046853900	\$0.	\$29,134.	\$29,134.
National Institute of Neurological Disorders & Stroke Axonal Growth and Guidance for Nervous System Repair				
Smith, George M	3046853900	\$0.	\$262,199.	\$262,199.
National Institute of Neurological Disorders & Stroke Axonal Growth and Guidance for Nervous System Repair				
Smith, George M	3048080400	\$0.	\$97,405.	\$97,405.
KY Spinal Cord and Head Injury Research Trust Engineering Chondroitinase AC for Expression Within the Injured Spinal Cord				
Smith, George M	3048105466	\$0.	\$204.	\$204.
National Institute of Neurological Disorders & Stroke Trimby Fellowship: Specific targeting of a neuronal subset using a novel chimeric vector pseudotype				
Smith, George M	3048105466	\$31,658.	\$0.	\$31,658.
National Institute of Neurological Disorders & Stroke Trimby Fellowship: Specific targeting of a neuronal subset using a novel chimeric vector pseudotype				
Smith, George M	3048105683	\$324,297.	\$0.	\$324,297.
National Institute of Neurological Disorders & Stroke Reconstruction of the Nigrostriatal pathway				
Snyder, Carol T	3048011900	\$0.	\$24,428.	\$24,428.
KY Council on Postsecondary Education Professional Education Preparation Program				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Physiology				
Snyder, Carol T	3048104856	\$0.	\$-5,600.	\$-5,600.
KY Council on Postsecondary Education Professional Education Preparation Program (PEPP)				
Snyder, Carol T	3048104856	\$137,500.	\$0.	\$137,500.
KY Council on Postsecondary Education Professional Education Preparation Program (PEPP)				
Stocker, Sean D	3048104468	\$0.	\$362,112.	\$362,112.
National Heart Lung and Blood Institute Central Nervous System Mechanisms of Obesity Hypertension				
Stocker, Sean D	3048105094	\$21,000.	\$0.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship Bardgett: Neural Mechanisms of Sympathetic Activation During Hyperinsulinemia and Obesity-Induced Hypertension				
Stocker, Sean D	3048105472	\$65,000.	\$0.	\$65,000.
American Heart Association Neural Mechanisms Mediating Decompensated Hemorrhage				
Taylor, Bradley Kenneth	3048105490	\$70,200.	\$0.	\$70,200.
National Institute on Drug Abuse Neuropeptidergic Inhibition of Spinal Pain Transmission				
Taylor, Bradley Kenneth	3048105491	\$297,996.	\$0.	\$297,996.
National Institute of Neurological Disorders & Stroke Neuropeptidergic Inhibition of Spinal Pain Transmission				
Taylor, Bradley Kenneth	3048105511	\$9,324.	\$0.	\$9,324.
National Institute of Neurological Disorders & Stroke Fellowship for Solway: Contribution of endogenous NPY signaling to chronic pain				
Taylor, Bradley Kenneth	3048105516	\$0.	\$204.	\$204.
National Institute of Neurological Disorders & Stroke Fellowship for Solway: Contribution of endogenous NPY signaling to chronic pain				
Taylor, Bradley Kenneth	3048105516	\$26,772.	\$0.	\$26,772.
National Institute of Neurological Disorders & Stroke Fellowship for Solway: Contribution of endogenous NPY signaling to chronic pain				
Taylor, Bradley Kenneth	3048105684	\$323,568.	\$0.	\$323,568.
National Institute of Neurological Disorders & Stroke PPAR Inhibition of Spinal Pain Transmission				
Taylor, Bradley Kenneth	3048105685	\$77,650.	\$0.	\$77,650.
National Institute on Drug Abuse Supraspinal Modulation of Neuropathic Pain				
Physiology	Totals:	\$4,389,486.	\$2,783,283.	\$7,172,769.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Psychiatry				
Brenzel, Allen J	3048105434	\$162,216.	\$0.	\$162,216.
Eastern KY University UTC-IV-E Training (4-51200) / Title IV-E Administrative				
Carvalho, Cletus Savio	3048011800	\$0.	\$1,260.	\$1,260.
Bristol Myers Squibb Company A Multicenter, Double-Blind, Study on the Efficacy and Safety of Aripiprazole in Combination				
Carvalho, Cletus Savio	3048011800	\$0.	\$2,520.	\$2,520.
Bristol Myers Squibb Company A Multicenter, Double-Blind, Study on the Efficacy and Safety of Aripiprazole in Combination				
De Leon, Jose	3048103703	\$0.	\$60,000.	\$60,000.
Genomas Inc SBIR: DNA Diagnostics for Minimizing Side-Effects of Psychotropics				
De Leon, Jose	3048103703	\$0.	\$83,997.	\$83,997.
Genomas Inc SBIR: DNA Diagnostics for Minimizing Side-Effects of Psychotropics				
Glaser, Paul E	3046986400	\$0.	\$9,324.	\$9,324.
Eli Lilly and Company Study of Atomoxetine HC1 in Treatment of Adults with ADHD & Comorbid Social Anxiety				
Glaser, Paul E	3048103808	\$0.	\$44.	\$44.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$3,072.	\$3,072.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$20,211.	\$20,211.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$6,263.	\$6,263.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$6,467.	\$6,467.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$3,771.	\$3,771.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Psychiatry				
Glaser, Paul E	3048103808	\$0.	\$18,152.	\$18,152.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$11,429.	\$11,429.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$4,635.	\$4,635.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$20,658.	\$20,658.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$1,685.	\$1,685.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$8,812.	\$8,812.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$6,837.	\$6,837.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048103808	\$0.	\$12,087.	\$12,087.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Kaak, Hans O	3048105254	\$10,000.	\$0.	\$10,000.
KY Cabinet for Health and Family Services UK CATS Project SJPC: Early Mental Health Training				
Lofwall, Michelle Renee	3048103695	\$0.	\$1,075.	\$1,075.
CRS Associates LLC Product Familiarity Interview: Post marketing Surveillance Project for Subutex and Suboxone				
Martin, Catherine A	3048104416	\$0.	\$42,501.	\$42,501.
Yaupon Therapeutics Inc SBIR: Lobeline Clinical Study in ADHD				
Psychiatry	Totals:	\$172,216.	\$324,800.	\$497,016.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Bernard, Andrew C	3046779000	\$0.	\$12,180.	\$12,180.
Northfield Laboratories A Phase III Randomized, Controlled, Open-Label, Multicenter, Parallel Group Study Using Provisions for Exception from Informed Consent Requirements Designed to Evaluate the Safety and Efficacy of Poly SFH-P Injection				
Bernard, Andrew C	3046779000	\$0.	\$-12,180.	\$-12,180.
Northfield Laboratories A Phase III Randomized, Controlled, Open-Label, Multicenter, Parallel Group Study Using Provisions for Exception from Informed Consent Requirements Designed to Evaluate the Safety and Efficacy of Poly SFH-P Injection				
Bernard, Andrew C	3046779000	\$0.	\$1,272.	\$1,272.
Northfield Laboratories A Phase III Randomized, Controlled, Open-Label, Multicenter, Parallel Group Study Using Provisions for Exception from Informed Consent Requirements Designed to Evaluate the Safety and Efficacy of Poly SFH-P Injection				
Bernard, Andrew C	3048104408	\$0.	\$34,265.	\$34,265.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$2,000.	\$2,000.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$21,673.	\$21,673.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$2,000.	\$2,000.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$92,595.	\$92,595.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$2,000.	\$2,000.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$3,240.	\$3,240.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Bernard, Andrew C	3048104408	\$0.	\$28,108.	\$28,108.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$32,177.	\$32,177.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048105127	\$0.	\$3,290.	\$3,290.
Pfizer Inc Prospective Evaluation of Sputum Staphylococcus Aureus Resistance Patterns				
Bernard, Andrew C	3048105127	\$2.	\$0.	\$2.
Pfizer Inc Prospective Evaluation of Sputum Staphylococcus Aureus Resistance Patterns				
Bonnell, Mark	3048105264	\$0.	\$6,298.	\$6,298.
Levitronix LLC Levitronix CentriMag VAS Failure-to-Wean from Cardiopulmonary Bypass Trial				
Bonnell, Mark	3048105264	\$2.	\$0.	\$2.
Levitronix LLC Levitronix CentriMag VAS Failure-to-Wean from Cardiopulmonary Bypass Trial				
Chang, Phillip K	3048105310	\$0.	\$2,520.	\$2,520.
Canica Design Inc A Prospective Evaluation of ABRA Abdominal Wall Closure System in Combination with V.A.C. Therapy Compared V.A.C. Therapy Alone in the Management of Open Abdomen				
Chang, Phillip K	3048105310	\$2.	\$0.	\$2.
Canica Design Inc A Prospective Evaluation of ABRA Abdominal Wall Closure System in Combination with V.A.C. Therapy Compared V.A.C. Therapy Alone in the Management of Open Abdomen				
Ferraris, Victor	3048079900	\$0.	\$-6,150.	\$-6,150.
Medicure Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
Ferraris, Victor	3048079900	\$0.	\$6,150.	\$6,150.
Medicure Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
Ferraris, Victor	3048079900	\$0.	\$6,150.	\$6,150.
Medicure Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Ferraris, Victor	3048079900	\$0.	\$-2,000.	\$-2,000.
Medicare Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
Ferraris, Victor	3048105521	\$0.	\$3,780.	\$3,780.
Dyax Corp KALAHARI 1: Kallikrein Antagonist (DX-88 Ecallantide) Effect on Blood Loss Associated w/Heart Surgery Requiring Institution of Bypass, Amendment 2 DX-88/16				
Ferraris, Victor	3048105521	\$3,780.	\$0.	\$3,780.
Dyax Corp KALAHARI 1: Kallikrein Antagonist (DX-88 Ecallantide) Effect on Blood Loss Associated w/Heart Surgery Requiring Institution of Bypass, Amendment 2 DX-88/16				
Gagliardi, Raymond	3048104040	\$0.	\$70,000.	\$70,000.
United States Surgical Corp Tyco Healthcare Minimally Invasive Surgery Fellowship				
HANNA, NADER	3046440200	\$0.	\$9,702.	\$9,702.
GenVec Inc GV 001.002.An Open-Label, Phase I, Dose-Escalation Study of Tumor Necrosis Factor-alpha (TNFerade Biologic) Gene Therapy with Radiation for Locally Advanced, Recurrent or Metastatic Solid Tumors				
HANNA, NADER	3046440200	\$0.	\$18,085.	\$18,085.
GenVec Inc GV 001.002.An Open-Label, Phase I, Dose-Escalation Study of Tumor Necrosis Factor-alpha (TNFerade Biologic) Gene Therapy with Radiation for Locally Advanced, Recurrent or Metastatic Solid Tumors				
Jeon, Hoonbae	3048103203	\$0.	\$4,198.	\$4,198.
Albert Einstein College of Medicine Cellcept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients with Long-Term Follow-up Post-Transplantation for Non Autoimmune				
Johnston, Thomas	3046661300	\$0.	\$2,910.	\$2,910.
Wyeth Research A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus vs Continued use of Calcineurin inhibitors in Renal Allograft Recipients				
Johnston, Thomas	3046661300	\$0.	\$456.	\$456.
Wyeth Research A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus vs Continued use of Calcineurin inhibitors in Renal Allograft Recipients				
Johnston, Thomas	3046661300	\$0.	\$-16,999.	\$-16,999.
Wyeth Research A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus vs Continued use of Calcineurin inhibitors in Renal Allograft Recipients				
Johnston, Thomas	3046771800	\$0.	\$2,687.	\$2,687.
Novartis DIRECT-Study: Diabetes Incidence after Renal Transplantation Neoral C-2 Monitoring versus Tacrolimus				
Johnston, Thomas	3046816700	\$0.	\$16,999.	\$16,999.
Wyeth Pharmaceuticals Inc A Randomized, Open-label Study to Compare the Safety and Efficacy of Two Different Rapamune Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Johnston, Thomas	3046816700	\$0.	\$732.	\$732.
Wyeth Pharmaceuticals Inc A Randomized, Open-label Study to Compare the Safety and Efficacy of Two Different Rapamune Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients				
Johnston, Thomas	3046944500	\$0.	\$13,447.	\$13,447.
Novartis A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				
Johnston, Thomas	3046944500	\$0.	\$21,024.	\$21,024.
Novartis A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				
Johnston, Thomas	3046944500	\$0.	\$25,704.	\$25,704.
Novartis A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				
Johnston, Thomas	3046944500	\$0.	\$5,017.	\$5,017.
Novartis A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				
Johnston, Thomas	3048064300	\$0.	\$4,105.	\$4,105.
Bristol Myers Squibb Company Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				
Johnston, Thomas	3048064300	\$0.	\$2,856.	\$2,856.
Bristol Myers Squibb Company Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				
Johnston, Thomas	3048064300	\$0.	\$1,029.	\$1,029.
Bristol Myers Squibb Company Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				
Johnston, Thomas	3048104315	\$0.	\$630.	\$630.
Bristol Myers Squibb Company A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant				
Johnston, Thomas	3048104315	\$0.	\$6,360.	\$6,360.
Bristol Myers Squibb Company A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant				
Johnston, Thomas	3048104407	\$0.	\$399.	\$399.
Wyeth Pharmaceuticals Inc A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Kearney, Paul A	3046969400	\$0.	\$9,339.	\$9,339.
Pfizer Inc Linezolid in the Treatment of Subjects iwth Nosocomial Pneumonia Proven to be due to Methicillin-Resistant Staphylococcus Aureus				
Kearney, Paul A	3048104280	\$0.	\$21,468.	\$21,468.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo Controlled, Paralledl-Group Study of Intravenous Methylalntrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair				
Kearney, Paul A	3048104280	\$0.	\$1,148.	\$1,148.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo Controlled, Paralledl-Group Study of Intravenous Methylalntrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair				
Kenady, Daniel E	3046561400	\$0.	\$9,702.	\$9,702.
GenVec Inc An Open Label Phase 1 Dose-Escalation Study of TNFerade Biologic with Radation Therapy as an Adjunct to Surgery or for Palliation in Soft Tissue Sarcoma of the Extremities				
Kenady, Daniel E	3046561400	\$0.	\$12,121.	\$12,121.
GenVec Inc An Open Label Phase 1 Dose-Escalation Study of TNFerade Biologic with Radation Therapy as an Adjunct to Surgery or for Palliation in Soft Tissue Sarcoma of the Extremities				
Kenady, Daniel E	3046633200	\$0.	\$672.	\$672.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$15,801.	\$15,801.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$869.	\$869.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$1,729.	\$1,729.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$938.	\$938.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$8,463.	\$8,463.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Kenady, Daniel E	3046633200	\$0.	\$50.	\$50.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$156.	\$156.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$1,633.	\$1,633.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$1,729.	\$1,729.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$13,867.	\$13,867.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$16,788.	\$16,788.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046919900	\$0.	\$2,658.	\$2,658.
IRx Therapeutics Inc A Phase 2, Open Label Trial of the Safety and Biological Effect of Pre-Operative Peri-Lymphatic Ultralow Dose of IRX-2 (with Cyclophamide, Indomethacin, and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck				
Kenady, Daniel E	3046919900	\$0.	\$939.	\$939.
IRx Therapeutics Inc A Phase 2, Open Label Trial of the Safety and Biological Effect of Pre-Operative Peri-Lymphatic Ultralow Dose of IRX-2 (with Cyclophamide, Indomethacin, and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck				
Kyprianou, Natasha	3048105153	\$437,021.	\$0.	\$437,021.
US Army Medical Research and Materiel Command Biomarker Discovery and Mechanistic Studies of Prostate Cancer using Targeted Proteomic Approaches				
Kyprianou, Natasha	3048105187	\$30,000.	\$0.	\$30,000.
American Urological Association Foundation Fellowship for Sakamoto: The Role of Talin in Prostate Cancer Progression				
McKeown, John W	3046972800	\$0.	\$10,000.	\$10,000.
Isotechnika Inc A Phase IIb, Randomized, Multicenter, Open-Label, Concentration-Controlled, Safety Study of ISA247 and Tacrolimus (Prograf) in De Novo Renal Transplant Patients				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
McKeown, John W	3046972800	\$0.	\$3,150.	\$3,150.
Isotechnika Inc A Phase IIb, Randomized, Multicenter, Open-Label, Concentration-Controlled, Safety Study of ISA247 and Tacrolimus (Prograf) in De Novo Renal Transplant Patients				
Minion, David	3046336100	\$0.	\$9,096.	\$9,096.
Edwards Lifesciences Pivotal, Multicenter, Prospective, Concurrent Control, Non Randomized Trial to Evaluate the Safety and Effectiveness of the Baxter Lifepath AAA Bifurcated Graft in Patients with Infrarenal Abdominal Aortic Aneurysm				
Mullett, Timothy	3048104442	\$0.	\$2,763.	\$2,763.
Fresenius Biotech North America Protocol EZ-2053-001: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary				
Mullett, Timothy	3048104442	\$0.	\$522.	\$522.
Fresenius Biotech North America Protocol EZ-2053-001: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary				
Mullett, Timothy	3048104442	\$0.	\$1,566.	\$1,566.
Fresenius Biotech North America Protocol EZ-2053-001: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary				
Mullett, Timothy	3048105640	\$2.	\$0.	\$2.
Covidien A Prospective Multi-Center Randomized clinical study to Evaluate the PleuraSeal Sealant System as an Adjunct to Standard Closure Techniques for Control of Visceral Pleural Air Leaks Following Elective Pulmonary Resection Via Open Thoracotomy				
Ramaiah, Chandrashekhar	3048105082	\$2.	\$0.	\$2.
IFlow Corp Multicenter Infection Surveillance Study Following Cardiac Surgical Procedures				
Ramaiah, Chandrashekhar	3048105352	\$0.	\$5,780.	\$5,780.
Merck and Company Inc A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity and Safety of a Single Dose of Merck 0657nl Staphylococcus Aureus Vaccine V710 in Adult Patients Scheduled for Cardiothoracic Surgery				
Ramaiah, Chandrashekhar	3048105352	\$0.	\$6,972.	\$6,972.
Merck and Company Inc A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity and Safety of a Single Dose of Merck 0657nl Staphylococcus Aureus Vaccine V710 in Adult Patients Scheduled for Cardiothoracic Surgery				
Ramaiah, Chandrashekhar	3048105352	\$2.	\$0.	\$2.
Merck and Company Inc A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity and Safety of a Single Dose of Merck 0657nl Staphylococcus Aureus Vaccine V710 in Adult Patients Scheduled for Cardiothoracic Surgery				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Ramaiah, Chandrashekhar	3048105545	\$2,472.	\$0.	\$2,472.
RibX Pharmaceuticals Inc A Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of RX-3341 Compared with Cefazolin for the Prevention of Surgical Site Infections Following Coronary Artery Bypass Graft Surgery				
Ramaiah, Chandrashekhar	3048105686	\$2.	\$0.	\$2.
Cubist Pharmaceuticals Inc A Clinical Outcomes and Safety Trial in Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume				
Ranjan, Dinesh	3046639300	\$0.	\$12,853.	\$12,853.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				
Ranjan, Dinesh	3046639300	\$0.	\$12,853.	\$12,853.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				
Ranjan, Dinesh	3046639300	\$0.	\$-12,853.	\$-12,853.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				
Ranjan, Dinesh	3046639300	\$0.	\$2,275.	\$2,275.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				
Ranjan, Dinesh	3048103804	\$0.	\$9,103.	\$9,103.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
Ranjan, Dinesh	3048103804	\$0.	\$979.	\$979.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
Ranjan, Dinesh	3048103804	\$0.	\$-4,110.	\$-4,110.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
Ranjan, Dinesh	3048103804	\$0.	\$3,672.	\$3,672.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
Ranjan, Dinesh	3048103804	\$0.	\$1,742.	\$1,742.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Ranjan, Dinesh	3048103804	\$0.	\$13,214.	\$13,214.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
Ranjan, Dinesh	3048103804	\$0.	\$6,095.	\$6,095.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
Ranjan, Dinesh	3048105361	\$2.	\$0.	\$2.
Novartis A 24 Month, Multi-Center, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de novo Liver Transplant Recipients				
Saha, Sib	3048103829	\$0.	\$29,358.	\$29,358.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$17,920.	\$17,920.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$6,575.	\$6,575.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$100.	\$100.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$755.	\$755.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$25.	\$25.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$23,974.	\$23,974.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$5,132.	\$5,132.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048104218	\$0.	\$5,002.	\$5,002.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Saha, Sib	3048104218	\$0.	\$16,506.	\$16,506.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
Saha, Sib	3048104218	\$0.	\$1,260.	\$1,260.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
Saha, Sib	3048104218	\$0.	\$5,002.	\$5,002.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
Tibbs, Phillip A	3046722800	\$0.	\$3,558.	\$3,558.
DePuy Spine A Post-Approval Evaluation of the Lumbar I/F Cage with VSP Spine System for PLIF				
Tibbs, Phillip A	3048082800	\$0.	\$65,015.	\$65,015.
DePuy Spine SLIM-Loc Plating fusion vs. DISCOVER Artificial Disc				
Tibbs, Phillip A	3048082800	\$0.	\$98,409.	\$98,409.
DePuy Spine SLIM-Loc Plating fusion vs. DISCOVER Artificial Disc				
Tibbs, Phillip A	3048082800	\$0.	\$4,968.	\$4,968.
DePuy Spine SLIM-Loc Plating fusion vs. DISCOVER Artificial Disc				
Tibbs, Phillip A	3048082800	\$0.	\$4,870.	\$4,870.
DePuy Spine SLIM-Loc Plating fusion vs. DISCOVER Artificial Disc				
Tibbs, Phillip A	3048104419	\$0.	\$6,503.	\$6,503.
Kyphon Inc Treatment of Lumbar Spinal Stenosis with X-Stop IPD in Moderately Symptomatic Patients to Assess the Long-Term Safety and Performance of X-Stop Interspinous Decompression System				
Tibbs, Phillip A	3048104419	\$0.	\$3,906.	\$3,906.
Kyphon Inc Treatment of Lumbar Spinal Stenosis with X-Stop IPD in Moderately Symptomatic Patients to Assess the Long-Term Safety and Performance of X-Stop Interspinous Decompression System				
Tibbs, Phillip A	3048104419	\$0.	\$410.	\$410.
Kyphon Inc Treatment of Lumbar Spinal Stenosis with X-Stop IPD in Moderately Symptomatic Patients to Assess the Long-Term Safety and Performance of X-Stop Interspinous Decompression System				
Tibbs, Phillip A	3048104419	\$0.	\$4,597.	\$4,597.
Kyphon Inc Treatment of Lumbar Spinal Stenosis with X-Stop IPD in Moderately Symptomatic Patients to Assess the Long-Term Safety and Performance of X-Stop Interspinous Decompression System				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Toborek, Michal	3046928600	\$0.	\$265,994.	\$265,994.
National Institute of Neurological Disorders & Stroke Tat-Mediated Brain Endothelial Cell Dysfunction				
Toborek, Michal	3046939200	\$0.	\$277,817.	\$277,817.
National Institute of Mental Health Tat, Amyloid Beta and Brain Endothelial Barrier Function				
Toborek, Michal	3048105020	\$0.	\$347,938.	\$347,938.
National Institute of Mental Health Implications of Caveolae in Tat Signaling and Integrity of Brain Endothelium				
Toborek, Michal	3048105020	\$366,250.	\$0.	\$366,250.
National Institute of Mental Health Implications of Caveolae in Tat Signaling and Integrity of Brain Endothelium				
Waid, Thomas	3046750500	\$0.	\$-1,817.	\$-1,817.
Roche Pharmaceutical Research Associates Inc An Open Label, Randomized, Multicenter Study To Evaluate The Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil and Sirolimus				
Waid, Thomas	3046750500	\$0.	\$630.	\$630.
Roche Pharmaceutical Research Associates Inc An Open Label, Randomized, Multicenter Study To Evaluate The Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil and Sirolimus				
Waid, Thomas	3046750500	\$0.	\$24,923.	\$24,923.
Roche Pharmaceutical Research Associates Inc An Open Label, Randomized, Multicenter Study To Evaluate The Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil and Sirolimus				
Waid, Thomas	3046750500	\$0.	\$1,260.	\$1,260.
Roche Pharmaceutical Research Associates Inc An Open Label, Randomized, Multicenter Study To Evaluate The Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil and Sirolimus				
Waid, Thomas	3046863600	\$0.	\$-24,923.	\$-24,923.
Roche Laboratories An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimans for Patients Following a Single Organ Renal Tansplantation in Comb				
Waid, Thomas	3046863600	\$0.	\$630.	\$630.
Roche Laboratories An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimans for Patients Following a Single Organ Renal Tansplantation in Comb				
Waid, Thomas	3046863600	\$0.	\$4,429.	\$4,429.
Roche Laboratories An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimans for Patients Following a Single Organ Renal Tansplantation in Comb				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Waid, Thomas	3048103550	\$0.	\$1,722.	\$1,722.
Astellas Pharma US Inc A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
Waid, Thomas	3048103550	\$0.	\$2,926.	\$2,926.
Astellas Pharma US Inc A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
Waid, Thomas	3048103550	\$0.	\$3,911.	\$3,911.
Astellas Pharma US Inc A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
Waid, Thomas	3048103550	\$0.	\$11,718.	\$11,718.
Astellas Pharma US Inc A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
Young, Alfred B	3048103840	\$0.	\$2,000.	\$2,000.
Virginia Commonwealth University A Multicenter Observational Study to Evaluate Dynamics of Endothelin and Markers of Cellular Apoptosis in Cerebrospinal Fluid and Plasma in Moderate and Severe Human Head Injury				
Young, Alfred B	3048103840	\$0.	\$-2,000.	\$-2,000.
Virginia Commonwealth University A Multicenter Observational Study to Evaluate Dynamics of Endothelin and Markers of Cellular Apoptosis in Cerebrospinal Fluid and Plasma in Moderate and Severe Human Head Injury				
Young, Alfred B	3048103840	\$0.	\$1,998.	\$1,998.
Virginia Commonwealth University A Multicenter Observational Study to Evaluate Dynamics of Endothelin and Markers of Cellular Apoptosis in Cerebrospinal Fluid and Plasma in Moderate and Severe Human Head Injury				
Young, Alfred B	3048104383	\$0.	\$-2.	\$-2.
National Institute of Neurological Disorders & Stroke CASTBI Trial Planning Grant: Cyclosporine in Traumatic Brain Injury				
Young, Alfred B	3048105409	\$0.	\$1,575.	\$1,575.
Adnexus Phase 1, Open-Label, Multit-Center Study to Evaluate the Safety and Tolerability of CT-322 Administered in Combination with Focal Brain Radiotherapy and Temozolomide to Subjects with Newly Diagnosed Glioblastoma Multiforme				
Young, Alfred B	3048105409	\$0.	\$3,465.	\$3,465.
Adnexus Phase 1, Open-Label, Multit-Center Study to Evaluate the Safety and Tolerability of CT-322 Administered in Combination with Focal Brain Radiotherapy and Temozolomide to Subjects with Newly Diagnosed Glioblastoma Multiforme				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Young, Alfred B	3048105409	\$2.	\$0.	\$2.
Adnexus Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of CT-322 Administered in Combination with Focal Brain Radiotherapy and Temozolomide to Subjects with Newly Diagnosed Glioblastoma Multiforme				
Young, Alfred B	3048105520	\$0.	\$4,410.	\$4,410.
Adnexus Tolerability and Efficacy of CT-322 (Angiocept) Monotherapy and Combination with Irinotecan in Patients with Recurrent Glioblastoma Multiforme CT-322.002				
Young, Alfred B	3048105520	\$2.	\$0.	\$2.
Adnexus Tolerability and Efficacy of CT-322 (Angiocept) Monotherapy and Combination with Irinotecan in Patients with Recurrent Glioblastoma Multiforme CT-322.002				
Young, Alfred B	3048105604	\$2.	\$0.	\$2.
Solvay Pharmaceuticals A Randomized, Double Blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients with Moderate and Severe Traumatic				
Yurek, David M	3046851500	\$0.	\$275,018.	\$275,018.
National Institute of Neurological Disorders & Stroke Stem Cell Adaptability in Parkinson's Disease				
Yurek, David M	3046851500	\$0.	\$30,558.	\$30,558.
National Institute of Neurological Disorders & Stroke Stem Cell Adaptability in Parkinson's Disease				
Yurek, David M	3048105192	\$137,321.	\$0.	\$137,321.
Michael J Fox Foundation for Parkinsons Disease DNA Nanoparticle Therapy for Parkinson's Disease				
Zwischenberger, Joseph	3048104857	\$0.	\$-291,361.	\$-291,361.
Medarray Inc SBIR: Novel Dense Hollow Fiber for Blood Gas Exchange				
Zwischenberger, Joseph	3048104857	\$291,361.	\$0.	\$291,361.
Medarray Inc SBIR: Novel Dense Hollow Fiber for Blood Gas Exchange				
Zwischenberger, Joseph	3048105207	\$291,361.	\$0.	\$291,361.
Medarray Inc SBIR: Novel Dense Hollow Fiber for Blood Gas Exchange				
Zwischenberger, Joseph	3048105367	\$20,000.	\$0.	\$20,000.
MC3 Inc STTR: Development of a Perfusion-induced Systemic Hyperthermia Delivery Apparatus				
Surgery	Totals:	\$1,579,588.	\$1,881,115.	\$3,460,703.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

	New Accounts	Adjustments to Existing Accounts	Total
Medicine			
Neurology			
Bensalem Owen, Meriem Katre nec 3048104422 Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$671.	\$671.
Bensalem Owen, Meriem Katre nec 3048104422 Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$152.	\$152.
Bensalem Owen, Meriem Katre nec 3048104422 Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$236.	\$236.
Bensalem Owen, Meriem Katre nec 3048104422 Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$8,902.	\$8,902.
Bensalem Owen, Meriem Katre nec 3048104797 Inc Research Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome	\$0.	\$-5,335.	\$-5,335.
Bensalem Owen, Meriem Katre nec 3048104797 Inc Research Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome	\$0.	\$60.	\$60.
Bensalem Owen, Meriem Katre nec 3048104797 Inc Research Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome	\$0.	\$7,564.	\$7,564.
Bensalem Owen, Meriem Katre nec 3048104797 Inc Research Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome	\$2.	\$0.	\$2.
Bensalem Owen, Meriem Katre nec 3048105553 Quintiles Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$4,559.	\$4,559.
Bensalem Owen, Meriem Katre nec 3048105553 Quintiles Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$2.	\$0.	\$2.
Bensalem Owen, Meriem Katre nec 3048105554 Quintiles Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome	\$0.	\$4,814.	\$4,814.
Bensalem Owen, Meriem Katre nec 3048105554 Quintiles Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome	\$0.	\$5,333.	\$5,333.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Bensalem Owen, Meriem Katre nec	3048105554	\$2.	\$0.	\$2.
Quintiles Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome				
Berger, Joseph R	3048102204	\$0.	\$18,292.	\$18,292.
UCB Pharma Double-blind Placebo Controlled, Randomized, Parallel-group, Phase II study in subjects with relapsing forms of Multiple Sclerosis to evaluate the effects of two doses of CDP323 over 24 weeks with a rater blind MRI follow up over 12 weeks				
Berger, Joseph R	3048102204	\$0.	\$14,736.	\$14,736.
UCB Pharma Double-blind Placebo Controlled, Randomized, Parallel-group, Phase II study in subjects with relapsing forms of Multiple Sclerosis to evaluate the effects of two doses of CDP323 over 24 weeks with a rater blind MRI follow up over 12 weeks				
Berger, Joseph R	3048103649	\$0.	\$49,000.	\$49,000.
Pfizer Inc JCV Expression During Treatment with MS Disease Modifying Drugs				
Berger, Joseph R	3048103649	\$0.	\$49,000.	\$49,000.
Pfizer Inc JCV Expression During Treatment with MS Disease Modifying Drugs				
Berger, Joseph R	3048104087	\$0.	\$522.	\$522.
PPD Development Inc A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons with Multiple Sclerosis with Cognitive Impairment				
Berger, Joseph R	3048104087	\$0.	\$6,833.	\$6,833.
PPD Development Inc A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons with Multiple Sclerosis with Cognitive Impairment				
Berger, Joseph R	3048105403	\$0.	\$4,077.	\$4,077.
Biogen Research Co A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)				
Berger, Joseph R	3048105403	\$2.	\$0.	\$2.
Biogen Research Co A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)				
Berger, Joseph R	3048105452	\$17,688.	\$0.	\$17,688.
Vanderbilt University CNS Viral Dynamics and Cellular Immunity During AIDS				
Cambi, Franca	3048079000	\$0.	\$288,422.	\$288,422.
National Institute of Neurological Disorders & Stroke PLP Alternative Splicing and Oligodendrocyte Differentiation				
Cambi, Franca	3048079000	\$0.	\$32,047.	\$32,047.
National Institute of Neurological Disorders & Stroke PLP Alternative Splicing and Oligodendrocyte Differentiation				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Cambi, Franca	3048105159	\$5,500.	\$0.	\$5,500.
Jacobs Ladder PLP/DM20 Alternative Splicing: Studies on Regulatory Sequences in Exon 3B				
Cambi, Franca	3048105397	\$79,285.	\$0.	\$79,285.
ELA Conseil Scientifique PLP/DM20 Alternative Splicing: Studies on Regulatory Sequences, Splicing Factors and Mutations Affecting Splicing in PMD Patients				
Cambi, Franca	3048105501	\$46,728.	\$0.	\$46,728.
National Institute of Neurological Disorders & Stroke Neuroprotection Exploratory Trials in PD (NET-PD)				
Chan, Jane	3048105211	\$0.	\$4,408.	\$4,408.
Sanofi Aventis US Inc An International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment with Teriflunomide 7mg Once Daily vs. and 14mg Once Daily vs				
Chan, Jane	3048105211	\$2.	\$0.	\$2.
Sanofi Aventis US Inc An International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment with Teriflunomide 7mg Once Daily vs. and 14mg Once Daily vs				
Fakhoury, Toufic A	3046747200	\$0.	\$846.	\$846.
Schwarz BioSciences Inc A Multi Center Double Blind Randomized Placebo Controlled Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg day, 400mg day, 600 mg day) as Adjunctive Therapy in Subjects with Partial Seizures				
Fakhoury, Toufic A	3046843900	\$0.	\$3,818.	\$3,818.
Schwarz BioSciences Inc An Open Label-Extension Trial to Determine Safety and Efficacy of Long Term SPM 927 in Patients with Partial Seizures. SP 756				
Fakhoury, Toufic A	3046843900	\$0.	\$762.	\$762.
Schwarz BioSciences Inc An Open Label-Extension Trial to Determine Safety and Efficacy of Long Term SPM 927 in Patients with Partial Seizures. SP 756				
Fakhoury, Toufic A	3046843900	\$0.	\$5,239.	\$5,239.
Schwarz BioSciences Inc An Open Label-Extension Trial to Determine Safety and Efficacy of Long Term SPM 927 in Patients with Partial Seizures. SP 756				
Fakhoury, Toufic A	3046978500	\$0.	\$12,132.	\$12,132.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 MG/DAY) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures				
Fakhoury, Toufic A	3046978500	\$0.	\$1,645.	\$1,645.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 MG/DAY) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Fakhoury, Toufic A	3048094100	\$0.	\$2,825.	\$2,825.
GlaxoSmithKline A Multi-Center, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures				
Fakhoury, Toufic A	3048103108	\$0.	\$9,391.	\$9,391.
Eisai Medical Research Inc A Double-Blind, Placebo-Controlled, Parallel-Group, Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures				
Fakhoury, Toufic A	3048103882	\$0.	\$6,038.	\$6,038.
UCB Pharma An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (16 to 70 years old) with Partial Onset Seizures				
Fakhoury, Toufic A	3048103882	\$0.	\$4,566.	\$4,566.
UCB Pharma An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (16 to 70 years old) with Partial Onset Seizures				
Fakhoury, Toufic A	3048103882	\$0.	\$-2,000.	\$-2,000.
UCB Pharma An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (16 to 70 years old) with Partial Onset Seizures				
Fakhoury, Toufic A	3048103882	\$0.	\$2,794.	\$2,794.
UCB Pharma An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (16 to 70 years old) with Partial Onset Seizures				
Fakhoury, Toufic A	3048103882	\$0.	\$9,943.	\$9,943.
UCB Pharma An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (16 to 70 years old) with Partial Onset Seizures				
Fakhoury, Toufic A	3048103882	\$0.	\$12,472.	\$12,472.
UCB Pharma An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (16 to 70 years old) with Partial Onset Seizures				
Fakhoury, Toufic A	3048103891	\$0.	\$19,233.	\$19,233.
Pharmaceutical Research Associates A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-On Therapy in Adult Subjects with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
Fakhoury, Toufic A	3048103891	\$0.	\$21,467.	\$21,467.
Pharmaceutical Research Associates A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-On Therapy in Adult Subjects with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
Fakhoury, Toufic A	3048104048	\$0.	\$10,483.	\$10,483.
Eisai Medical Research Inc An Open Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Onset Seizures				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Fakhoury, Toufic A	3048104048	\$0.	\$-1,018.	\$-1,018.
Eisai Medical Research Inc An Open Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Onset Seizures				
Fakhoury, Toufic A	3048104048	\$0.	\$14,210.	\$14,210.
Eisai Medical Research Inc An Open Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Onset Seizures				
Fakhoury, Toufic A	3048104048	\$0.	\$1,596.	\$1,596.
Eisai Medical Research Inc An Open Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Onset Seizures				
Fakhoury, Toufic A	3048104396	\$0.	\$14,153.	\$14,153.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$2,129.	\$2,129.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$3,937.	\$3,937.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$4,259.	\$4,259.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$2,589.	\$2,589.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$4,970.	\$4,970.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$21,533.	\$21,533.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$5,857.	\$5,857.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Fakhoury, Toufic A	3048104533	\$0.	\$7,031.	\$7,031.
Marinus Pharmaceuticals Inc An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Ganaxolone as Add-on Therapy in Adult Patients with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
Fakhoury, Toufic A	3048104574	\$0.	\$-2,000.	\$-2,000.
Ortho McNeil Pharmaceuticals A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures				
Fakhoury, Toufic A	3048104574	\$0.	\$2,000.	\$2,000.
Ortho McNeil Pharmaceuticals A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures				
Fakhoury, Toufic A	3048104596	\$0.	\$2,994.	\$2,994.
UCB Pharma An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 years or Older Suffering from Epilepsy				
Fakhoury, Toufic A	3048104596	\$0.	\$16,184.	\$16,184.
UCB Pharma An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 years or Older Suffering from Epilepsy				
Fakhoury, Toufic A	3048105126	\$0.	\$1,789.	\$1,789.
Pfizer Inc An Open Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures				
Fakhoury, Toufic A	3048105126	\$0.	\$1,998.	\$1,998.
Pfizer Inc An Open Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures				
Fakhoury, Toufic A	3048105126	\$2.	\$0.	\$2.
Pfizer Inc An Open Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures				
Fakhoury, Toufic A	3048105126	\$0.	\$794.	\$794.
Pfizer Inc An Open Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures				
Fakhoury, Toufic A	3048105381	\$0.	\$2,000.	\$2,000.
PPD Development Inc An International, Double-Blind, Randomized, Multi-Center, Parallel Group, Historical-Control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (16 to 75 years old) With Partial Onset Seizures With or Without				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Fakhoury, Toufic A	3048105381	\$2.	\$0.	\$2.
PPD Development Inc An International, Double-Blind, Randomized, Multi-Center, Parallel Group, Historical-Control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (16 to 75 years old) With Partial Onset Seizures With or Without				
Fakhoury, Toufic A	3048105382	\$2.	\$0.	\$2.
PPD Development Inc An Open-Label, Multinational, Multicenter, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam, Used at a Flexible Dose up to a Maximum of 150 mg/day, in Subjects aged 16 years or older suffering from Epilepsy				
Fakhoury, Toufic A	3048105453	\$0.	\$13,504.	\$13,504.
Eisai Medical Research Inc A Double-blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures				
Fakhoury, Toufic A	3048105453	\$2.	\$0.	\$2.
Eisai Medical Research Inc A Double-blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures				
Fakhoury, Toufic A	3048105760	\$2.	\$0.	\$2.
Eisai Medical Research Inc An Open-label Extension Phase of the Double-blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007(perampanel)Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures				
Houff, Sidney A	3048103412	\$0.	\$287.	\$287.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
Houff, Sidney A	3048103412	\$0.	\$292.	\$292.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
Houff, Sidney A	3048103412	\$0.	\$391.	\$391.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
Houff, Sidney A	3048103412	\$0.	\$773.	\$773.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
Houff, Sidney A	3048104530	\$0.	\$1,260.	\$1,260.
Genzyme Corp A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients with Relapsing Multiple Sclerosis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Houff, Sidney A	3048104530	\$0.	\$6,629.	\$6,629.
Genzyme Corp A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients with Relapsing Multiple Sclerosis				
Kasarskis, Edward J	3048105231	\$2.	\$0.	\$2.
Kendle International A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients				
Kasarskis, Edward J	3048105655	\$15,910.	\$0.	\$15,910.
Massachusetts General Hospital Clinical Trial of Ceftriaxone in ALS (Supplement): Pilot Study of Lithium in ALS Patients.				
Maragos, William F	3048104750	\$100,000.	\$0.	\$100,000.
American Heart Association Targeted Mitochondrial Uncoupling in Focal Cerebral Ischemia				
Pettigrew, Luther C	3046450600	\$0.	\$1,859.	\$1,859.
Mayo Foundation Siblings with Ischemic Stroke (SWISS)				
Pettigrew, Luther C	3046749700	\$0.	\$1,100.	\$1,100.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
Pettigrew, Luther C	3046749700	\$0.	\$10,100.	\$10,100.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
Pettigrew, Luther C	3046749700	\$0.	\$2,200.	\$2,200.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
Pettigrew, Luther C	3046749700	\$0.	\$1,500.	\$1,500.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
Pettigrew, Luther C	3046749700	\$0.	\$2,500.	\$2,500.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
Pettigrew, Luther C	3048038100	\$0.	\$30,033.	\$30,033.
Miami University Albumin in Stroke (ALIAS) Trial				
Pettigrew, Luther C	3048103228	\$0.	\$4,999.	\$4,999.
Parexel International Co NeuroThera Effectiveness and Safety Trial - 2 (NEST-2)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Pettigrew, Luther C	3048103228	\$0.	\$10,998.	\$10,998.
Parexel International Co NeuroThera Effectiveness and Safety Trial - 2 (NEST-2)				
Slevin, John T	3046609500	\$0.	\$278,531.	\$278,531.
AMGen Within Subject, Dose-Escalation Trial of Continuously Infused Intraputamental (Ipu) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Subjects with Idiopathic Parkinson's Disease				
Slevin, John T	3048072800	\$0.	\$1,018.	\$1,018.
Quintiles Inc A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations				
Slevin, John T	3048072800	\$0.	\$887.	\$887.
Quintiles Inc A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations				
Slevin, John T	3048103836	\$0.	\$1,750.	\$1,750.
American Parkinsons Disease Association American Parkinson Disease Association Information Center				
Slevin, John T	3048104006	\$0.	\$1,620.	\$1,620.
Quintiles Inc A Multi-Centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinsons' Disease Patients with Motor Fluctuations				
Slevin, John T	3048104006	\$0.	\$187.	\$187.
Quintiles Inc A Multi-Centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinsons' Disease Patients with Motor Fluctuations				
Slevin, John T	3048104006	\$0.	\$57.	\$57.
Quintiles Inc A Multi-Centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinsons' Disease Patients with Motor Fluctuations				
Slevin, John T	3048105130	\$0.	\$3,602.	\$3,602.
University of Rochester Study of Anti-Depresants in Parkinson's Disease (SAD PD)				
Slevin, John T	3048105130	\$2.	\$0.	\$2.
University of Rochester Study of Anti-Depresants in Parkinson's Disease (SAD PD)				
Slevin, John T	3048105407	\$36,752.	\$0.	\$36,752.
American Parkinsons Disease Association Parkinson Disease Infomation and Referral Center				
Slevin, John T	3048105543	\$2.	\$0.	\$2.
University of Rochester A Randomized Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1,3 and 6 mg Twice Daily) in Patients with Early Parkinson Disease (Aplindore-211)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Slevin, John T	3048105620	\$2.	\$0.	\$2.
Quintiles Inc Open -label, 6-12 months Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations, Protocol# S187.3.004				
Smith, Charles D	3048104409	\$0.	\$6,080.	\$6,080.
Neuronetrix Inc Evaluation of Handheld Evoked Response Potentials (ERP) System as an Effective Method to Diagnose Alzheimer's Disease				
Smith, Charles D	3048104409	\$0.	\$3,544.	\$3,544.
Neuronetrix Inc Evaluation of Handheld Evoked Response Potentials (ERP) System as an Effective Method to Diagnose Alzheimer's Disease				
Smith, Charles D	3048104409	\$0.	\$-2.	\$-2.
Neuronetrix Inc Evaluation of Handheld Evoked Response Potentials (ERP) System as an Effective Method to Diagnose Alzheimer's Disease				
Smith, Charles D	3048104409	\$0.	\$4,343.	\$4,343.
Neuronetrix Inc Evaluation of Handheld Evoked Response Potentials (ERP) System as an Effective Method to Diagnose Alzheimer's Disease				
Tucker, Tarvez	3048104872	\$0.	\$4,385.	\$4,385.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 iin Treatment of Acute Migraine in Patients with Stable Vascular Disease				
Tucker, Tarvez	3048104872	\$0.	\$1,283.	\$1,283.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 iin Treatment of Acute Migraine in Patients with Stable Vascular Disease				
Tucker, Tarvez	3048104872	\$0.	\$1,869.	\$1,869.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 iin Treatment of Acute Migraine in Patients with Stable Vascular Disease				
Tucker, Tarvez	3048104872	\$0.	\$2,038.	\$2,038.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 iin Treatment of Acute Migraine in Patients with Stable Vascular Disease				
Tucker, Tarvez	3048104872	\$0.	\$140.	\$140.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 iin Treatment of Acute Migraine in Patients with Stable Vascular Disease				
Tucker, Tarvez	3048104872	\$0.	\$2,500.	\$2,500.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 iin Treatment of Acute Migraine in Patients with Stable Vascular Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Tucker, Tarvez	3048104872	\$0.	\$4,410.	\$4,410.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in Treatment of Acute Migraine in Patients with Stable Vascular Disease				
Tucker, Tarvez	3048104872	\$2.	\$0.	\$2.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in Treatment of Acute Migraine in Patients with Stable Vascular Disease				
Vaishnav, Anand G	3046746400	\$0.	\$1,670.	\$1,670.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$4,825.	\$4,825.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$1,670.	\$1,670.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$3,080.	\$3,080.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$19,725.	\$19,725.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$10,750.	\$10,750.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$15,810.	\$15,810.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$2,760.	\$2,760.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046788400	\$0.	\$2,273.	\$2,273.
Boehringer Ingelheim Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo-Controlled Study of Aggrenox vs. Clopidogrel + Aspirin, With and Without Micardis (PRoFESS)				
Vaishnav, Anand G	3046788400	\$0.	\$131.	\$131.
Boehringer Ingelheim Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo-Controlled Study of Aggrenox vs. Clopidogrel + Aspirin, With and Without Micardis (PRoFESS)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Vaishnav, Anand G	3048103205	\$0.	\$5,000.	\$5,000.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
Vaishnav, Anand G	3048103205	\$0.	\$-6,080.	\$-6,080.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
Vaishnav, Anand G	3048103205	\$0.	\$6,080.	\$6,080.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
Vaishnav, Anand G	3048103205	\$0.	\$1,714.	\$1,714.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
Vaishnav, Anand G	3048103205	\$0.	\$9,924.	\$9,924.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
Vaishnav, Anand G	3048103205	\$0.	\$5,326.	\$5,326.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
Vaishnav, Anand G	3048103205	\$0.	\$-100.	\$-100.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
Vaishnav, Anand G	3048103205	\$0.	\$201.	\$201.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
Vaishnav, Anand G	3048103205	\$0.	\$201.	\$201.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
Neurology	Totals:	\$301,893.	\$1,214,579.	\$1,516,472.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Ophthalmology				
Ambati, Jayakrishna	3048102202	\$0.	\$75,000.	\$75,000.
Burroughs Wellcome Fund Target-Independent Suppression of Angiogenesis by siRNAs				
Ambati, Jayakrishna	3048102202	\$0.	\$75,000.	\$75,000.
Burroughs Wellcome Fund Target-Independent Suppression of Angiogenesis by siRNAs				
Ambati, Jayakrishna	3048103313	\$0.	\$500.	\$500.
American Health Assistance Foundation The Role of SPARC in Macular Propensity for CNV				
Ambati, Jayakrishna	3048103313	\$0.	\$12,000.	\$12,000.
American Health Assistance Foundation The Role of SPARC in Macular Propensity for CNV				
Ambati, Jayakrishna	3048103313	\$0.	\$37,500.	\$37,500.
American Health Assistance Foundation The Role of SPARC in Macular Propensity for CNV				
Ambati, Jayakrishna	3048103629	\$0.	\$355,097.	\$355,097.
National Eye Institute Pro- and Anti-Angiogenic Effect of Vascular Endothelial Growth Factor-A				
Ambati, Jayakrishna	3048104229	\$0.	\$50,585.	\$50,585.
Taigen Biotechnology Co Ltd Taigen Antagonist: Prevention and Regression of Laser-Induced Choroidal Neovascularization.				
Ambati, Jayakrishna	3048104491	\$0.	\$366,250.	\$366,250.
National Eye Institute Intrinsic Anti-Angiogenic Activity of siRNA				
Ambati, Jayakrishna	3048105168	\$35,000.	\$0.	\$35,000.
International Retinal Research Foundation The Heterogeneous Immunovascular Effects of Small Interfering RNA in the Posterior Segment				
Ambati, Jayakrishna	3048105276	\$20,000.	\$0.	\$20,000.
Fight for Sight Inc Fellowship for Albuquerque: Establishing the Role of the Novel Endogenous sVEGFR-2 in Corneal Lymphangiogenesis and Transplant Rejection				
Ambati, Jayakrishna	3048105306	\$280,616.	\$0.	\$280,616.
Doris Duke Charitable Foundation Short non-Interfering RNAs as Novel Therapies for Age Related Macular Degeneration				
Blackburn, Peter	3046948500	\$0.	\$59,285.	\$59,285.
Control Delivery Systems Inc A Randomized, Double-Masked, Parallel Group, Multi-Center Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 pg/day and				
Capoor, Seema	3048105202	\$0.	\$3,914.	\$3,914.
Allergan Pharmaceuticals Inc A 6 Day, Phase 3, Multicenter, Randomized, Double-Masked, Parallel Study to Compare the Safety and Efficacy of Gatifloxacin 0.5% Ophthalmic Solution BID with that of Vehicle in the Treatment of Acute Bacterial Conjunctivitis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Ophthalmology				
Capoor, Seema	3048105202	\$2.	\$0.	\$2.
Allergan Pharmaceuticals Inc A 6 Day, Phase 3, Multicenter, Randomized, Double-Masked, Parallel Study to Compare the Safety and Efficacy of Gatifloxacin 0.5% Ophthalmic Solution BID with that of Vehicle in the Treatment of Acute Bacterial Conjunctivitis				
Fannon, Michael	3048088600	\$0.	\$331,032.	\$331,032.
National Heart Lung and Blood Institute Computer Modeling of Perlecan as a Vascular Regulator				
Mohan, Royce	3048103665	\$0.	\$358,925.	\$358,925.
National Eye Institute Molecular Targets of Corneal Antianangiogenesis				
Mohan, Royce	3048104877	\$289,553.	\$0.	\$289,553.
National Cancer Institute Novel Modular Vascular Patterning Assay for HTS				
Pearson, Paul A	3048050700	\$0.	\$-2,012.	\$-2,012.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion(SCORE) Study				
Pearson, Paul A	3048050700	\$0.	\$4,099.	\$4,099.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion(SCORE) Study				
Pearson, Paul A	3048050700	\$0.	\$2,012.	\$2,012.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion(SCORE) Study				
Pearson, Paul A	3048050700	\$0.	\$7,735.	\$7,735.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion(SCORE) Study				
Pearson, Paul A	3048050700	\$0.	\$7,429.	\$7,429.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion(SCORE) Study				
Pearson, Paul A	3048050700	\$0.	\$4,177.	\$4,177.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion(SCORE) Study				
Pearson, Paul A	3048050700	\$0.	\$234.	\$234.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion(SCORE) Study				
Pearson, Paul A	3048105483	\$110,000.	\$0.	\$110,000.
Research to Prevent Blindness Research To Prevent Blindness Unrestricted Grant				
Pearson, Paul A	3048105619	\$2.	\$0.	\$2.
Thrombogenics A Randomized, Placebo Controlled, Double-Masked, Multicenter of Microplamin Intavitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Ophthalmology</u>				
Raisler, Brian J	3048081400	\$0.	\$50,000.	\$50,000.
Research to Prevent Blindness The Role of Cellular Immunity in Neovascular Ischemic Retinopathies				
Ophthalmology	Totals:	\$735,173.	\$1,798,762.	\$2,533,935.
<u>Orthopaedic Surgery</u>				
Lattermann, Christian	3048105458	\$2.	\$0.	\$2.
Advanced Technologies and Regenerative Medicine A multicenter, Randomized, Pivotal Study to Evaluate the Safety and Efficacy of the Cartilage Autograft Implantation				
Orthopaedic Surgery	Totals:	\$2.	\$0.	\$2.
<u>Radiation Medicine</u>				
Kudrimoti, Mahesh	3048044300	\$0.	\$200.	\$200.
TRIAD Burden of Illness Inc Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-small Cell Lung or Ovarian Cancers				
Kudrimoti, Mahesh	3048104578	\$0.	-\$2.	-\$2.
Endo Pharmaceutical Inc A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled study to assess the Efficacy and Safety of ENDO3285 for Prevention or Delay to Onset of Severe Oral Mucositis in Patients with Head and Neck Cancer Receiving Chemoradiotherapy				
Kudrimoti, Mahesh	3048104578	\$0.	\$1,800.	\$1,800.
Endo Pharmaceutical Inc A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled study to assess the Efficacy and Safety of ENDO3285 for Prevention or Delay to Onset of Severe Oral Mucositis in Patients with Head and Neck Cancer Receiving Chemoradiotherapy				
Kudrimoti, Mahesh	3048105244	\$0.	\$6,811.	\$6,811.
AMGen A Phase 2 Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck				
Kudrimoti, Mahesh	3048105244	\$0.	\$3,039.	\$3,039.
AMGen A Phase 2 Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck				
Kudrimoti, Mahesh	3048105244	\$2.	\$0.	\$2.
AMGen A Phase 2 Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck				
Kudrimoti, Mahesh	3048105396	\$0.	-\$2.	-\$2.
SciClone Pharmaceuticals Inc A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-controlled, Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Subjects				
Kudrimoti, Mahesh	3048105396	\$2.	\$0.	\$2.
SciClone Pharmaceuticals Inc A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-controlled, Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Subjects				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Radiation Medicine</u>				
McGarry, Ronald	3046594300	\$0.	\$1,400.	\$1,400.
American College of Radiology Support of Ongoing Activities with the American College of Radiology				
McGarry, Ronald	3046594300	\$0.	\$59,450.	\$59,450.
American College of Radiology Support of Ongoing Activities with the American College of Radiology				
McGarry, Ronald	3048105548	\$0.	\$4,098.	\$4,098.
American College of Radiology Radiation Therapy Oncology Group: Master Agreement				
McGarry, Ronald	3048105548	\$2.	\$0.	\$2.
American College of Radiology Radiation Therapy Oncology Group: Master Agreement				
Randall, Marcus	3048105280	\$8,800.	\$0.	\$8,800.
Gynecologic Oncology Group Chair or Co-Chair of the Corpus Committee				
Rangnekar, Vivek M	3048105266	\$0.	\$302,065.	\$302,065.
National Cancer Institute Mechanism of Apoptosis and Inhibition of Tumor Progression and Metastasis by Par-4				
Rangnekar, Vivek M	3048105266	\$302,065.	\$0.	\$302,065.
National Cancer Institute Mechanism of Apoptosis and Inhibition of Tumor Progression and Metastasis by Par-4				
Rangnekar, Vivek M	3048105462	\$150,000.	\$0.	\$150,000.
KY Lung Cancer Research Fund Suppression of Lung Cancer Progression by Extracellular Par-4/SAC Protein				
St Clair, William H	3048103792	\$0.	\$250,538.	\$250,538.
National Cancer Institute Redox Modulation Of Prostate Cancer				
Warren, Graham W	3048104845	\$50,000.	\$0.	\$50,000.
American Society of Clinical Oncology ASCO Young Investigator Award: Nicotine in the Regulation of Lung Cancer Treatment Response				
Radiation Medicine	Totals:	\$510,871.	\$629,397.	\$1,140,268.
<u>Physical Medicine and Rehabilitation</u>				
Adams, Lumy Sawaki	3048104590	\$0.	\$-5,481.	\$-5,481.
American Heart Association Enhancing Cortical Plasticity with Nerve Stimulation in Stroke Patients with Severe Motor Deficit				
Adams, Lumy Sawaki	3048104591	\$0.	\$-59,100.	\$-59,100.
National Institute of Child Health and Human Develop Sensory-driven Motor Recovery in Poorly Recovered Subacute Stroke Patients				
Adams, Lumy Sawaki	3048104592	\$0.	\$10,998.	\$10,998.
National Institute of Child Health and Human Develop Driving Neuroplasticity with Nerve Stimulation and Modified CIT				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Physical Medicine and Rehabilitation</u>				
Adams, Lumy Sawaki	3048104753	\$0.	\$-194.	\$-194.
Charles A Dana Foundation Enhancement of Post-Stroke Neural Plasticity with Atomoxetine: A Pilot Study				
Adams, Lumy Sawaki	3048104753	\$36,600.	\$0.	\$36,600.
Charles A Dana Foundation Enhancement of Post-Stroke Neural Plasticity with Atomoxetine: A Pilot Study				
McEwen, Melanie L	3048104272	\$0.	\$111,267.	\$111,267.
Craig H Neilsen Foundation NIM811 Treatment for Pediatric Spinal Cord Injury				
Shahid Salles, Sara	3048105345	\$6,700.	\$0.	\$6,700.
University of California Irvine United States multi-center study to access the validity and reliability of the Spinal Cord Independence Measure (SCIM) III				
Springer, Joe E	3048104366	\$0.	\$98,588.	\$98,588.
KY Spinal Cord and Head Injury Research Trust Therapeutic Potential of NEU2000, A Dual Acting Pharmacological Agent in the Treatment of Acute Spinal Cord Injury				
Physical Medicine and Rehabilitation	Totals:	\$43,300.	\$156,078.	\$199,378.
	Medicine Totals:	\$60,359,384.	\$48,347,066.	\$108,706,450.
<u>Pharmacy</u>				
<u>Pharmacy</u>				
Stinchcomb, Audra L	3048103101	\$0.	\$310,666.	\$310,666.
National Institute on Drug Abuse Naltrexone Prodrugs for transdermal Delivery				
Stinchcomb, Audra L	3048104879	\$7,325.	\$0.	\$7,325.
AllTranz Evaluation of a Drug for Dermal Delivery				
Pharmacy	Totals:	\$7,325.	\$310,666.	\$317,991.
<u>Pharmaceutical Tech</u>				
Al-Ghananeem, Abeer	3048103825	\$0.	\$88,971.	\$88,971.
US Worldmeds LLC Formulation Development of Intravenous and Oral Dosage Forms				
Anderson, Bradley D	3048105301	\$60,001.	\$0.	\$60,001.
Boehringer Ingelheim Optimizing Oral Absorption of Poorly Water Soluble Drug Candidates: Mechanisms and Predictive Models for the Selection of Excipients to Maintain Supersaturation by Inhibiting Nucleation and Crystallization				
Black, Esther P	3048103763	\$0.	\$72,310.	\$72,310.
KY Lung Cancer Research Fund Dusp4 Activity in Non-Small Cell Lung Cancers: An Opportunity for Intervention?				
Black, Esther P	3048105446	\$100,000.	\$0.	\$100,000.
Joans Legacy Lung Cancer Foundation Dual Targeted Therapy - Can MEK Inhibition Improve Response and Reduce Acquired Resistance in EGFR-Dependent NSCLC				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Pharmacy				
Pharmaceutical Tech				
Bummer, Paul M	3048103769	\$0.	\$290,101.	\$290,101.
National Cancer Institute Development of Dosage Forms and Delivery Systems for Anti-Tumor Agents				
Bummer, Paul M	3048105670	\$100,000.	\$0.	\$100,000.
Abbott Laboratories Critical Factors Influencing Solubilization in the GI Tract by Lipid-Based Drug Delivery Systems				
Crooks, Peter A	3046581000	\$0.	\$99,000.	\$99,000.
US Worldmeds LLC KSTC R & D Voucher: Product development and formulation				
Crooks, Peter A	3046698800	\$0.	\$4,153.	\$4,153.
Yaupon Therapeutics Inc Post Doctoral Fellowship				
Crooks, Peter A	3046698800	\$0.	\$15,000.	\$15,000.
Yaupon Therapeutics Inc Post Doctoral Fellowship				
Crooks, Peter A	3046831000	\$0.	\$65,800.	\$65,800.
Washington University Radiosensitization by the Cellular Heat Shock Response				
Crooks, Peter A	3046989300	\$0.	\$4,520.	\$4,520.
Yaupon Therapeutics Inc Lobeline Epimer Ratio Determination Study				
Crooks, Peter A	3048048700	\$0.	\$9,000.	\$9,000.
Pradama Inc Novel Bone-Targeting Agents				
Crooks, Peter A	3048105198	\$72,550.	\$0.	\$72,550.
University of Rochester A Novel Thiadiazolidine-Dione Targets Human Leukemia Stem Cells				
Dwoskin, Linda P	3046930400	\$0.	\$545,671.	\$545,671.
National Institute on Drug Abuse Development of Novel Therapies for Methamphetamine Abuse				
Dwoskin, Linda P	3048103421	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Vidya Narayanaswami: The Role of Angiotensin in Nicotine Reward and Nicotine Induced Hypertension				
Leggas, Markos	3048105723	\$41,250.	\$0.	\$41,250.
Arno Therapeutics Inc PK/PD Studies of AR-67/DB-67 in Myelodysplasia Patients				
Li, Tonglei	3046864900	\$0.	\$118,532.	\$118,532.
National Science Foundation CAREER: Towards Fundamental Understanding and Rational Control of Crystal Growth				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Pharmacy				
<u>Pharmaceutical Tech</u>				
Li, Tonglei	3048103700	\$0.	\$20,000.	\$20,000.
PhRMA Foundation Fellowship for Aubrey-Medendorp: Investigation of Surface Energy Using Atomic Force Microscopy				
Loftin, Charles D	3048103234	\$0.	\$290,629.	\$290,629.
National Heart Lung and Blood Institute Prostanoid-dependent Abdominal Aortic Aneurysm Formation				
Loftin, Charles D	3048104759	\$0.	\$10,000.	\$10,000.
PhRMA Foundation Fellowship for Julie Oestreich: The Effects of P2Y12 Polymorphisms on Platelet Receptor Expression and Activation				
Loftin, Charles D	3048104759	\$20,000.	\$0.	\$20,000.
PhRMA Foundation Fellowship for Julie Oestreich: The Effects of P2Y12 Polymorphisms on Platelet Receptor Expression and Activation				
Loftin, Charles D	3048104759	\$0.	-\$15,000.	-\$15,000.
PhRMA Foundation Fellowship for Julie Oestreich: The Effects of P2Y12 Polymorphisms on Platelet Receptor Expression and Activation				
Nixon, Kimberly	3048104311	\$0.	\$292,729.	\$292,729.
National Institute on Alcohol Abuse and Alcoholism Ethanol Alteration of the Neurogenic Niche				
Nixon, Kimberly	3048104493	\$0.	\$170,258.	\$170,258.
National Institute on Alcohol Abuse and Alcoholism Neurogenesis and neurodegeneration in adolescent binge alcohol exposure				
Rohr, Jurgen	3046893000	\$0.	\$246,853.	\$246,853.
National Cancer Institute Biosynthetic Key Steps of Angucycline Antitumor Drugs				
Rohr, Jurgen	3048105065	\$0.	\$239,859.	\$239,859.
National Cancer Institute Novel Aureolic Acid-Type Antitumor Agents				
Rohr, Jurgen	3048105065	\$251,484.	\$0.	\$251,484.
National Cancer Institute Novel Aureolic Acid-Type Antitumor Agents				
Rohr, Jurgen	3048105731	\$7,403.	\$0.	\$7,403.
National Cancer Institute ARRA: Biosynthetic Key Steps of Angucycline Antitumor Drugs				
Stinchcomb, Audra L	3048105002	\$30,524.	\$0.	\$30,524.
National Institute on Drug Abuse NRSA Fellowship for Swadley: Transdermal Delivery of Hydroxyphenylarachidonylamides				
Van Lanen, Steven	3048105216	\$10,000.	\$0.	\$10,000.
Daiichi Pharmaceutical Corp Biosynthesis of Nucleoside Antibiotics				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Pharmacy</u>				
<u>Pharmaceutical Tech</u>				
Zhan, Chang-Guo	3048046400	\$0.	\$46,032.	\$46,032.
University of Michigan Development of Esterases for the Treatment of Cocaine Overdose and Abuse				
Zhan, Chang-Guo	3048046900	\$0.	\$446,186.	\$446,186.
National Institute on Drug Abuse Redesign of Butyrylcholinesterase for Cocaine Metabolism				
Zhan, Chang-Guo	3048104655	\$0.	\$27,064.	\$27,064.
MITRE Corporation Enzyme Analysis and Design				
Zhan, Chang-Guo	3048104655	\$0.	\$34,114.	\$34,114.
MITRE Corporation Enzyme Analysis and Design				
Zhan, Chang-Guo	3048105116	\$498,945.	\$0.	\$498,945.
National Institute on Drug Abuse High-Activity Mutants of Cocaine Esterase for Treatment of Drug Addiction				
Zheng, Guangrong	3048105479	\$183,125.	\$0.	\$183,125.
National Institute on Drug Abuse Development of Antagonists for M5 Muscarinic Acetylcholine Receptor				
Pharmaceutical Tech	Totals:	\$1,375,282.	\$3,142,782.	\$4,518,064.
<u>Pharmacy Practice & Science</u>				
Adams, Val R	3048104062	\$0.	\$21,216.	\$21,216.
University of North Carolina EGFR Targeted Nanoparticles to Overcome Paclitaxel resistant Breast Cancer				
Blumenschein, Karen M	3048104895	\$5,000.	\$0.	\$5,000.
American Foundation for Pharmaceutical Ed Do Patients and Pharmacists Agree on the Interpretation of Verbal Probability Statements				
Gatz, Jennifer L	3048090700	\$0.	\$40,000.	\$40,000.
PhRMA Foundation Predictors of Absconding from State Psychiatric Hospitals				
Rippetoe Freeman, Patricia E	3048105700	\$67,313.	\$0.	\$67,313.
KY Cabinet for Health and Family Services KASPER Evaluation				
Steinke, Douglas Theodore	3048104573	\$0.	\$30,000.	\$30,000.
PhRMA Foundation Gender Disparities in type 2 Diabetes Medication Utilization: A Population Based Study Using Medicaid Data				
Talbert, Jeffery C	3048104965	\$905,686.	\$0.	\$905,686.
Department for Mental Health Mental Retardation Service Research Information Systems Management for KY Department for Mental Health/Mental Retardation				
Talbert, Jeffery C	3048105182	\$1,722,468.	\$0.	\$1,722,468.
KY Cabinet for Health and Family Services Money Follows the Person (MFP)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Pharmacy</u>				
<u>Pharmacy Practice & Science</u>				
Talbert, Jeffery C	3048105430	\$73,831.	\$0.	\$73,831.
Urban Institute Effects of Medicaid Reform on Access to Care, Program Sustainability, and Administrative Efficiency in Idaho and KY				
Talbert, Jeffery C	3048105544	\$250,000.	\$0.	\$250,000.
KY Cabinet for Health and Family Services Medicaid Utilization Study				
Pharmacy Practice & Science	Totals:	\$3,024,298.	\$91,216.	\$3,115,514.
	Pharmacy Totals:	\$4,406,905.	\$3,544,664.	\$7,951,569.
<u>Health Sciences</u>				
<u>Rehabilitation Sciences</u>				
Capilouto, Gilson J	3048104021	\$0.	\$114,012.	\$114,012.
Arizona State University Discourse Processing in Healthy Aging				
Dupont-Versteegden, Esther	3048049900	\$0.	\$277,005.	\$277,005.
National Institute on Aging Integrated Study of Musculoskeletal Loss and Restoration				
Kitzman, Patrick H	3048104899	\$16,706.	\$0.	\$16,706.
KY Science and Technology Co Inc Planning Grant for Establishing a Collaborative Team to Investigate: Health and Quality of Life Related Challenges for Individuals with Spinal Cord Injury, Living in Medically Underserved Areas of Kentucky, Receiving Rehabilitation Services				
Kleinert, Jane	3048105322	\$0.	\$2,160.	\$2,160.
KY Health Services Cabinet Kentucky Youth Advocacy Project				
Kleinert, Jane	3048105322	\$150,000.	\$0.	\$150,000.
KY Health Services Cabinet Kentucky Youth Advocacy Project				
McKeon, Patrick	3048105627	\$750.	\$0.	\$750.
Southeast Athletic Trainers Association The Effect of Talocrural Joint Postural Control in those with Chronic Ankle Instability				
Patel, Rita R.	3048105549	\$5,000.	\$0.	\$5,000.
American Speech Language Hearing Foundation High Speed Digital Analysis of Vocal Fold Vibration in Children				
Rehabilitation Sciences	Totals:	\$172,456.	\$393,177.	\$565,633.
<u>Administrative Services</u>				
Peterson, Charlotte A.	3048049700	\$0.	\$269,470.	\$269,470.
National Institute on Aging Changes in Myogenic Progenitor Potential with Age				
Administrative Services	Totals:	\$0.	\$269,470.	\$269,470.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Health Sciences</u>				
<u>Clinical Sciences</u>				
Baker, Doris J	3048105077	\$2.	\$0.	\$2.
Genzyme Corp Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis: CAMMS323 and 324				
Bruckner, Geza G	3048104972	\$25,000.	\$0.	\$25,000.
KY Diabetes Research Trust Fund Developing Health Sciences Students to Be Health Navigators for Diabetes Prevention and Care				
Chendil, Damodaran	3048097100	\$0.	\$354,641.	\$354,641.
National Center for Complementary & Alternative Med Novel Herbal Medicine for the Treatment of Prostate Cancer				
Ko, Chemyong	3046997400	\$0.	\$23,141.	\$23,141.
National Institute of Child Health and Human Develop Endothelin-2 in Ovarian Follicle Rupture				
Ko, Chemyong	3046997400	\$0.	\$208,273.	\$208,273.
National Institute of Child Health and Human Develop Endothelin-2 in Ovarian Follicle Rupture				
Powdrill, Samuel G	3048104898	\$0.	\$70,460.	\$70,460.
Health Resources and Services Administration Targeted Training for Physician Assistant Students Caring for At Risk Populations in Kentucky				
Powdrill, Samuel G	3048104898	\$107,130.	\$0.	\$107,130.
Health Resources and Services Administration Targeted Training for Physician Assistant Students Caring for At Risk Populations in Kentucky				
Clinical Sciences	Totals:	\$132,132.	\$656,515.	\$788,647.
	Health Sciences Totals:	\$304,588.	\$1,319,162.	\$1,623,750.
<u>Public Health</u>				
<u>Public Health Leadership Institute</u>				
Scutchfield, F Douglas	3048104880	\$0.	\$-7,500.	\$-7,500.
KY Department for Public Health KY Public Health Leadership Institute				
Scutchfield, F Douglas	3048104880	\$150,000.	\$0.	\$150,000.
KY Department for Public Health KY Public Health Leadership Institute				
Public Health Leadership Institute	Totals:	\$150,000.	\$-7,500.	\$142,500.
<u>Preventive Med & Environmental Health</u>				
Allweiss, Pamela H	3048105242	\$154,334.	\$0.	\$154,334.
Center for Disease Control and Prevention IPA for Centers for Disease Control and Prevention				
Brion, Gail	3046936300	\$0.	\$72,808.	\$72,808.
University of Louisville Health Effects of Occupational Exposure in PGDP Workers				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Public Health</u>				
<u>Preventive Med & Environmental Health</u>				
Figgs, Larry W	3048085600	\$0.	\$31,500.	\$31,500.
Lexington Fayette County Health Department Manager, Evironmental Health and Protection				
Preventive Med & Environmental Health	Totals:	\$154,334.	\$104,308.	\$258,642.
<u>Health Behavior</u>				
Alexander, Linda	3048105074	\$74,973.	\$0.	\$74,973.
American Legacy Foundation Exploring Organizational, Cultural and Individual Barriers Associated with the Utilization of a Worksite Tobacco Cessation Program				
Alexander, Linda	3048105672	\$65,226.	\$0.	\$65,226.
KY Department for Public Health Social, Environmental and Societal Variables Influencing African-American Participation in Tobacco Cessation Programs: A Pilot Study				
Cecil, James C	3048105009	\$0.	-\$24,267.	-\$24,267.
KY Health Services Cabinet Institute for Maternal and Child Health Education and Training				
Cecil, James C	3048105009	\$0.	\$127,460.	\$127,460.
KY Health Services Cabinet Institute for Maternal and Child Health Education and Training				
Cecil, James C	3048105009	\$65,100.	\$0.	\$65,100.
KY Health Services Cabinet Institute for Maternal and Child Health Education and Training				
Crosby, Richard	3048012800	\$0.	\$596,178.	\$596,178.
National Institute of Allergy and Infectious Diseases Do Condoms Protect from Non-Viral Sexually Transmitted Infections?				
Crosby, Richard	3048105243	\$366,250.	\$0.	\$366,250.
National Institute of Mental Health A Brief, Clinic-Based, HIV Prevention Program for African American Teen Males				
Crosby, Richard	3048105243	\$0.	\$366,250.	\$366,250.
National Institute of Mental Health A Brief, Clinic-Based, HIV Prevention Program for African American Teen Males				
Crosby, Richard	3048105330	\$5,869.	\$0.	\$5,869.
Charm Inc Intent for Collaborating Project between CHARM, Inc. and the University of Kentucky Research Foundation				
Crosby, Richard	3048105344	\$23,729.	\$0.	\$23,729.
Charm Inc Intent for Collaborating Project between CHARM, Inc. and the University of Kentucky Research Foundation				
Crosby, Richard	3048105678	\$50,000.	\$0.	\$50,000.
Indiana University Rural HIV/STD Prevention Project				
Health Behavior	Totals:	\$651,147.	\$1,065,621.	\$1,716,768.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Public Health</u>				
<u>Health Services Management</u>				
Costich, Julia F	3048103756	\$0.	\$-15,456.	\$-15,456.
University of Southern Mississippi Public Health Finance: Advancing a Field of Study				
Costich, Julia F	3048103756	\$0.	\$15,456.	\$15,456.
University of Southern Mississippi Public Health Finance: Advancing a Field of Study				
Costich, Julia F	3048104871	\$63,000.	\$0.	\$63,000.
KY Department for Public Health Core Curriculum for Bioterrorism Preparedness				
Costich, Julia F	3048105628	\$95,838.	\$0.	\$95,838.
KY Cabinet for Health and Family Services Harmonizing State Privacy Law Collaborative Project				
Hill, Raymond E	3048104955	\$5,000.	\$0.	\$5,000.
KY Department for Public Health SCBD Diabetes Education/Training				
Scutchfield, F Douglas	3048103603	\$0.	\$2,107,904.	\$2,107,904.
Robert Wood Johnson Foundation Public Health Systems and Services Research Center				
Health Services Management	Totals:	\$163,838.	\$2,107,904.	\$2,271,742.
<u>Epidemiology</u>				
Browning, Steven	3048104983	\$15,720.	\$0.	\$15,720.
St Elizabeth Medical Center Evaluation of Northern Kentucky Womens Cardiovascular Assessment, Risk Reduction and Care Collaborative				
Hopenhayn, Claudia	3048104991	\$20,069.	\$0.	\$20,069.
KY Health Services Cabinet SCBL - Behavioral Risk Factor Surveillance System Analysis				
Robl, Joyce M	3048104903	\$0.	\$2,700.	\$2,700.
KY Department for Public Health KY Birth Surveillance Registry				
Robl, Joyce M	3048104903	\$55,700.	\$0.	\$55,700.
KY Department for Public Health KY Birth Surveillance Registry				
Epidemiology	Totals:	\$91,489.	\$2,700.	\$94,189.
<u>Biostatistics</u>				
Branscum, Adam	3048105456	\$3,000.	\$0.	\$3,000.
University of Tennessee Development of an On-site Diagnostic Device for Johne's Disease				
Mendiondo, Marta S	3048105172	\$25,000.	\$0.	\$25,000.
Florida Department of Elder Affairs Evaluation of Florida's Public Guardianship Program				
Biostatistics	Totals:	\$28,000.	\$0.	\$28,000.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Public Health</u>				
<u>Gerontology</u>				
Teaster, Pamela B	3048105687	\$23,150.	\$0.	\$23,150.
National Committee Prevention of Elder Abuse Empowering Elder Abuse Organizations Through Local, State and National Efforts				
Gerontology	Totals:	\$23,150.	\$0.	\$23,150.
<u>Center for Prevention Research</u>				
Clayton, R R	3048076300	\$0.	\$257,355.	\$257,355.
Robert Wood Johnson Foundation Tobacco Etiology Research Network: Analysis and Dissemination				
Harris, Torrie	3048104838	\$38,150.	\$0.	\$38,150.
KY River Community Care Inc Using Medications Safely: Prevention for Generation Rx Evaluation of a Prescription Drug Abuse Prevention Program				
Jones, Jeffery A	3048104854	\$10,000.	\$0.	\$10,000.
KY Department of Education School Health Atlas: Spatial Analysis of Coordinated School Health Data				
Jones, Jeffery A	3048104854	\$0.	\$800.	\$800.
KY Department of Education School Health Atlas: Spatial Analysis of Coordinated School Health Data				
Jones, Jeffery A	3048104904	\$83,723.	\$0.	\$83,723.
Foundation for a Healthy KY Foundation for a Healthy Kentucky, Coordinated School Health Grants Evaluation				
Jones, Jeffery A	3048105356	\$3,000.	\$0.	\$3,000.
Lexington Fayette Urban County Government Evaluation of 21st Century Grant				
Center for Prevention Research	Totals:	\$134,873.	\$258,155.	\$393,028.
<u>KY Injury Prevention & Research Center</u>				
Bunn, Terry L	3048104873	\$38,184.	\$0.	\$38,184.
KY Department for Public Health Occupational Safety and Health Surveillance				
Bunn, Terry L	3048104889	\$268,150.	\$0.	\$268,150.
National Institute of Occupational Safety and Health Kentucky Occupational Safety and Health Surveillance				
Costich, Julia F	3048104742	\$311,688.	\$0.	\$311,688.
KY Department for Public Health State Injury Prevention Program				
Costich, Julia F	3048104743	\$66,000.	\$0.	\$66,000.
KY Department for Public Health KIPRC Consumer Product Safety Commission				
Costich, Julia F	3048105076	\$124,260.	\$0.	\$124,260.
Center for Disease Control and Prevention Public Health Injury Surveillance and Prevention Program				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Public Health</u>				
<u>KY Injury Prevention & Research Center</u>				
Costich, Julia F	3048105314	\$23,921.	\$0.	\$23,921.
Northern Kentucky Chamber of Commerce Northern KY Small Business Health Insurance Feasibility Study				
Costich, Julia F	3048105671	\$60,005.	\$0.	\$60,005.
KY Hospital Association KY Trauma Registry 2009-2010				
McCool, Robert H	3048104997	\$143,470.	\$0.	\$143,470.
Center for Disease Control and Prevention Kentucky Residential Fire Injury Prevention Project				
Pollack, Susan H	3048005000	\$0.	\$10,000.	\$10,000.
Allstate Foundation Injury Free/Allstate Safe Playgrounds 2004				
Pollack, Susan H	3048104945	\$0.	\$-62,000.	\$-62,000.
KY Department for Public Health Pediatric and Adolescent Injury Prevention Program				
Pollack, Susan H	3048104945	\$179,300.	\$0.	\$179,300.
KY Department for Public Health Pediatric and Adolescent Injury Prevention Program				
Singleton, Michael	3048105061	\$134,331.	\$0.	\$134,331.
KY Department for Public Health Acquired Brain Injury and Spinal Cord Injury Surveillance				
Singleton, Michael	3048105079	\$0.	\$40,000.	\$40,000.
National Highway Traffic Safety Administration The Crash Outcome Data Evaluation System (CODES) Data Network Program				
Singleton, Michael	3048105079	\$40,000.	\$0.	\$40,000.
National Highway Traffic Safety Administration The Crash Outcome Data Evaluation System (CODES) Data Network Program				
Walsh, Sabrina L	3048105075	\$206,774.	\$0.	\$206,774.
Center for Disease Control and Prevention National Violent Death Reporting System (NVDRS)				
KY Injury Prevention & Research Center	Totals:	\$1,596,083.	\$-12,000.	\$1,584,083.
<u>Southeast Cntr for Ag Health & Injury Pr</u>				
Donovan, Teresa	3048105262	\$6,000.	\$0.	\$6,000.
Colorado State University Developing and Testing Interactive CD Health and Safety Curricula for 4-H Youth (Year 2)				
McKnight, Robert H	3048104770	\$60,148.	\$0.	\$60,148.
Center for Disease Control and Prevention Agricultural Safety and Health Training for Public Health Graduate Students				
McKnight, Robert H	3048105073	\$63,346.	\$0.	\$63,346.
KY Department for Medicaid Services Dept. of Medicaid Services KCHIP Migrant Outreach Project				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Public Health</u>				
<u>Southeast Cntr for Ag Health & Injury Pr</u>				
McKnight, Robert H	3048105180	\$1,036,294.	\$0.	\$1,036,294.
National Institute of Occupational Safety and Health Southeast Center for Agricultural Health and Injury Prevention				
McKnight, Robert H	3048105357	\$10,000.	\$0.	\$10,000.
Colorado State University High Plains Intermountain Center for Agriculture Health & Safety - Agriculture Center Evaluation for Kentucky				
Southeast Cntr for Ag Health & Injury Pr	Totals:	\$1,175,788.	\$0.	\$1,175,788.
<u>Council on Aging</u>				
Johnson, Helen A	3048104769	\$0.	\$95,091.	\$95,091.
KY Department for Public Health UK 2008 2009 Emergency Preparedness for Aging Training				
Johnson, Helen A	3048104769	\$96,000.	\$0.	\$96,000.
KY Department for Public Health UK 2008 2009 Emergency Preparedness for Aging Training				
Johnson, Helen A	3048104874	\$361,631.	\$0.	\$361,631.
Health Resources and Services Administration OVAR/GEC Interdisciplinary Care				
Johnson, Helen A	3048105128	\$23,036.	\$0.	\$23,036.
Department for Mental Health Mental Retardation Service 2008 PASRR Skills Training				
Smith, Michael D	3048105413	\$100,000.	\$0.	\$100,000.
Bernard Osher Foundation Osher Lifelong Learning Institue				
Council on Aging	Totals:	\$580,667.	\$95,091.	\$675,758.
<u>Center for Public Health Syst & Svcs Res</u>				
Dearinger, Angela Tackett	3048105692	\$40,708.	\$0.	\$40,708.
KY Public Health Association Kentucky Public Health Research Network (KPHReN)				
Scutchfield, F Douglas	3048105268	\$25,000.	\$0.	\$25,000.
National Library of Medicine Increasing the Availability and Promoting the Use of the National Library of Medicine's Datasets for Public Health Systems Research				
Scutchfield, F Douglas	3048105321	\$115,000.	\$0.	\$115,000.
Public Health Foundation Center of Excellence for Public Health Workforce Research and Policy				
Scutchfield, F Douglas	3048105395	\$17,552.	\$0.	\$17,552.
Ohio State University Buckeye Bluegrass Regional Leadership Academy				
Center for Public Health Syst & Svcs Res	Totals:	\$198,260.	\$0.	\$198,260.
	Public Health Totals:	\$4,947,629.	\$3,614,279.	\$8,561,908.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Assoc Provost Undergrad Educati</u>				
<u>Undergraduate Studies</u>				
Scheff, Suzanne	3048105454	\$18,000.	\$0.	\$18,000.
Puget Sound Center For Teaching Learning and Technol Kentucky Girls STEM Collaborative Project				
Undergraduate Studies	Totals:	\$18,000.	\$0.	\$18,000.
Assoc Provost Undergrad Education Totals:		\$18,000.	\$0.	\$18,000.
<u>Agriculture</u>				
<u>International Programs</u>				
Reed, Michael R	3046123000	\$0.	\$7,201.	\$7,201.
Thai Ministry of Agriculture and Cooperatives Scholarships for Thai Ministry of Agriculture Officials				
Reed, Michael R	3046900500	\$0.	\$20,389.	\$20,389.
Foreign Agricultural Service Technical Assistance to the Extension System in Serbia				
Reed, Michael R	3048105051	\$13,000.	\$0.	\$13,000.
Department of Agriculture The Norman E. Borlaug International Agricultural Science and Technology Fellows Program for El Salvador				
Reed, Michael R	3048105578	\$70,008.	\$0.	\$70,008.
Foreign Agricultural Service Borlaug International Science Program for Africa				
International Programs	Totals:	\$83,008.	\$27,590.	\$110,598.
<u>Assoc Dean Research/Director AES</u>				
Cox, Nancy Marguerite	3048087900	\$0.	\$5,590.	\$5,590.
Agricultural Research Service ARS/SCA Cooperative Agreement				
Cox, Nancy Marguerite	3048104698	\$487,426.	\$0.	\$487,426.
KY Horse Racing Authority Equine Medical Director				
Cox, Nancy Marguerite	3048105003	\$0.	\$5,259.	\$5,259.
KY Council on Postsecondary Education Equine Trust Fund				
Cox, Nancy Marguerite	3048105003	\$80,000.	\$0.	\$80,000.
KY Council on Postsecondary Education Equine Trust Fund				
Cox, Nancy Marguerite	3048105135	\$0.	\$3,264.	\$3,264.
Agricultural Research Service Acquisition of Goods and Services for USDA offices in Ag North -- 2008-09				
Cox, Nancy Marguerite	3048105135	\$31,500.	\$0.	\$31,500.
Agricultural Research Service Acquisition of Goods and Services for USDA offices in Ag North -- 2008-09				
Assoc Dean Research/Director AES	Totals:	\$598,926.	\$14,113.	\$613,039.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Tracy Farmer Cntr for the Environment</u>				
Hanley, Carol D	3048104808	\$205,000.	\$0.	\$205,000.
KY Department of Military Affairs 4-H Community-Based Science				
Hanley, Carol D	3048105507	\$140,000.	\$0.	\$140,000.
KY Council on Postsecondary Education Science Literacy Project for Middle School Teachers				
Hanley, Carol D	3048105802	\$20,000.	\$0.	\$20,000.
National Association of Counties Mill Creek Elementary Stream and Wetland Restoration Project				
Tracy Farmer Cntr for the Environment	Totals:	\$365,000.	\$0.	\$365,000.
<u>Agr Economics</u>				
Hu, Wuyang	3048105429	\$19,907.	\$0.	\$19,907.
University of Hawaii Analysis of Current Market Demand for Ahi Poke and Consumer Trend Analysis				
Meyer, Alphonse L	3046809500	\$0.	\$30,000.	\$30,000.
KY Beef Network Value-Added Targeted Marketing of Feeder Cattle				
Meyer, Alphonse L	3048105088	\$51,169.	\$0.	\$51,169.
University of Georgia Supporting and Enhancing the Role of SARE in Extension and Other Land Grant University Programs				
Meyer, Alphonse L	3048105122	\$20,000.	\$0.	\$20,000.
University of Georgia Sustainable Agriculture Research and Education (SARE) Model State Program Assistant				
Meyer, Alphonse L	3048105123	\$10,000.	\$0.	\$10,000.
University of Georgia Kentucky's SARE 2008-2009 Model State Program and Professional Development Program Plan of Work				
Meyer, Alphonse L	3048105176	\$8,528.	\$0.	\$8,528.
University of Georgia Agent Training for the Development of a Program in Farm Transitions				
Pushkarskaya, Helen N	3048104888	\$142,756.	\$0.	\$142,756.
Cooperative State Research Education and Extension On-line Math Modules				
Robbins, Lynn W	3048103813	\$0.	\$620.	\$620.
KY Governor's Office of Agricultural Policy KADB: Pilot Farm Management Cost-Share Program				
Robbins, Lynn W	3048103813	\$0.	\$-2,000.	\$-2,000.
KY Governor's Office of Agricultural Policy KADB: Pilot Farm Management Cost-Share Program				
Walters, Cory Gene	3048105580	\$1,000.	\$0.	\$1,000.
Texas A&M University 2008 Farm Bill Training				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Agr Economics</u>				
Woods, Timothy A	3046997000	\$0.	\$1,500.	\$1,500.
KY Center for Cooperative Development Cooperatives Intern Program				
Woods, Timothy A	3048105373	\$17,909.	\$0.	\$17,909.
Iowa State University Using MarketMaker Demographics Tools to Estimate Market Potential for Value-Added Agriculture Products				
Woods, Timothy A	3048105509	\$33,000.	\$0.	\$33,000.
KY Farmers Market Association Inc Farmers Market Technology and Food Safety				
Agr Economics	Totals:	\$304,269.	\$30,120.	\$334,389.
<u>Biosystems & Ag Eng</u>				
Colliver, Donald G	3048104859	\$0.	\$-25,000.	\$-25,000.
National Renewable Energy Laboratory Solar Decathlon - 2009				
Colliver, Donald G	3048104967	\$54,520.	\$0.	\$54,520.
KY Office of Energy Policy Renewable Energy/Energy Efficiency (REEE) Program Support				
Fehr, Robert L	3048104782	\$95,651.	\$0.	\$95,651.
KY Office of Energy Policy Energy - A Cooperative Extension Program for Kentucky's Building Systems Energy Needs				
Fehr, Robert L	3048105017	\$89,200.	\$0.	\$89,200.
KY Health Services Cabinet Radon: Cooperative Extension Radon and Indoor Air Quality Education				
Higgins, Stephen F	3048104835	\$5,000.	\$0.	\$5,000.
Fayette County Conservation District On-Farm Water Enhancement Program for a Spring Development				
Higgins, Stephen F	3048104836	\$1,500.	\$0.	\$1,500.
Fayette County Conservation District On-Farm Water Enhancement Program for a Forage Area				
McNeill, S G	3048105590	\$22,000.	\$0.	\$22,000.
Ohio State University Incidence and Spread of Insects from Bucket Elevator Leg Boots				
Payne, Frederick A	3048105108	\$1,175,481.	\$0.	\$1,175,481.
National Institute for Hometown Security Technology Optimization of a Milk Transport Security System				
Shearer, Scott A	3048105137	\$97,579.	\$0.	\$97,579.
Case New Holland America LLC CNH Master Agreement				
Shearer, Scott A	3048105185	\$468,551.	\$0.	\$468,551.
Cooperative State Research Education and Extension Precision Agriculture: Precision Resource Management Phase IV				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Biosystems & Ag Eng</u>				
Shearer, Scott A	3048105571	\$31,116.	\$0.	\$31,116.
KY Soybean Promotion Board Quantification and Mitigation of Pesticide Application Errors on Kentucky Soybean Farms				
Wilhoit, John H	3048105650	\$75,000.	\$0.	\$75,000.
Tobacco Education and Research Council Inc Pre-Wilting Burley Tobacco to Enhance Manual and Mechanical Harvesting and Housing				
Workman, Stephen R	3048104900	\$100,000.	\$0.	\$100,000.
Cooperative State Research Education and Extension International Education and Training for Food, Fiber, and Energy Production				
Workman, Stephen R	3048105389	\$20,000.	\$0.	\$20,000.
Texas A&M University 2008 Southern Regional Water Resource Project				
Biosystems & Ag Eng	Totals:	\$2,235,598.	\$-25,000.	\$2,210,598.
<u>Plant & Soil Sciences</u>				
Bertsch, Paul M	3048104999	\$0.	\$-931.	\$-931.
Environmental Protection Agency Bioavailability, Toxicity, and Trophic Transfer of Manufactured ZnO Nanoparticles: A View from the Bottom				
Bertsch, Paul M	3048104999	\$51,598.	\$0.	\$51,598.
Environmental Protection Agency Bioavailability, Toxicity, and Trophic Transfer of Manufactured ZnO Nanoparticles: A View from the Bottom				
Bertsch, Paul M	3048105034	\$50,000.	\$0.	\$50,000.
Department of Energy Environmental Remediation Science at Beamline X26A at the National Synchrotron Light Source				
Bertsch, Paul M	3048105332	\$110,000.	\$0.	\$110,000.
Duke University Center for the Environmental Implications of Nanotechnology (CEIN)				
Bertsch, Paul M	3048105513	\$12,858.	\$0.	\$12,858.
University of Georgia 2008 PLM and Chemical Analysis, Savannah River National Laboratory and Washington Savannah River Company				
Bertsch, Paul M	3048105682	\$41,500.	\$0.	\$41,500.
University of Chicago Synchrotron X-ray Microprobe and Microspectroscopy Research in Low Temperature Geochemistry				
Bruening, William P	3048105404	\$50,000.	\$0.	\$50,000.
KY Soybean Promotion Board Performance of Soybean Varieties in Kentucky				
Bruening, William P	3048105428	\$60,000.	\$0.	\$60,000.
KY Small Grain Growers Association Equipment Grant: Plot Combine				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Plant & Soil Sciences</u>				
Chappell, Joseph	3048105226	\$249,925.	\$0.	\$249,925.
National Science Foundation Development of a Sustainable Production Platform for Renewable Petroleum Based Oils in Algae				
D'Angelo, Elisa Marie	3048105209	\$10,000.	\$0.	\$10,000.
University of Georgia S. Lucas-SARE: Effects of organic amendments on aggregation and microbial community dynamics in soils				
Davies, H Maelor	3048105197	\$531,337.	\$0.	\$531,337.
Philip Morris International Management SA Nicotiana Germplasm Survey				
Davies, H Maelor	3048105376	\$31,800.	\$0.	\$31,800.
Tobacco Education and Research Council Inc A Survey of 'GM' Technologies Appropriate to Tobacco Production for its Traditional Markets				
Green, Jonathan D	3048104665	\$116,188.	\$0.	\$116,188.
Cooperative State Research Education and Extension Integrated Weed Management Strategies to Increase Pasture Productivity				
Grove, J H	3048105566	\$10,000.	\$0.	\$10,000.
KY Soybean Promotion Board Soybean Yield Response to Soil P & K Availability: Optimizing Fertilization Expenses				
Grove, J H	3048105568	\$21,000.	\$0.	\$21,000.
KY Soybean Promotion Board Sensing Soybean Canopy Development and Crop Stress: Understanding the Relationship to Grain Yield				
Herbek, James H	3048105567	\$3,000.	\$0.	\$3,000.
KY Soybean Promotion Board Optimum Planting Date for Soybean				
Hildebrand, David F	3048105189	\$90,000.	\$0.	\$90,000.
Consortium for Plant Biotechnology Research Inc Oilseeds as a Renewable Source of Epoxy Fatty Acids				
Hildebrand, David F	3048105380	\$59,474.	\$0.	\$59,474.
United Soybean Board Further Development of Soybeans with Higher Levels of Improved Oil and Enhanced Fungal Resistance				
Hildebrand, David F	3048105487	\$10,000.	\$0.	\$10,000.
Ashland Inc Increasing Epoxy Fatty Acid Accumulation in Oilseeds				
Hunt, Arthur G	3048105143	\$0.	\$3,000.	\$3,000.
National Science Foundation Collaborative Proposal: CPSF30 at the Convergence of RNA Processing, Cellular Signaling and Development in Plants				
Hunt, Arthur G	3048105143	\$224,991.	\$0.	\$224,991.
National Science Foundation Collaborative Proposal: CPSF30 at the Convergence of RNA Processing, Cellular Signaling and Development in Plants				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Plant & Soil Sciences</u>				
Karathanasis, Anastasios D	3048104924	\$0.	\$16,398.	\$16,398.
KY Health Services Cabinet Soil Morphology Training for On-Site Sewage Disposal Systems				
Karathanasis, Anastasios D	3048104924	\$2.	\$0.	\$2.
KY Health Services Cabinet Soil Morphology Training for On-Site Sewage Disposal Systems				
Lee, Brad Davis	3048105666	\$45,181.	\$0.	\$45,181.
Texas A&M University 2008 Southern Regional Water Resource Project				
Lee, Chad D	3048105104	\$0.	\$75,630.	\$75,630.
Iowa State University Agronomic Limitations of Soybean Yield and Seed Quality in U.S.				
Lee, Chad D	3048105104	\$74,128.	\$0.	\$74,128.
Iowa State University Agronomic Limitations of Soybean Yield and Seed Quality in U.S.				
Lee, Chad D	3048105353	\$6,000.	\$0.	\$6,000.
KY Small Grain Promotion Council Wheat Yield in 15-inch Rows				
Lee, Chad D	3048105354	\$10,000.	\$0.	\$10,000.
KY Small Grain Promotion Council Wheat Yield Response to Old Corn Rows				
Lee, Chad D	3048105569	\$81,793.	\$0.	\$81,793.
KY Soybean Promotion Board SOY MVP: Kentucky Soybean Management Verification Program, Year 2				
Martin, James R	3048105161	\$3,000.	\$0.	\$3,000.
KY Small Grain Growers Association Application Timing for Italian Ryegrass Control in Conventional & No-tillage Wheat				
Martin, James R	3048105162	\$2,800.	\$0.	\$2,800.
KY Small Grain Growers Association Influence of Timing of Topdressing Nitrogen Fertilizer Relative to Application of Osprey Herbicide				
McCulley, Rebecca L	3048104653	\$0.	\$39,385.	\$39,385.
Duke University Effects of Warming and Altered Precipitation Regime on Managed Grassland Structure and Function				
McCulley, Rebecca L	3048105142	\$50,419.	\$0.	\$50,419.
National Science Foundation Collaborative Research: Decomposition in Drylands: Soil Erosion and UV Interactions				
McNear, David H	3048105203	\$397,500.	\$0.	\$397,500.
Cooperative State Research Education and Extension Response to Soil Processes to an Above Ground Plant-Fungal Symbiosis from Rhizosphere to Regional Scales				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Plant & Soil Sciences</u>				
Miller, Robert D	3048105704	\$50,000.	\$0.	\$50,000.
Burley Tobacco Growers Cooperative Association Inc Breeding for Reduced Nicotine Content in Burley Tobacco				
Murdock, Lloyd W	3048105163	\$5,000.	\$0.	\$5,000.
KY Small Grain Growers Association Improving Nitrogen Application Technology Under Kentucky Conditions				
Pearce, Robert C	3048105708	\$20,000.	\$0.	\$20,000.
Burley Tobacco Growers Cooperative Association Inc Development of a Method to Confirm the Country of Origin of Tobacco Samples				
Pearce, Robert C	3048105709	\$20,000.	\$0.	\$20,000.
Burley Tobacco Growers Cooperative Association Inc Improved Methods for the Application of Contact and Local Systemic Suckercides to Burley Tobacco				
Pearce, Robert C	3048105710	\$5,000.	\$0.	\$5,000.
Burley Tobacco Growers Cooperative Association Inc Support for Innovative Tobacco Growers Program				
Schwab, Gregory J	3048105165	\$6,000.	\$0.	\$6,000.
KY Small Grain Growers Association Wheat Management for Wet-Natured Soils				
Schwab, Gregory J	3048105572	\$3,000.	\$0.	\$3,000.
KY Soybean Promotion Board Soybean Fertilization: Is Hidden Hunger Reducing Yield?				
Slack, Charles H	3048105661	\$6,000.	\$0.	\$6,000.
Monsanto Co Service Order No. 6 Dicamba-Tolerant Soybean: Weed Control				
Slack, Charles H	3048105675	\$1,200.	\$0.	\$1,200.
Monsanto Co Formulation Testing of Encapsulated Acetochlor in Soybeans - Service Order No. 8				
Slack, Charles H	3048105679	\$4,800.	\$0.	\$4,800.
Monsanto Co Encapsulated Acetochlor in Soybeans EUP Academic - Service Order No. 7				
Smith, Samuel Ray	3048104784	\$150,889.	\$0.	\$150,889.
Ceres Inc Biomass Field Trials				
Tsyusko, Olga V	3048105259	\$58,998.	\$0.	\$58,998.
University of Georgia Collaborative Research: The Evolution of Heterostylous Breeding Systems in Populations of Oxalis Alpina in the Sky Islands of the United States and Mexico				
Urine, Jason M	3048104803	\$0.	\$158,770.	\$158,770.
Environmental Protection Agency The Fate and Effects of Nanosized Metal Particles Along a Simulated Terrestrial Food Chain Investigated Using Genomic and Microspectroscopic Techniques				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Plant & Soil Sciences</u>				
Unrine, Jason M	3048104803	\$159,127.	\$0.	\$159,127.
Environmental Protection Agency The Fate and Effects of Nanosized Metal Particles Along a Simulated Terrestrial Food Chain Investigated Using Genomic and Microspectroscopic Techniques				
Van Doren, Saratha Kumudini	3048105570	\$15,550.	\$0.	\$15,550.
KY Soybean Promotion Board Final Development of a Yield Loss Prediction Tool for Soybean Rust				
Van Sanford, D A	3048030900	\$0.	\$131,300.	\$131,300.
Agricultural Research Service US Wheat & Barley Scab Initiative's Networking and Facilitation Office and Website				
Van Sanford, D A	3048104461	\$0.	\$2,160.	\$2,160.
Virginia Polytechnic Institute and State University Wheat CAP Grant				
Van Sanford, D A	3048105167	\$39,750.	\$0.	\$39,750.
KY Small Grain Growers Association Soft Red Winter Wheat Breeding and Variety Development				
Van Sanford, D A	3048105647	\$56,865.	\$0.	\$56,865.
Agricultural Research Service Accelerating the Development of FHB-Resistant Soft Red Winter Wheat Varieties				
Wendroth, Ole Otto	3048105052	\$324,000.	\$0.	\$324,000.
Cooperative State Research Education and Extension Dynamics of Soil State Variables and Related Processes Across a Land Use Gradient in Spatial and Temporal Transition				
Wendroth, Ole Otto	3048105166	\$4,500.	\$0.	\$4,500.
KY Small Grain Growers Association Soil Mineral Nitrogen and Crop Biomass Dynamics of Winter Wheat in Space and Time in a Farmer's Field				
Zhu, Hongyan	3048103109	\$0.	\$160,000.	\$160,000.
National Science Foundation Function of non-legume orthologs of legume genes required for nodulation and arbuscular mycorrhizal symbiosis				
Plant & Soil Sciences	Totals:	\$3,335,173.	\$585,712.	\$3,920,885.
<u>Animal and Food Sciences</u>				
Amaral-Phillips, Donna M	3048104479	\$0.	\$15,000.	\$15,000.
University of Nebraska DAIReXNET: A National Dairy Information and Communications Resource				
Boatright, William L	3048105000	\$0.	\$401,222.	\$401,222.
Cooperative State Research Education and Extension Formation and Reactivity of Carbon-Centered Radicals in Isolated Soy Proteins				
Boatright, William L	3048105000	\$23,662.	\$0.	\$23,662.
Cooperative State Research Education and Extension Formation and Reactivity of Carbon-Centered Radicals in Isolated Soy Proteins				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Animal and Food Sciences</u>				
Bullock, Kevin D	3048104807	\$50,000.	\$0.	\$50,000.
Cornell University National Beef Cattle Evaluation Consortium				
Cantor, Austin H	3048104339	\$0.	\$17,804.	\$17,804.
Alltech Biotechnology Inc Student Sponsorship Agreement for Lizza Macalintal				
Cantor, Austin H	3048104339	\$0.	\$11,042.	\$11,042.
Alltech Biotechnology Inc Student Sponsorship Agreement for Lizza Macalintal				
Coffey, Richard D	3048105656	\$25,000.	\$0.	\$25,000.
KY Governor's Office of Agricultural Policy Development and Implementation of a High-Rise Swine Manure Composting Production Facility				
Cromwell, Gary L	3048105115	\$5,000.	\$0.	\$5,000.
Department of Agriculture Developing Nutrient Requiement and Feeding Guidelines				
Harmon, David L	3046522900	\$0.	\$299,750.	\$299,750.
Hills Pet Nutrition Inc Nutrient Utilization in the Dog				
Harmon, David L	3048104079	\$0.	\$30,000.	\$30,000.
Alltech Biotechnology Inc Student Sponsorship Agreement - Holder				
Harmon, David L	3048105375	\$0.	\$-299,750.	\$-299,750.
Hills Pet Nutrition Inc Nutrient Utilization in the Dog 2009-1010				
Harmon, David L	3048105375	\$299,750.	\$0.	\$299,750.
Hills Pet Nutrition Inc Nutrient Utilization in the Dog 2009-1010				
Harmon, David L	3048105405	\$5,685.	\$0.	\$5,685.
Elanco Animal Health Elanco Animal Health Clinical Research Study Agreement - UKYDH0802				
Harmon, David L	3048105406	\$28,506.	\$0.	\$28,506.
Elanco Animal Health Elanco Animal Health Clinical Research Study Agreement - UKYDH0803				
Hennig, B	3048105614	\$1,964,908.	\$0.	\$1,964,908.
National Institute of Environmental Health Sciences Nutrition and Superfund Chemical Toxicity				
Lawrence, Laurie M	3048104078	\$0.	\$30,000.	\$30,000.
Alltech Biotechnology Inc Sponsored Student Stipend - Brummer				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Animal and Food Sciences</u>				
Lindemann, Merlin D	3048105271	\$20,000.	\$0.	\$20,000.
Agricultural Research Service Impact of Fibrous Feedstuff on Marker Appearance and Disappearance, and on Nutrient Digestibility in Finishing Pigs				
McLeod, Kyle R	3048089100	\$0.	\$224,614.	\$224,614.
Hills Pet Nutrition Inc Essential Amino Acid and Fatty Acid Studies in Cats				
McLeod, Kyle R	3048105398	\$0.	\$-224,614.	\$-224,614.
Hills Pet Nutrition Inc Essential Amino Acid and Fatty Acid Studies in Cats 2009-2010				
McLeod, Kyle R	3048105398	\$224,614.	\$0.	\$224,614.
Hills Pet Nutrition Inc Essential Amino Acid and Fatty Acid Studies in Cats 2009-2010				
Pescatore, Anthony J	3048105347	\$32,400.	\$0.	\$32,400.
Alltech Biotechnology Inc Student Sponsorship Agreement for Anthony Quant				
Suman, Surendranath P	3048105343	\$99,999.	\$0.	\$99,999.
Cooperative State Research Education and Extension Differentiating Sarcoplasmic Proteomes of Color-Stable and Color-Labile Beef Muscles				
Vanzant, Eric S	3048105349	\$906,841.	\$0.	\$906,841.
National Institute for Hometown Security Animal Health Sensing and Surveillance: Early Disease Detection for Food Supply and Public Health Protection				
Xiong, Youling	3048104806	\$15,000.	\$0.	\$15,000.
KY State University Sensory evaluation of prawns from different genetic strains				
Animal and Food Sciences	Totals:	\$3,701,365.	\$505,068.	\$4,206,433.
<u>Entomology</u>				
Bessin, Ricardo T	3048105631	\$10,700.	\$0.	\$10,700.
University of Florida Southern region Program to Clear Pest Control Agents for Minor Use				
Dobson, Stephen Leonard	3046961000	\$0.	\$71,354.	\$71,354.
University of Queensland Genetic Modification of Mosquito Populations to Make Them Incapable of Transmitting Dengue Virus				
Dobson, Stephen Leonard	3048035600	\$0.	\$310,665.	\$310,665.
National Institute of Allergy and Infectious Diseases Eradication of a Primary Filariasis Vector Population at an Endemic Field Site				
Harwood, James Douglas	3048104921	\$95,733.	\$0.	\$95,733.
KY Science and Technology Co Inc KSEF R&D Excellence: A Molecular Approach to Elucidate the Role of Invasive Mollusk Pests in Kentucky Agriculture				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Entomology</u>				
Johnson, Douglas W	3048105164	\$2,404.	\$0.	\$2,404.
KY Small Grain Growers Association Migration Patterns for Aphid Pests of Small Grains as Indexed by Capture in an Aphid Suction Trap (Year 3)				
Johnson, Douglas W	3048105576	\$2,404.	\$0.	\$2,404.
KY Soybean Promotion Board Migration patterns for soybean aphid as indexed by capture in an aphid suction trap				
Lucas, Patricia A	3048104706	\$0.	\$25,000.	\$25,000.
North Carolina State University State Contact and IPM Documents for Kentucky				
Obrycki, John J	3048104886	\$68,565.	\$0.	\$68,565.
Animal and Plant Health Inspection Service Light Brown Apple Moth National Survey				
Obrycki, John J	3048104920	\$211,000.	\$0.	\$211,000.
Cooperative State Research Education and Extension Intraguild Predation between Aphidophagous Lady Beetles: Chemical Perspectives on Community Effects				
Obrycki, John J	3048105411	\$10,000.	\$0.	\$10,000.
KY Energy and Environment Cabinet Hemlock Woolly Adelgid Sampling Surveys				
Obrycki, John J	3048105461	\$96,314.	\$0.	\$96,314.
Animal and Plant Health Inspection Service Cooperative Agricultural Pest Survey				
Obrycki, John J	3048105575	\$4,334.	\$0.	\$4,334.
Department of Agriculture Biological Control of the Hemlock Woolly Adelgid				
Obrycki, John J	3048105660	\$708,602.	\$0.	\$708,602.
Animal and Plant Health Inspection Service Emerald Ash Borer Survey and Outreach in Kentucky				
Obrycki, John J	3048105662	\$11,234.	\$0.	\$11,234.
Animal and Plant Health Inspection Service Light Brown Apple Moth (LBAM) National Survey				
Obrycki, John J	3048105727	\$50,000.	\$0.	\$50,000.
Slow the Spread Foundation Monitor Gypsy Moth Populations for Slow the Spread Program				
Palli, Subba R	3046862500	\$0.	\$174,086.	\$174,086.
National Institute of General Medical Sciences Molecular Analysis of Juvenile Hormone Action				
Palli, Subba R	3046862500	\$0.	\$193,429.	\$193,429.
National Institute of General Medical Sciences Molecular Analysis of Juvenile Hormone Action				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Entomology</u>				
Potter, Daniel A	3048105072	\$26,530.	\$0.	\$26,530.
Dow AgroSciences Evaluation of Transgenic Turfgrasses for Resistance to Root-Feeding White Grubs				
Potter, Daniel A	3048105160	\$10,000.	\$0.	\$10,000.
ParaTechs Corp Development of a new production system for baculovirus pesticides				
Potter, Daniel A	3048105253	\$9,750.	\$0.	\$9,750.
University of Georgia Hammons - SARE: Sustainable Management for Scarab Pests Impacting Grape Production in the Southern Region				
Webb, Bruce Allen	3048104390	\$0.	\$137,632.	\$137,632.
ParaTechs Corp Enhancement of the Baculovirus Expression Vector System				
Zhou, Xuguo	3048105426	\$50,270.	\$0.	\$50,270.
KY Science and Technology Co Inc Kentucky Commercialization Fund: Integration of Double Stranded RNA into Baiting System: A Novel Genetic Control Strategy for Termites				
Entomology	Totals:	\$1,367,840.	\$912,166.	\$2,280,006.
<u>Forestry</u>				
Barton, Christopher D	3046929100	\$0.	\$61,237.	\$61,237.
Forest Service Enhancement of Disturbed Upper Coastal Plain Stream Systems: Establishing Restoration Criteria and Strategies for a Stream Mitigation Bank				
Barton, Christopher D	3048105156	\$25,000.	\$0.	\$25,000.
American Chestnut Foundation American Chestnut Restoration on Surface Mined Sites in Appalachia				
Bullard, Steve	3048105502	\$10,000.	\$0.	\$10,000.
Forest Service Collaborative Efforts in Southern Forestry Recruiting				
Connors, Terrance E	3048104944	\$17,000.	\$0.	\$17,000.
University of Georgia Forest Biomass Training for Kentucky				
Cox, John J	3048105007	\$0.	\$8,500.	\$8,500.
KY Department of Fish and Wildlife Terrestrial Nuisance Species Management Plan				
Cox, John J	3048105007	\$8,500.	\$0.	\$8,500.
KY Department of Fish and Wildlife Terrestrial Nuisance Species Management Plan				
Cox, John J	3048105307	\$70,000.	\$0.	\$70,000.
KY Department of Fish and Wildlife Calf Survival, Meningeal Worm Impacts, Dispersal, and Population Expansion in an Eastern Kentucky Elk Herd				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Forestry</u>				
Cox, John J	3048105338	\$30,000.	\$0.	\$30,000.
KY Department of Fish and Wildlife The Common Raven in Cliff Habitat: Detection and Occupancy				
Cox, John J	3048105390	\$98,000.	\$0.	\$98,000.
KY Department of Fish and Wildlife Dispersal & Population Expansion of the Black Bear in Eastern Kentucky				
Cushing, Tamara L	3048104929	\$24,100.	\$0.	\$24,100.
KY Environmental and Public Protection Cabinet Development of a Property Tax Assessment Guidelines for Woodland Owners in Kentucky				
Fei, Songlin	3048104996	\$15,000.	\$0.	\$15,000.
KY Environmental and Public Protection Cabinet Crosswalk and Develop GIS Mapping Applications and Accomplishment Monitoring Geospatial Database				
Lacki, Michael J	3048105309	\$48,703.	\$0.	\$48,703.
KY Department of Fish and Wildlife Status, Distribution, and Reproductive Characteristics of River Otters in Kentucky				
Lhotka, John M	3048104887	\$0.	\$-495.	\$-495.
Forest Service Evaluating Seedling Development, Stand Structure, and Understory Microenvironment Six Growing Seasons Following Midstory Removal				
Lhotka, John M	3048104887	\$5,683.	\$0.	\$5,683.
Forest Service Evaluating Seedling Development, Stand Structure, and Understory Microenvironment Six Growing Seasons Following Midstory Removal				
Lhotka, John M	3048105695	\$14,435.	\$0.	\$14,435.
Department of Agriculture Silvicultural Approaches for Regenerating Upland Stands in the Northern Cumberland Plateau				
Stringer, Jeffrey W	3048104998	\$20,000.	\$0.	\$20,000.
KY Environmental and Public Protection Cabinet Forest Stewardship Public Awareness, Publicity, and Training				
Stringer, Jeffrey W	3048105014	\$20,000.	\$0.	\$20,000.
KY Environmental and Public Protection Cabinet Kentucky Woodland Magazine Special Forest Health Issue				
Stringer, Jeffrey W	3048105015	\$20,000.	\$0.	\$20,000.
KY Environmental and Public Protection Cabinet Kentucky Woodland Magazine Special Pine Management Issue				
Stringer, Jeffrey W	3048105339	\$24,435.	\$0.	\$24,435.
KY Department of Fish and Wildlife Technical Support for Paul VanBooven Wildlife Management Area				
Stringer, Jeffrey W	3048105648	\$294,000.	\$0.	\$294,000.
KY Energy and Environment Cabinet Economic Impact of Fire on Forest Product Values in the Appalachian Regions of Kentucky and Tennessee				
Forestry	Totals:	\$744,856.	\$69,242.	\$814,098.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Family & Consumer Sciences</u>				
Adler, Linda C	3048105012	\$5,500.	\$0.	\$5,500.
Auburn University Kentucky Healthy Homes and Communities				
Ashurst, Kerri Lynn	3048105210	\$0.	\$50,000.	\$50,000.
Kansas State University Kentucky Operation: Military Kids				
Ashurst, Kerri Lynn	3048105210	\$50,000.	\$0.	\$50,000.
Kansas State University Kentucky Operation: Military Kids				
Ashurst, Kerri Lynn	3048105457	\$0.	\$42,499.	\$42,499.
Kansas State University Operation Military Kids: Camp Initiative/Joint Family Support Assistance Program Supplement				
Ashurst, Kerri Lynn	3048105457	\$42,501.	\$0.	\$42,501.
Kansas State University Operation Military Kids: Camp Initiative/Joint Family Support Assistance Program Supplement				
Murray, Deborah A	3048105659	\$10,000.	\$0.	\$10,000.
Morehead State University Rural Health Care Services Outreach and Rural Health Network Development Program				
Stephenson, Laura F	3048105517	\$90,890.	\$0.	\$90,890.
University of Tennessee Investor Education for College Students				
Vail, Ann	3048104885	\$602,473.	\$0.	\$602,473.
Cooperative State Research Education and Extension Health Education Leadership, KY				
Family & Consumer Sciences	Totals:	\$801,364.	\$92,499.	\$893,863.
<u>Horticulture</u>				
Archbold, Douglas D	3048105716	\$2,270.	\$0.	\$2,270.
Cornell University Coordinate Wine Grape Variety Evaluations in the Eastern USA				
Coolong, Timothy	3048105642	\$14,791.	\$0.	\$14,791.
University of Georgia Sweet Potatoes: A Profitable Crop for Small Farms in Rural Eastern Kentucky				
Durham, Richard E	3048104490	\$0.	\$15,000.	\$15,000.
University of Nebraska eXtension Consumer Horticulture Certified Cop Leadership Funds 2008				
Durham, Richard E	3048104490	\$0.	\$-14,800.	\$-14,800.
University of Nebraska eXtension Consumer Horticulture Certified Cop Leadership Funds 2008				
Durham, Richard E	3048104490	\$0.	\$14,800.	\$14,800.
University of Nebraska eXtension Consumer Horticulture Certified Cop Leadership Funds 2008				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Horticulture</u>				
Fulcher, Amy F	3048105336	\$3,000.	\$0.	\$3,000.
University of Florida Efficacy of PGRs on Branch Architecture of Container-Grown Shrubs				
Fulcher, Amy F	3048105693	\$18,744.	\$0.	\$18,744.
North Carolina State University Multi-State Crop Profile and Pest Management Strategic Plan for Nursery Crops				
Ingram, Dewayne L	3046999200	\$0.	\$25,364.	\$25,364.
Department of Agriculture New Crop Opportunities, KY, Phase VII				
Ingram, Dewayne L	3048104696	\$0.	\$42,000.	\$42,000.
Cooperative State Research Education and Extension New Crop Opportunities, Phase IX				
Jones, Richard T	3048105401	\$10,000.	\$0.	\$10,000.
KY Department of Agriculture Ginseng Monitoring and Research Project				
Horticulture	Totals:	\$48,805.	\$82,364.	\$131,169.
<u>Plant Pathology</u>				
Farman, Mark L	3048093200	\$0.	\$111,017.	\$111,017.
National Science Foundation Telomere Hypervariability in the fungus, Magnaporthe oryzae - a model plant pathogen				
Ghabrial, Said A	3048103102	\$0.	\$34,000.	\$34,000.
University of Illinois Soybean Health: Rust Gene Discovery Initiative				
Ghabrial, Said A	3048103225	\$0.	\$54,484.	\$54,484.
University of Illinois Towards developing rust-resistant soybeans: identifying genes for rust resistance				
Ghabrial, Said A	3048105010	\$36,380.	\$0.	\$36,380.
University of Illinois Construction of a DNA-Based Virus Induced Gene Silencing Tools for Functional Genomics of Soybeans				
Ghabrial, Said A	3048105565	\$30,563.	\$0.	\$30,563.
KY Soybean Promotion Board Use of a Novel Virus-Based Vector in the Search for Resistance to the Soybean Cyst Nematode and Other Important Soybean Pathogens				
Goodin, Michael M	3048104575	\$0.	\$150,000.	\$150,000.
National Science Foundation A Host Protein Interaction and Localization Map for a Plant				
Hershman, Donald E	3048103103	\$0.	\$5,122.	\$5,122.
Agricultural Research Service Uniform Trial on Integrated management of FHB: Kentucky				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Plant Pathology</u>				
Hershman, Donald E	3048105519	\$30,000.	\$0.	\$30,000.
North Central Soybean Research Program Sentinel Plots to Monitor the Spread of Soybean Rust in US Soybean Production Regions				
Hershman, Donald E	3048105564	\$9,061.	\$0.	\$9,061.
KY Soybean Promotion Board Can Foliar Applied Fungicides Reduce Yield Loss in Soybean Caused by Soybean Cyst Nematode?				
Hershman, Donald E	3048105646	\$31,246.	\$0.	\$31,246.
KY Soybean Promotion Board 2009 Kentucky Soybean Rust Monitoring and Early Warning Systems				
Kachroo, Aardra P	3048104449	\$0.	\$102,908.	\$102,908.
United Soybean Board Enhancing Soybean Yield by Manipulating the Expression of Seed Trait-Determining Genes				
Kachroo, Pradeep	3048103749	\$0.	\$86,297.	\$86,297.
Boyce Thompson Institute for Plant Research Genetic, molecular and biochemical basis of resistance to turnip crinkle virus in Arabidopsis				
Kachroo, Pradeep	3048103749	\$0.	\$2,275.	\$2,275.
Boyce Thompson Institute for Plant Research Genetic, molecular and biochemical basis of resistance to turnip crinkle virus in Arabidopsis				
Kachroo, Pradeep	3048104688	\$0.	\$300,000.	\$300,000.
National Science Foundation Glycerol Metabolism and Its Role in Biotrophy Versus Necrotrophy in an Arabidopsis/Fungal Hemibiotroph Model System				
Nagy, Peter D	3048086400	\$0.	\$36,924.	\$36,924.
National Institute of Allergy and Infectious Diseases Roles of host RNA binding proteins in virus replication				
Nagy, Peter D	3048105025	\$98,010.	\$0.	\$98,010.
KY Science and Technology Co Inc KSEF R&D Excellence: Identification of Anti-Prion Drugs Active against Plant Viruses				
Nagy, Peter D	3048105026	\$0.	\$162,000.	\$162,000.
National Science Foundation The Role of a Host Ion Pump in RNA Virus Recombination				
Nagy, Peter D	3048105026	\$150,000.	\$0.	\$150,000.
National Science Foundation The Role of a Host Ion Pump in RNA Virus Recombination				
Nagy, Peter D	3048105621	\$170,000.	\$0.	\$170,000.
National Institute of Allergy and Infectious Diseases Functional role of a host metabolic enzyme in viral replication				
Nagy, Peter D	3048105714	\$170,970.	\$0.	\$170,970.
National Institute of Allergy and Infectious Diseases ARRA: The Role of the Host Ca/Mn Pump in Emergence of Novel Viral RNA Recombinants				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Plant Pathology</u>				
Scharld, Christopher L	3048105181	\$448,178.	\$0.	\$448,178.
Cooperative State Research Education and Extension Advanced Genetic Technologies				
Scharld, Christopher L	3048105694	\$144,000.	\$0.	\$144,000.
West Virginia University Biochemical and Genetic Basis of Ergot Alkaloid Diversification				
Vaillancourt, Lisa	3048104901	\$140,010.	\$0.	\$140,010.
Cooperative State Research Education and Extension The Role of Signal Peptidase in the Pathogenic Association of the Anthracnose Stalk Rot Fungus Colletotrichum Graminicola with Maize				
Vincelli, Paul	3048104024	\$0.	\$39,000.	\$39,000.
University of Florida Southern Region Plant Diagnostic Network, IPM PIPE 2007, KY Component				
Vincelli, Paul	3048104300	\$0.	\$7,200.	\$7,200.
KY State University Biofumigation for Soil Health in Organic High Tunnel and Conventional Field Vegetable Production Systems				
Plant Pathology	Totals:	\$1,458,418.	\$1,091,227.	\$2,549,645.
<u>Community & Leadership Devel</u>				
Clore, Danielle T	3048105624	\$4,500.	\$0.	\$4,500.
Greater Cincinnati Foundation Campus Connects Student Philanthropy Project				
Hains, Bryan	3048105365	\$15,000.	\$0.	\$15,000.
Fayette County Public Schools Eastside Technical Center's Secondary Veterinary Science Program				
Jones, Kenneth R	3048105630	\$25,000.	\$0.	\$25,000.
National Four H Council Engaging Youth, Serving Community 7 (EYSC7)				
Nah, Seungahn	3048105038	\$12,000.	\$0.	\$12,000.
American University The Kentucky Citizen Media Project: The Lexington Commons (via New Voices)				
Community & Leadership Devel	Totals:	\$56,500.	\$0.	\$56,500.
<u>Veterinary Science</u>				
Artiushin, Sergey C	3048104963	\$42,393.	\$0.	\$42,393.
KY Science and Technology Co Inc KSEF R&D Excellence: Rapid Test for S. Equi and L. Interrogans in Clinical Specimens from Horses				
Chambers, Thomas M	3048105193	\$0.	\$8,907.	\$8,907.
Science Applications International Co Testing Methods for Influenza Infection in Equine Models				
Chambers, Thomas M	3048105193	\$10,371.	\$0.	\$10,371.
Science Applications International Co Testing Methods for Influenza Infection in Equine Models				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Veterinary Science</u>				
Chambers, Thomas M	3048105726	\$35,543.	\$0.	\$35,543.
Intervet Inc Does Vaccination of Very Young Foals with FluAvert in the Presence of Maternal Antibodies Protect them from Infection?				
Issel, Charles J	3046978700	\$0.	\$235,485.	\$235,485.
IDEXX Laboratories Inc Equine Infectious Anemia Diagnostics				
Issel, Charles J	3048105557	\$347,500.	\$0.	\$347,500.
University of Pittsburgh EIAV Envelope Variation and Vaccine Efficacy				
Veterinary Science	Totals:	\$435,807.	\$244,392.	\$680,199.
<u>Landscape Architecture</u>				
Crankshaw, Ned	3048105311	\$48,923.	\$0.	\$48,923.
City of Bardstown Rural Heritage Development Initiative Design Guidelines				
Landscape Architecture	Totals:	\$48,923.	\$0.	\$48,923.
<u>Regulatory Services</u>				
McMurry, Stephen W	3048104801	\$31,028.	\$0.	\$31,028.
Food and Drug Administration Medicated Feed Mill & BSE Rule Inspections				
Regulatory Services	Totals:	\$31,028.	\$0.	\$31,028.
<u>Livestock Diag Disease Center</u>				
Carter, Craig N	3048104564	\$0.	\$1,204.	\$1,204.
KY Department of Agriculture Bovine Spongiform Encephalopathy (BSE) Testing and Related Services				
Carter, Craig N	3048104664	\$0.	-\$39,224.	-\$39,224.
KY Department for Public Health CHFS/DPH UK West Nile Virus Testing and Related Services				
Carter, Craig N	3048104664	\$40,000.	\$0.	\$40,000.
KY Department for Public Health CHFS/DPH UK West Nile Virus Testing and Related Services				
Carter, Craig N	3048105173	\$31,128.	\$0.	\$31,128.
Texas A&M University R Equi Phneumonia: Airborne Exposure and Foal Immunity / Rhodococcus Equi Airborne Environmental Study				
Carter, Craig N	3048105224	\$400,000.	\$0.	\$400,000.
KY Department of Agriculture Diagnostic Laboratory Services for Farmers and Agribusinesses				
Carter, Craig N	3048105394	\$271,315.	\$0.	\$271,315.
Cooperative State Research Education and Extension Kentucky Statewide Food Animal Health Risk Surveillance and Disease Cluster Detection Initiative				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Livestock Diag Disease Center</u>				
Carter, Craig N	3048105653	\$5,000.	\$0.	\$5,000.
KY Department of Fish and Wildlife Diagnostic Services for KY Dept of Fish and Wildlife				
Livestock Diag Disease Center	Totals:	\$747,443.	\$-38,020.	\$709,423.
<u>Area Extension Field Programs</u>				
Adkins, Gwenda L	3048104913	\$113,000.	\$0.	\$113,000.
Steele Reese Foundation Family Consumer Science Program Assistant for Environmental Education				
Jacobs, Charlene W	3048104973	\$10,000.	\$0.	\$10,000.
KY Arts Council Extension and Arts Grant				
Area Extension Field Programs	Totals:	\$123,000.	\$0.	\$123,000.
<u>Family & Consumer Sciences</u>				
Vail, Ann	3048104902	\$0.	\$1,964,566.	\$1,964,566.
KY Health Services Cabinet Food Stamp Nutrition Education ZABE				
Vail, Ann	3048104902	\$343,470.	\$0.	\$343,470.
KY Health Services Cabinet Food Stamp Nutrition Education ZABE				
Family & Consumer Sciences	Totals:	\$343,470.	\$1,964,566.	\$2,308,036.
<u>e-Extension</u>				
Griffin, Ashley S	3048104498	\$0.	\$-5,000.	\$-5,000.
University of Nebraska HorseQuest Community of Practice				
Griffin, Ashley S	3048104498	\$0.	\$15,000.	\$15,000.
University of Nebraska HorseQuest Community of Practice				
Griffin, Ashley S	3048104498	\$0.	\$-4,000.	\$-4,000.
University of Nebraska HorseQuest Community of Practice				
Wood, Craig H	3046887200	\$0.	\$52,000.	\$52,000.
University of Nebraska ECOP/CSREES E-eXtension-Supplement				
Wood, Craig H	3046887200	\$0.	\$38,000.	\$38,000.
University of Nebraska ECOP/CSREES E-eXtension-Supplement				
Wood, Craig H	3046887200	\$0.	\$101,000.	\$101,000.
University of Nebraska ECOP/CSREES E-eXtension-Supplement				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>e-Extension</u>				
Wood, Craig H	3048104096	\$0.	\$295,913.	\$295,913.
University of Nebraska The Transformation of Cooperative Extension				
e-Extension	Totals:	\$0.	\$492,913.	\$492,913.
<u>Agr Programs</u>				
Husband, Andrea L	3048105154	\$43,941.	\$0.	\$43,941.
Cooperative State Research Education and Extension Addressing Animal and Agriculture Issues in Community Emergency Planning				
Palmer, Gary K	3048104777	\$45,901.	\$0.	\$45,901.
KY Natural Resources Environmental Protection Cabinet University of Kentucky Cooperative Extension Service Liaison				
Yeargan, Ricky N	3048072700	\$0.	\$50,000.	\$50,000.
Purdue University Development of an Animal Emergency/Biosecurity Management Course				
Yeargan, Ricky N	3048072700	\$0.	\$15,000.	\$15,000.
Purdue University Development of an Animal Emergency/Biosecurity Management Course				
Agr Programs	Totals:	\$89,842.	\$65,000.	\$154,842.
<u>Nutrition and Food Science</u>				
Kurzynske, Janet S	3048102104	\$0.	\$140,000.	\$140,000.
Cooperative State Research Education and Extension Promoting Life Skills in Middle School Youth				
Kurzynske, Janet S	3048105665	\$48,000.	\$0.	\$48,000.
Cooperative State Research Education and Extension Children, Youth, and Families Education and Research Network - Program Component				
Kurzynske, Janet S	3048105749	\$37,500.	\$0.	\$37,500.
Department of Agriculture Children, Youth and Families at Risk Liaison				
Nutrition and Food Science	Totals:	\$85,500.	\$140,000.	\$225,500.
<u>Family Studies</u>				
Mimbs, Cheryl A.	3048105175	\$10,000.	\$0.	\$10,000.
KY Department of Education Teacher Educators' Professional Development Grant - FY 09				
Vail, Ann	3048104829	\$33,220.	\$0.	\$33,220.
KY Health Services Cabinet Healthy Marriage Child Support Community Demonstration Program				
Werner-Wilson, Ronald J.	3048104829	\$0.	\$192,662.	\$192,662.
KY Health Services Cabinet Healthy Marriage Child Support Community Demonstration Program				
Family Studies	Totals:	\$43,220.	\$192,662.	\$235,882.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Merchandising, Apparel & Textiles</u>				
Easter, Elizabeth P	3046898300	\$0.	\$38,608.	\$38,608.
National Association of Institutional Linen Management Quality Control Laboratory For NAILM				
Wesley, Scarlett Clouse	3048105582	\$35,890.	\$0.	\$35,890.
KY Department of Agriculture Marketing Potential of Fresh Food Products to Hispanic Consumers: Exploring a New Market Opportunity				
Merchandising, Apparel & Textiles	Totals:	\$35,890.	\$38,608.	\$74,498.
<u>Ky Tobacco Research & Dev Center</u>				
Chambers, Orlando D	3048105391	\$0.	\$2,488.	\$2,488.
Metabolix Inc Industrial Product Field Test				
Chambers, Orlando D	3048105391	\$9,973.	\$0.	\$9,973.
Metabolix Inc Industrial Product Field Test				
Littleton, John M	3048104656	\$0.	\$61,438.	\$61,438.
Naprogenix STTR: Hypericum Extracts as Potential Anti-Relapse Medications in Alcoholism				
Littleton, John M	3048104657	\$0.	\$76,140.	\$76,140.
Naprogenix STTR: Transgenic Plant Cells as a Source of Hepatoprotective Drugs				
Littleton, John M	3048105602	\$108,800.	\$0.	\$108,800.
Naprogenix Potential Anti-Relapse Drugs: A Plant Genomics Approach				
Ky Tobacco Research & Dev Center	Totals:	\$118,773.	\$140,066.	\$258,839.
	Agriculture Totals:	\$17,204,018.	\$6,625,288.	\$23,829,306.
<u>Minority Affairs</u>				
<u>Minority Affairs</u>				
Thomas, Toni	3048105087	\$69,769.	\$0.	\$69,769.
KY Council on Postsecondary Education Governor's Minority Student College Preparation Program				
Minority Affairs	Totals:	\$69,769.	\$0.	\$69,769.
<u>Student Support Services</u>				
Wims, Lydia E	3046933700	\$0.	\$284,207.	\$284,207.
Department of Education Student Support Services				
Wims, Lydia E	3048105748	\$3,000.	\$0.	\$3,000.
KentuckyCAN Inc Know How 2 Go Grant				
Student Support Services	Totals:	\$3,000.	\$284,207.	\$287,207.
	Minority Affairs Totals:	\$72,769.	\$284,207.	\$356,976.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Student Affairs</u>				
<u>Student Affairs</u>				
Edwards, Dorothy Jo	3048102109	\$0.	\$176,309.	\$176,309.
Department of Justice Grants to Reduce Violent Crimes Against Women on Campus--Supplemental				
Student Affairs	Totals:	\$0.	\$176,309.	\$176,309.
	Student Affairs Totals:	\$0.	\$176,309.	\$176,309.
<u>Library Administration</u>				
<u>Library Administration</u>				
Birdwhistell, Terry L	3046673500	\$0.	\$10,000.	\$10,000.
KY Oral History Commission Kentucky Legislature Oral History Interviewing and Transcribing Project				
Boyd, Douglas A.	3048104841	\$3,200.	\$0.	\$3,200.
KY Historical Society The Horse Industry in Kentucky Oral History Project				
Boyd, Douglas A.	3048105460	\$3,500.	\$0.	\$3,500.
KY Historical Society The Horse Industry in Kentucky Oral History Project				
Boyd, Douglas A.	3048105486	\$10,000.	\$0.	\$10,000.
KY Historical Society Kentucky Legislature Oral History Project				
Greider, Antoinette	3048090900	\$0.	\$108,513.	\$108,513.
Lexmark International Inc Lexmark International, Inc. Information Center				
Weig, Eric C	3048104781	\$212,581.	\$0.	\$212,581.
KY Council on Postsecondary Education Kentuckiana Digital Library Program				
Library Administration	Totals:	\$229,281.	\$118,513.	\$347,794.
<u>Medical Center Library</u>				
Stith, Janet B	3046555600	\$0.	\$3,132.	\$3,132.
Frontier School Midwifery Family Nursing Consulting Agreement UKCMC Library & Frontier School Midwifery and Family Nursing				
Medical Center Library	Totals:	\$0.	\$3,132.	\$3,132.
	Library Administration Totals:	\$229,281.	\$121,645.	\$350,926.
<u>Office of the Provost</u>				
<u>Art Museum</u>				
Walsh-Piper, Kathleen A	3048105068	\$10,000.	\$0.	\$10,000.
Lexarts Teacher Outreach Initiative				
Walsh-Piper, Kathleen A	3048105169	\$20,000.	\$0.	\$20,000.
Keeneland Foundation Hoof Beats and Heart Beats: The American Horse				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Office of the Provost</u>				
<u>Art Museum</u>				
Walsh-Piper, Kathleen A	3048105183	\$1,200.	\$0.	\$1,200.
KY Humanities Council Master Works by Kentucky Painters, 1819-1930 Lecture and Book Signing				
Walsh-Piper, Kathleen A	3048105489	\$10,000.	\$0.	\$10,000.
Central Indiana Community Foundation Sculpture Garden				
Art Museum	Totals:	\$41,200.	\$0.	\$41,200.
<u>Partnership Inst. for Math and Science</u>				
Eakin, Paul M	3048104971	\$57,000.	\$0.	\$57,000.
Northern KY University KCM Regional Coordinator / Mathematics Outreach Specialist				
Eakin, Paul M	3048105634	\$20,000.	\$0.	\$20,000.
Northern KY University Kentucky Early Mathematics Testing Program				
Yopp, John H	3048105364	\$34,995.	\$0.	\$34,995.
AT&T Foundation An Innovative Approach to Promoting Success for At-Risk Students: The Partnership Enhancement Program				
Zeidler-Watters, Kimberly Jean	3048105080	\$0.	\$4,428.	\$4,428.
KY Department of Education Developing Algebraic Thinking				
Zeidler-Watters, Kimberly Jean	3048105080	\$200,000.	\$0.	\$200,000.
KY Department of Education Developing Algebraic Thinking				
Zeidler-Watters, Kimberly Jean	3048105081	\$0.	\$2,484.	\$2,484.
KY Department of Education Partnering to Progress				
Zeidler-Watters, Kimberly Jean	3048105081	\$200,000.	\$0.	\$200,000.
KY Department of Education Partnering to Progress				
Zeidler-Watters, Kimberly Jean	3048105139	\$180,000.	\$0.	\$180,000.
KY Department of Education Math and Science Leadership Network				
Zeidler-Watters, Kimberly Jean	3048105248	\$46,000.	\$0.	\$46,000.
KY Science and Technology Co Inc ARSI- Math / Science PD Project				
Zeidler-Watters, Kimberly Jean	3048105589	\$140,000.	\$0.	\$140,000.
KY Council on Postsecondary Education Number Properties and Operations				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Office of the Provost</u>				
<u>Partnership Inst. for Math and Science</u>				
Zeidler-Watters, Kimberly Jean	3048105591	\$140,000.	\$0.	\$140,000.
KY Council on Postsecondary Education Putting All Students on Track (PAST YR 2)				
Partnership Inst. for Math and Science	Totals:	\$1,017,995.	\$6,912.	\$1,024,907.
<u>International Affairs</u>				
Bettez, David J	3048104939	\$49,000.	\$0.	\$49,000.
German American Fulbright Summer Institute for Students with Immigrant Backgrounds from Germany				
Herron, Shana L	3048104969	\$40,000.	\$0.	\$40,000.
Freeman Foundation National Consortium for Teaching About Asia - Year XI and XII				
Herron, Shana L	3048105305	\$150,000.	\$0.	\$150,000.
Freeman Foundation Undergraduate Asian Studies Program				
International Affairs	Totals:	\$239,000.	\$0.	\$239,000.
Office of the Provost Totals:		\$1,298,195.	\$6,912.	\$1,305,107.
<u>Arts & Sciences</u>				
<u>Anthropology</u>				
Ahler, Steven R	3048104779	\$5,839.	\$0.	\$5,839.
KY Department of Fish and Wildlife Phase i Archaeological Survey of Proposed Cape Hills Lake Construction Site at Henderson Sloughs Wildlife Management Area				
Ahler, Steven R	3048105342	\$11,455.	\$0.	\$11,455.
Boone County Planning Commission A Proposal to Perform Phase I Archaeological Survey on Selected Tracts within the Woolper Creek Valley in Boone County, Kentucky				
Ahler, Steven R	3048105532	\$1,808.	\$0.	\$1,808.
KY Heritage Council College Hill Boat Ramp and Parking Lot, Madison County, Kentucky				
Ahler, Steven R	3048105715	\$12,449.	\$0.	\$12,449.
Edmonson County Water District A proposal to perform Phase I Archaeological Survey of Proposed Water Lines, Flow Meters, and Leak Detecting Meters in the Edmonson County Water District				
Anglin, Mary Kivas	3048105111	\$7,991.	\$0.	\$7,991.
National Science Foundation Doctoral Dissertation Social Categories and Health Care Outcomes: HIV Positive African American Women and Survival in the Urban South				
Cliggett, Lisa C	3048104701	\$0.	\$15,012.	\$15,012.
National Science Foundation Semiar: Tonga Timeline-Appraising 60 years of multidisciplinary research in Southern Province, Zambia				
McBride, Kim A	3048105069	\$0.	\$89,000.	\$89,000.
KY Heritage Council Kentucky Archaeological Survey				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Anthropology</u>				
McBride, Kim A	3048105069	\$89,000.	\$0.	\$89,000.
KY Heritage Council Kentucky Archaeological Survey				
Pollack, David	3048105328	\$79,364.	\$0.	\$79,364.
KY Finance and Administration Cabinet Proposal for Cultural Resources Survey of Eastern State Hospital, Lexington, Kentucky				
Stottman, Michael Jay	3048105067	\$41,598.	\$0.	\$41,598.
Riverside the Farnsley Moremen Landing Farnsley-Moreman Landing, Building Blocks of History Education Program, 2008-2009				
Anthropology	Totals:	\$249,504.	\$104,012.	\$353,516.
<u>Ky Archaeoloigcal Survey</u>				
McBride, Kim A	3048104746	\$0.	\$59,000.	\$59,000.
KY Heritage Council Historic Preservation Initiative				
McBride, Kim A	3048104746	\$75,000.	\$0.	\$75,000.
KY Heritage Council Historic Preservation Initiative				
Pollack, David	3048104824	\$80,000.	\$0.	\$80,000.
KY Department of Military Affairs Historic Preservation of Select Kentucky Army National Guard Facilities and Locations				
Pollack, David	3048104968	\$16,000.	\$0.	\$16,000.
KY Nature Preserves Commission Archaeological Survey of HLCF Tracts at Various State Nature Preserves and Natual Areas				
Pollack, David	3048105213	\$100,000.	\$0.	\$100,000.
National Park Service Archaeological Site Inventory of Chestnut Mountain				
Pollack, David	3048105425	\$0.	\$80,827.	\$80,827.
KY Finance and Administration Cabinet Archaeological Services in Relation to the Skeletal Remains at the Kentucky Horse Park				
Pollack, David	3048105425	\$25,000.	\$0.	\$25,000.
KY Finance and Administration Cabinet Archaeological Services in Relation to the Skeletal Remains at the Kentucky Horse Park				
Pollack, David	3048105558	\$12,000.	\$0.	\$12,000.
KY Department of Fish and Wildlife Archaeological Surveys for Wildlife Management Areas 1009				
Stottman, Michael Jay	3048104907	\$4,500.	\$0.	\$4,500.
Canfield Development Company Archaeological Survey of Glenview Woods, Jefferson County, Kentucky				
Ky Archaeoloigcal Survey	Totals:	\$312,500.	\$139,827.	\$452,327.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Chemistry</u>				
Anthony, John Edward	3046842200	\$0.	\$107,000.	\$107,000.
US Office of Naval Research Photovoltaic Devices from Self-Assembled Organic Semiconductors				
Anthony, John Edward	3048104433	\$0.	\$115,000.	\$115,000.
National Science Foundation A Exploration of Higher Acenes				
Anthony, John Edward	3048105188	\$103,696.	\$0.	\$103,696.
Pennsylvania State University TiO2 Nanotube Array-Organic Semiconductor Heterojunction Solar Cells for Efficient, Low Cost, Large Area Scalable Energy Conversion				
Atwood, David A	3048105308	\$15,000.	\$0.	\$15,000.
Land O Lakes Inc Inhibition of Phosphate Crystalization				
Bachas, Leonidas G	3048105596	\$103,096.	\$0.	\$103,096.
Western KY University Versatile Biosensing Platform for Monitoring Bone Markers for Space Medicine (State Match)				
Bachas, Leonidas G	3048105598	\$144,343.	\$0.	\$144,343.
Western KY University Versatile Biosensing Platform for Monitoring Bone Markers for Space Medicine				
Butterfield, David A	3048104986	\$81,666.	\$0.	\$81,666.
United Negro College Fund Redox Proteomics Analysis of the Sence-Accelerated Prone Mouse (SAMP8) as a Model of Immunosenescence following in vivo Ferulic Acid Treatment				
Clouthier, Dennis J	3048104912	\$0.	\$264,000.	\$264,000.
National Science Foundation Laser Spectroscopy of Main Group Reactive Intermediates				
Clouthier, Dennis J	3048104912	\$161,800.	\$0.	\$161,800.
National Science Foundation Laser Spectroscopy of Main Group Reactive Intermediates				
Daunert, Sylvia	3048104224	\$0.	\$96,431.	\$96,431.
University of California Irvine C-MEMS/C-NEMS for Miniature Biofuels Cells				
Daunert, Sylvia	3048104893	\$0.	\$56,159.	\$56,159.
National Science Foundation Collaborative Research: Extended Life Implantable Biosensor Platform				
Daunert, Sylvia	3048104893	\$51,524.	\$0.	\$51,524.
National Science Foundation Collaborative Research: Extended Life Implantable Biosensor Platform				
Daunert, Sylvia	3048105125	\$48,729.	\$0.	\$48,729.
Binational Agricultural Research & Development Fun A Whole-Cell Biosensor Panel for Agriculture Endocrine Disruptors				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Arts & Sciences				
Chemistry				
Daunert, Sylvia	3048105588	\$376,016.	\$0.	\$376,016.
National Institute of General Medical Sciences Modified Photoproteins as Labels and Molecular Switches in Bioanalysis				
Grossman, Robert B	3048105341	\$218,913.	\$0.	\$218,913.
National Science Foundation Web-Based Interactive Organic Chemistry Homework				
Holmes, Stephen M	3048074800	\$0.	\$52,429.	\$52,429.
KY Science and Technology Co Inc KSEF R&D Excellence: Molecule-Based Magnetic Clusters Constructed from Poly(pyrazolyl) borate Acetylde and Butadiynylde Building Blocks				
Holmes, Stephen M	3048074800	\$0.	\$-76,214.	\$-76,214.
KY Science and Technology Co Inc KSEF R&D Excellence: Molecule-Based Magnetic Clusters Constructed from Poly(pyrazolyl) borate Acetylde and Butadiynylde Building Blocks				
Holmes, Stephen M	3048080800	\$0.	\$-298,136.	\$-298,136.
National Science Foundation CAREER: Construction of Magnetic Cyanide-, Acetylde-, and Butadiynylde-Based Clusters				
Ji, Tae H	3046875900	\$0.	\$284,764.	\$284,764.
National Institute of General Medical Sciences Intermolecular Activation of GPCR				
Knecht, Marc R.	3048104966	\$25,000.	\$0.	\$25,000.
Petroleum Research Fund Biomimetic Synthesis of Heterogeneous Catalysts				
Lynn, Bert C	3046839000	\$0.	\$164,695.	\$164,695.
National Institute on Aging Mitochondrial Proteome Changes in Alzheimer's Disease				
Selegue, J P	3046856800	\$0.	\$24,167.	\$24,167.
Research Co Organometallic Heterocycles: Synthesis, Structure, and Applications				
Yates, S W	3048103226	\$0.	\$260,000.	\$260,000.
National Science Foundation Using fast Neutrons to Explore Nuclear Structure				
Chemistry	Totals:	\$1,329,783.	\$1,050,295.	\$2,380,078.
Geography				
Karan, P P	3048105089	\$9,000.	\$0.	\$9,000.
Society of Woman Geographers Fellowship Kedzoir: Pollution Knowledge and Hydropolitics in the Ganges River Basin				
Roberts, Susan	3048105054	\$7,800.	\$0.	\$7,800.
National Science Foundation Doctoral Dissertation Research: African Oil Palm Plantation Expansion and Geographies of Hope in Ecuadorian Choco Region				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Geography</u>				
Secor, Anna J	3048104982	\$9,504.	\$0.	\$9,504.
National Science Foundation Doctoral Dissertation Research: Immigrant Family Detention: The Family, Law, Security, and Space in U.S Immigration Policy and Practice				
Sherriff, Rosemary Lynne	3048104015	\$0.	\$35,152.	\$35,152.
National Park Service Tree-ring Reconstruction of Insect Outbreaks in Lake Clark and Katmai National Park and Preserve				
Geography	Totals:	\$26,304.	\$35,152.	\$61,456.
<u>Geology</u>				
Moecher, David P	3048068900	\$0.	\$51,117.	\$51,117.
National Science Foundation Identifying the Limitations and Expanding the Utility of Detrital Mineral U-Pb Geochronology to Tectonic Studies				
Moecher, David P	3048105337	\$168,650.	\$0.	\$168,650.
National Science Foundation Upgrade of the University of Kentucky ARL SEMQ Electron Probe Microanalyzer				
Thomas, William A	3048104970	\$13,357.	\$0.	\$13,357.
US Geological Survey Palinspastic Reconstruction Around a Recess in the Appalachian Thrust Belt in Georgia				
Geology	Totals:	\$182,007.	\$51,117.	\$233,124.
<u>Mathematics</u>				
Braun, Benjamin J.	3048104679	\$70,262.	\$0.	\$70,262.
National Science Foundation Topological and Algebraic Combinatorics				
Eakin, Paul M	3046635800	\$0.	\$599,177.	\$599,177.
National Science Foundation Appalachian Mathematics and Science Partnership				
Hislop, Peter D	3048104748	\$130,889.	\$0.	\$130,889.
National Science Foundation Correlations and Transport for Random Schrodinger Operators				
Kang, Sung	3048103694	\$0.	\$-82,287.	\$-82,287.
National Science Foundation Image Deblurring and Decomposition: Texture and Color Image Analysis				
Lee, C W	3048105223	\$143,552.	\$0.	\$143,552.
University of Louisville Geometry Assessments for Secondary Teachers (GAST)				
Man, Chi-Sing	3048105050	\$166,198.	\$0.	\$166,198.
National Science Foundation Some Studies in the Mathematics and Mechanics of Textured and Prestressed Polycrystalline Materials				
Nagel, Uwe R	3048105523	\$39,341.	\$0.	\$39,341.
National Security Agency Hilbert Functions and Betti Numbers				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Mathematics</u>				
Readdy, Margaret	3048105524	\$8,603.	\$0.	\$8,603.
National Science Foundation The 2009 Graduate Student Combinatorics Conference				
Wang, Changyou	3048000400	\$0.	\$40,000.	\$40,000.
National Science Foundation Collaborative Research: L-Infinity Variational Problems and the Aronsson Equation				
Ye, Qiang	3048105712	\$178,250.	\$0.	\$178,250.
National Science Foundation High Relative Accuracy Iterative Algorithms for Large Scale Matrix Eigenvalue Problems with Applications				
Mathematics	Totals:	\$737,095.	\$556,890.	\$1,293,985.
<u>Physics and Astronomy</u>				
Brill, J W	3048104621	\$0.	\$125,000.	\$125,000.
National Science Foundation Position-Dependent Properties of Novel Electronic Materials: Tunneling, Infrared, and Electromechanical Measurements				
Brill, J W	3048104621	\$160,000.	\$0.	\$160,000.
National Science Foundation Position-Dependent Properties of Novel Electronic Materials: Tunneling, Infrared, and Electromechanical Measurements				
Crawford, Christopher B.	3048105131	\$5,000.	\$0.	\$5,000.
Oak Ridge Associated Universities Development of a Parity-Violating Neutron-Capture Experiment (NDT) for the Spallation Neutron Source (SNS): Measurement of Neutron Depolarization in D20				
Crawford, Christopher B.	3048105632	\$29,994.	\$0.	\$29,994.
Los Alamos National Laboratory Magnetic Field Studies for Neutron EDM Beam Guide				
Das, Sumit Ranjan	3046999400	\$0.	\$12,000.	\$12,000.
National Science Foundation Research on Gauge Theories, Gravity and Strings				
DeLong, L E	3046114000	\$0.	\$120,000.	\$120,000.
Department of Energy Dynamic Flux Line Response in Layered Superconductors with Tailored Defect Structures				
Eides, Michael	3048104663	\$0.	\$59,999.	\$59,999.
National Science Foundation Theory of Light Hydrogenlike Bound States: High Order Corrections to Lamb Shift, Hyperfine Splitting, and g-Factors				
Elitzur, Moshe	3048105097	\$358,261.	\$0.	\$358,261.
National Science Foundation Radiative signatures of dust and lines: From protostellar disks to active galactic nuclei				
Elitzur, Moshe	3048105333	\$15,000.	\$0.	\$15,000.
Jet Propulsion Laboratory Is the Structure of the Dusty Torus Related to the Physics of Accretion Disk?				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Arts & Sciences				
Physics and Astronomy				
Ferland, Gary	3048104595	\$0.	\$120,207.	\$120,207.
National Aeronautics and Space Administration Unraveling the Message of the Light; Spectral Diagnostics of AGN, Starbursts, and Star-forming Regions				
Gardner, Susan V	3046921600	\$0.	\$12,600.	\$12,600.
Department of Energy Tests of Fundamental Symmetries				
Gardner, Susan V	3046921600	\$0.	\$100,000.	\$100,000.
Department of Energy Tests of Fundamental Symmetries				
Levenson, Nancy A	3048105443	\$22,845.	\$0.	\$22,845.
Jet Propulsion Laboratory Disentangling the Starburst-AGN Connection				
Liu, Kehfei	3046169100	\$0.	\$180,000.	\$180,000.
Energy Research Research in Theoretical Nuclear Physics				
Martin, Nicholas L	3048005800	\$0.	\$126,089.	\$126,089.
National Science Foundation E2E and Laser Assisted Electron Impact Studies of Helium Ionization				
Murthy, Ganpathy	3048104379	\$0.	\$100,000.	\$100,000.
National Science Foundation Mesoscopic Quantum Critical Regimes and Disorder-Driven Deconfinement				
Plaster, Bradley R.	3048105057	\$0.	\$25,200.	\$25,200.
Department of Energy Fundamental Electroweak and Hadronic Physics Studies of the Neutron				
Plaster, Bradley R.	3048105057	\$105,000.	\$0.	\$105,000.
Department of Energy Fundamental Electroweak and Hadronic Physics Studies of the Neutron				
Shlosman, Isaac	3048105711	\$78,971.	\$0.	\$78,971.
National Science Foundation Evolution of Inner Halos: Disk Growth and First Generation of Galactic Bars				
Troland, Thomas H	3048104809	\$18,000.	\$0.	\$18,000.
Western KY University Fellowship for Mathew Lykins: The Origins of Stars and Planets-A Continuing Study of the Role of Magnetic Fields in the W3 Star Formation Region of the Galaxy				
Physics and Astronomy	Totals:	\$793,071.	\$981,095.	\$1,774,166.
Psychology				
Bardo, Michael T	3048104928	\$0.	\$595,465.	\$595,465.
National Institute on Drug Abuse CDART - Center for Drug Abuse Research Translation				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Arts & Sciences				
Psychology				
Bardo, Michael T	3048104928	\$0.	\$164,641.	\$164,641.
National Institute on Drug Abuse CDART - Center for Drug Abuse Research Translation				
Bardo, Michael T	3048104928	\$1,303,218.	\$0.	\$1,303,218.
National Institute on Drug Abuse CDART - Center for Drug Abuse Research Translation				
Bardo, Michael T	3048105713	\$29,508.	\$0.	\$29,508.
National Institute on Drug Abuse Fellowship for Thomas Wooters: Reinforcing and Neurochemical Effects of Cocaine in a Rident Model of ADHD				
Carlson, Charles R	3048105063	\$56,000.	\$0.	\$56,000.
Eastern State Hospital Clinical Training Agreement with Eastern State Hospital				
Fillmore, Mark	3048052100	\$0.	\$236,388.	\$236,388.
National Institute on Alcohol Abuse and Alcoholism Mechanisms Of Alcohol Tolerance And Priming In Humans				
Giancola, Peter	3046840800	\$0.	\$272,382.	\$272,382.
National Institute on Alcohol Abuse and Alcoholism Individual Differences in Alcohol-Related Aggression				
Prendergast, Mark A	3048105299	\$333,594.	\$0.	\$333,594.
National Institute on Alcohol Abuse and Alcoholism Hippocappal neurotoxicity induced by ethanol withdraw				
Smith, Gregory T	3048104634	\$0.	\$497,302.	\$497,302.
National Institute on Alcohol Abuse and Alcoholism Developmental Transitions and Risk for Alcohol Use				
Smith, Gregory T	3048105064	\$30,239.	\$0.	\$30,239.
National Institute on Alcohol Abuse and Alcoholism Fellowship for Melissa Cyders: Longitudinal & Experimental Analysis of Positive Urgency				
Zentall, Thomas R	3046628100	\$0.	\$20.	\$20.
National Institute of Mental Health Effect of Prior Effort on Reward Value				
Psychology	Totals:	\$1,752,559.	\$1,766,198.	\$3,518,757.
Statistics				
YOSHIDA, RURIKO	3048105141	\$280,000.	\$0.	\$280,000.
National Institute of General Medical Sciences Geometry of Gene Cophylogenies as Relates to Genome Evolution and Speciation				
Statistics	Totals:	\$280,000.	\$0.	\$280,000.
Sociology				
Janoski, Thomas	3048105732	\$194,978.	\$0.	\$194,978.
National Science Foundation ARRA: RAPID: Lean Production Auto Plants				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Sociology</u>				
Oser, Carrie	3048103624	\$0.	\$143,583.	\$143,583.
National Institute on Drug Abuse Rural Drug Abuse Treatment: Organizations, Counselors, and Client Outcomes				
Oser, Carrie	3048104523	\$0.	\$57,317.	\$57,317.
National Institute on Drug Abuse African American Female Drug Users: HIV, Health Disparities, & Criminality				
Oser, Carrie	3048104523	\$0.	\$515,844.	\$515,844.
National Institute on Drug Abuse African American Female Drug Users: HIV, Health Disparities, & Criminality				
Som Castellano, Rebecca Lorraine	3048105096	\$3,125.	\$0.	\$3,125.
Rural Sociological Society School Lunch Programs and the American Diet: Exploring a Contested Food Terrain				
Wilkinson, D Y	3048105530	\$1,135.	\$0.	\$1,135.
KY Humanities Council 1968: A Dramatic Moment in American Political History and Culture				
Sociology	Totals:	\$199,238.	\$716,744.	\$915,982.
<u>Biological Sciences</u>				
Cassone, Vincent	3048105121	\$203,054.	\$0.	\$203,054.
Texas A&M Research Foundation Coordination of Circadian Physiology in Diverse Organism: Project 4: Pacemaker Properties of the Avian Pineal				
Cassone, Vincent	3048105531	\$4,937.	\$0.	\$4,937.
University of Michigan Role of Clock Genes in Colonic Motility				
Jones, Grace M	3046941900	\$0.	\$284,764.	\$284,764.
National Institute of General Medical Sciences Role of USP Ligand Binding Pocket During Development				
Osborn, Jeffrey	3046858000	\$0.	\$21,500.	\$21,500.
KY Science and Technology Co Inc Noyce Loan/Scholarship Program				
Peterson, Martha L	3048104756	\$0.	\$412,506.	\$412,506.
University of Louisville Subcontract, Kentucky Biomedical Research Infrastructure Network				
Voss, Stephen Randal	3046896000	\$0.	\$207,302.	\$207,302.
National Science Foundation Operational Support for the Ambystoma Genetic Stock Center				
Voss, Stephen Randal	3048070900	\$0.	\$100,000.	\$100,000.
KY Spinal Cord and Head Injury Research Trust Functional Analysis of Candidate Genes Identified from Naturally Regenerating Spinal Cords of the Salamander (Ambystoma)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Arts & Sciences				
<u>Biological Sciences</u>				
Voss, Stephen Randal	3048093100	\$0.	\$258,426.	\$258,426.
National Center for Research Resources Genome Resources for Model Amphibians				
Voss, Stephen Randal	3048093100	\$0.	\$52,740.	\$52,740.
National Center for Research Resources Genome Resources for Model Amphibians				
Westneat, David F	3048007700	\$0.	\$15,807.	\$15,807.
KY Department of Fish and Wildlife Ecological and Behavioral Interactions between Golden-Winged (Vermivora chrysoptera) and Blue-Winged Warblers (V. pinus) in Eastern Kentucky.				
Westneat, David F	3048105078	\$1,000.	\$0.	\$1,000.
Animal Behavior Society Animal Behavior-The Effects of Grassland Restoration on Avian Mating Patterns				
Westneat, David F	3048105586	\$400.	\$0.	\$400.
Sigma XI Scientific Research Society Inc Does food supplementation affect patterns of female settlement, mate choice, and extra-pair behavior in the indigo bunting?				
Wigginton, Andrew J	3048105114	\$0.	\$7,041.	\$7,041.
KY Department of Environmental Protection Assessment of Ecological Conditions Compared to Environmental Sampling at the Paducah Gaseous Diffusion Plant With a Reassessment of Previous Analysis				
Wigginton, Andrew J	3048105114	\$205,959.	\$0.	\$205,959.
KY Department of Environmental Protection Assessment of Ecological Conditions Compared to Environmental Sampling at the Paducah Gaseous Diffusion Plant With a Reassessment of Previous Analysis				
Biological Sciences	Totals:	\$415,350.	\$1,360,086.	\$1,775,436.
<u>Modern & Classical Languages</u>				
Desormeaux, Daniel	3048105134	\$50,400.	\$0.	\$50,400.
National Endowment for the Humanities A Scholarly Edition of Toussaint Louverture's Memoirs				
Jiang, Wei	3048105062	\$40,738.	\$0.	\$40,738.
KY Department of Education UK/Chinese Online Course Development				
Slaymaker, Douglas N	3048105351	\$6,000.	\$0.	\$6,000.
Japan Foundation Building a Japan Studies Concentration at the University of Kentucky				
Modern & Classical Languages	Totals:	\$97,138.	\$0.	\$97,138.
<u>Russian and Eastern Studies</u>				
Fiedler, Theodore	3046345400	\$0.	\$61,503.	\$61,503.
Omar Ibn Al Khattab Foundation Lectureship in Islamic Studies				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Arts & Sciences				
<u>Russian and Eastern Studies</u>				
Fiedler, Theodore	3046345400	\$0.	\$25,000.	\$25,000.
Omar Ibn Al Khattab Foundation Lectureship in Islamic Studies				
Fiedler, Theodore	3046345400	\$0.	\$60,028.	\$60,028.
Omar Ibn Al Khattab Foundation Lectureship in Islamic Studies				
Russian and Eastern Studies	Totals:	\$0.	\$146,531.	\$146,531.
	Arts & Sciences Totals:	\$6,374,549.	\$6,907,947.	\$13,282,496.
<u>Business & Economics</u>				
<u>Management</u>				
Holbein, Gordon F	3048105408	\$38,770.	\$0.	\$38,770.
KY Economic Development Cab Business Plan Competition				
Muralidhar, Krishnamurty	3048105424	\$19,872.	\$0.	\$19,872.
KY Department of Education UK/FERPA Confidentiality Study				
Management	Totals:	\$58,642.	\$0.	\$58,642.
<u>Center for Business & Econ Res</u>				
Jepsen, Christopher	3048104796	\$171,000.	\$0.	\$171,000.
Spencer Foundation Women's Economic Returns from Obtainig a GED				
Troske, Kenneth R	3048104935	\$49,959.	\$0.	\$49,959.
Kentucky Workforce Development Cabinet Update and Maintenance of the Mercer Computerized Model				
Troske, Kenneth R	3048105368	\$55,529.	\$0.	\$55,529.
KY Community & Technical College System/University of Economic Returns from Obtaining KCTCS Certificates and Diplomas				
Troske, Kenneth R	3048105705	\$55,000.	\$0.	\$55,000.
KentuckianaWorks Proposal to Study the Kentuckiana Works Program				
Center for Business & Econ Res	Totals:	\$331,488.	\$0.	\$331,488.
<u>B&E Poverty Center</u>				
Ziliak, James P	3048105303	\$107,804.	\$0.	\$107,804.
Meals on Wheels Association of American Foundation Update on Senior Hunger in America				
B&E Poverty Center	Totals:	\$107,804.	\$0.	\$107,804.
	Business & Economics Totals:	\$497,934.	\$0.	\$497,934.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Education				
<u>Educational Leadership Studies</u>				
Bjork, Lars	3048105527	\$135,000.	\$0.	\$135,000.
KY Council on Postsecondary Education Embedded Teacher Learning Through Online Modules: Leveraging Professional Development Resources in KY				
Hausman, Charles	3048104721	\$61,506.	\$0.	\$61,506.
KY Department of Education CEO Superintendent Network				
Educational Leadership Studies	Totals:	\$196,506.	\$0.	\$196,506.
<u>Curriculum & Instruction</u>				
Burns, Leslie David	3046791200	\$0.	\$1,100.	\$1,100.
University of California Berkeley Bluegrass Writing Project - Program Income				
Burns, Leslie David	3046791200	\$0.	\$250.	\$250.
University of California Berkeley Bluegrass Writing Project - Program Income				
Burns, Leslie David	3046791200	\$0.	\$100.	\$100.
University of California Berkeley Bluegrass Writing Project - Program Income				
Burns, Leslie David	3046791200	\$0.	\$250.	\$250.
University of California Berkeley Bluegrass Writing Project - Program Income				
Burns, Leslie David	3046791200	\$0.	\$800.	\$800.
University of California Berkeley Bluegrass Writing Project - Program Income				
Burns, Leslie David	3046791200	\$0.	\$800.	\$800.
University of California Berkeley Bluegrass Writing Project - Program Income				
Burns, Leslie David	3046791200	\$0.	\$810.	\$810.
University of California Berkeley Bluegrass Writing Project - Program Income				
Ma, Xin	3048105518	\$0.	\$78,603.	\$78,603.
CNA Corp Reading Proficiency by 2014: Developing Strategies for Kentucky Middle and High Schools				
Ma, Xin	3048105518	\$10,000.	\$0.	\$10,000.
CNA Corp Reading Proficiency by 2014: Developing Strategies for Kentucky Middle and High Schools				
Smith, Douglas C	3048105274	\$4,000.	\$0.	\$4,000.
KY Department for Technical Education UK Perkins Leadership Funding to Improve CTE- Professional Development Education				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Education</u>				
<u>Curriculum & Instruction</u>				
Smith, Felicia C	3048105157	\$0.	\$1.	\$1.
KY Department of Education Carry Forward: Early Childhood Teacher Academy-Undergraduate Project UK Collaborative Center for Literacy Development				
Smith, Felicia C	3048105157	\$0.	\$-130,282.	\$-130,282.
KY Department of Education Carry Forward: Early Childhood Teacher Academy-Undergraduate Project UK Collaborative Center for Literacy Development				
Smith, Felicia C	3048105157	\$130,282.	\$0.	\$130,282.
KY Department of Education Carry Forward: Early Childhood Teacher Academy-Undergraduate Project UK Collaborative Center for Literacy Development				
Swan, Kathleen O	3048105597	\$15,000.	\$0.	\$15,000.
Illinois State University Library of Congress Digital Documentary Kits Proposal to the Midwest Center for Teaching with Primary Sources				
Curriculum & Instruction	Totals:	\$159,282.	\$-47,568.	\$111,714.
<u>Educational & Counseling Psych</u>				
Love, Keisha	3048105219	\$2,500.	\$0.	\$2,500.
Kuder Inc Promoting Enhanced Career Opportunities for Underprivileged Teens (PECOT)				
Educational & Counseling Psych	Totals:	\$2,500.	\$0.	\$2,500.
<u>Kinesiology and Health Promoti</u>				
Beighle, Aaron	3048105480	\$29,468.	\$0.	\$29,468.
University of Nebraska Effects of Environmental Changes at Recess on Physical Activity Levels in Socioeconomically Disadvantaged of Children in Nebraska				
Noland, Melody P	3048105474	\$45,000.	\$0.	\$45,000.
Professional Golfers Associaton of America Play Golf America University Program				
Shapiro, Robert	3046974000	\$0.	\$2,500.	\$2,500.
Drayer Physical Therapy Institute Research Assistantship to Study Biomechanical and Gender Issues in Sport				
Shapiro, Robert	3048105275	\$97,264.	\$0.	\$97,264.
KY Science and Technology Co Inc KSEF R&D Excellence: A novel Biomechanical Approach for Preventing Spinal Disorders				
Kinesiology and Health Promoti	Totals:	\$171,732.	\$2,500.	\$174,232.
<u>Educational Policy Studies & Evaluation</u>				
Carey, K W	3048104814	\$61,843.	\$0.	\$61,843.
KY Council on Postsecondary Education Development and Implementation of the Statewide Assessment of College Level Learning				
Educational Policy Studies & Evaluation	Totals:	\$61,843.	\$0.	\$61,843.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Education				
Special Ed & Rehab Counseling				
Bausch, Margaret	3046935500	\$0.	\$99,996.	\$99,996.
Department of Education Kentucky Assistive and Rehabilitation Technology Training (KARTT)				
Collins, Belva J	3046941400	\$0.	\$199,810.	\$199,810.
Special Education and Rehabilitative Services Special Education Leadership Program in Distance Education Teacher Preparation				
Grisham-Brown, Jennifer L	3046971800	\$0.	\$75,050.	\$75,050.
Kent State University Preparing Tomorrow's Early Childhood Intervention Leaders				
Grisham-Brown, Jennifer L	3048104727	\$235,000.	\$0.	\$235,000.
KY Department of Education Deaf/Blind Project Supplemental Grant				
Grisham-Brown, Jennifer L	3048104802	\$250,000.	\$0.	\$250,000.
KY Department of Education KIDS NOW Evaluation Project 08-09				
Grisham-Brown, Jennifer L	3048105255	\$165,145.	\$0.	\$165,145.
KY Department of Education Kentucky Deaf Blind Project (Main Grant)				
Jung, Lee Ann	3046963700	\$0.	\$199,987.	\$199,987.
Department of Education Project Increasing the Number, Competence, and Resources of Early Interventions in Areas of Shortage (INCREAS) - (Alternate Name = "Combined Priority for Personnel Preparation")				
Jung, Lee Ann	3048104858	\$96,000.	\$0.	\$96,000.
KY Health Services Cabinet UK First Steps Part C Coordinator 08-09				
McCormick, Katherine	3048104813	\$235,514.	\$0.	\$235,514.
KY Health Services Cabinet University of Kentucky First Step Technical Assistance Team				
McCormick, Katherine	3048105284	\$62,738.	\$0.	\$62,738.
Jumpstart For Young Children Inc Higher Education Affiliate Partnership				
Sampers, Jackie L	3048105049	\$104,760.	\$0.	\$104,760.
KY Health Services Cabinet UK First Steps Evaluation Coordinator				
Schuster, John W	3046831600	\$0.	\$249,996.	\$249,996.
Department of Education Reaching Educators with an Alternate Certification for Teachers (REACT)				
Schuster, John W	3048104791	\$200,000.	\$0.	\$200,000.
Special Education and Rehabilitative Services Special Education Leadership Program in Applied Behavior Analysis (SELABA) in Distance Teacher Preparation				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Education</u>				
<u>Special Ed & Rehab Counseling</u>				
Slaton, Deborah B	3048104816	\$127,181.	\$0.	\$127,181.
KY Department of Education Reading First Coach 2008-2009				
Stenhoff, Donald M	3048104726	\$29,144.	\$0.	\$29,144.
KY Department of Education Behavior Web Home Page				
Special Ed & Rehab Counseling	Totals:	\$1,505,482.	\$824,839.	\$2,330,321.
<u>Education Teacher Educ & Cert</u>				
Boulay, Rose Marlaine	3048105689	\$25,000.	\$0.	\$25,000.
KY Department of Education University of Kentucky 2009 FEA Summer Camp				
Education Teacher Educ & Cert	Totals:	\$25,000.	\$0.	\$25,000.
<u>Collaborative Center for Literacy Develo</u>				
Cantrell, Susan Chambers	3048104820	\$99,998.	\$0.	\$99,998.
KY Department of Education Kentucky Reading First Evaluation Project				
Cantrell, Susan Chambers	3048105441	\$648,013.	\$0.	\$648,013.
Danville Schools Kentucky Content Literacy Consortium: Striving Readers Grant				
Smith, Felicia C	3048104811	\$469,854.	\$0.	\$469,854.
KY Department of Education Adolescent Literacy Project 0809				
Smith, Felicia C	3048104917	\$150,000.	\$0.	\$150,000.
KY Department of Education Early Childhood Teacher Academy-Undergraduate Project UK Collaborative Center for Literacy Development				
Smith, Felicia C	3048104947	\$345,390.	\$0.	\$345,390.
KY Council on Postsecondary Education Kentucky Adult Education Literacy Institute-KAELI 08-09				
Smith, Felicia C	3048105329	\$0.	\$10,800.	\$10,800.
KY Department of Education Early Childhood Teacher Academy: Three-Five at the Undergraduate and Graduate Level				
Smith, Felicia C	3048105329	\$200,000.	\$0.	\$200,000.
KY Department of Education Early Childhood Teacher Academy: Three-Five at the Undergraduate and Graduate Level				
Collaborative Center for Literacy Develo	Totals:	\$1,913,255.	\$10,800.	\$1,924,055.
	Education Totals:	\$4,035,600.	\$790,571.	\$4,826,171.
<u>Engineering</u>				
<u>Visualization Center</u>				
Bailey, Stephen P	3048105214	\$3,000.	\$0.	\$3,000.
Research Channel Smoking and Tobacco Policy Research				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Engineering</u>				
<u>Visualization Center</u>				
Donohue, Kevin D	3048105037	\$80,000.	\$0.	\$80,000.
Federal Bureau of Investigation Statistical Array Geometries for Real-Time Covert Surveillance with Parallel Computer Implementations				
Firey, Abigail	3048105171	\$49,133.	\$0.	\$49,133.
National Endowment for the Humanities Carolingian Canon Law Project: A Collaborative Initiative				
Hassebrook, Laurence G	3048104933	\$40,000.	\$0.	\$40,000.
National Institute for Hometown Security Supplement to Real-Time 3D Finger and Palm-Print Scanner for Entry and Access Portal Security				
Hassebrook, Laurence G	3048105312	\$199,721.	\$0.	\$199,721.
Flashscan 3D Miniature, Non-Contact Rolled Equivalent Fingerprint Collection Device				
Hassebrook, Laurence G	3048105370	\$988,511.	\$0.	\$988,511.
National Institute for Hometown Security Rolled Equivalent, 3-D Fingerprint and Palm Print Scanner				
Lau, Daniel L	3048104954	\$46,562.	\$0.	\$46,562.
KY Science and Technology Co Inc KSEF R&D Excellence: Integral Lens Array Imaging as an Anti-Counterfeit Marker				
Seales, William B	3048053000	\$0.	\$1,697,000.	\$1,697,000.
US Army Surgical Technology Integration With Tools For Cognitive Human Factors (STITCH)				
Seales, William B	3048105432	\$477,484.	\$0.	\$477,484.
Duke University Integrating Digital Papyrology 2				
Walcott, Bruce L	3048043800	\$0.	\$910,332.	\$910,332.
US Army Large Rapidly Deployable Immersive Visualization for Training and Simulation in Urban Terrains				
Yang, Ruigang	3046875100	\$0.	\$100,000.	\$100,000.
National Science Foundation CAREER: The Light Portal: 3D Reconstruction and Visualization over Space and Time				
Yang, Ruigang	3048104957	\$324,993.	\$0.	\$324,993.
National Science Foundation CPA-G&V: Self-Completion of 4D (Space+Time)Models				
Yang, Ruigang	3048105109	\$60,000.	\$0.	\$60,000.
VSee Lab Inc STTR Phase I: Rapidly Deployable Display with Continuous Self-Correction				
Yang, Ruigang	3048105174	\$65,189.	\$0.	\$65,189.
Direct i2i Technologies Inc STTR Phase 1: Eye-Gaze Correction for more Effective Telepresence				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
<u>Visualization Center</u>				
Yang, Ruigang	3048105698	\$74,702.	\$0.	\$74,702.
Robert Bosch LLC Non-Invasive Iris Acquisition and Recognition				
Visualization Center	Totals:	\$2,409,295.	\$2,707,332.	\$5,116,627.
<u>Computer Science</u>				
Calvert, Kenneth L	3048051100	\$0.	\$65,564.	\$65,564.
National Science Foundation NeTS-NBD: Collaborative Research: Human-Centered Networking for the Home				
Cheng, Fuhua	3048103223	\$0.	\$75,000.	\$75,000.
KY Science and Technology Co Inc Kentucky Commercialization Fund: Portable Digital Mouth & Occlusion Reproducer				
Griffioen, James N	3048105220	\$132,973.	\$0.	\$132,973.
BBN Technologies Instrumentation Tools for a GENI Prototype				
Hayes, Jane E	3048104958	\$0.	\$7,900.	\$7,900.
National Science Foundation CPA-SEL-T:Collaborative Research:Traceability+:a Service Oriented Framework to Support Value-added software Traceability				
Hayes, Jane E	3048104958	\$250,000.	\$0.	\$250,000.
National Science Foundation CPA-SEL-T:Collaborative Research:Traceability+:a Service Oriented Framework to Support Value-added software Traceability				
Marek, Victor W	3048105296	\$214,773.	\$0.	\$214,773.
Department of Defense IPA Agreement for Victor Marek				
Seales, William B	3048047200	\$0.	\$300,000.	\$300,000.
National Science Foundation EDUCE: Enhanced Digital Unwrapping for Conservation and Exploration				
Computer Science	Totals:	\$597,746.	\$448,464.	\$1,046,210.
<u>Kentucky Transportation Center</u>				
Agent, Kenneth R	3048105555	\$60,000.	\$0.	\$60,000.
KY Transportation Cabinet Identification and Analysis of Crash Locations RS-09-01				
Agent, Kenneth R	3048105574	\$80,450.	\$0.	\$80,450.
KY Transportation Cabinet Safety Belt and Child Safety Survey OP-09-06				
Anderson, Patsy P	3048104345	\$0.	\$-47,500.	\$-47,500.
KY Transportation Cabinet LTAP Safety Circuit Rider Program				
Anderson, Patsy P	3048105573	\$93,893.	\$0.	\$93,893.
KY Transportation Cabinet FHWA/LTAP Technology Transfer Assistance to Local Agencies				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Engineering</u>				
<u>Kentucky Transportation Center</u>				
Chen, Mei	3048105282	\$19,405.	\$0.	\$19,405.
KY Transportation Cabinet Kentucky ADMS Update for 2006-2007 - Planning Study No 17				
Chen, Mei	3048105515	\$20,000.	\$0.	\$20,000.
KY Transportation Cabinet Travel Time Based Congestion Measures for Freeway Corridors - Planning Study No 18				
Crabtree, Joseph D	3046531300	\$0.	\$56,880.	\$56,880.
KY Transportation Cabinet Development, Deployment, and Testing of an Integrated Commercial Motor Vehicle Safety System				
Crabtree, Joseph D	3048043200	\$0.	\$50,000.	\$50,000.
KY Transportation Cabinet Support of Kentucky s PRISM and CVISN Programs, Research Study-Federal no. 20				
Crabtree, Joseph D	3048103539	\$0.	\$83,819.	\$83,819.
KY Transportation Cabinet Southeast Regional Research Initiative (SERRI) Integrated Threat Tracking and Information System, Research Study-Federal no. 22				
Crabtree, Joseph D	3048104950	\$340,000.	\$0.	\$340,000.
KY Transportation Cabinet Deployment and Evaluation of a Next Generation Virtual Weigh Station, Research Study Federal No. 26				
Crabtree, Joseph D	3048104951	\$300,000.	\$0.	\$300,000.
KY Transportation Cabinet Electronic License Plate and Screening System, Research Study-Federal No. 25				
Crabtree, Joseph D	3048105503	\$384,306.	\$0.	\$384,306.
KY Transportation Cabinet Automated Prism Screening System, Research Study-Federal No. 27				
Crabtree, Joseph D	3048105522	\$2,800,000.	\$0.	\$2,800,000.
National Institute for Hometown Security North American Transportation Security Center				
Graves, Ronnie C	3048105384	\$15,000.	\$0.	\$15,000.
KY Transportation Cabinet Warm Mix Asphalt Performance Warren County IM NH 65-1 (90) Federal Aid Research Task No. 176				
Graves, Ronnie C	3048105385	\$15,000.	\$0.	\$15,000.
KY Transportation Cabinet Warm Mix Asphalt Performance - Simpson County IM NH 65-1 (83) 5, Federal Aid Research Task No. 175				
Graves, Ronnie C	3048105386	\$15,000.	\$0.	\$15,000.
KY Transportation Cabinet Warm Mix Asphalt Performance - Grant County IM NH 75-6 (96), Federal Aid Research Task No. 174				
Graves, Ronnie C	3048105387	\$15,000.	\$0.	\$15,000.
KY Transportation Cabinet Warm Mix Asphalt Performance - Grant County IM NH 75-6 (95) 146, Federal Aid Research Task No. 173				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Engineering</u>				
<u>Kentucky Transportation Center</u>				
Graves, Ronnie C	3048105388	\$15,000.	\$0.	\$15,000.
KY Transportation Cabinet Warm Mix Asphalt Performance - Warren - Simpson County IM NH 65-1 (81) Federal Aid Research Task No. 172				
Graves, Ronnie C	3048105742	\$38,000.	\$0.	\$38,000.
KY Transportation Cabinet Distress Evaluation of Gohmann Asphalt and Construction Materials Warranty of Asphalt Pavements, Kentucky Highway Investigative Task No. 65				
Green, Eric R	3048105292	\$177,687.	\$0.	\$177,687.
KY Justice Cabinet Evaluation Plan for the Ticketing Aggressive Cars and Trucks (TACT) Program in Kentucky Year 2				
Grossardt, Theodore H	3046337100	\$0.	\$150,000.	\$150,000.
KY Transportation Cabinet Information Technology Technical Assistance Project -- Federal Aid Research Task No. 88				
Grossardt, Theodore H	3048104480	\$0.	\$25,515.	\$25,515.
University of Tennessee Southeastern Transportation Center Transportation Systems Management Program				
Grossardt, Theodore H	3048104979	\$141,073.	\$0.	\$141,073.
Wilbur Smith Associates Milton-Madison Bridges Structured Public Involvement Support Project				
Hopwood, Theodore	3048103723	\$0.	\$93,770.	\$93,770.
KY Transportation Cabinet Investigation of Voids/Cracking on the I-25 Twin Bridges over the Ohio River in Kenton County, KY--Kentucky Highway Investigative Task No. 60				
Hopwood, Theodore	3048104617	\$0.	\$120,113.	\$120,113.
Northwestern University Continuation of the Midwest Bridge Working Group - Phase XIII				
Hopwood, Theodore	3048104617	\$0.	\$6,000.	\$6,000.
Northwestern University Continuation of the Midwest Bridge Working Group - Phase XIII				
Hunsucker, David Q	3046553100	\$0.	\$42,000.	\$42,000.
NORPASS Inc NORPASS Program Support				
Hunsucker, David Q	3046815100	\$0.	\$102,892.	\$102,892.
KY Transportation Cabinet Advantage CVO Operations and Maintenance, Research Study-State No. 10.				
Hunsucker, David Q	3046815100	\$0.	\$99,500.	\$99,500.
KY Transportation Cabinet Advantage CVO Operations and Maintenance, Research Study-State No. 10.				
Rister, Bradley W	3048105477	\$23,000.	\$0.	\$23,000.
KY Transportation Cabinet I-65 Jefferson County (128-132) In-Situ Pavment Evaluation, Federal Aid Research Task No. 177				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Engineering</u>				
<u>Kentucky Transportation Center</u>				
Toussaint, Paul	3048104705	\$0.	\$38,000.	\$38,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program KCTRP 09-29 (Part III)				
Toussaint, Paul	3048104705	\$220,000.	\$0.	\$220,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program KCTRP 09-29 (Part III)				
Toussaint, Paul	3048104707	\$0.	\$25,000.	\$25,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 09-29				
Toussaint, Paul	3048104707	\$3,849,606.	\$0.	\$3,849,606.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 09-29				
Toussaint, Paul	3048105033	\$54,500.	\$0.	\$54,500.
KY Transportation Cabinet Construction Co-op Tech Program - Federal Aid Research Task no. 171				
Walton, Jennifer R	3048105663	\$150,000.	\$0.	\$150,000.
KY Transportation Cabinet Evaluation of the Cumberland Gap Tunnel Intelligent Transportation System Projects ITS 982 (001) and ITS 9921 (001), Research Study-Federal No. 28				
Kentucky Transportation Center	Totals:	\$8,826,920.	\$845,989.	\$9,672,909.
<u>Chemical and Materials Engin.</u>				
Anderson, Kimberly Ward	3048103212	\$0.	\$103,000.	\$103,000.
National Science Foundation Adsorption of Treponema Pallidum Protein to Functionalized Alkanethiol Self-Assembled Monolayers for Improving Biocompatibility				
Anderson, Kimberly Ward	3048103842	\$0.	\$599,955.	\$599,955.
National Science Foundation IGERT: Building Leadership Through a Program on Engineered Bioactive Interfaces and Devices				
Anderson, Kimberly Ward	3048103842	\$0.	\$599,907.	\$599,907.
National Science Foundation IGERT: Building Leadership Through a Program on Engineered Bioactive Interfaces and Devices				
Anderson, Kimberly Ward	3048105636	\$102,132.	\$0.	\$102,132.
National Science Foundation REU Site: A Multidisciplinary Research Experience in Engineered Bioactive Interfaces and Devices				
Balk, Thomas John	3048060700	\$0.	\$5,000.	\$5,000.
American Iron and Steel Institute Developing Ferrous Matallurgy Course Material For An Updated Materials Engineering Curriculum at the University Of Kentucky				
Balk, Thomas John	3048104919	\$99,930.	\$0.	\$99,930.
KY Science and Technology Co Inc R&D Excellence: Nanoporous Nickel as an Alternative to Raney Nickel				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
<u>Chemical and Materials Engin.</u>				
Balk, Thomas John	3048105263	\$80,000.	\$0.	\$80,000.
National Science Foundation CAREER: Understanding Nanoscale Deformation by Characterizing the Mechanical Behavior of Nanoporous Noble Metals				
Bhattacharyya, Dibakar	3046984300	\$0.	\$8,500.	\$8,500.
J M Huber Corp Functionalization and Characterization of Silica Materials for High Value Applications				
Bhattacharyya, Dibakar	3048104774	\$87,900.	\$0.	\$87,900.
Compact Membrane Systems Inc SBIR: Novel Pharmaceutical Solvent-Water Separation System				
Bhattacharyya, Dibakar	3048105158	\$25,000.	\$0.	\$25,000.
NEI Corporation SBIR: A New Class of Nanocomposite Treatment Media for Efficient Mercury Remediation				
Cheng, Yang-Tse	3048105346	\$0.	\$14,900.	\$14,900.
General Motors Research Strategies for Mitigating Stress-Induced Damages to Lithium Ion Battery Electrodes				
Cheng, Yang-Tse	3048105346	\$36,361.	\$0.	\$36,361.
General Motors Research Strategies for Mitigating Stress-Induced Damages to Lithium Ion Battery Electrodes				
Gulke, Eric A	3048103782	\$0.	\$149,995.	\$149,995.
Ashland Inc Nanofluids for Advanced Military Mobility Systems - Coolants, Fuels and Lubricants				
Gulke, Eric A	3048103803	\$0.	\$250,000.	\$250,000.
KY Council on Postsecondary Education State DOE EPSCoR Match: Nanoscale Materials and Architecture for Energy Conversion				
Gulke, Eric A	3048104376	\$0.	\$28,618.	\$28,618.
Optical Dynamics Co Len-forming Nanocomposite for High-strength, Clear Ophthalmic Lenses				
Gulke, Eric A	3048105030	\$23,102.	\$0.	\$23,102.
Environmental Protection Agency EPA polymer nanocomposite applications				
Gulke, Eric A	3048105459	\$80,000.	\$0.	\$80,000.
Optical Dynamics Co SBIR Phase II: Lens-forming Nanocomposite for High-strength, Clear Ophthalmic Lenses				
Gulke, Eric A	3048105625	\$0.	\$-1.	\$-1.
Environmental Protection Agency High-Resolution Microscopy Characterization of Nanomaterial Samples				
Gulke, Eric A	3048105625	\$8,774.	\$0.	\$8,774.
Environmental Protection Agency High-Resolution Microscopy Characterization of Nanomaterial Samples				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
<u>Chemical and Materials Engin.</u>				
Hilt, James Z	3048105021	\$99,656.	\$0.	\$99,656.
KY Science and Technology Co Inc KSEF R&D Excellence: FTIR Imaging for Microscale Analysis of Hydrogel Patterning Reactions				
Hinds, Bruce J	3048057100	\$0.	\$289,703.	\$289,703.
National Institute on Drug Abuse Gated Carbon Nanotube Membrane Transdermal Drug Delivery				
Hinds, Bruce J	3048105302	\$220,000.	\$0.	\$220,000.
Statkraft Development AS Aligned Carbon Nanotube Membranes for Forward Osmosis Power Generation				
Hinds, Bruce J	3048105696	\$398,871.	\$0.	\$398,871.
Defense Advanced Research Projects Agency Ordered Molecular Transporters				
Knutson, Barbara	3048104976	\$81,236.	\$0.	\$81,236.
KY Office of Energy Policy Separation and Recovery of High-value Pentose Derivatives from Cellulosic Biomass using Mol+				
Knutson, Barbara	3048105505	\$0.	\$-999,964.	\$-999,964.
Cooperative State Research Education and Extension Separation and recovery of high value pentose derivatives from cellulosic biomass using molecular imprinting				
Knutson, Barbara	3048105505	\$999,964.	\$0.	\$999,964.
Cooperative State Research Education and Extension Separation and recovery of high value pentose derivatives from cellulosic biomass using molecular imprinting				
Yang, Fuqian	3048104717	\$222,600.	\$0.	\$222,600.
National Science Foundation Collaborative Research: Making nanostructured ceramics from micrometer-sized starting powders				
Yang, Fuqian	3048105419	\$7,000.	\$0.	\$7,000.
University of Tennessee Characterization of Localized Residual Stresses in Bulk Metallic Glass				
Yang, Fuqian	3048105420	\$7,000.	\$0.	\$7,000.
University of Tennessee Electromechanical Effort on the Formation and Growth of Tin Whiskers				
Yang, Fuqian	3048105421	\$64,861.	\$0.	\$64,861.
Lexmark International Inc Mechanical Property Analysis of Ink Jet Heater Thin Film Materials				
Zhai, Tongguang	3048103774	\$0.	\$-6,000.	\$-6,000.
National Science Foundation CAREER: Quantitative Understanding of the Effects of Micro and Macro-Texture on Fatigue Crack Initiation and Early Growth in High Performance Alloys				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Engineering</u>				
<u>Chemical and Materials Engin.</u>				
Zhai, Tongguang	3048103774	\$0.	\$6,000.	\$6,000.
National Science Foundation CAREER: Quantitative Understanding of the Effects of Micro and Macro-Texture on Fatigue Crack Initiation and Early Growth in High Performance Alloys				
Chemical and Materials Engin.	Totals:	\$2,644,387.	\$1,049,613.	\$3,694,000.
<u>CFFLS</u>				
Huffman, Gerald P	3046900100	\$0.	\$87,605.	\$87,605.
Department of Energy Development of Novel Technologies for the Production and Storage of Hydrogen from Coal Using C1 Chemistry				
Huffman, Gerald P	3046900100	\$0.	\$350,000.	\$350,000.
Department of Energy Development of Novel Technologies for the Production and Storage of Hydrogen from Coal Using C1 Chemistry				
Huffman, Gerald P	3048103876	\$0.	\$1,312,000.	\$1,312,000.
US Army Production of Military Fuels by C1 Chemistry				
CFFLS	Totals:	\$0.	\$1,749,605.	\$1,749,605.
<u>Civil Engineering</u>				
Fox, James F	3048105120	\$246,294.	\$0.	\$246,294.
National Science Foundation Collaborative Research: REU SITE: Coal Mining Impacts on Soil Carbon Storage and Impacts in Appalachian Headwater Streams: A Research Experience for Undergraduates				
Harik, Issam E	3048095500	\$0.	\$17,280.	\$17,280.
KY Transportation Cabinet Deployment of Remote Monitoring Instrumentation on the US 41 N Bridge over the Ohio River--Kentucky Highway Investigative Task No. 56				
Maloney, William F	3048105348	\$20,000.	\$0.	\$20,000.
Virginia Polytechnic Institute and State University Analysis of NIOSH FACE Reports				
Yost, Scott	3048105734	\$144,500.	\$0.	\$144,500.
CH2MHill Inc Physical Scale Hydraulic Model of the DRGWQTC Pump Stations				
Civil Engineering	Totals:	\$410,794.	\$17,280.	\$428,074.
<u>Mining Engineering</u>				
Lusk, Braden Trex	3048105371	\$0.	\$-398,240.	\$-398,240.
National Institute for Hometown Security Response of Curtain Wall Architectural Envelopes to Negative Phase Blast Effects				
Lusk, Braden Trex	3048105371	\$874,750.	\$0.	\$874,750.
National Institute for Hometown Security Response of Curtain Wall Architectural Envelopes to Negative Phase Blast Effects				
Lusk, Braden Trex	3048105372	\$0.	\$-401,128.	\$-401,128.
National Institute for Hometown Security Blast Protection for Power Transformers				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
Mining Engineering				
Lusk, Braden Trex	3048105372	\$824,738.	\$0.	\$824,738.
National Institute for Hometown Security Blast Protection for Power Transformers				
Tao, Dongping	3048104234	\$0.	\$105,424.	\$105,424.
Virginia Polytechnic Institute and State University Improving Coal Flotation Recovery Using Cavitation Concepts				
Tao, Dongping	3048105431	\$53,000.	\$0.	\$53,000.
BCI Engineers & Scientists Inc FIPR-Deep Cone Thickening Process for Phosphatic Clay Disposal				
Tao, Dongping	3048105508	\$69,364.	\$0.	\$69,364.
Canadian Natural Resources Ltd Development and Performance Evaluation of Innovative Clay Binders (Part II)				
Tao, Dongping	3048105583	\$275,000.	\$0.	\$275,000.
Illinois Clean Coal Institute Development of Novel Rotary Triboelectrostatic Separator for Dry Cleaning of Pulverized Fine Coal at Power Plants				
Mining Engineering	Totals:	\$2,096,852.	-\$693,944.	\$1,402,908.
Electrical and Computer Engineering				
Adams, Robert J	3046777800	\$0.	\$226,775.	\$226,775.
US Office of Naval Research Efficient Iterative and Direct Solvers for Electromagnetic Simulations				
Adams, Robert J	3048105324	\$0.	\$30,000.	\$30,000.
US Office of Naval Research Modular Fast Direct Solvers for Electromagnetic Modeling				
Adams, Robert J	3048105324	\$60,000.	\$0.	\$60,000.
US Office of Naval Research Modular Fast Direct Solvers for Electromagnetic Modeling				
Gedney, Stephen D	3048105132	\$0.	\$101,375.	\$101,375.
ERC Inc DGFETD/MSCAT Enhancement				
Gedney, Stephen D	3048105132	\$9,215.	\$0.	\$9,215.
ERC Inc DGFETD/MSCAT Enhancement				
Hastings, Jeffrey T	3048105023	\$100,000.	\$0.	\$100,000.
KY Science and Technology Co Inc KSEF: Liquid Phase Electron-Beam Induced Processing				
Heath, J R	3046947100	\$0.	\$14,444.	\$14,444.
Lexmark International Inc Systemic Approach to SOC Evaluation and Verification				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
Electrical and Computer Engineering				
Heath, J R	3046947100	\$0.	\$16,439.	\$16,439.
Lexmark International Inc Systemic Approach to SOC Evaluation and Verification				
Holloway, Lawrence E	3048104730	\$0.	\$1,185.	\$1,185.
Adaptive Intelligent Systems LLC SBIR Phase 1: A Modified GMAW System for Distortion Reduction and Travel Speed Increase through Separate Heat Input and Deposition Rate Control				
Lau, Daniel L	3048082200	\$0.	\$25,000.	\$25,000.
M2 Technologies Inc Anti-Sniper Infrared Targeting Systems (ASITS) Phase IIIa				
Lau, Daniel L	3048082200	\$0.	\$45,865.	\$45,865.
M2 Technologies Inc Anti-Sniper Infrared Targeting Systems (ASITS) Phase IIIa				
Liao, Yuan	3048104853	\$248,002.	\$0.	\$248,002.
National Science Foundation Transmission line fault location utilizing sparse measurements				
Liao, Yuan	3048104938	\$10,000.	\$0.	\$10,000.
KY Science and Technology Co Inc KY EPSCoR: Exploring new operating and control algorithms for the composite electric power system				
Liao, Yuan	3048105040	\$20,000.	\$0.	\$20,000.
EON US Development of a New Power Course Focusing on Advanced Power Software				
Liao, Yuan	3048105041	\$70,000.	\$0.	\$70,000.
EON US Power Flow and Stability Analysis and Development of Tools Facilitating Simulations Studies				
Lumpp, James E	3048104695	\$0.	\$7,000.	\$7,000.
KY Science and Technology Co Inc KY Space Initiative: Site Preparation for Space Systems Laboratory Spacecraft Assembly & Test Facility				
Lumpp, James E	3048105644	\$20,385.	\$0.	\$20,385.
Western KY University Kentucky Space Grant Consortium- Travel Support for Kentucky Space Student Workforce Development				
Lumpp, James E	3048105645	\$21,000.	\$0.	\$21,000.
Western KY University Kentucky Space Grant Consortium- Facilities Upgrades for KySat-1 and Student Workforce Development				
Lumpp, Janet K	3048105269	\$18,000.	\$0.	\$18,000.
Western KY University KSGC Fellowship: Integrated Structural-Electrical Composite Spacecraft Graduate Fellowship				
Lumpp, Janet K	3048105374	\$26,761.	\$0.	\$26,761.
Western KY University Integrated Structural-Electrical Composite Spacecraft (InSECS)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
Electrical and Computer Engineering				
Smith, William T	3048105600	\$79,543.	\$0.	\$79,543.
Lexmark International Inc Macro EMI Debug Tool				
Todd, Lee T	3048032200	\$0.	\$489,771.	\$489,771.
National Science Foundation LSAMP: Kentucky-West Virginia Alliance for Minority Participation				
Electrical and Computer Engineering	Totals:	\$682,906.	\$957,854.	\$1,640,760.
UK Center for Manufacturing				
Holloway, Lawrence E	3048104587	\$0.	\$55,464.	\$55,464.
Adaptive Intelligent Systems LLC Sensor Torch Based Adaptive Intelligent Control for Circumferential Welding of Pipes: SBIR Phase II				
Holloway, Lawrence E	3048105273	\$900,000.	\$0.	\$900,000.
Small Business Administration Innovation Extension Centers to Assist Small and Rural Manufacturers with Innovation				
Jawahir, Ibrahim S	3048105639	\$375,000.	\$0.	\$375,000.
South Carolina Research Authority Next Generation Manufacturing Initiative (NGMTI) Program				
Walcott, Bruce L	3048105616	\$3,000.	\$0.	\$3,000.
KY Department of Education UK 2008 STLP Showcase				
Zhang, Yuming	3048105042	\$364,269.	\$0.	\$364,269.
National Science Foundation Control of Metal Transfer at Given Arc Variables				
UK Center for Manufacturing	Totals:	\$1,642,269.	\$55,464.	\$1,697,733.
Mechanical Engineering				
Jawahir, Ibrahim S	3048105455	\$255,000.	\$0.	\$255,000.
South Carolina Research Authority Risk Assessment for Next Generation Readiness (RANGER)				
Karaca, Haluk E.	3048105071	\$0.	\$40,000.	\$40,000.
Western KY University Development of High-Temperature Shape Memory Alloys for Aerospace Applications				
Karaca, Haluk E.	3048105071	\$5,000.	\$0.	\$5,000.
Western KY University Development of High-Temperature Shape Memory Alloys for Aerospace Applications				
Lebeau, Raymond P	3048105319	\$72,012.	\$0.	\$72,012.
National Aeronautics and Space Administration Development and Application of Computational Simulations for Observed Persistent and Time-Varying Phenomena in the Atmospheres of the Ice Giants				
McDonough, James M	3048104978	\$18,000.	\$0.	\$18,000.
Western KY University Fellowship for Joshua Strodtbeck: Mathematical and Numerical Studies of Large-Eddy Simulation of Compressive Flow				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
<u>Mechanical Engineering</u>				
Menguc, M P	3048105022	\$100,000.	\$0.	\$100,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Experimental Investigation of Near-Field Radioactive Transfer for High-Efficiency Thermophotovoltaic Power Generators				
Sheng, Jian	3048104689	\$0.	\$-400,002.	\$-400,002.
National Science Foundation CAREER: Simultaneous Measurement of Wall Deformation and 3-D Flow Structures for Flow-Structure Interaction Investigations				
Sheng, Jian	3048104689	\$400,002.	\$0.	\$400,002.
National Science Foundation CAREER: Simultaneous Measurement of Wall Deformation and 3-D Flow Structures for Flow-Structure Interaction Investigations				
Smith, Suzanne W	3048104340	\$0.	\$10,000.	\$10,000.
Mevicon Inc Deployment Measurement of Stowed Thin Film Shells				
Smith, Suzanne W	3048104988	\$0.	\$71,486.	\$71,486.
L3 Communications Corp Inflatable Wing Structural Design and Analysis				
Smith, Suzanne W	3048104988	\$5,000.	\$0.	\$5,000.
L3 Communications Corp Inflatable Wing Structural Design and Analysis				
Smith, Suzanne W	3048105241	\$76,486.	\$0.	\$76,486.
L3 Communications Corp Inflatable Wing Structural Design and Analysis				
Smith, Suzanne W	3048105417	\$2,400.	\$0.	\$2,400.
National Academy of Sciences Student Leadership Workshop for Women in Engineering				
Smith, Suzanne W	3048105471	\$81,374.	\$0.	\$81,374.
NextGen Aeronautics SUAVE Phase II: Materials, Modeling and Integrated Environment Testing				
Smith, Suzanne W	3048105581	\$41,500.	\$0.	\$41,500.
US Equestrian Federation Improving Equestrian Jump Safety				
Mechanical Engineering	Totals:	\$1,056,774.	\$-278,516.	\$778,258.
<u>IR4TD</u>				
Saito, Kozo	3048104800	\$0.	\$9.	\$9.
Toyota Motor Co IRSIS Phase 2 Line Trial				
Saito, Kozo	3048104800	\$49,956.	\$0.	\$49,956.
Toyota Motor Co IRSIS Phase 2 Line Trial				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Engineering</u>				
<u>IR4TD</u>				
Saito, Kozo	3048105315	\$30,000.	\$0.	\$30,000.
KY Science and Technology Co Inc KY New Energy Ventures Fund: Production and Characterization of Bio-fuel from Vegetable Oil Residue				
Saito, Kozo	3048105318	\$25,075.	\$0.	\$25,075.
Toyota Motor Co Wax Detection				
IR4TD	Totals:	\$105,031.	\$9.	\$105,040.
	Engineering Totals:	\$20,472,974.	\$6,859,150.	\$27,332,124.
<u>Law</u>				
<u>Law</u>				
Davis, Mary J	3048105178	\$357,738.	\$0.	\$357,738.
Department of Justice University of Kentucky Legal Education Access Program (LEAP)				
Davis, Mary J	3048105415	\$18,000.	\$0.	\$18,000.
Bureau of Prisons Legal Assistance to Inmates				
Law	Totals:	\$375,738.	\$0.	\$375,738.
	Law Totals:	\$375,738.	\$0.	\$375,738.
<u>Communication & Information Stu</u>				
<u>School of Journalism</u>				
Barnes, Beth	3048105222	\$26,008.	\$0.	\$26,008.
American International Health Alliance Partnering with ZAMCOM to train Zambian Journalists in coverage of HIV/AIDS.				
School of Journalism	Totals:	\$26,008.	\$0.	\$26,008.
<u>Communication</u>				
Cohen, Elisia	3048105629	\$14,048.	\$0.	\$14,048.
Washington University Communication-Based Strategies to Eliminate Cancer Disparities				
Noar, Seth Michael	3048104503	\$0.	\$20,218.	\$20,218.
National Institute of Mental Health Enhancing Message Design in Tailored, Computerized HIV/STI Interventions				
Noar, Seth Michael	3048104503	\$0.	\$181,955.	\$181,955.
National Institute of Mental Health Enhancing Message Design in Tailored, Computerized HIV/STI Interventions				
Sellnow, Timothy L	3048104430	\$0.	\$285,842.	\$285,842.
University of Minnesota National Center for Food Protection and Defense: Robust Case Study Analysis of Media				
Sellnow, Timothy L	3048105658	\$60,000.	\$0.	\$60,000.
University of Southern California Letter of Intent: Risk Communication in Case of Intentional Food Contamination				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Communication & Information Stu</u>				
<u>Communication</u>				
Zimmerman, Rick S	3046965300	\$0.	\$458,003.	\$458,003.
National Institute of Mental Health Targeting Mass Media Campaigns for HIV, STD and Pregnancy Prevention				
Communication	Totals:	\$74,048.	\$946,018.	\$1,020,066.
<u>School of Library & Information Science</u>				
Huber, Jeffrey Todd	3048105350	\$7,300.	\$0.	\$7,300.
KY Department for Libraries and Archives KDLA LSTA Kentucky Guide Program				
Kim, Sujin	3048104876	\$339,420.	\$0.	\$339,420.
Institute of Museum and Library Services Librarians for the 21st Century: A Study of Metadata Framework for Digitized Pathologic Images				
School of Library & Information Science	Totals:	\$346,720.	\$0.	\$346,720.
Communication & Information Studies Totals:		\$446,776.	\$946,018.	\$1,392,794.
<u>Design</u>				
<u>Design</u>				
Carpenter, Clyde R	3046816600	\$0.	\$23,190.	\$23,190.
KY Transportation Cabinet Interns for Cultural Historic Assessment of Highway Projects				
Carpenter, Clyde R	3048105060	\$10,000.	\$0.	\$10,000.
City of Elkton City of Elkton Comprehensive Plan				
Carpenter, Clyde R	3048105118	\$12,000.	\$0.	\$12,000.
Todd County County of Todd Comprehensive Plan				
Carpenter, Clyde R	3048105603	\$8,000.	\$0.	\$8,000.
City of Guthrie City of Guthrie Comprehensive Plan				
Speaks, Michael Angelo	3048105029	\$50,000.	\$0.	\$50,000.
Louisville Metro Government Urban Design Studio 2008-2009				
Design	Totals:	\$80,000.	\$23,190.	\$103,190.
Design Totals:		\$80,000.	\$23,190.	\$103,190.
<u>Social Work</u>				
<u>Social Work</u>				
Badger, Karen	3048105335	\$14,000.	\$0.	\$14,000.
Phoenix Society for Burn Survivors Station Night Club Fire Needs Assessment				
Cerel, Julie A	3048105257	\$99,996.	\$0.	\$99,996.
Substance Abuse & Mental Health Services Administr University of Kentucky KEEP: Increasing Networks for Campus Awareness to Suicide and Emergencies (UK-IN-CASE)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Social Work</u>				
<u>Social Work</u>				
Cerel, Julie A	3048105272	\$58,578.	\$0.	\$58,578.
Department for Mental Health Mental Retardation Service Suicide Prevention for Youth - SPYCE Project Evaluation				
Cook-Craig, Patricia G	3048105136	\$37,000.	\$0.	\$37,000.
KY Association of Sexual Assault Programs EMPOWER Project				
Gillen, Martie L	3048104918	\$235,681.	\$0.	\$235,681.
KY Health Services Cabinet Post Secondary - Successful Transitions Program & Comprehensive Family Services				
Godlaski, Theodore M	3048105320	\$64,410.	\$0.	\$64,410.
KY River Community Care Inc Assertive Community Living for Appalachian Dually Diagnosed Adults Grant (ACLADDA)-Project Evaluation				
Hall, Jennifer G	3048105066	\$900,000.	\$0.	\$900,000.
Administration for Children and Families National Quality Improvement Center on the Privatization of Child Welfare Services				
Hall, Jennifer G	3048105638	\$90,288.	\$0.	\$90,288.
KY Cabinet for Health and Family Services KY Diligent Recruitment of Families for Children in the Foster Care System - Project MATCH				
Rompf, Elizabeth L	3048104932	\$8,199.	\$0.	\$8,199.
Eastern KY University Public Child Welfare Certification Program				
Segress, Melissa Jh	3048104916	\$83,401.	\$0.	\$83,401.
KY Health Services Cabinet Citizens Review Panel				
Segress, Melissa Jh	3048104923	\$31,134.	\$0.	\$31,134.
Eastern KY University Training Resource Center: Consulting Services				
Segress, Melissa Jh	3048104930	\$114,402.	\$0.	\$114,402.
Eastern KY University Training Resource Center: Medically Fragile				
Segress, Melissa Jh	3048104931	\$5,093.	\$0.	\$5,093.
Eastern KY University Training Resource Center: Cultural Diversity				
Segress, Melissa Jh	3048104934	\$0.	\$206,497.	\$206,497.
Eastern KY University Training Resource Center: Resource Parent Mentor Program/Retention				
Segress, Melissa Jh	3048104934	\$351,869.	\$0.	\$351,869.
Eastern KY University Training Resource Center: Resource Parent Mentor Program/Retention				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Social Work</u>				
<u>Social Work</u>				
Segress, Melissa Jh	3048105100	\$299,149.	\$0.	\$299,149.
Eastern KY University Training Resource Center: Office of Technology & Outcome Support				
Segress, Melissa Jh	3048105101	\$405,731.	\$0.	\$405,731.
Eastern KY University Training Resource Center: Adoption Support Programs				
Sprang, Mary	3048105423	\$400,000.	\$0.	\$400,000.
Substance Abuse & Mental Health Services Administr Child and Adolescent Trauma Treatment Institute				
Sprang, Mary	3048105651	\$440,119.	\$0.	\$440,119.
University of Louisville Pandemic Planning and Preparedness Program				
Tindall, Michele Staton	3048105313	\$0.	\$-800.	\$-800.
HOPE Center of Lexington Evaluation for the Center on Substance Abuse Treatment Men (CSAT-Men)				
Tindall, Michele Staton	3048105313	\$45,000.	\$0.	\$45,000.
HOPE Center of Lexington Evaluation for the Center on Substance Abuse Treatment Men (CSAT-Men)				
Tindall, Michele Staton	3048105363	\$91,800.	\$0.	\$91,800.
Chrysalis Inc Chrysalis House PPW-2 Evaluation				
Tindall, Michele Staton	3048105392	\$60,000.	\$0.	\$60,000.
KY Administrative Office of the Courts AOC Drug Court Evaluation - Christian County				
Tindall, Michele Staton	3048105481	\$56,460.	\$0.	\$56,460.
Volunteers of America of Los Angeles Volunteers of America Los Angeles				
Weeks, Pamela L	3048105227	\$429,594.	\$0.	\$429,594.
Eastern KY University Training Resource Center: Credit for Learning Program				
Social Work	Totals:	\$4,321,904.	\$205,697.	\$4,527,601.
<u>Cntr for Stdy of Violence Against Childr</u>				
Clark, James J	3048105133	\$200,000.	\$0.	\$200,000.
KY Cabinet for Health and Family Services Comprehensive Assessment and Training Services Project - Title IV-B				
Sprang, Mary	3048105146	\$658,000.	\$0.	\$658,000.
KY Cabinet for Health and Family Services Comprehensive Assessment and Training Services Project- Title V				
Cntr for Stdy of Violence Against Childr	Totals:	\$858,000.	\$0.	\$858,000.
	Social Work Totals:	\$5,179,904.	\$205,697.	\$5,385,601.

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Graduate School</u>				
<u>Martin School of Public Policy</u>				
Berger, Philip K	3048105340	\$0.	\$-10.	\$-10.
University of Cincinnati Worker Health and Safety Cooperative Agreement				
Berger, Philip K	3048105340	\$145,530.	\$0.	\$145,530.
University of Cincinnati Worker Health and Safety Cooperative Agreement				
Jennings, Edward T	3048104847	\$210,975.	\$0.	\$210,975.
KY Department of Military Affairs Hazard Mitigation Grants Program FY 2009 and 2010				
Jennings, Edward T	3048105230	\$105,430.	\$0.	\$105,430.
KY Council on Developmental Disabilities Policy Analysis for the Kentucky Council on Developmental Disabilities				
Toma, E F	3048105577	\$960,150.	\$0.	\$960,150.
National Science Foundation Research, Evaluation, and Technical Assistance: Student Outcome Effects of the Appalachian Math and Science Partnership				
Martin School of Public Policy	Totals:	\$1,422,085.	\$-10.	\$1,422,075.
<u>Graduate School Dean</u>				
Blackwell, J L	3048104269	\$0.	\$40,500.	\$40,500.
National Science Foundation National Science Foundation Graduate Fellowship Program				
Graduate School Dean	Totals:	\$0.	\$40,500.	\$40,500.
<u>Center for Biomedical Engineering</u>				
Bruce, Eugene N	3048105587	\$59,101.	\$0.	\$59,101.
National Institute on Aging Dynamics of Sleep Fragmentation in the Elderly				
Evans, Joyce M	3048104848	\$4,985.	\$0.	\$4,985.
Western KY University Internship for Rachel Moore: Efficacy of Countermeasures to Cardiovascular Deconditioning in Men and Women During Simulated Moon Explorations				
Knapp, Charles F	3048104489	\$0.	\$166,666.	\$166,666.
Western KY University NASA EPSCoR: Efficacy of Countermeasures to Cardiovascular Deconditioning in Men and Women During Simulated Moon Explorations				
Knapp, Charles F	3048104834	\$125,000.	\$0.	\$125,000.
Western KY University NASA EPSCoR 2007, State Match to NNX07AT58A: Efficacy of Countermeasures to Cardiovascular Deconditioning in Men and Women During Simulated Moon Explorations				
Patwardhan, Abhijit	3048104817	\$60,500.	\$0.	\$60,500.
American Heart Association Great Rivers Affiliate Restitution of Repolarization Duration: Hysteresis, Alternans and Spatial Heterogeneity				

Sponsored Project Awards Received Through UKRF Fiscal Year 2009 as of 6/30/2009

		New Accounts	Adjustments to Existing Accounts	Total
<u>Graduate School</u>				
<u>Center for Biomedical Engineering</u>				
Puleo, David A	3048072600	\$0.	\$28,700.	\$28,700.
Shriners Hospital for Crippled Children Recapitulation of a Growth Plate in a Rabbit Model				
Center for Biomedical Engineering	Totals:	\$249,586.	\$195,366.	\$444,952.
	Graduate School Totals:	\$1,671,671.	\$235,856.	\$1,907,527.
<u>Fine Arts</u>				
<u>Music</u>				
Mason, Daniel	3048105729	\$1,000.	\$0.	\$1,000.
National String Project Consortium UK String Project				
Pen, Ronald A	3048105281	\$2,500.	\$0.	\$2,500.
Lexarts Bluegrass IN the Blugrass				
Music	Totals:	\$3,500.	\$0.	\$3,500.
	Fine Arts Totals:	\$3,500.	\$0.	\$3,500.
	University Totals:	\$167,929,959.	\$88,810,753.	\$256,740,712.